<SEC-DOCUMENT>0001144204-18-059983.txt : 20181114
<SEC-HEADER>0001144204-18-059983.hdr.sgml : 20181114
<ACCEPTANCE-DATETIME>20181114163404
ACCESSION NUMBER:		0001144204-18-059983
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20181114
DATE AS OF CHANGE:		20181114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NANOVIRICIDES, INC.
		CENTRAL INDEX KEY:			0001379006
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				760674577
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36081
		FILM NUMBER:		181184480

	BUSINESS ADDRESS:	
		STREET 1:		1 CONTROLS DRIVE
		CITY:			SHELTON
		STATE:			CT
		ZIP:			06484
		BUSINESS PHONE:		(203) 937-6137

	MAIL ADDRESS:	
		STREET 1:		1 CONTROLS DRIVE
		CITY:			SHELTON
		STATE:			CT
		ZIP:			06484
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tv506169_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>QUARTERLY REPORT UNDER SECTION 13 OR
15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the quarterly period ended September
30, 2018 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Commission File Number: <B>001-36081</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANOVIRICIDES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of Company as specified in
its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEVADA</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76-0674577</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1 Controls Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shelton, Connecticut 06484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(203) 937-6137</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Company&rsquo;s telephone number, including
area code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during
the preceding 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="background-color: white">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted&nbsp;pursuant
to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). <FONT STYLE="font-family: Times New Roman, Times, Serif">Yes&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the Company
is a larger accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 20%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="vertical-align: top; width: 18%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 17%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 30%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 15%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the Company
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of November 14, 2018, there were approximately
69,383,000 shares of common stock of the registrant issued and outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NanoViricides, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; width: 90%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I FINANCIAL INFORMATION</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Financial Statements</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>Balance Sheets at September 30, 2018 (Unaudited) and June 30, 2018</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>3</U></FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>Statements of Operations for the Three Months Ended September 30, 2018 and 2017 (Unaudited)</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>4</U></FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>Statement
    of Changes in Stockholders&rsquo; Equity for the period from July 1, 2018 through September 30, 2018
    (Unaudited)</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>5</U></FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>Statements of Cash Flows for the Three Months Ended September 30, 2018 and 2017 (Unaudited)</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>6</U></FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>Notes to the Financial Statements (Unaudited)</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>7</U></FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.&nbsp;&nbsp; Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3. &nbsp; Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.&nbsp; &nbsp;Controls and Procedures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    II OTHER INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.&nbsp;&nbsp; Legal Proceedings</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.&nbsp;&nbsp; Unregistered Sales of Equity Securities and Use of Proceeds</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.&nbsp;&nbsp; Defaults Upon Senior Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.&nbsp;&nbsp; Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#b_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.&nbsp;&nbsp; Other Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#b_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#c_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.&nbsp;&nbsp; Exhibits and Reports on Form 8-K</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#c_001">45</A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="#c_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right"><A HREF="#c_002">46</A></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>NanoViricides, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Balance Sheets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">September 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">June 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>(Unaudited)</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; white-space: nowrap">ASSETS</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">CURRENT ASSETS:</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right; white-space: nowrap">6,082,365</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right; white-space: nowrap">7,081,771</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt; white-space: nowrap">Prepaid expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">201,532</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">240,257</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; white-space: nowrap">Total Current Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">6,283,897</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">7,322,028</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">PROPERTY AND EQUIPMENT</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Property and equipment</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">14,055,637</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">14,018,383</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt; white-space: nowrap">Accumulated depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">(3,348,610</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">(3,177,290</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; white-space: nowrap">Property and equipment, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">10,707,027</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">10,841,093</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">TRADEMARK AND PATENTS</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Trademark and patents</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">458,954</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">458,954</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt; white-space: nowrap">Accumulated amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">(86,094</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">(84,025</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; white-space: nowrap">Trademark and patents,&nbsp;net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">372,860</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">374,929</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">OTHER ASSETS</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Security deposits</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">3,515</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">3,515</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt; white-space: nowrap">Service agreements</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">3,222</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">4,647</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; white-space: nowrap">Other Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">6,737</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">8,162</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 27pt; white-space: nowrap">Total Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; white-space: nowrap">17,370,521</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; white-space: nowrap">18,546,212</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; white-space: nowrap">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">CURRENT LIABILITIES:</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Accounts payable</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">320,097</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">223,339</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Accounts payable &ndash; related party</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">718,457</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">107,468</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Derivative liability - warrants</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">122,541</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">298,092</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt; white-space: nowrap">Accrued expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">231,175</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">253,049</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; white-space: nowrap">Total Current Liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">1,392,270</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">881,948</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">COMMITMENTS AND CONTINGENCIES</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">STOCKHOLDERS' EQUITY:</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 9pt; white-space: nowrap"><P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in">Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 5,064,110</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.25in">and 4,531,394 shares issued and outstanding, at September 30, 2018 and June 30, 2018,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.25in">respectively</P></TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">5,064</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">4,531</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 9pt; white-space: nowrap"><P STYLE="margin-top: 0; margin-bottom: 0">Common stock, $0.001 par value; 150,000,000 shares authorized, 69,382,560 and 69,171,740</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.25in">shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively</P></TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">69,383</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">69,172</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; white-space: nowrap">Additional paid-in capital</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">101,437,413</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">101,282,707</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt; white-space: nowrap">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">(85,533,609</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">(83,692,146</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; white-space: nowrap">Total Stockholders' Equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">15,978,251</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; white-space: nowrap">17,664,264</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; white-space: nowrap">Total Liabilities and Stockholders' Equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; white-space: nowrap">17,370,521</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; white-space: nowrap">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; white-space: nowrap">18,546,212</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying notes to the financial
statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>Nanoviricides, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Statements of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">OPERATING EXPENSES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">1,411,483</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">1,451,906</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">627,615</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">778,540</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,039,098</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,230,446</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">LOSS FROM OPERATIONS</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,039,098</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,230,446</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">OTHER INCOME (EXPENSE):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,084</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,394</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(125,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Discount on convertible debentures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(239,351</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Change in fair value of derivatives</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">175,551</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">564,848</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other income, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">197,635</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">224,891</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">LOSS BEFORE INCOME TAXES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,841,463</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,005,555</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">INCOME TAX PROVISION</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,841,463</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,005,555</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Net loss per common share &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">69,185,965</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">63,307,083</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>See accompanying
notes to the financial statements&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A>NanoViricides, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Statement of Changes in Stockholders' Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the period from July 1, 2018 through
September 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series A Preferred</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock:</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock: Par $0.001</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Par&nbsp;$0.001</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number <BR> of</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional<BR> Paid-in</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total<BR> Stockholders'</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Balance, June 30, 2018</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,531,394</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,531</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">69,171,740</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">69,172</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">101,282,707</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(83,692,146</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">17,664,264</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Series A Preferred Stock issued for employee stock compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">532,716</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">533</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">54,494</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for consulting and legal services rendered</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">191,510</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">192</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">79,268</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">79,460</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock options issued for compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants issued to Scientific Advisory Board</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,543</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,543</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Common shares issued for Directors fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,310</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,481</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,841,463</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,841,463</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, September 30, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,064,110</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,064</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">69,382,560</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">69,383</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">101,437,413</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(85,533,609</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,978,251</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the financial
statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A>Nanoviricides, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Statements of Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Three Months ended</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">(1,841,463</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">(2,005,555</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Preferred shares issued as compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55,027</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">158,799</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Common shares issued as compensation and for services</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">86,960</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Warrants granted to Scientific Advisory Board</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,543</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,773</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Stock-based compensation expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,920</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Depreciation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">171,320</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">166,189</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,069</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,068</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(175,551</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(564,848</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Amortization of debt discount on convertible debenture</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">239,351</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Prepaid expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,725</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,254</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,425</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">96,758</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(45,427</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accounts payable - related party</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">610,989</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">478,088</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(21,874</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">188</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Deferred interest payable</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(41,667</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">NET CASH USED IN OPERATING ACTIVITIES</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(962,152</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,556,788</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchase of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(37,254</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(30,433</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">NET CHANGE IN CASH AND CASH EQUIVALENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(999,406</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,587,221</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,081,771</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,099,461</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,082,365</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,512,240</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Interest paid</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">166,667</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying notes to the financial
statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>NANOVIRICIDES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, 2018 AND 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 1 - Organization and Nature of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NanoViricides, Inc. (the Company&rdquo;)
is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization
of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma
field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the
nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical
trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety,
bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract
organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a company with several drugs in
various stages of early development. In our lead antiviral program against herpes viruses, i.e. the HerpeCide&trade; program alone,
we have drug candidates against at least five indications at different stages of development. Of these, our shingles drug candidate
is expected to enter human clinical trials in the very near future. It is in advanced, IND-enabling pre-clinical studies at present,
and large-scale production is being performed to supply the safety-toxicology study. In addition, our drug candidates against HSV-1
 &ldquo;cold sores&rdquo; and HSV-2 &ldquo;genital herpes&rdquo; are in advanced studies and are expected to follow the shingles
drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV
(Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). Chicken pox is re-emerging as a major disease especially in European
countries, with 23,500 confirmed cases in the first six months of 2018. In addition, we have drugs in development against all influenzas
in our FluCide&trade; program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our drugs are based on several patents,
patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc.
(&ldquo;TheraCour&rdquo;), to which we have broad, exclusive licenses in perpetuity. The first license agreement we executed with
TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases:
Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza
and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour.&nbsp;&nbsp;Pursuant
to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by
TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis,
viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.&nbsp; In addition, the Company is negotiating a
license for VZV (shingles, chicken pox virus), and the remaining human herpesviruses from TheraCour. For this purpose, the Company
has conducted a valuation for the shingles and PHN indications. The negotiation process has begun in earnest, with Dr. Irach Taraporewala being appointed as the new Chief Executive Officer of the Company, effective September 1, 2018.
To date, TheraCour has not withheld any licenses for antiviral nanomedicines that NanoViricides has asked for, and we anticipate
that the licenses to the remaining herpes viruses including VZV will be executed once the due diligence process is completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 - Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Basis of Presentation &ndash; Interim Financial Information</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim financial
statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States
of America (&ldquo;U.S. GAAP&rdquo;) for interim financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X of the Securities and Exchange Commission for Interim Reporting.&nbsp;&nbsp;Accordingly, they do not include all
of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements
furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management,&nbsp;considered
necessary for a fair presentation of the results for the interim periods presented.&nbsp;&nbsp;Interim results are not necessarily
indicative of the results for the full year.&nbsp;&nbsp;The accompanying financial statements and the information included under
the heading &ldquo;Management&rsquo;s Discussion and Analysis or Plan of Operation&rdquo; should be read in conjunction with our
Company&rsquo;s audited financial statements and related notes included in our Company&rsquo;s Form 10-K for the fiscal year ended
June 30, 2018 filed with the SEC on October 13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a summary of significant accounting
policies, see the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed on October 13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Reclassifications and Prior Year Adjustments</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. The
Company reclassified $296,678 of expenses related to the Company&rsquo;s laboratory facilities out of general and administrative
expenses into research and development expenses for consistency with current year presentation. The reclassifications had no impact
on the reported results of operations and net loss reported for the three months ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Net Loss per Common Share</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed
by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per
common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding
shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through
stock options, warrants, convertible preferred stock, and convertible debentures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the number of
potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">Potentially&nbsp;Outstanding&nbsp;Dilutive&nbsp;Common&nbsp;Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For&nbsp;the</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For&nbsp;the</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Options and Warrants</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,412,039</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,685,292</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total potentially outstanding dilutive common shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,412,039</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,685,292</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2017, the number of potentially
dilutive shares of the Company&rsquo;s common stock into which the Series C debenture could be converted based upon the conversion
provisions contained in the debenture was 952,381. The Series C debenture was redeemed for common stock effective November 13,
2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also issued 5,064,110 shares
of Series A Preferred Stock to investors and others as of September 30, 2018. Only in the event of a &ldquo;change of control&rdquo;
of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A &ldquo;Change of Control&rdquo;
is defined as an event in which the Company&rsquo;s shareholders become 60% or less owners of a new entity as a result of a change
of ownership, merger or acquisition of the Company or the Company&rsquo;s intellectual property. In the absence of a Change of
Control event, the Series A convertible Preferred Stock is not convertible into common stock, and does not carry any dividend rights
or any other financial effects. At September 30, 2018, the number of potentially dilutive shares of the Company&rsquo;s common
stock into which these Series A Preferred shares can be converted into is 17,724,385, and is not included in diluted earnings per
share since the shares are contingently convertible only upon a Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following represents the basic and
diluted per share calculations for loss from continuing operations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For&nbsp;the&nbsp;three&nbsp;months ended <BR> September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Calculation of basic and diluted loss per share of common stock:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to common stockholders</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,841,463</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,005,555</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Denominator for basic and diluted weighted average shares of common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,185,965</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,307,083</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share of common stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series C debenture was redeemed for Common Stock effective
November 13, 2017. See Note 7. The Series C debenture was excluded from the loss per share calculation for the three-month period
ended September 30, 2017 because the impact is anti-dilutive.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Recently Issued Accounting Pronouncements</U></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the SEC issued the
final rule on Disclosures About Changes in Stockholder&rsquo;s Equity For filings on Form 10-Q, which extends to interim
periods the annual requirement in SEC Regulation S-X, Rule 3-04,2 to disclose (1) changes in stockholders&rsquo; equity and
(2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required).
Pursuant to the final rule, registrants must now analyze changes in stockholders&rsquo; equity, in the form of
reconciliation, for &ldquo;the current and comparative year-to-date [interim] periods, with subtotals for each interim
period,&rdquo; i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 permits the
disclosure of changes in stockholders&rsquo; equity (including dividend-per-share amounts) to be made either in a separate
financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after
November 5, 2018. The staff of the SEC has indicated it would not object if the filer&rsquo;s first presentation of the
changes in shareholders&rsquo; equity is included in its form 10-Q for the quarter that begins after the effective date of
the amendments. Therefore, the Company expects to conform to this rule in its Form 10-Q for the quarter ending  December 31,
2018. The Company believes that the final rule will not have a material effect on its consolidated financial statements and
disclosures.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies
to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&rsquo;s
own operations by issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal
year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that
the adoption of this ASU will have a significant impact on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued
Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2017-11. &ldquo;Earnings Per Share (Topic 260); Distinguishing
Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments
with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of
Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11
revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging &ndash; Contracts
in Entity&rsquo;s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for
a scope exception from derivative accounting. An entity still is required to determine whether instruments would be
classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If
they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is
effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018,
and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may
apply this standard retrospectively to outstanding financial instruments with a down round feature by means of
a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption.
The Company is currently in the process of assessing the impact of this ASU on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 - Liquidity and Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s financial statements
have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization
of assets and liquidation of liabilities in the normal course of business. As reflected in the financial statements, the Company
has an accumulated deficit at September 30, 2018 of approximately $85.5 million and a net loss of approximately $1.8 million and
net cash used in operating activities of approximately $1 million for the three months then ended. In addition, the Company has
not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged
exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced
any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as
the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will
achieve or maintain profitability in the future. As of September 30, 2018, the Company had available cash and cash equivalents
of approximately $6.1 million. These factors raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management adjusted its planned expenditures,
activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional
financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has made several adjustments
to its past expenditures in the ensuing annual budget, eliminating several expenses including a reduction in workforce and consultants
to the extent feasible without affecting its program of drug development. In addition, the Company has focused its efforts primarily
on a single lead program to minimize cost outlays, namely taking the shingles drug candidate against VZV into human clinical trials.
Management&rsquo;s budget indicates that these changes have freed up sufficient funds to allow for the ensuing costs of the external
advanced IND-enabling studies of this drug candidate. Management has considered several options for obtaining additional funds
that will be needed for future human clinical trials and to obtain the additional license from TheraCour for VZV and the remaining
human herpes viruses. The Company is also evaluating the possibility of obtaining a mortgage on its fully owned cGMP-capable laboratory
facility in Shelton, CT, in order to free up a portion of the fixed capital for usage as liquid working capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company believes that
it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these
milestones, the Company would experience substantial improvement in the liquidity of the Company&rsquo;s stock, and would significantly
improve the Company&rsquo;s ability to raise funds on the public markets at terms that may be substantially superior to the terms
we are offered at present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that as a result of
the&nbsp;management plan, the Company&rsquo;s existing resources and access to the capital markets will be sufficient to fund the
Company&rsquo;s planned operations and expenditures through November 2019. However, the Company cannot provide assurance that its
plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than
it currently anticipates. The accompanying unaudited financial statements do not include any adjustments that may result from the
outcome of such unidentified uncertainties.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements do not include any adjustments related
to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
be necessary should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 - Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Related Parties</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related parties with whom the Company had
transactions are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 25%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related Parties</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 73%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationship</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anil R. Diwan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President, significant stockholder and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irach Taraporewala</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TheraCour Pharma, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity owned and controlled by a significant stockholder</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton Boniuk, MD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant stockholder</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>September 30,</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30,</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-size: 10pt"><I><U>Account Payable &ndash; Related Party</U></I></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive
licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza
and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and
indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic
installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative
expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the
licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month&rsquo;s<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
invoice to be applied as a prepayment towards expenses.&nbsp;On October 2, 2018, the Company entered into an agreement with TheraCour
Pharma, Inc. for a waiver of the two month worth of prepaid balance advance of anticipated invoicing and the application of the
current advance as a credit against current open invoices, Additionally, TheraCour has agreed to defer $25,000 per month of development
fees for six months, beginning with July 2018. Accounts payable due TheraCour on the reporting date was</FONT></P></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">718,457</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">107,468</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the three months ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, <BR> 2017</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Research and Development Costs Paid to Related Parties</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company&rsquo;s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2018 and June 30, 2018.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">846,688</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">847,093</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Debenture Interest Payable to a Director</U></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Coupon interest expense on the $5,000,000
Series C Debenture paid to Dr. Milton Boniuk for the three months ended September 30, 2017 was $125,000. The Series C debenture
was redeemed for Common Stock effective November 13, 2017. See Note 7.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 5 - Property and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, stated at cost,
less accumulated depreciation consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30,&nbsp;<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,&nbsp;<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: justify">GMP Facility</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,020,471</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,011,230</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">Land</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">260,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">260,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">Office Equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">57,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">57,781</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">Furniture and Fixtures</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Lab Equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,711,778</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,683,765</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">Total Property and Equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,055,637</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,018,383</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Less Accumulated Depreciation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,348,610</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,177,290</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Property and Equipment, Net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,707,027</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,841,093</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense for the three months
ended September 30, 2018 and 2017 was $171,320 and $166,189, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6 - Trademark and Patents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trademark and patents, stated at cost,
less accumulated amortization consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30,<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">Trademarks and Patents</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">458,954</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">458,954</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Less Accumulated Amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(86,094</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(84,025</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Trademarks and Patents, Net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">372,860</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">374,929</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense amounted to $2,069
and $2,068 for the three months ended September 30, 2018 and 2017, respectively.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 - Convertible Debenture and Derivatives&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Debenture - Series C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s Series C Convertible
Debenture, in the amount of $5,000,000, was redeemed on November 13, 2017. For the three month period ended September 30, 2017,
the Holder of the Company&rsquo;s Series C Convertible Debenture elected to receive $125,000 of their coupon interest payment
and $41,667 of deferred interest payment in cash.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s Series C Debenture
in the amount of $5,000,000 was due to mature on June 30, 2018. On November 13, 2017, the Company entered into a Debenture Redemption
Agreement (the &ldquo;Agreement&rdquo;) with the Holder, to redeem (the &ldquo;Redemption&rdquo;) its $5,000,000 Series C Convertible
Debenture (the &ldquo;Debenture&rdquo;) for an aggregate of 5,500,000 shares of the Company&rsquo;s $0.001 par value Common Stock
(&ldquo;Purchase Price&rdquo;) comprising 5,000,000 shares for the principal of the Debenture and 500,000 shares for unpaid coupon
interest from October 1, 2017 through June 30, 2018. The unpaid interest included $60,274 of accrued interest through November
13, 2017, $314,726 in coupon interest through June 30, 2018 and $125,000 of unpaid deferred interest. The price per share was equal
to the closing price of the Company&rsquo;s stock on Friday, November 10, 2017 of one ($1.00) dollar per share. The Holder waived
all early redemption penalty payments provided for in the Debenture for consideration of 150,000 shares of the Company&rsquo;s
$0.001 par value Series A Convertible Preferred Stock. The Company did not incur placement agent fees in redemption of the Series
C Convertible Debenture. The Company recognized a non-cash loss on extinguishment of debt of $1,348,247 on the extinguishment of
the aforesaid principal attributable to the Series C Debentures into the Company&rsquo;s common and preferred stock. The loss on
extinguishment arises from, the obligation to issue 150,000 shares of the Company&rsquo;s Series A Preferred shares with a fair
value of $364,337, as of November 13, 2017, obligation to issue 314,726 shares of the Company&rsquo;s $0.001 par value Common Stock
with a fair value of $314,726 as of November 13, 2017, in consideration of Debenture coupon interest from the redemption date through
June 30, 2018, and unamortized discount of $684,633 as of the redemption date, offset by the derivative liability of ($15,449)
as of the redemption date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the redemption agreement for
the Company&rsquo;s Series C Debenture, the Company issued 5,500,000 shares of its registered Common Stock from its shelf registration
and the 150,000 shares of its Series A Preferred Stock upon receiving consent to issue the shares pursuant to New York Stock Exchange
(&ldquo;NYSE&rdquo;) regulations. The Company submitted a request for authorization to issue the Common Stock and Series A Preferred
Shares to the NYSE, which was authorized on March 18, 2018 and the shares were issued on March 21, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2014, in conjunction with the
issuance of the Company&rsquo;s Series C Convertible Debentures, the Company issued 187,000 shares of its Series A Convertible
Preferred Stock (the &ldquo;Series A&rdquo;) to Dr. Milton Boniuk, pursuant to the terms of the Debenture. Proceeds received in
a financing transaction are allocated to the instruments issued prior to evaluating hybrid contracts for bifurcation of embedded
derivatives. Since the Series A Convertible Preferred Stock is classified as equity, the proceeds allocated to the Preferred Stock
are recorded at relative fair value. The fair value of the Series A was $1,645,606 at issuance and the relative fair value was
calculated as $1,152,297. The remaining amount of the proceeds was allocated to the Debenture and a debt discount of $1,152,297
was recorded to offset the amount of the proceeds allocated to the Series A. Then, the embedded derivative was bifurcated at its
fair value of $1,879,428 with the remaining balance allocated to the host instrument (Debenture). The total debt discount was amortized
over the actual term of the Debenture using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized amortization of
this discount as an additional interest charge to &ldquo;Discount on convertible debentures&rdquo; in the amount of $ -0- and $239,351
for the three month periods ended September 30, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 8 &ndash; Accrued expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September
    30,<BR> &nbsp;2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,&nbsp;<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left">Severance payment- Eugene Seymour</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">133,333</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">233,333</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued&nbsp;&nbsp;payroll</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">49,576</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,716</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Professional Services</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">48,266</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued Expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">231,175</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">253,049</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9  - Equity Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2018 the Board of Directors
approved an extension of the employment agreement with Dr. Anil Diwan, the Company&rsquo;s President. Pursuant to the terms of
the employment agreement, the Company&rsquo;s Board of Directors authorized the issuance of 525,000 of the Company&rsquo;s Series
A preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30, 2020 and June
30, 2021 and are subject to forfeiture. The Company recognized a non-cash compensation expense related to the issuance of the Series
A Preferred stock of $47,260 for the three months ended September 30, 2018. The balance of $513,430 will be recognized as the shares
vest and service is rendered.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30,
2018, the Company&rsquo;s Board of Directors authorized the issuance of 7,716 fully vested shares of its Series A Convertible Preferred
stock for employee compensation. The Company recorded an expense of $7,767.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the Series A Preferred stock was the following
for the dates indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Value</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 62%; text-align: right"><FONT STYLE="font-size: 10pt">7/11/2018</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">525,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">560,690</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7/31/2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,572</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,795</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8/31/2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,572</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,374</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">9/30/2018</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,572</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,598</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">532,716</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">568,457</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is currently no market for the shares
of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company
as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred
stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater
of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the
voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A
Preferred stock at each issuance used the following inputs:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The common stock price was in the range $.42 to $.58;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculated weighted average number of shares of common stock in the period;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A 26.63% premium over the common shares for the voting preferences;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.22% to 19.25% of the total;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 2.09 years;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.42% to 32.24% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 55.76% to 61.17% volatility, 2.09% to 2.11% risk free rate) applied to the converted common.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2018, the Company entered
into an Employment Agreement with Dr. Irach Taraporewala as Chief Executive Officer of the Company beginning on September 1,
2018. Dr. Taraporewala was granted options to purchase up to 300,000 shares of the Company&rsquo;s common stock, par value
$0.001 per share at an exercise price equal to 20% above the closing bid price of $0.41 of the common stock on September 1,
2018 (&ldquo;Effective Date&rdquo;). The options shall vest in three, equal, annual installments commencing on the Effective Date. The
fair value of the options was $35,761 of which $11,920 was recognized and recorded as compensation expense for the three
months ended September 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of
the options granted to Dr. Taraporewala on the date of grant using a lattice simulation model that values the options based upon
a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the Scientific Advisory
Board (SAB) was granted fully vested warrants to purchase 11,432 shares of common stock with an exercise price of $.41 per share
expiring in August 2022.&nbsp;&nbsp;The fair value of the warrants was $1,543 and was recorded as consulting expense for the three
months ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of
the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the
following weighted-average assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (year)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 17.85pt; text-indent: -9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 17.85pt; text-indent: -9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected annual rate of quarterly dividends</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 17.85pt; text-indent: -9pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free rate(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.71</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30,
2018, the Company&rsquo;s Board of Directors authorized the issuance of 191,510 fully vested shares of its common stock with a
restrictive legend for consulting services. The Company recorded an expense of $79,460 for the three months, which was the fair
value on the dates of issuance.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30,
2018, the Company&rsquo;s Board of Directors authorized the issuance of 19,310 fully vested shares of its common stock with a restrictive
legend for Director Services. The Company recorded an expense of $7,500 for the three months, which was the fair value on the
date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 - Stock Warrants and Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Stock Warrants</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock&nbsp;Warrants</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;<BR> Average&nbsp;<BR> Exercise<BR> Price&nbsp;<BR> per&nbsp;share&nbsp;<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average&nbsp;<BR> Remaining&nbsp;<BR> Contractual&nbsp;Term<BR> (years)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic&nbsp;Value<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif; text-align: left">Outstanding and exercisable at June 30, 2018</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,969,588</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.80</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">.53</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,432</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">.41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Expired</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,868,981</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5.25</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Outstanding and exercisable at September 30, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,112,039</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4.48</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">.63</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of the above warrants, 3,679,127 expire
in fiscal year ending June 30, 2019; 68,592 expire in fiscal year ending June 30, 2020, 57,160 expire in fiscal year ending June
30, 2021, 45,728 expire in the fiscal year ending June 30, 2022 and 261,432 warrants expire in the fiscal year ending June 30,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Stock Options</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock&nbsp;Options</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;<BR> Average&nbsp;<BR> Exercise<BR> Price&nbsp;<BR> per&nbsp;share&nbsp;<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average&nbsp;<BR> Remaining&nbsp;<BR> Contractual&nbsp;Term<BR> (years)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic&nbsp;Value<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif">Granted</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">300,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">.50</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Outstanding at September 30, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">300,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">.50</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2.92</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of the above options, 100,000 are vested
and exercisable as of September 30, 2018, 100,000 become vested and exercisable on September 1, 2019 and 100,000 become vested
and exercisable on September 1, 2020. The options expire on August 31, 2021. The options will not become vested and exercisable
until the option is vested pursuant to the vesting schedule set forth above, provided that Dr. Taraporewala continues to be employed
by, or provide service to, the Company. If Dr. Taraporewala&rsquo;s continuous service terminates for any reason other than cause,
any such option exercisable as of the date of termination may be exercised at any time by the participant prior to the expiration
date. If Dr. Taraporewala&rsquo;s continuous service should be terminated for &ldquo;Cause&rdquo; (as defined in the option), then
any outstanding option, vested or unvested, shall terminate immediately and shall no longer be exercisable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of
the option grant at $35,761 and recognized the estimated value of the vested and exercisable options as a compensation expense
of $11,920 for the three months ended September 30, 2018. The Company will recognize the remaining unrecognized fair value of the
option grant of $23,841 in installments over the vesting period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of the options granted
to Dr. Taraporewala on the date of grant using a lattice model that values the options based upon a stock price modeled such that it follows a geometric Brownian
motion with constant drift and volatility:</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 89%; font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life (year)</TD>
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 17.85pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55.09</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 17.85pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected annual rate of quarterly dividends</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 17.85pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free rate(s)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.71</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: 0.4in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left">Expected forfeiture (attrition) rate (%)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected volatility is based on historical
volatility of the Company&rsquo;s common stock and the expected life of options. The Company estimates
forfeitures at the time of valuation and reduces expense ratably over the vesting period. This estimate is adjusted periodically
based on the extent to which actual forfeitures differ or are expected to differ, from the previous estimate.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 - Fair Value Measurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair value measurements<I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2018 and June 30, 2018
the estimated fair values of the liabilities measured on a recurring basis are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Fair&nbsp;Value&nbsp;Measurements&nbsp;at</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,&nbsp;2018:</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level&nbsp;1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level&nbsp;2)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level&nbsp;3)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; width: 61%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Derivative liability - warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">122,541</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Fair&nbsp;Value&nbsp;Measurements&nbsp;at</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,&nbsp;2018:</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level&nbsp;1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level&nbsp;2)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level&nbsp;3)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; width: 61%">Derivative liability - warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; width: 10%">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; width: 10%">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; width: 10%">298,092</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the Company&rsquo;s
registered direct offerings of Units, consisting of the Company&rsquo;s common stock and warrants, on September 12, 2013 and January
24, 2014, the Company issued an aggregate of 5,425,363 warrants, of which 2,479,935 and 5,290,006, are outstanding at September
30, 2018 and June 30, 2018, respectively. Additionally, the Company issued 135,216 warrants to the placement agents of which 76,306
and 135,216, are also outstanding at September 30, 2018 and June 30, 2018, respectively, for a total number of 2,556,241 and 5,425,222
warrants outstanding and issued as of September 30, 2018 and June 30, 2018, respectively, pursuant to the aforesaid registered
direct offerings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock purchase
warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under
applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain
full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants
described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company used a lattice model to calculate
the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future
projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise
and full reset features.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants were valued as of September
30, 2018 and June 30, 2018 with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 5-year warrants issued on 9/12/13 and 1/24/14 included Investor and Placement Agent Warrants with an exercise price of $5.25 and $6.05 (subject to adjustments-full ratchet reset).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock price would fluctuate with the Company projected volatility.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of <B>2 times</B> the projected exercise/reset price or <B>2 times</B> the stock price.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">1 Year</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 81%; font: 10pt Times New Roman, Times, Serif">9/30/18</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">64</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">6/30/18</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">56</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary factors driving the economic
value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the
remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned
to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value
was then probability weighted and discounted to the present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present the activity
for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fair&nbsp;Value&nbsp;Measurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp; &nbsp; <B>&nbsp; &nbsp; &nbsp; &nbsp;
 &nbsp; &nbsp; &nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair&nbsp;Value&nbsp;Measurement</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Using Significant Unobservable Inputs</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.8pt"><B>Derivative</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 15.4pt"><B>Liability-</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrant</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif">Beginning balance at July 1, 2018</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">298,092</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions during the year</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(175,551</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Transfer in and out of Level 3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at September 30, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">122,541</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 12 - Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Legal Proceedings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no pending legal proceedings
against the Company to the best of the Company&rsquo;s knowledge as of the date hereof and to the Company&rsquo;s knowledge, no
action, suit or proceeding has been threatened against the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Dr. Diwan, President and
Chairman of the Board of Directors, entered into an extension of employment agreement effective July 1, 2018 for a term of three
years. Dr. Diwan&rsquo;s will be paid an annual base salary of $400,000. Additionally, Dr. Diwan was awarded a grant of 525,000
shares of the Company&rsquo;s Series A Preferred Stock. 175,000 shares vest equally on June 30, 2019, 2020 and
2021. Any unvested shares are subject to forfeiture.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Dr. Irach
Taraporewala, the Company&rsquo;s Chief Executive Officer, entered into an employment agreement effective September 1, 2018,
for a term of three years. Dr. Taraporewala will be paid an annual base salary of $360,000. Additionally, Dr. Taraporewala
was awarded a grant of 300,000 options to purchase shares of the Company&rsquo;s Common Stock. 100,000 options vested on
September 1, 2018 and the remainder of the options will vest over the two year vesting period and are
subject to forfeiture.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 3, 2010, the Company entered into
an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development.&nbsp;&nbsp;The employment
agreement provides for a term of four years with a base salary of $150,000.&nbsp;&nbsp;In addition, the Company issued 26,786 shares
of Series A Preferred Stock and 35,715 shares of common stock upon entering into the agreement, and issued an additional 26,786
shares of Series A Preferred Stock and 35,715 shares of common stock on each anniversary date of the agreement. The shares of Series
A Preferred Stock were issued in recognition of Dr. Tatake&rsquo;s work towards the achievement of several patents by the Company.
The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its
review of current industry compensation arrangements and Employment agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 3, 2010, the Company entered into
an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer.&nbsp;&nbsp;The employment agreement provided
for a term of four years with a base salary of $150,000.&nbsp;&nbsp;In addition, the Company issued 35,715 shares of common stock
upon entering into the agreement, and issued an additional 35,715 shares of common stock on each anniversary date of the agreement.
The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its
review of current industry compensation arrangements and Employment agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 30, 2013, the Company entered into
an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer.&nbsp;&nbsp;The employment agreement provided for
a term of three years with a base salary of $9,000 per month and 2,572 shares of Series A Preferred Stock, also on a monthly basis.
On January 1, 2015, her cash compensation was increased to $10,800 per month. The Agreement is renewable on an annual basis. The
Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review
of current industry compensation arrangements and Employment agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>License Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dependent upon its license agreement with TheraCour (See Note 4). If the Company lost the
right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends,
the Company will incur substantial delays and costs in development of its drug candidates. The Company is currently negotiating
for a license for VZV from the Licensor, TheraCour. For this purpose, the Company has conducted a valuation
for the shingles and PHN indications. Dr. Irach Taraporewala was appointed as the new Chief Executive Officer of the Company, effective
September 1, 2018, and is leading the negotiation process with TheraCour. TheraCour has not withheld any licenses for antiviral
nanomedicines sought by the Company and we anticipate that the licenses for VZV will be executed once the due diligence process
is completed.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 13 - Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: justify">On October 29, 2018, the Board
of Directors of NanoViricides, Inc. (the &ldquo;Company&rdquo;) elected James Sapirstein as a new member of the Board. Mr.&nbsp;Sapirstein
is an Independent Member of the Board of Directors and will serve as a member of the Company&rsquo;s Audit, Compensation and Nominating
Committees.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PART I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="b_001"></A><B>Item 2. Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion should be read
in conjunction with the information contained in the financial statements of the Company and the notes thereto appearing elsewhere
herein and in conjunction with the Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
set forth in the Company&rsquo;s Annual Report on Form 10-K for the year ended June 30, 2018. Readers should carefully review the
risk factors disclosed in this Form 10-K and other documents filed by the Company with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this report, the terms &ldquo;Company&rdquo;,
 &ldquo;we&rdquo;, &ldquo;our&rdquo;, &ldquo;us&rdquo; and &ldquo;NNVC&rdquo; refer to NanoViricides, Inc., a Nevada corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>PRELIMINARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Report contains forward-looking statements
within the meaning of the federal securities laws. All statements other than statements of historical fact made in this report
are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial
position are forward-looking statements. These include statements about our expectations, beliefs, intentions or strategies for
the future, which we indicate by words or phrases such as &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;will,&rdquo; &ldquo;we believe,&rdquo; &ldquo;Company believes,&rdquo; &ldquo;management believes&rdquo;
and similar language. These forward-looking statements can be identified by the use of words such as &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo;
 &ldquo;could,&rdquo; &ldquo;possibly,&rdquo; &ldquo;probably,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;may,&rdquo; &ldquo;will,&rdquo; or &ldquo;should,&rdquo; or other variations or similar words. No assurances can be given
that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management&rsquo;s
current expectations and are inherently uncertain. The forward-looking statements are based on the current expectations of NanoViricides,
Inc. and are inherently subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under
 &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; in this report. Actual
results may differ materially from results anticipated in these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors are also advised to refer to
the information in our previous filings with the Securities and Exchange Commission (SEC), especially on Forms 10-K, 10-Q and 8-K,
in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic
results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors
to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recent Developments</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are pleased to report that Dr. Irach
B. Taraporewala has joined as our new Chief Executive Officer (CEO) as of September 1, 2018. Dr. Taraporewala was previously the
founding CEO and President of Ohr Pharmaceutical, Inc. (&ldquo;Ohr&rdquo;), from April 2010 until December 2015. During his 5 years
of leadership at Ohr, he played a critical role in taking the company from preclinical stage through successful Phase II clinical
trials.&nbsp;Dr. Taraporewala&nbsp;ensured that the Company was well capitalized, oversaw the up-listing of the Company&rsquo;s
common stock to the&nbsp;NASDAQ exchange, and completed several successful rounds of financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to Ohr, Dr. Taraporewala was Vice
President of Regulatory Affairs and Clinical Research at Mystic Pharmaceuticals Inc., Austin, TX, from April 2008 to March 2010.
At Mystic, he led the regulatory strategy for the Company's ophthalmic and intranasal drug products, as well as drug delivery systems.
Earlier, Dr. Taraporewala served at a well-known pharmaceutical consulting and clinical research organization, PAREXEL International
Corp., as Senior Consultant in the Drug Development Consulting Division. In this position, he provided technical expertise and
regulatory advice to small and large biotechnology and pharmaceutical company clients worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Taraporewala holds a Ph.D. degree in
Medicinal Chemistry from the Philadelphia College of Pharmacy, University of the Sciences in Philadelphia (1984).&nbsp; He holds
a Master of Science degree in Organic Chemistry, and a Bachelor of Science degree in Chemistry and Microbiology, both from the
University of Bombay, India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Taraporewala was appointed as a member
of the Board of Directors by the Board as of November 1, 2018.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition we are pleased to report that
Mr. James Sapirstein has joined the Board of Directors of the Company as of November 1, 2018, as an independent director. He has
also become a member of the Audit Committee, the Compensation Committee, and the Nomination Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Sapirstein has over 35 years of experience
in the pharmaceutical industry. He has held various roles in small as well as big pharmaceutical companies, including as CEO for
multiple small companies. He has also served and is currently serving as a Director of multiple pharmaceutical companies and of
pharmaceutical industry associations. He has been part of almost two dozen drug product launches and specifically either led or
has been a key member of several HIV product launches into different new classes of therapeutics at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Sapirstein began his career in 1984
with big pharmaceutical companies, joining Eli Lilly in Sales; moving on to Hoffmann-LaRoche in 1987 where he served for almost
a decade as part of its commercial teams in the USA and abroad, rising to become a Product Director; and thereafter at Bristol
Myers Squibb (BMS) as the Director of International Marketing in the Infectious Diseases group in 1996. While at BMS, he worked
on several important HIV/AIDS projects including Secure the Future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Sapirstein&rsquo;s entry into the world
of smaller pharma companies began with Gilead Sciences, Inc. (GILD) in 2000 where he led the Global Marketing team in its launch
of Viread (tenofovir). Later, in 2002, he accepted the position of Executive Vice President, Metabolic and Endocrinology, for Serono
Laboratories, acquired by Merck GMBH in 2006. Thereafter in 2006, he became the founding CEO of Tobira Therapeutics, then a private
company. In 2012, Mr. Sapirstein became the CEO of Alliqua Biomedical at Alliqua, Inc. Thereafter, he served as CEO of Contravir
Pharmaceuticals (CTRV) from March 2014 until October 2018. Mr. Sapirstein has raised over $120 Million dollars in venture capital
and public capital markets financing in his various engagements as CEO. He was named as a Finalist for Ernst &amp; Young Entrepreneur
of the Year award in 2015 as well as in 2016. Mr. Sapirstein received an MBA from Fairleigh Dickinson University in 1997, and a
BS (Pharmacy) from Rutgers University in 1984.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Sapirstein currently holds Board positions
on Enochian Biosciences (ENOB), RespireRx Pharmaceuticals (RSPI) and the privately held company Leading Biosciences. He is the
Chairman of the Board for BioNJ, an association of biopharma industries in New Jersey. In addition, he is a Board Director for
BIO, the leading Biopharma Industries Organization promoting public policy and networking in the healthcare space, where he sits
on both the Health Section and Emerging Companies Section Governing Boards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Sapirstein&rsquo;s appointment as an
Independent Director of the Board, as well as Dr. Taraporewala&rsquo;s appointment as a Member of the Board, are to be ratified
by shareholder vote at the forthcoming Annual General Meeting of the Company, scheduled on November 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of Mr. Sapirstein&rsquo;s appointment,
the Company has regained full compliance with the listing requirements of NYSE-American for having a majority of independent directors
and three members on its Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the appointments, of Dr. Taraporewala
and Mr. Sapirstein the Company his significantly bolstered its pharmaceutical industry expertise at both the executive management
level and the Board level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additilanlly, management has continued
and accelerated its efforts at investor outreach and communications significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Irach B. Taraporewala, Chief Executive
Officer of the Company, presented a corporate overview and discussed the Company&rsquo;s progress in taking its first drug candidate
into human clinical trials at the MicroCap Investment Conference, held on October 1-2, 2018 at the Essex House Hotel in New York
City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Anil Diwan, President and Chairman
of the Board of NanoViricides, presented the Company and introduced the Company&rsquo;s new CEO, Dr. Irach Taraporewala, at the
20th Annual Rodman &amp; Renshaw Global Investment Conference, sponsored by H.C. Wainwright &amp; Co., LLC, held on September 4-6,
2018 at the St. Regis New York Hotel in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to this reporting period, the
Company has engaged Zacks Investment Research for the purpose of developing and disseminating investment research analysis reports
on the Company. Previously, the Company has reported that we have engaged The Money Channel NYC for the purpose of investor and
brokerage outreach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Background - The Nanoviricide&reg;
Platform Technology</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NanoViricides, Inc. is a globally leading
company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide&reg; technology
enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle
becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points
per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction
of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide
technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular
virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby
enabling complete control of a virus infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our anti-viral therapeutics, that we call
 &ldquo;nanoviricides&reg;&rdquo; are designed to appear to the virus like the native host cell surface to which it binds. Since
these binding sites for a given virus do not change despite mutations and other changes in the virus, we believe that our drugs
will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus, provided the virus-binding
portion of the nanoviricide is engineered appropriately. Viruses would not be able to escape the nanoviricide by viral mutations
since they continue to bind to the same cellular receptor and thus would be captured by the nanoviricide. Virus escape by mutations
is a major problem in the treatment of viral diseases using conventional drugs. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company develops its class of drugs,
that we call nanoviricides&reg;, using a platform technology. This approach enables rapid development of new drugs against a number
of different viruses. A nanoviricide is a &ldquo;biomimetic&rdquo; - it is designed to &ldquo;look like&rdquo; the cell surface
to the virus. To accomplish this, we have developed a polymeric micelle structure composed of PEG and fatty acids that is designed
to create a surface like the cell membrane, with the fatty acids going inside of the micelle. On this surface, we chemically attach,
at regular intervals, virus-binding ligands. The virus is believed to be attracted to the nanomicelle by these ligands, and thereby
binds to the nanoviricide using the same glycoproteins that it uses for binding to a host cell. Upon such binding, a &ldquo;lipid
mixing&rdquo; interaction between the lipid envelope of the virus and the nanomicelle is thought to take place, leading to the
virus attempting to enter the nanomicelle. We believe many different kinds of viruses are likely to get destroyed in this process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We engineer the ligands to &ldquo;mimic&rdquo;
the same site on the cell surface protein to which the virus binds. These sites do not change no matter how much a given virus
mutates. Thus, we believe that if a virus so mutates that it is not attacked by our nanoviricide, then it also would not bind to
the human host cell receptor effectively and therefore would be substantially reduced in its pathogenicity. Our success at developing
broad-spectrum nanoviricides depends upon how successfully we can design decoys of the cell surface receptor as ligands, among
other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NanoViricides, Inc. is one of a few bio-pharma
companies that has all the capabilities needed from research and development to marketable drug manufacture in the small quantities
needed for human clinical trials. At our campus at 1 Controls Drive, Shelton, CT, we possess state of the art nanomedicines characterization
facilities that we believe enable us to perform pre-IND nanomedicine analysis and characterization studies of any of our various
drug candidates in house. In addition, we believe we now have the ability to scale up production of any of our drug candidates,
and implement state of the art in-process controls as well as post-process analysis controls in order to establish robust c-GMP-capable
production methodologies. We also have a Biological Safety Level 2 (BSL2) certified virological cell culture lab at this campus.
We are able to perform initial cell culture based screening of large numbers of drug candidates for effectiveness and safety against
certain of the viruses that we have targeted for drug development. This capability boosts our drug development capabilities significantly.
Other than this limited initial screening, all of the biological testing and characterization of our drug candidates continues
to be performed by external academic or institutional collaborators and contract research organizations (CRO). In particular, all
of the animal studies are performed by our collaborators and CROs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Product Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have focused our efforts almost exclusively
on the HerpeCide&trade; program, given our budgets and current financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have at least eight different
drug development programs, attesting to the strength of our platform technology. Of these, 4 of the indications are under the HerpeCide&trade;
program. We are currently working on 3 of these indications (VZV, HSV-1 and HSV-2) in parallel, as explained below (priority level
1). The v-ARN program is at a lower priority level. In addition, we continue to work on the FluCide&trade; program at the lower
priority 3. HIVCide&trade; program is at priority level 4. We will continue to seek funding for further development in the remaining
programs, namely Dengue and Ebola/Marburg antivirals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential broad-spectrum nature of
our anti-HSV drug candidates is enabling several anti-Herpes indications under our HerpeCide&trade; program. Of these, our (i)
Topical Treatment for Shingles (VZV) is currently moving most rapidly towards clinical stage. We believe that the other anti-Herpes
drug candidates, would follow this lead drug to the clinical stage, namely, (ii) skin cream for the treatment of orolabial herpes
(&ldquo;cold sores&rdquo;) and recurrent herpes labialis (RHL) mostly caused by HSV-1, and (iii) skin cream for the treatment of
genital herpes caused by HSV-2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a fourth indication, (iv)
ocular eye drops treatment for external eye herpes keratitis (HK), caused by HSV-1 or HSV-2, is expected to follow with the same
API or a close variant thereof into further drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, we have announced that we have
begun preclinical drug development work on a fifth indication under the HerpeCide program, namely (v) viral Acute Retinal Necrosis
(v-ARN), intravitreal injection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reports that it is close to
identifying a clinical candidate for VZV shingles skin cream topical treatment. We are currently scaling up the production of our
lead candidates to make sufficient amounts for IND-enabling toxicology studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has announced that it has expanded
its <I>in vivo</I> testing agreement with the University of Wisconsin to encompass testing its topical anti-herpes agents in animal
models of HSV-induced dermal, ocular and genital herpes virus infections, in March 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company announced on December 6, 2017,
that it has begun an initial safety and toxicology evaluation of its optimized nanoviricides&reg; drug candidates developed against
varicella-zoster virus (VZV), the shingles virus. This preliminary safety/toxicology study in the rat animal model is an important
step in the drug development pathway for a treatment for shingles, a debilitating infection of human skin by VZV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A preliminary non-GLP safety and toxicology
study in rats was performed at AR Biosystems, Beverly, MA to provide information for designing the IND enabling non-GLP and GLP
safety/toxicology (&ldquo;Tox Package) studies. That study was designed to (i) evaluate the direct effects of topical delivery
of the drug candidates on the skin, (ii) assess if the drugs attain detectable levels in the blood, and also (iii) evaluate whether
there are any effects on the blood and primary organs, in uninfected animals. The results of this study will provide the basis
and focus for the IND-enabling GLP safety and toxicology studies that are required for the IND submission to the U.S. FDA. As a
result of the success of its drug lead optimization process, the Company selected two clinical development candidates for further
evaluation in this initial safety/toxicology study. The animal experiment portion of this study has been completed as of the end
of January 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No clinically observable adverse safety
and toxicology effects were seen in this study of the Company&rsquo;s optimized topical dermal drug candidates. There were no adverse
effects on the skin at the treatment sites. Equally importantly, the results of the non-GLP safety and toxicology study showed
that there were no overall observable systemic effects either. There were no observable direct effects on the primary organ function
whether the drug was administered to the skin or administered systemically. This includes liver and kidney function. This is important
as the liver and kidneys are major organs involved in drug toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These results are consistent with the positive
findings in a model of VZV (the shingles virus) infection of human skin in which no safety or toxicology concerns have been observed,
further demonstrating the safety of these drug candidates. The drug candidates have shown strong effectiveness in these shingles
virus studies as well, as previously reported. Further, these candidates have demonstrated strong anti-viral activities against
HSV-1, HSV-2, and VZV in cell culture studies using multiple cell lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dermal topical treatment of rats with formulated
drug candidates was evaluated in this study as a primary objective, since skin is the primary breakout site of HSV-1, HSV-2, and
VZV infections. Additionally, the same drug candidates as formulated for systemic delivery were employed to evaluate potential
systemic safety/toxicological effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The success of our drug candidates in this
preliminary rat safety/toxicology study has cleared the path for taking these candidates into formal GLP safety/toxicology studies
that are required for filing an IND. We believe that, additionally, the results of this preliminary rat safety/toxicology study
also give us confidence that the dermal topical treatments we are developing for the treatment of HSV-1 cold sores, and HSV-2 genital
ulcers also should also exhibit similar strong safety characteristics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s drug candidates in
HerpeCide&trade; program are being developed for direct topical application on the affected areas to control the infections. Direct
topical application enables delivery of the highest possible concentrations of the active substance directly at the site of infection.
This allows for maximal clinical effectiveness, while at the same time minimizing side effects that are seen with systemic therapy
(such as oral drugs or injectables).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have already begun to scale up production
of these tested candidates to the larger amounts as estimated to be required for the ensuing IND-enabling Toxicology (&ldquo;Tox
Package&rdquo;) studies. We have estimated the amount of the candidate that will be needed to be supplied for such a study, based
on discussions with BASi, Inc., IN, the service provider, and Biologics Consulting Group, VA, our regulatory consultants. We have
increased the scale of production to meet this required quantity and have the ability to produce kilogram quantities of materials.
We are also working on detailed optimization of the manufacture and characterization of the materials at different synthetic steps
as will be needed for the Chemistry, Manufacture, and Controls (CMC) section of an IND application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market size for anti-shingles drugs
is currently estimated to be in the range of several billions of dollars, even after a new shingles vaccine, Shingrix&reg; (GlaxoSmithKline)
has become available, based on a recent report by Dr. Myers of BioEnsemble, LLC, pharma industry consultants, commissioned by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More specifically, the report estimated
that our anti-shingles drug could reach peak annual sales of as much as $2 Billion, depending upon the effectiveness determined
in clinical trials, at an assumed 50% market penetration, if it is effective in reducing incidence of post-herpetic neuralgia (PHN).
Based on current pre-clinical data, we believe that there is a very strong probability that our shingles treatment would significantly
minimize the shingles pain, accelerate healing, and minimize nerve damage, thereby minimizing the occurrence and severity of post-herpetic
neuralgia (PHN). Our pre-clinical drug design efforts have been aimed at developing a treatment for shingles that would have pain
reduction effects as well as healing effects on skin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initially, we plan on performing clinical
trials based on VZV related biomarkers and clinical pathology, which we believe would be sufficient for a first indication for
approval of the drug for treatment of shingles by the US FDA. Sales of an effective drug against shingles with this limited indication
are projected to reach several hundreds of millions of dollars. We plan on performing observations regarding PHN in these clinical
trials so that an informed PHN clinical trial may be performed later to extend the drug indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have developed strong chemical manufacturing
process controls that enable us to produce the backbone polymers with highly restricted and reproducible molecular size range.
In fact, we have achieved highly reproducible and scalable processes that have yielded the same polymer molecular sizes across
production scales from 10g to 500g. In other words, we are now able to control the length of the backbone polymer to within one
monomer unit, irrespective of production scale (at least up to about 1 kg scale).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that this is a remarkable and
possibly unmatched achievement in the field of nanomedicines. We have scaled up the production of the polymer backbone &ldquo;nanomicelle&rdquo;
to kilogram scales, and do not anticipate any manufacturing constraints at present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the synthesis of small chemicals,
such as the ligands we use to direct the nanoviricide against a specific type of virus, is substantially easier to scale up than
the synthesis of polymers. We have been able to scale up production of the two different ligands under potential clinical development
consideration for VZV shingles treatment already. We anticipate being able to scale up to approximately 500g levels or more, as
necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of chemically covalently connecting
the ligands to the polymer backbone, to produce the nanoviricides, is now being optimized for scalability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our polymer backbone itself is designed
based on the route of application. In the case of the shingles drug candidate, as well as for HSV-1 cold sores, and for HSV-2 genital
ulcers, the route is dermal topical application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are now working on final formulation
of the &ldquo;drug product&rdquo; as well. After synthesizing the active chemical component, additional substances called &ldquo;excipients&rdquo;
are added to it to provide specific desired characteristics. The resulting substance is called the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thus we are on course to be able to manufacture
the required quantities of materials for the Tox Package studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to VZV, we are also developing
dermal topical drugs against HSV-1 cold sores and HSV-2 genital ulcers. Dr. Brandt&rsquo;s Lab at CORL, the University of Wisconsin,
Madison, WI, is validating animal models for the study and evaluation of relative efficacies of different treatments for HSV-1
infection in mice as well as for HSV-2 infection in mice. If their animal models are successful in differentiating effectiveness
of different drug candidates, then we will be able to evaluate our drug candidates for the treatment of HSV-1 cold sores as well
as for the treatment of HSV-2 genital ulcers, in addition to the VZV testing being performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ligands currently in use for the nanoviricide
drug candidates against VZV shingles were actually developed using computer models of HSV binding to its cellular receptor, and
not against VZV itself. Our program shifted to advance a VZV candidate as our first indication due to various considerations that
led to the prioritization of the different drug indications. The Company identified certain advantages that would enable earlier
entry into clinical trials for the shingles candidates. The Company is currently negotiating for a license for VZV, Shingles Virus,
from the Company&rsquo;s licensor, TheraCour Pharma, Inc. (&ldquo;TheraCour&rdquo;). The shingles drug development program has
been moving rapidly primarily because of the quick turnaround time and high responsiveness of the Dr. Moffat Lab at SUNY Syracuse,
our critical collaborator for human skin effectiveness studies of our drug candidates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One of the advantages of the shingles program
is that the pre-clinical drug development is performed directly in a human skin model, bypassing any animal model, providing significant
confidence that a human clinical studies outcome would parallel the preclinical study outcome. VZV does not infect animals other
than humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently scheduling the time-slots
for the IND-enabling non-GLP and GLP Safety/Toxicology (&ldquo;Tox Package&rdquo;) studies with BASi, IN, our CRO for this task.
Thus, we have made significant and substantial progress in the reporting quarter towards the goal of filing our first IND application,
and we continue to build on this progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NanoViricides, Inc. reported in July 2017,
that its anti-shingles nanoviricides&reg; drug candidates achieved dramatic reduction in infection of human skin by the varicella-zoster
virus (VZV), the shingles virus. These findings corroborate the previously reported findings of inhibition of VZV infection of
human cells in culture. VZV is restricted to human tissue and only infects and replicates in human tissue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over the time course of VZV infection,
the nanoviricides&reg; drug candidates showed marked inhibition of VZV infection, replication and spread in human skin cultured
<I>ex vivo</I>. The data suggest that select nanoviricides&reg; drug candidates may have direct virucidal activity based on their
antiviral effects within the first 24 hours after viral infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The antiviral effect of certain nanoviricide
drug candidates was substantially greater than the effect of the standard positive control of cidofovir added into media. Even
more remarkably, the effect of these nanoviricides drug candidates was equivalent to a topical formulation of 1% cidofovir applied
directly onto the skin patch. A topical skin cream containing 2% cidofovir is clinically used in very severe cases of shingles.
However, the cytotoxicity of cidofovir is known to cause ulceration of the skin to which it is applied, followed by natural wound
healing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Histopathology
studies have demonstrated a lack of VZV-associated lesions in nanoviricide-treated skin patches. This work was presented as a
poster presentation by the Moffat group at the 31st International Conference on Antiviral Research held June 11 - June 15, 2018
in Porto, Portugal, </FONT>(<U>https://www.isar-icar.com/page/31icar</U>)<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since VZV causes skin lesions as a result
of direct attack of the re-awakened virus released from nerve endings onto the human skin cells, this ex vivo human skin patch
model involving VZV infection of cultured human skin <I>ex vivo</I> is considered to be a close representation of natural course
of shingles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has previously reported that
these same nanoviricides&reg; compounds displayed potent inhibition of VZV infection of a human retinal epithelial pigment cell
line in an <I>in vitro</I> cell culture virus infection model with no evidence of toxicity to the cells. These <I>ex vivo</I> and
<I>in vitro</I> studies are a critical step in the selection of final clinical drug development candidates for safety and toxicology
studies with the goal of an IND submission to the FDA for the topical treatment of shingles in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These human skin studies were performed
in the laboratory of Dr. Jennifer Moffat at SUNY Upstate Medical University in Syracuse, NY. The Company previously reported the
collaboration with Dr. Moffat, an internationally recognized expert on varicella-zoster virus. She has extensive experience in
varicella-zoster virus (VZV) infection, pathogenesis, and anti-viral agent discovery. The National Institutes of Health has a contract
with Dr. Moffat&rsquo;s lab for evaluating anti-viral compounds against VZV, although the Company chose to set up a direct collaboration
with Dr. Moffat rather than going through the NIH program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Vivien Boniuk, then Consultant in Ophthalmology
at the Company, presented the successful results of certain anti-herpes nanoviricide treatments for v-ARN at the 2017 Annual meeting
of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology held in New Orleans, LA, on November
10, 2017. In this study, HSV-2 infection was given to mice as a single injection to cause v-ARN. The mice that received either
of two nanoviricides drug candidates simultaneously with the virus in this single injection, showed significant improvements using
a number of parameters. In contrast, mice that received foscarnet injection simultaneously with the virus did not show any improvements.
Of note, foscarnet is a current standard of treatment, although the treatment is long in duration and arduous, being multiple intravitreal
injections. In addition, another group of HSV-2 infected animals received acyclovir by intraperitoneal injection (50mg/kg), twice
daily for 7 days, as a positive control. Acyclovir and its derivatives are also used currently for treating v-ARN, although the
clinical efficacy is limited and generally requires long durations of treatment. Vehicle treated and untreated negative controls
also were employed. These studies were performed in the lab of Dr. Curtis Brandt at CORL, University of Wisconsin, Madison, WI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both nanoviricides tested showed remarkable
efficacy using multiple parameters. In particular, nanoviricide-A treated group showed viral load going down to undetectable levels
by day 7 itself (approximately 4 logs viral load reduction from baseline), whereas acyclovir group showed no reduction in viral
load from baseline at day 7, but approximately 2 logs reduction at day 9, indicating a much lower efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both nanoviricides A and B resulted in
100% maintenance of body mass by day 9, indicating complete control of infection. However, the acyclovir group showed a loss of
at least 10% body mass, close to the nearly 15% loss in the negative controls, indicating that it was either much less effective
than the nanoviricides A and B or was somewhat toxic to the animals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The mean disease score for the vitreous
infiltrate (fluid inside the eye) was zero (best) for 9 days with nanoviricide A treatment, and was about 0.5 for acyclovir treated
group, whereas it was about 4 (worst) in untreated and vehicle groups, indicating that nanoviricide A was more effective than the
acyclovir treatment in this model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In both nanoviricide A and nanoviricide
B groups, the retina was protected fully from viral damage, which is very significant. In contrast, the acyclovir treated group
showed retinal damage approximately similar to the vehicle treated group, in spite of reduced viral load in the acyclovir group,
indicating that acyclovir may have been toxic. These results were also confirmed by histological staining of retinal sections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Taken together, both nanoviricide A and
nanoviricide B had substantial effectiveness in protecting the retina, in spite of the high infectious dose of HSV-2 employed in
this model. Significantly, they were both substantially more effective than foscarnet (single injection) or acyclovir (bid 7days)
in this particular study. If these results are reproducible, then the Company would be able to identify a clinical candidate for
v-ARN as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of note, both nanoviricides tested against
v-ARN are closely chemically related to those that have shown significant efficacy against varicella zoster virus (VZV) in the
human skin patch model in Professor Moffat&rsquo;s lab at the Upstate Medical Center, SUNY, Syracuse, NY. We have previously shown
that closely chemically related nanoviricides were also effective against HSV-1 in animal models as well as in cell culture models.
This is important because about 50% of v-ARN cases are caused by VZV, about 40+% caused by HSV-2, with HSV-1 and CMV accounting
for a small percentage of cases. VZV does not infect mice, and therefore the HSV-2 v-ARN model should be indicative model for our
drug development. Thus the broad-spectrum activity of our nanoviricides against multiple different herpesvirus types has been instrumental
in rapid expansion of our HerpeCide program.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional successful studies on v-ARN
are expected to add a fifth indication to the Company&rsquo;s growing portfolio of anti-herpes drug indications, further expanding
the potential market. The Company intends to maximize shareholder value from its broad-spectrum anti-herpes nanoviricides asset
by aggressively expanding its portfolio of herpesvirus indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">v-ARN is a disease of the retina of the
eye caused by various herpes viruses that leads to severe loss of vision and blindness. The infecting agent in this study was herpes
simplex virus-2 (HSV-2), the type of herpes virus that also causes genital herpes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acute Retinal Necrosis is characterized
by severe ocular inflammation, retinal necrosis, and a high incidence of retinal detachment (RD) leading to visual loss and blindness.
This disease is caused by members of the herpesvirus family, including, herpes simplex virus-2 (HSV-2), varicella zoster virus
(VZV), and herpes simplex virus (HSV-1). An estimated 50,000 new and recurrent cases of ocular herpes per year are reported in
the United States alone, and in a small proportion of the patients, the disease escalates to v-ARN. We anticipate that ocular herpes
or v-ARN may qualify for an orphan disease indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current development has focused on
API suitable for formulating into a skin ointment for the treatment of VZV shingles, HSV-1 cold sores, or HSV-2 genital ulcers.
As these drug candidates advance further, we plan on performing fully integrated drug development for developing eye drops for
treatment of external eye infections such as herpes keratitis (a disease of the external eye). Thereafter we plan on undertaking
the development of suitable materials for intravitreous or sub-retinal injections for the treatment of certain viral diseases involving
the retina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have recently reported that we have
extended the contracts with both the Moffat Lab, UMC, SUNY Syracuse, as well as the Brandt Lab, CORL, UW, Madison to continue to
perform more advanced studies in preparation of an IND for shingles topical treatment and for v-ARN intravitreal treatment, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have continued work on
our other drug candidates albeit at a very low priority. These include (vi) Injectable FluCide&trade; for hospitalized patients
with severe influenza, (vii) Oral FluCide&trade; for out-patients, (viii) DengueCide&trade;, a broad spectrum nanoviricide designed
to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic
Fever (DHS) and Dengue Shock Syndrome (DSS), and (ix) HIVCide&trade; for HIV/AIDS. In addition, the Company has research programs,
enabled by the robust nanoviricides platform technology, to develop drugs against Rabies virus, Ebola and Marburg viruses, and
other viruses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, the Company does not have any
commercialized products. The Company continues to add to its existing portfolio of products through our internal discovery and
clinical development programs and also seeks to do so through an in-licensing strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received an &ldquo;Orphan Drug
Designation&rdquo; for our DengueCide&trade; drug from the USFDA as well as the European Medicines Agency (EMA). This orphan drug
designation carries significant economic benefits for the Company, upon approval of a drug.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we have demonstrated that we
can rapidly develop different types of formulations for different routes of administration, such as injectable, skin cream, lotion,
gel, and even oral, because of the inherent strength of the nanoviricide platform tailorable technology. The technology also enables
us to develop nasal sprays and bronchial aerosols. We plan to develop the appropriate formulations as necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our drug programs are established
to target what we believe are unmet medical needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Herpes simplex viral infections cause keratitis
of the eye, and severe cases of infection may sometimes necessitate corneal transplants. Oral and genital herpes is also a well-known
disease, with no cure and existing treatments that are not very effective. Shingles, caused by VZV, a herpesvirus, does not have
an effective treatment at present, although some drugs are approved for use in shingles. Adenoviral Epidemic Kerato-Conjunctivitis
(EKC) is a severe pink eye disease that may lead to blurry vision in certain patients after recovery. The epidemic and pandemic
potential as well as the constantly changing nature of influenza viruses is well known. The HIV/AIDS worldwide epidemic and the
 &ldquo;curse of slow death&rdquo; nature of HIV viral infection are also well known. Dengue viral infection is also known as &ldquo;breakbone
fever&rdquo;. What is worse, is that when a patient is infected with a dengue virus a second time, if the virus is a different
serotype, then it can cause a severe dengue disease, or dengue hemorrhagic syndrome, with very high morbidity and a high rate of
fatality. This is because, the patient&rsquo;s immune system mounts an attack, but the antibodies that it generates, directed at
the previous infecting virus, are not effective against the new infection, and instead the new infecting virus uses them to hitch
a ride into host cells that it infects more severely. This phenomenon is called &ldquo;Antibody-Dependent Enhancement&rdquo; or
 &ldquo;ADE&rdquo; for short.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States alone, approximately
1 million cases of shingles (i.e. zoster) occur annually. The risk of zoster increases with age, and with decreased immune system
function, such as occurs in diabetics. Zoster is characterized by pain and rash. Discrete cutaneous lesions occur in groups on
the skin. The Company believes that this presentation enables topical therapy for control of the viral outbreak.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One in four patients develop zoster-related
pain that lasts more than 30 days. If it persists more than 3 months, it is called post-herpetic neuralgia (PHN), and may persist
for years. It is thought that zoster-associated pain and PHN is a result of chronic ganglionitis, i.e. continued low-grade production
of the virus in the infected ganglia and related immune response. The Company believes that effective control of the virus production
would minimize or eliminate PHN, a debilitating morbidity of zoster.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Zoster occurs mostly in the abdominal region.
However, in 20% of cases, it occurs in the head area, with reactivation involving trigeminal distribution. These cases of zoster
can lead to serious complications including hemorrhagic stroke (VZV vasculopathy), VZV encephalitis, ophthalmic complications,
and may result in fatalities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently available anti-herpes drugs have
had limited impact on zoster. Thus, an effective drug with a good safety profile could have a dramatic impact on zoster as well
as possibly PHN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">External eye infections with HSV-1 have
been reported to be the leading cause of infectious blindness in the developed world, with recurrent episodes of viral reactivation
leading to progressive scarring and opacity of the cornea. HSV epithelial keratitis afflicts the epithelium of the cornea. In some
cases, the disease progresses to HSV stromal keratitis, which is a serious condition. HSV stromal keratitis involves the stroma,
the layer of tissue in the cornea, which is deeper in the eye than the epithelium. Its pathology disease involves the HSV infection
of stromal cells, and also involves the inflammatory response to this infection. It can lead to permanent scarring of the cornea
resulting in diminished vision. More serious cases require corneal replacement surgery. About 75% of corneal replacements are known
to fail in a 20-year time frame, due to graft versus host disease (i.e. rejection of the foreign implant by the body), requiring
a new procedure, or resulting in blindness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Herpes keratitis incidence rates in the
USA alone are reported to be in the range of 65,000 to 150,000 patients per year. Of these approximately 10,000 per year may be
estimated as requiring corneal transplants. The estimates of incidence rates vary widely based on source, and are also assumed
to be underreported. A corneal transplant costs approximately $15,000 to $25,000 for the surgery, with additional costs for follow
on drugs and treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This scenario exists in spite of available
drugs, namely the acyclovir class of drugs, trifluridine, and others, that are used for treatment of herpes keratitis. The failure
of these drugs is primarily due to limited safety resulting in insufficient drug availability at the site of infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company is developing
broad-spectrum eye drop formulations that are expected to be effective against a majority of the viral infections of the external
eye. Most of these viral infections are from adenoviruses or from herpesviruses. The Company has shown excellent efficacy of its
drug candidates against EKC (adenoviral epidemic kerato-conjunctivitis) in an animal model. Further, our anti-HSV drug candidates
have shown excellent efficacy in cell culture studies, as well as in a lethal skin infection animal model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thus, an effective drug with a good safety
profile could have a dramatic impact on ocular viral infections. Merit-based compensation for the herpes keratitis treatment would
enable strong financial incentive and could result in potential revenues in the several hundreds of millions range, depending upon
the effectiveness of the drug. The Company believes that it has sufficient production capacity at its current site to supply the
US requirement of the drug for treatment of (ocular) herpes keratitis upon drug licensure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Topical treatment of herpesvirus infections
is important because of the disfiguring nature of herpesvirus breakouts, the associated local pain, and the fact that the virus
grows in these breakouts to expand its domain within the human host further. Topical treatment can deliver much higher local levels
of drugs than a systemic treatment can, and thus can be more effective and safer at the same time. Systemic drug treatment results
in side effects because of the high systemic drug concentrations that need to be achieved and the large drug quantities that must
be administered. Since the virus remains mostly localized in the area of the rash and connected nerve apparatus, using high concentrations
of drugs delivered in small quantities topically would allow maximizing the effectiveness while minimizing the side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Herpesviruses become latent in neuronal
cells or in ganglia, and cause periodic localized breakouts that appear as skin rashes and lesions. Systemic drug treatment results
in side effects because of the high systemic drug concentrations that need to be achieved and the large drug quantities that must
be administered. Since the virus remains mostly localized in the area of the rash and connected nerve apparatus, using high concentrations
of drugs delivered in small quantities topically would allow maximizing the effectiveness while minimizing the side effects, leading
to minimizing viral production at the site. Such effective local control of the virus titer is expected to lead to reduction in
recurrence of herpesvirus &ldquo;cold sores&rdquo; or genital ulcers, and reduction in shingles related PHN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential broad-spectrum nature of
our anti-HSV drug candidates is expected to enable several antiviral indications. Thus, HSV-1 primarily affects skin and mucous
membranes causing &ldquo;cold sores&rdquo;. HSV-2 primarily affects skin and mucous membranes leading to genital herpes. HSV-1
infection of the eye causes herpes keratitis that can lead to blindness in some cases. In addition, human herpesvirus-3 (HHV-3),
a.k.a. varicella-zoster virus (VZV), causes chickenpox in children and when reactivated in adults, causes shingles. Shingles breakouts
are amenable to topical treatment, as are the HSV cold sores, genital lesions, and herpes keratitis of the eye. Most of these indications
do not have satisfactory treatments at present, if any. Further, the treatment of herpesvirus infections caused by acyclovir- and
famciclovir- resistant mutants is currently an unmet medical need. Drugs with mechanisms of action other than DNA-polymerase inhibitors
(such as acyclovir) are needed for effective treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The childhood chickenpox vaccine has reduced
the cases of chickenpox, but this is a live attenuated virus vaccine that persists in the body. All adults who have had chickenpox
in childhood continue to harbor the chickenpox virus, and are expected to develop shingles at some time, with the risk of shingles
increasing with age or weakening of the immune system surveillance. In addition to the shingles breakout itself, post-herpetic
neuralgia (pain) (PHN) is a significant morbidity of shingles, and to a lesser extent, of oral and genital herpes. PHN is initially
caused probably by the inflammation and immune response related to the local virus expansion, but persists well after the virus
has subsided, the blisters have scabbed off, and the skin has recovered, due to the nerve damage that results from the local large
viral load during infection. Current PHN treatments are symptomatic, affecting the pain signaling circuit (such as novocaine, pramoxine,
capsaicin, etc.), and do not produce lasting control. An effective therapy that results in strong local control of the virus production
during the breakout itself is expected to minimize the resulting immune responses and nerve damage, and thereby minimize or possibly
eliminate PHN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company thus believes that it can develop
its broad-spectrum anti-herpes drug candidate towards at least five topical indications, namely, (a) shingles, (b) oral herpes
(&ldquo;cold sores&rdquo;), (c) genital herpes, (d) herpes keratitis (external eye infection), and (e) ocular herpes including
v-ARN (internal eye infection). As the HerpeCide&trade; program progresses, it is likely that additional herpesvirus related pathologies
may become amenable to treatment with our herpesvirus drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our nanoviricides in the HerpeCide&trade;
program at present are designed as topical treatment for the breakout of shingles or herpes sores. Our animal studies results are
very significant considering that topical acyclovir in the form of a cream as well as an ointment, are approved for the treatment
of cold sores. We believe our strong anti-herpes nanoviricide&reg; drug candidates are capable of reaching approval as a drug for
topical use against herpes cold sores, based on these datasets. Further drug development is necessary towards the goal of drug
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, valacyclovir (Valtrex&reg;)
is approved as an oral drug for the treatment of severe shingles, but it has limited effectiveness. Another oral drug known as
 &ldquo;FV-100&rdquo; was studied in clinical trials for the treatment of shingles by Bristol-Myers Squibb, and later by Contravir.
FV-100 works only against VZV and does not work against other herpesviruses. A Phase 3 study with PHN as end-point was completed
in November 2017. Further development appears to have been stopped for FV-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is also a new preventive vaccine
for shingles, &ldquo;Shingrix&rdquo;. Given the number of cases of severe shingles, we believe that there is an unmet medical need
for developing a topical skin cream for the treatment of shingles, even with a successful introduction of this vaccine. The Shingrix
vaccine has been recently also been shown to produce adverse effects such as painful injection site reactions and pain in a significant
number of patients. Local application of a nanoviricide drug should enable delivery of stronger, local doses of medicine, with
a stronger patient benefit, than oral systemic dosing allows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Existing therapies against HSV include
acyclovir and drugs chemically related to it. These drugs must be taken orally or by injection. Available topical treatments, including
formulations containing acyclovir or chemically related anti-HSV drugs, are not very effective. Currently, there is no cure for
herpes infection. Brincidofovir (CMX001) is being developed by Chimerix. It failed in a Phase 3 clinical trial for hCMV in organ
transplants, and its Phase1/2 clinical trial for HSV in neonates was withdrawn recently. Cidofovir is a known highly effective
but also toxic, broad-spectrum nucleoside analog, drug that was modified with a lipidic chain structure to create brincidofovir.
Pritelivir, by AiCuris, is a DNA Helicase/Primase inhibitor (HSV-1 and HSV-2) that has successfully completed certain Phase 2 clinical
trials, and its indication in immune-compromised patients has received a fast track status from the US FDA. Letermovir (Merck/AiCuris),
a terminase complex inhibitor, is effective only against hCMV and has entered a Phase 3 clinical study in kidney transplant patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both the safety and effectiveness of any
new drug has to be determined experimentally. The safety of a nanoviricide drug is expected to depend upon the safety of the nanomicelle
portion as well as the safety of the antiviral ligand. We have observed excellent safety of our injectable anti-influenza drug
candidates. This leads us to believe that the nanomicelle backbones of these drug candidates that were evaluated in preliminary
safety studies should be safe in most if not all routes of administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current market size for drugs for the
treatment of various herpes infections is well over $4B. Similarly, the current market size for the treatment of influenza infections
is in excess of $4B, and that for HIV treatments is in excess of $40B. The total market sizes for the drug development programs
we have in progress are estimated at around $100B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that when effective topical
treatments against VZV shingles, HSV-1 cold sores and HSV-2 genital ulcers are introduced, their market sizes are likely to expand
substantially, as has been demonstrated in the case of HIV as well as Hepatitis C.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our timelines depend upon several assumptions,
many of which are outside the control of the Company, and thus are subject to delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently focused on topical drug
development against several indications related to infections by herpes family viruses. The Company recognized, after consultations
with its FDA regulatory advisors, namely Biologics Consulting Group (of Alexandria, VA), and several other experts in the field,
that the development of these topical drug candidates towards human clinical trials is likely to be considerably faster than the
development of our anti-influenza systemic (injectable) drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we are now one of the very few
small pharmaceutical drug innovators that possess their own cGMP or cGMP-capable manufacturing facility (see below). With our new
campus and pilot-scale c-GMP-capable manufacturing facility, we are now in a position to advance our drug candidates into clinical
trials, produce the pre-clinical &ldquo;tox package&rdquo; batches, and the clinical drug substance batches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Management Discussion - Current Drug
Development Strategy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the reported quarter we have continued
to focus our drug development work plans primarily on our lead anti-shingles and anti-Herpes-virus programs. In particular, we
have focused on a work plan towards clinical development candidate for the topical skin ointment for the treatment of shingles
outbreak. Because of the broad-spectrum nature of our anti-herpes drug candidates, we have also simultaneously continued further
development of our drug candidates for four additional indications in the HerpeCide&trade; project, namely, cold sores, genital
ulcers, external ocular viral infections, and viral acute retinal necrosis. We have also continued to work on our anti-influenza
drug development programs under the FluCide&trade; project at a slow pace. The FluCide program is expected to be quite expensive
for development, based on our pre-IND discussions with the US FDA. We have therefore prioritized our resources with the goal of
filing our first IND in the shortest possible timeframe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The anti-VZV drug development program has
moved rapidly towards clinical candidate declaration stage because of several factors, namely (a) that it was simply the existing
HSV-1 drug program in which the existing candidates were re-tested for effectiveness against VZV, (b) that we have had a highly
successful collaboration with Dr. Moffat Lab at SUNY Syracuse with rapid turnaround times, and (c) the drug candidates were found
to be highly effective against VZV in these studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NanoViricides currently has existing licenses
from TheraCour Pharma, Inc., (TheraCour), our development partner and where the intellectual property has originated, for HSV-1
and HSV-2, but not for the remaining herpesviruses. NanoViricides has disclosed our intention to obtain licenses for VZV as well
as other remaining unlicensed herpesvirus indications from TheraCour Pharma. As is the standard process with such agreements, and
the process that we have followed in the past, the Company needs to obtain a valuation of the assets under consideration. We retained
Dr. Carolyn Myers of BioEnsemble LLC, an expert in in-licensing, out-licensing, valuations, and M&amp;A in pharmaceutical industry
to help with the valuations and related matters. Dr. Myers presented her initial report to our Board of Directors on December 9,
2017. Thereafter, we have asked that further modeling and analysis be performed incorporating additional assumptions that reflect
the current situation more closely than in the model that was presented, such as the subsequent approval of Shingrix vaccine in
early 2018. Dr. Myers has recently presented us with a revised valuation report on the VZV as of October 2018. Additional consultations
with Dr. Myers on various aspects of the licenses sought are ongoing. We anticipate license agreements will be drafted and the
terms and conditions will be negotiated soon. TheraCour has in the past not denied any licenses for any virus programs that we
initiated. We have retained counsel to prepare and negotiate the new license agreement on our behalf. The Company intends to complete
these new license negotiations soon. Due to the departure of our former Chief Executive Officer, we were unable to negotiate such
terms until the vacancy was just recently filled by Dr. Taraporewala. If we cannot come to an agreement with TheraCour for the
shingles license, we will continue and accelerate our work on the HSV-1 (cold sores) and HSV-2 (genital ulcers) indications, which
we believe will be using essentially the same or closely related dermal topical drug candidates as in development under the VZV
banner at present in the HerpeCide&trade; program. The Company already has licenses for these indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has continued the development
of anti-HSV-1 and anti-HSV-2 drug candidates, and has tested the same against VZV in cell cultures, in addition to against HSV-1
and HSV-2. Since the candidates showed preliminary efficacy against VZV as well, the Company added shingles as an additional indication
to pursue under the HerpeCide&trade; program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our earlier animal studies for efficacy
testing of HSV-1 drug candidates in a mouse dermal model of the infection were performed by Professor Ken Rosenthal&rsquo;s Lab
at NEOUCOM/NEOMED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged Dr. Brandt&rsquo;s Lab
at CORL, University of Wisconsin, Madison, WI, to further develop their animal models of dermal HSV-1 and HSV-2 infections in mice
and to make them suitable for screening of drugs for relative efficacy. They are working on validating their HSV-1 mouse model
for discriminative efficacy of different existing drugs. Once they can establish that the model distinguishes different effective
drugs, we will be able to use the model for testing our HerpeCide drug candidates against HSV-1, and optimizing the same only if
necessary. Following HSV-1 model development, we have commissioned Dr. Brandt&rsquo;s Lab to perform similar studies for their
HSV-2 genital infection mouse model as well. Dr. Brandt&rsquo;s Lab developed the mouse model of viral Acute Retinal Necrosis (v-ARN)
caused by HSV-1 that we have tested some of our drug candidates in as reported elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent developments and our discussions
with our regulatory advisors and consultants indicate that the shingles drug candidate may be likely to reach the human clinical
evaluation phase earliest compared to the other drug candidates. Other drug candidates in the HerpeCide project are expected to
follow into clinical stage rapidly thereafter. This is primarily because of the topical treatment nature of the drug candidates
we have chosen to develop in these indications. The FluCide drug candidates are now expected to enter human clinical stage later
than the HerpeCide drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Animal model studies of lethal herpesvirus
infection using the highly pathogenic and neurotropic HSV-1 H129 strain in two different sites resulted in 85% to 100% survival
in animals treated with certain anti-HSV nanoviricide drug candidates, while control animals uniformly died. We reported on these
studies in April 2015, from Professor Emeritus Ken Rosenthal&rsquo;s lab at NEOMED, and in August 2015, from TransPharm Preclinical
Solutions, LLC, Jackson, MI (TransPharm), a CRO. Previously, we have improved the anti-HSV drug candidates in cell culture studies
and were able to achieve significant effectiveness before engaging into animal studies.&nbsp;We re-designed the anti-HSV drug candidates
so that the solutions would not run off the skin when applied. With this redesign, our drug candidates demonstrated complete survival
of HSV-1 H129 lethally infected animals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company thus has achieved animal studies
efficacy proof of concept for HSV-1 skin topical treatment. The Company believes that the broad-spectrum nature of these drug candidates
should allow effectiveness against related herpesvirus types such as HSV-2 as well as the more distantly related HHV-3 aka VZV
or chickenpox/shingles virus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has established additional
collaborations towards IND-enabling development of drug candidates against the four indications listed earlier. We now have collaboration
agreements with the CORL at the University of Wisconsin, the Campbell Lab at the University of Pittsburgh, and, the Moffat Lab
at SUNY Upstate Medical Center, for the evaluation of our nanoviricides&reg; drug candidates in models of ocular herpesvirus and
adenovirus infections as well as VZV infections in <I>in vitro </I>and <I>ex vivo</I> models. The Company also now has the ability
to perform initial screening of our drug candidates in our BSL2 certified Virology Lab in Shelton, CT, against several viruses
that include various strains and subtypes of HSV-1, HSV-2, VZV, and Influenza.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has previously reported the
successes of its nanoviricides drug candidates in pre-clinical studies of dermal herpes virus infections in mouse models. The studies
in Dr. Brandt&rsquo;s laboratory, namely CORL, at the University of Wisconsin will be critical in optimizing our anti-herpes drug
candidates against ocular herpes virus infections. The goal of these studies will be to identify a drug development candidate as
a treatment for ocular keratitis in humans caused by herpes simplex virus infections.&nbsp;We anticipate undertaking these studies
as we are testing our HerpeCide drug candidates developed as skin ointment/cream against all three of dermal HSV-1, genital HSV-2,
and VZV models. The treatment of ocular keratitis requires an eye drops formulation. We have tested certain of our polymer backbones
in eye drop formulation application successfully previously. However, we are at present constrained by resource availability and
the workload of moving our first drug candidate into IND stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has continued to test several
drug candidates with different formulation consistencies in multiple studies in order to select a clinical development candidate
for the topical treatment of shingles. Following identification of the clinical development candidate, the Company will engage
into scaled up production of said drug candidate at our Scale-Up Lab at our Shelton, CT campus. The Scale-up Lab has been in operation
since June 2015, and we have scaled most production operations to 200g scale previously, and some steps to kilogram level scales
recently; levels sufficient to provide clinical trial material supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has initiated manufacture of
our shingles drug candidates as it is scaling up the production processes to meet the quantity requirements for the IND-enabling
safety/toxicology studies. We will also continue to perform additional pre-clinical studies in parallel to the &ldquo;Tox Package&quot;
studies. These studies include formulation optimization studies, dose-response efficacy studies, efficacy studies with different
viral strains, and PK/PD studies (pharmacokinetics and pharmacodynamics studies) in standard animal models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that its anti-herpes
drug candidates for the treatment of cold sores and for genital lesions should lead to effective control of the cold sores rapidly,
and may also lead to a long lag time before a new recurrence episode occurs. This is because it is believed that recurrence rates
increase by virtue of further infection of new nerve endings from the site of the herpesvirus outbreak, which result in additional
nerve cells harboring the virus. If this in situ re-infection is limited, which we believe is the primary mechanism of nanoviricide
drugs, then it is expected that the number of HSV harboring reservoir cells should decrease, and recurrence rate should go down.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that it will be able
to expand its anti-herpes portfolio in the future to include many other herpesviruses such as cytomegalovirus (CMV), HHV-6A, HHV-6B,
KSHV, and Epstein-Barr virus (EBV, cause of mononucleosis). This would lead to a very large number of therapeutic indications beyond
the four or five indications we are currently targeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company thus continues to expand its
portfolio of opportunities, while also making progress towards the clinical trials stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continues to work on its anti-influenza
drug candidates in parallel to its HerpeCide program. We are developing Injectable FluCide&trade; for hospitalized patients with
severe influenza as our first, broad-spectrum anti-influenza drug candidate. We have demonstrated the very first effective orally
available nanomedicine, namely oral FluCide&trade; for outpatients with influenza. The development of Oral FluCide is expected
to follow behind Injectable FluCide. These programs are being conducted at a much lower priority, with the highest priority being
given to the various indications in the HerpeCide programs. Development of an anti-Influenza drug candidate has been estimated
to be an extremely expensive process with a long drug development timeframe. This is because of the large number of virus types
and subtypes that change rapidly within and over seasons. The Company at present does not have the resources to engage into a full-fledged
anti-Influenza drug development program. Additionally, Xofluza&reg;, a new drug with a novel mechanism of action (an endonuclease
inhibitor) was very recently approved in the USA (Roche/Genentech). While it reduced viral load significantly in clinical trials,
it did not have a significant effect on the time course of the clinical pathology of influenza infection in the clinical trials
that led to its approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thus, an effective therapy for patients
hospitalized with severe influenza continues to be an unmet need. In addition, a single injection treatment of non-hospitalized
patients would be a viable drug if it provides superior benefits to existing therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of our limited
resources, we have now assigned lower development priorities to our other drug candidates in our pipeline such as DengueCide&trade;
(a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue
Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS)) and HIVCide&trade; (a potential &ldquo;Functional
Cure&rdquo; for HIV/AIDS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we have demonstrated that we
can rapidly develop different types of formulations for different routes of administration, such as injectable, skin cream, lotion,
gel, and even oral, because of the inherent strength of the nanoviricide platform tailorable technology. The technology also enables
us to develop nasal sprays and bronchial aerosols. We plan to develop the appropriate formulations as necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Campus in Shelton, CT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our campus at Shelton, CT, is now fully operative. With our R&amp;D discovery labs, Analytical Labs, the
Bio labs for virology R&amp;D, the Process Scale-Up production facility, and the cGMP-capable manufacturing facility established
at our new Shelton campus, we are in a strong position than ever to move our drug development programs into the clinic rapidly.
Staff is being trained to achieve full cGMP compliance to support clinical trial manufacture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Process Scale-Up Production Capability
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Process Scale-up area is operational
at scales of about 200g to 1kg per step for different chemical synthesis and processing steps. It comprises reactors and process
vessels on chassis or skids, ranging from 1L to 50L capacities, as needed. Many of the reactors or vessels have been designed by
us for specific tasks related to our unique manufacturing processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>cGMP Production Capability </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our versatile, customizable cGMP-capable
manufacturing facility is designed to support the production of kilogram-scale quantities of any of our nanoviricides drugs. In
addition, it is designed to support the production of the drug in any formulation such as injectable, oral, skin cream, eye drops,
lotions, etc. The production scale is designed so that clinical batches for Phase I, Phase II, and Phase III can be made in this
facility. The clean room suite contains areas suitable for the production of sterile injectable drug formulations, which require
special considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have planned certain minimal infrastructure
modifications to improve the capabilities of the cGMP-compliant facility, based on our experience in the Scale-up operations. Certain
of these improvements are expected to add a separate production suite for the manufacture of skin cream in an area that was designated
for such further expansion. These infrastructure improvements will be undertaken only after appropriate level of funding becomes
available, of which there can be no assurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After these infrastructure improvements,
we plan to produce at least three consecutive batches of a drug product and satisfy that said drug product is within our own defined
specifications. If we are satisfied with such strong reproducibility of our processes, we plan to register the facility as a cGMP
manufacturing facility with the US FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, we plan on moving operations
to our cGMP-capable manufacturing suite as the operational steps are developed to the level needed for moving them into this facility.
This requires the development of draft-level Standard Operating Procedures, training, and drill-through of operations. We will
also need to establish a Quality Assurance and Quality Control Department. As yet we have not hired any dedicated Quality Assurance
and Quality Control personnel due to constraints on our budget. Our current staff is busy developing our pre-clinical HerpeCide
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are able to attract and hire quality
candidates that we severely need, we anticipate that it will take at least six months to one year for each such person to be fully
productive as an integrated part of our team. In the past, we have been very fortunate that newly hired personnel were immediately
productive in tasks delineated to them, and they were productively integrated within a short time frame of several months into
independent but integrated parts of our team. However, this is not always the case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate in a completely novel area of
medicines, which is broadly described as polymeric-micelle based drug conjugates and complex nanomedicines. Our technologies are
also completely novel, and unmatched in the industry. As such, we anticipate a longer training period for new employees than in
normal small chemical or biological drugs. We continue to seek talented scientists and engineers with specialized training. However,
it is difficult to attract such talent for a small, pre- revenue pharma company such as ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We employ the same team that developed
the small-scale synthesis chemistry for translation of those chemical syntheses into clinical-scale processes, and also to perform
the related chemical engineering, quality control, quality assurance, and regulatory tasks along the way. Because of the small
size of our scientific staff, this results in significant serialization of efforts. However, the personnel cost, as well as the
time and expense cost of transfer of knowledge and training of a separate dedicated team is avoided because the same expert scientists
who have developed the chemistries are also involved in scaling them up into process scale. To enable such extensive multi-tasking,
we have a continuous training program in place, with both formal and informal components. We believe that this approach helps us
keep drug development costs as low as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our BSL-2 Certified Virology Lab </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have significantly enhanced our internal
anti-viral cell culture testing capabilities at our Shelton campus. We have achieved BSL-2 (Biological Safety Level 2) certification
from the State of Connecticut for our Virology suite at the new campus. This suite comprises three individual virology workrooms,
enabling us to work on several different viruses and strains at the same time. This facility is designed only for cell culture
studies on viruses, and no animal studies can be conducted at any of our own facilities. We have brought in Brian Friedrich, Ph.D.
as the Company&rsquo;s Virologist. Dr. Friedrich has previously performed drug screening of hundreds of candidates against several
viruses including alphaviruses, bunyaviruses, and filoviruses (namely, Ebola and Marburg, which are BSL-4), to discover potential
therapeutics, while he was at United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Brian has also worked
extensively on Flaviviruses, specifically West Nile Virus, while at University of Texas Medical Branch (UTMB). He has also worked
on HIV as part of his PhD thesis. Dengue viruses as well as the Zika virus belong to the Flavivirus family.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Friedrich has established several different
types of assays for screening of candidates against VZV, HSV-1 and HSV-2 in our lab, and is establishing assays for Influenza viruses
and HIV. We believe that having developed the internal capabilities for cell culture testing of our ligands and nanoviricides against
a variety of viruses has substantially strengthened and accelerated our drug development programs. We believe that this internal
screening enables speedy evaluation of a much larger number of candidates than external collaborations allow. This has significantly
improved our ability of finding highly effective ligands and performing structure-activity-relationship studies of the same in
a short time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Manufacturing Requirements of Some of
Our Drug Candidates </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The HerpeCide program drug product batch
requirements are estimated to be fairly modest because of the topical nature of treatment. In consultation with BASi and BCG, we
have currently estimated a batch size of approximately 1~2&nbsp;kg will be sufficient for the full &ldquo;Tox Package&rdquo; (i.e.
safety and toxicology) studies of our dermal topical shingles drug candidate. We are estimating that a ~500g batch will be more
than sufficient for initial Phase-I human clinical studies as well. Our current estimate for a Phase IIa human clinical efficacy
study is also in the range of a ~500g batch requirement. We already have the facilities for producing up to 1kg per batch or more.
Many of our synthesis steps have already been scaled up to ~1kg scales. Thus we believe that we have sufficient production capability
for the amounts of the HerpeCide drugs that would be needed for tox package as well as clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we move our drug candidates into clinical
studies, we plan to perform further scale-up studies to get to about 1kg per batch production scale. In the current facility, we
may be able to manufacture about 10kg to 20kg of cGMP product annually. Depending upon the drug&rsquo;s potency and indication,
this production size may fetch modest revenues of around $50M to $500M, depending upon the cost metrics, enabling profitable market
entry. Such initial commercialization would allow the Company to turn itself into a stand-alone pharmaceutical company, by enabling
capital formation for larger scale manufacturing facilities and fueling further growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>NanoViricides Business Strategy in
Brief </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NanoViricides, Inc. intends to perform
the regulatory filings and own all the regulatory licenses for the drugs it is currently developing. The Company will develop these
drugs in part via subcontracts to TheraCour Pharma, Inc., the exclusive source for these nanomaterials. The Company plans to market
these drugs either on its own or in conjunction with marketing partners. The Company also plans to actively pursue co-development,
as well as other licensing agreements with other Pharmaceutical companies. Such agreements may entail up-front payments, milestone
payments, royalties, and/or cost sharing, profit sharing and many other instruments that may bring early revenues to the Company.
Such licensing and/or co-development agreements may shape the manufacturing and development options that the company may pursue.
There can be no assurance that the Company will be able to enter into co-development or other licensing agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has kept its capital expenditures
to a minimum in the past, and we intend to continue to do the same, in order to conserve our cash for drug development purposes,
and in order to minimize additional capital requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Collaborations, Agreements and Contracts</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our strategy is to minimize capital expenditure.
We therefore rely on third party collaborations for the testing of our drug candidates. We continue to engage with our previous
collaborators. We also seek to engage with additional collaborators, as necessitated for the progress of our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have signed a collaboration agreement
with the Professor Moffat Lab at SUNY Upstate Medical Center, Syracuse, NY, for evaluating safety and effectiveness studies of
our drug candidates in cell culture and in animal models for shingles VZV infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have signed a collaboration agreement
with the CORL at the University of Wisconsin, Madison, WI, for HSV-1 and HSV-2, with focus on small animal models for ocular disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged Biologics Consulting Group,
Inc., to help us with the US FDA regulatory submissions. We are also engaged with Australian Biologics Pty, Ltd to help us with
clinical trials and regulatory approvals in Australia. We believe that cGMP-like manufactured product is acceptable for entering
human clinical trials in Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate completing master services
agreements, after performing our due diligence, with additional parties in furtherance of our anti-viral drug development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have continued to achieve significant
milestones in our drug development activities. All of our drug development programs are presently at pre-clinical or advanced pre-clinical
stage. We believe we are advancing these programs at a faster pace than industry peers. We continue to test several drug candidates
under each program even though we may achieve extremely strong results with some of the candidates&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Patents, Trademarks, Proprietary
Rights: Intellectual Property</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The nanomedicine technologies licensed
from TheraCour Pharma, Inc. (&ldquo;TheraCour&rdquo;) serve as the foundation for our intellectual property. NanoViricides holds
a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for
the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis
C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus. The Company has entered into
an Additional License Agreement with TheraCour granting NanoViricides the exclusive licenses in perpetuity for technologies developed
by TheraCour for the additional virus types: Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Viruses causing viral
Conjunctivitis (a disease of the eye) and Ocular Herpes, and Ebola/Marburg viruses. NanoViricides may want to add further virus
types to its drug pipeline, which would require negotiation with TheraCour for the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These licenses are not limited to underlying
patents, but also include the know-how, trade secrets, and other important knowledge base that is utilized for developing the drugs
and making them successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, these extremely broad licenses
are not limited to some specific chemical structures, but comprise all possible structures that we could deploy against the particular
virus, based on these technologies. In addition, the licenses are held in perpetuity by NanoViricides for worldwide use. The licenses
are also exclusively provided to NanoViricides for the licensed products so NanoViricides is the only party that can further sublicense
the resulting drugs to another party, if it so desires. The licenses can revert only in the case of a default by NanoViricides.
The terms of default are such that, effectively, TheraCour would be able to take the licenses back only in the event that NanoViricides
files bankruptcy or otherwise declares insolvency and the inability to conduct its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A fundamental Patent Cooperation Treaty
(&ldquo;PCT&rdquo;) patent application, on which the nanoviricides&reg; technology is based, has resulted in additional issued
patents in Europe and Korea. As with issuances in other countries including the United States, these patents have been allowed
with a very broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions,
methods of making the same, and uses of the same. The corresponding original &ldquo;pi-polymer&rdquo; international application,
namely, PCT/US06/01820, was filed under the Patent Cooperation Treaty (PCT) system in 2006. Several other patents have already
been granted previously in this patent family in various countries and regions, including Australia, ARIPO, Canada, China, Hong
Kong, Indonesia, Israel, Japan, Mexico, New Zealand, OAPI, Philippines, Singapore, Vietnam, South Africa, and the USA. Prosecution
in several other countries continues. In May 2012, the US Patent (No. 8,173,764) was granted for &ldquo;Solubilization and Targeted
Delivery of Drugs with Self-Assembling Amphiphilic Polymers.&rdquo; The US patent term is expected to last through October 1, 2028,
including anticipated extensions in compensation for time spent in clinical trials. This US Patent has been allowed with a very
broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions, methods of
making the same, and uses of the same. The disclosed structures enable self-assembling, biomimetic nanomedicines. Estimated expiry
dates for these patents range nominally from 2027 to 2029 with various extensions accounting for delays in clinical trials. Additional
issuances are expected in Europe, and in several other countries around the world.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to this basic PCT application
that covers the &ldquo;pi-polymer&rdquo; structure itself, another PCT application, PCT/US2007/001607, that discloses making antiviral
agents from the TheraCour family of polymers and such structures is in various stages of prosecution in several countries, and
has already issued in at least seven countries and regions. The counterparts of the international PCT application have issued as
a granted patent in Australia, Japan, China, ARIPO, Mexico, New Zealand, OAPI, Pakistan, and, South Africa to date. Additional
issuances are expected in Europe, USA, and in several other countries around the world. This patent application covers antivirals
based on the TheraCour polymeric micelle technologies, their broad structures and compositions of matter, pharmaceutical compositions,
methods of making the same, and their uses. The nominal expiry dates are expected to range from 2027 to 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More than 61 patents have been issued globally
on the basis of the two international PCT patent families that cover the fundamental aspects of our platform technology. Additional
patent grants are expected to continue as the applications progress through prosecution processes. All of the resulting patents
have substantially broad claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patents are issued to the inventors
Anil R. Diwan, PhD, Jayant G. Tatake, PhD, and Ann L. Onton, all of who are among the founders of NanoViricides, Inc. The patents
have been assigned to AllExcel, Inc., the Company at which the groundbreaking work was performed. AllExcel, Inc. has contractually
transferred this intellectual property to TheraCour Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NanoViricides has entered into a Memorandum
of Understanding with TheraCour, whereby TheraCour will initiate discovery and development for drug candidates for a new virus
or indication upon request. If the resulting drug candidates are worthy of further drug development, NanoViricides may determine
that it should enter into a licensing agreement with TheraCour. In such a case, NanoViricides would obtain an independent asset
valuation for the asset(s) to be licensed from a party experienced in such valuations. NanoViricides and TheraCour would thereafter
negotiate the terms of compensation for the new license agreement. However, there can be no assurance that an agreement for licenses
for new viruses will be entered into on terms that are favorable to NanoViricides. We believe this process has been generally beneficial
for NanoViricides, since this process saves NanoViricides from the cost of acquiring and paying for licenses that it may not want
to pursue further. At present, TheraCour has licensed to NanoViricides HSV-1 and HSV-2, but has not licensed the VZV area, nor
has it licensed any of the remaining herpesviruses. Licensing of these assets is currently in process as described earlier. However,
there can be no assurance that the Company will be able to enter into an agreement with TheraCour for such license or that the
agreement will be on terms that are favorable to the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents and other proprietary rights are
essential for our operations. If we have a properly designed and enforceable patent, it can be more difficult for our competitors
to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us
from using technology we create. As part of our business strategy, we actively seek patent protection both in the United States
and internationally and intend to file additional patent applications, when appropriate, to cover improvements in our compounds,
products and technology. We also rely on trade secrets, internal know-how, technological innovations and agreements with third
parties to develop, maintain and protect our competitive position. Our ability to be competitive will depend on the success of
this strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the drugs by
themselves, Shingles antiviral topical treatment, HerpeCide for Cold Sores, HerpeCide for genital ulcers, antiviral nanoviricide
eye drops, Injectable FluCide, Oral FluCide, DengueCide, HIVCide, RabiCide, and others, may be eligible for patent protection.
The Company plans on filing patent applications for protecting these drugs when we have definitive results from in-vitro or in-vivo
studies that enable further drug development and IND application filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issued patents have nominal expiry
dates in 2026 to 2029. The dates can be further extended in several countries and regions for the additional allowances due to
the regulatory burden of drug development process, or other local considerations, such as licensing to a local majority held company.
Many countries allow up to five years extension for regulatory delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No patent applications have been filed
for the actual drug candidates that we intend to develop as drugs as of now. We intend to file the patent application for FluCide
and HerpeCide compounds before entering human clinical trials. The estimated expiry date for the FluCide and HerpeCide patents,
if and when issued, would be no earlier than 2038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may obtain patents for our compounds
many years before we obtain marketing approval for them. Because patents have a limited life, which may begin to run prior to the
commercial sale of the related product, the commercial value of the patent may be limited. However, we may be able to apply for
patent term extensions, based on delays experienced in marketing products due to regulatory requirements. There is no assurance
we would be able to obtain such extensions. The Company controls the research and work TheraCour performs on its behalf and no
costs may be incurred without the prior authorization or approval of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents relating to pharmaceutical, biopharmaceutical
and biotechnology products, compounds and processes such as those that cover our existing compounds, products and processes and
those that we will likely file in the future, do not always provide complete or adequate protection. Future litigation or reexamination
proceedings regarding the enforcement or validity of our licensor, TheraCour Pharma Inc.&rsquo;s existing patents or any future
patents, could invalidate TheraCour&rsquo;s patents or substantially reduce their protection. In addition, the pending patent applications
and patent applications filed by TheraCour, may not result in the issuance of any patents or may result in patents that do not
provide adequate protection. As a result, we may not be able to prevent third parties from developing the same compounds and products
that we have developed or are developing. In addition, certain countries do not permit enforcement of our patents, and manufacturers
are able to sell generic versions of our products in those countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on unpatented trade secrets
and improvements, unpatented internal know-how and technological innovation. In particular, a great deal of our material manufacturing
expertise, which is a key component of our core material technology, is not covered by patents but is instead protected as a trade
secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and
vendors. These agreements provide that all confidential information developed or made known to an individual during the course
of their relationship with us will be kept confidential and will not be used or disclosed to third parties except in specified
circumstances. In the case of employees, the agreements provide that all inventions made by the individual while employed by us
will be our exclusive property. We cannot be certain that these parties will comply with these confidentiality agreements, that
we have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered
by our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Trademarks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2010, the United States Patent
and Trademark Office granted trademark registration number 3,777,001 to the Company for the standard character mark &ldquo;nanoviricides&rdquo;
(the &ldquo;Mark&rdquo;) for International Class 5, pharmaceutical preparation for the treatment of viral diseases. The Mark was
registered on the Principal Register and is protected in all its letterforms, including corresponding plural and singular forms,
various forms of capitalization, and fonts and designs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Analysis of Financial Condition,
and Result of Operations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2018, we had cash and
equivalents of $6,082,365, prepaid expenses of $201,532, and net property and equipment of $10,707,027. Accounts payable and accrued
expenses were $1,269,729 and current derivative liabilities-warrants were $122,541. Stockholders&rsquo; equity was $15,978,251
at September 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In comparison, as of June 30, 2018, we
had cash and equivalents of $7,081,771, and $240,257 in prepaid expenses, and net property and equipment stood at $10,841,093.
Accounts payable and accrued expenses were $583,856 and current derivative liabilities-warrants were $298,092. Stockholders&rsquo;
equity was $17,664,264 at June 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three-month period ended September
30, 2018 we used $962,152 in cash toward operating activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not anticipate any major capital
costs going forward in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management adjusted its planned expenditures,
activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional
financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has made several adjustments to its past expenditures in the ensuing annual budget, eliminating
several expenses including a reduction in workforce and consultants to the extent feasible without affecting its program of drug
development. In addition, the Company has focused its efforts primarily on a single lead program to minimize cost outlays, namely
taking the shingles drug candidate against VZV into human clinical trials. Management&rsquo;s budget indicates that these changes
have freed up sufficient funds to allow for the ensuing costs of the external advanced IND-enabling studies of this drug candidate.
Management has considered several options for obtaining additional funds that will be needed for future human clinical trials and
the license of VZV. The Company is also evaluating the possibility of obtaining a mortgage on its fully owned cGMP-capable laboratory
facility in Shelton, CT, in order to free up a portion of the fixed capital for usage as liquid working capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company believes that
it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these
milestones, the Company would experience substantial improvement in the liquidity of the Company&rsquo;s stock, and would significantly
improve the Company&rsquo;s ability to raise funds on the public markets at terms that may be substantially superior to the terms
we are offered at present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that as a result of
the&nbsp;management plan, the Company&rsquo;s existing resources and access to the capital markets will be sufficient to fund the
Company&rsquo;s planned operations and expenditures through November 2019. However, the Company cannot provide assurance that its
plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than
it currently anticipates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not currently have any
revenue. All of the Company&rsquo;s products are in the development stage and require successful development through regulatory
processes before commercialization. We have generated funding through the issuances of debt and private placement of common stock
and also the sale of our registered securities. The Company does not currently have any long-term debt. We have not generated any
revenues and we may not be able to generate revenues in the near future. We may not be successful in developing our drugs and start
selling our products when planned, or we may not become profitable in the future. We have incurred net losses in each fiscal period
since inception of our operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Research and Development Costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not maintain separate
accounting line items for each project in development. The Company maintains aggregate expense records for all research and development
conducted. Because at this time all of the Company&rsquo;s projects share a common core material, the Company allocates expenses
across all projects at each period-end for purposes of providing accounting basis for each project. Project costs are allocated
based upon labor hours performed for each project. Far fewer man-hours are spent on the projects at low priority than the projects
at high priority. In this quarter, we have focused primarily on our HerpeCide program drug candidates, while continuing limited
work on our FluCide program</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has signed several cooperative
research and development agreements with different agencies and institutions. The Company expects to enter into additional cooperative
agreements with other governmental and non-governmental, academic, or commercial, agencies, institutions, and companies. There
can be no assurance that a final agreement may be achieved and that the Company will execute any of these agreements. However,
should any of these agreements materialize, the Company will need to implement a system to track these costs by project and account
for these projects as customer-sponsored activities and show these project costs separately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has limited experience with
pharmaceutical drug development. Thus, our budget estimates are not based on experience, but rather based on advice given by our
associates and consultants. As such these budget estimates may not be accurate. In addition, the actual work to be performed is
not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional
work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget.
Such changes may also have an adverse impact on our projected timeline of drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that this coming year&rsquo;s
work plan will lead us to obtain certain information about the safety and efficacy of one of the drugs under development in animal
models. If our studies are not successful, we will have to develop additional drug candidates and perform further studies. If our
studies are successful, then we expect to be able to undertake further studies in animal models to obtain necessary data regarding
the pharmaco-kinetic and pharmaco-dynamic profiles of our drug candidates, provided that appropriate levels of funding become available.
We believe this data will enable us to file an Investigational New Drug Application, towards the goal of obtaining FDA approval
for testing the drugs in human patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a biopharmaceutical company
and did not have any revenue for the three-month periods ended September 30, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenues</I></B>&nbsp;&ndash; The
Company is currently a non-revenue producing entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Expenses</I></B>&nbsp;&ndash;
Research and development expenses for the three months ended September 30, 2018 decreased $40,423 to $1,411,483 from $1,451,906
for the three months ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General and Administration Expenses&nbsp;</I></B>&ndash;
General and administrative expenses for the three months ended September 30, 2018 decreased $150,925 to $627,615 from $778,540
for the three months ended September 30, 2017<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interest Income</I></B>&ndash; Interest
income decreased $2,310 to $22,084 for the three months ended September 30, 2018 from interest income of $24,394 for the three
months ended September 30, 2017. Interest income included interest on cash equivalent deposits in interest-bearing accounts at
market rates. The decrease is due to a decrease in the balances in our investment accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interest Expense </I></B>&ndash;
Interest expense decreased $125,000, to $-0- for the three months ended September 30, 2018, from $125,000 for the three months
ended September 30, 2017 due to the redemption of the Company&rsquo;s Series C Debenture as of November 13, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Expenses</I></B>&nbsp;&ndash;
Discount on convertible debentures for the three months ended September 30, 2018 decreased $239,351 to $0 from the three months
ended September 30, 2017 due to the redemption of the Company&rsquo;s Series C Debenture as of November 13, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Change in fair value of derivatives</I></B>&ndash;
Change in fair value of derivatives for the three months ended September 30, 2018 decreased $389,297 to $175,551 from $564,848
for the three months ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B>&nbsp;&ndash; There is no provision
for income taxes due to ongoing operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Loss&nbsp;</I></B>- For the
three months ended September 30, 2018, the Company had a net loss of ($1,841,463), or ($0.03) per share on a fully diluted basis
compared to a net loss of ($2,005,555) or ($0.03) per share on a fully diluted basis for the three months ended September 30,
2017. The decrease in the reported loss for the three-month period ended September 30, 2018 is attributable mainly to a decrease
in operating expenses of approximately $191,000, and a decrease of expenses related to the Company&rsquo;s Series C Debenture
which was redeemed as of November 13, 2017, which resulted in a decrease for the three months ended September 30, 2018 of $125,000
in interest expense and a decrease in discount on convertible debentures of $239,351. These decreased expenses were offset by
a decrease in the gain on the change in fair value of derivatives for the three months ended September 30, 2018 of $389,297. Additionally
the cost of compensation paid in Company Securities was reduced.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidity and Capital Reserves</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had cash and cash equivalents
of $6,082,365 as of September 30, 2018 and current liabilities of $1,392,270, inclusive of account payables to a related party,
TheraCour Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since inception, the Company has expended
substantial resources on research and development. Consequently, we have sustained substantial losses. The Company has an accumulated
deficit of approximately $85,533,600 at September 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management adjusted its planned expenditures,
activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional
financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has made several
adjustments to its past expenditures in the ensuing annual budget, eliminating several expenses including a reduction in
workforce and consultants to the extent feasible without affecting its program of drug development. In addition, the Company
has focused its efforts primarily on a single lead program to minimize cost outlays, namely taking the shingles drug
candidate against VZV into human clinical trials. Management&rsquo;s budget indicates that these changes have freed up
sufficient funds to allow for the ensuing costs of the external advanced IND-enabling studies of this drug candidate.
Management has considered several options for obtaining additional funds that will be needed for future human clinical trials
and license of VZV. The Company is also evaluating the possibility of obtaining a mortgage on its fully owned
cGMP-capable laboratory facility in Shelton, CT, in order to free up a portion of the fixed capital for usage as liquid
working capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company believes that
it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these
milestones, the Company would experience substantial improvement in the liquidity of the Company&rsquo;s stock, and would significantly
improve the Company&rsquo;s ability to raise funds on the public markets at terms that may be substantially superior to the terms
we are offered at present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that as a result of
the&nbsp;management plan, the Company&rsquo;s existing resources and access to the capital markets will be sufficient to fund the
Company&rsquo;s planned operations and expenditures through November 2019. However, the Company cannot provide assurance that its
plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than
it currently anticipates. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our estimates for external costs are based
on various preliminary discussions and &ldquo;soft&rdquo; quotes from contract research organizations that provide pre-clinical
and clinical studies support. The estimates are also based on certain time estimates for achievement of various objectives. If
we miss these time estimates or if the actual costs of the development are greater than the early estimates we have at present,
our drug development cost estimates may be substantially greater than anticipated now. In that case, we may have to re-prioritize
our programs and/or seek additional funding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have direct experience
in taking a drug through human clinical trials. In addition, we depend upon external collaborators, service providers and consultants
for much of our drug development work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management intends to use capital and debt
financing, as required, to fund the Company&rsquo;s operations. Management also intends to pursue non-diluting funding sources
such as government grants and contracts as well as licensing agreements with other pharmaceutical companies. There can be no assurance
that the Company will be able to obtain such additional capital resources or that such financing will be on terms that are favorable
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Off Balance Sheet Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not entered into any off-balance
sheet arrangements during the three months ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="b_002"></A>ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market risk is the risk of loss arising
from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates and commodity prices.
We currently have no foreign operations and are not exposed to foreign currency fluctuations. Our primary exposure to market risk
is interest rate risk associated with our short-term cash equivalent investments, which the Company deems to be non-material. The
Company does not have any financial instruments held for trading or other speculative purposes and does not invest in derivative
financial instruments, interest rate swaps or other investments that alter interest rate exposure. The Company does not have any
credit facilities with variable interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="b_003"></A><B>ITEM 4. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 64.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disclosure controls and procedures (as
defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;))
are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that
we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
rules and forms of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we
file under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief
financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure
controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems,
not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be
faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can
only provide reasonable, not absolute, assurance that the above objectives have been met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2018, an evaluation
was carried out under the supervision and with the participation of our management, including our interim Chief Executive Officer
and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule
15d-15(f) under the Securities Exchange Act of 1934). Based on this evaluation, our interim Chief Executive Officer and Chief Financial
Officer have concluded that the Company&rsquo;s disclosure controls and procedures were not effective as of September 30, 2018,
due to material weaknesses in internal control described in Part II, Item 9A of our 10-K for the fiscal year ended June 30, 2018.
These material weaknesses remain unremediated as of September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Changes in Internal Control Over Financial
Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than what was described below, there
were no material changes in our system of internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities
Exchange Act of 1934) during the reporting period ended September 30, 2018 that has materially affected, or is reasonably likely
to materially affect, our internal control over financial reporting. However, as noted below, we have begun to implement changes
in our internal control over financial reporting to address the material weaknesses described above.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Remediation Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are remediating the material weaknesses
by, among other things, implementing a process of enhanced review of all financial transactions.&nbsp;The actions that we are taking
are subject to ongoing senior management review and Audit Committee oversight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective September 1, 2018, the Company
has appointed Dr. Irach Taraporewala as Chief Executive Officer, an experienced pharmaceutical industry executive, to provide additional
management review of financial reporting and the period-end closing processes identified. Dr. Taraporewala is currently undergoing
training in certain aspects of these tasks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide additional training
and development classes for management, accounting and finance staff regarding current changes in accounting for income taxes and
deferred income taxes, pursuant to ASC 740, to enhance their current skills and understanding of the components of deferred taxation
and accounting for income taxes.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes the foregoing efforts
will effectively remediate the material weakness identified above.&nbsp;As we continue to evaluate and work to improve our internal
control over financial reporting, management may execute additional measures to address potential control deficiencies or modify
the remediation plan described above and will continue to review and make necessary changes to the overall design of our internal
controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_004"></A>PART II. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="b_005"></A>ITEM 1. LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may be a party to
legal proceedings in the ordinary course of our business in addition to those described below. We do not, however, expect such
other legal proceedings to have a material adverse effect on our business, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no legal proceedings against
the Company to the best of the Company&rsquo;s knowledge as of the date hereof and to the Company&rsquo;s knowledge, no action,
suit or proceeding has been threatened against the Company.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_006"></A>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</B></FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2018 the Board of Directors
approved an extension of the employment agreement with Dr. Anil Diwan, the Company&rsquo;s President. Pursuant to the terms of
the employment agreement, the Company&rsquo;s Board of Directors authorized the issuance of 525,000 shares of the Company&rsquo;s
Series A preferred stock to Dr. Anil Diwan. 175,000 shares vest equally on June 30, 2019, June 30, 2020 and June 30, 2021. Any
unvested shares are subject to forfeiture. The Company recognized a non-cash compensation expense related to the issuance of the
Series A Preferred stock of $47,260 for the three months ended September 30, 2018. The balance of $513,430 will be recognized as
the shares vest and service is rendered.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30,
2018, the Company&rsquo;s Board of Directors authorized the issuance of 7,716 fully vested shares of its Series A Convertible
Preferred stock for employee compensation. The Company recorded an expense of $7,767.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2018, the Company entered into
an Employment Agreement with Dr. Irach Taraporewala as Chief Executive Officer of the Company beginning on September 1, 2018. Dr.
Taraporewala was granted options to purchase up to 300,000 shares of the Company&rsquo;s common stock, par value $0.001 per share
at an exercise price equal to 20% above the closing bid price of $0.41 of the common stock on the Effective Date. The options shall
vest in three, equal, annual installments commencing on the Effective Date. The fair value of the options was $35,761 of which
$11,920 was recognized and recorded as compensation expense for the three months ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the Scientific Advisory
Board (SAB) was granted fully vested warrants to purchase 11,432 shares of common stock with an exercise price of $.41 per share
expiring in August 2022.&nbsp;&nbsp;The fair value of the warrants was $1,543 and was recorded as consulting expense for the three
months ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30,
2018, the Company&rsquo;s Board of Directors authorized the issuance of 191,510 fully vested shares of its common stock with a
restrictive legend for consulting services. The Company recorded an expense of $79,460 for the three months, which was the fair
value on the dates of issuance.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30,
2018, the Company&rsquo;s Board of Directors authorized the issuance of 19,310 fully vested shares of its common stock with a restrictive
legend for Director Services. The Company recorded an expense of $7,500 for the three months, which was the fair value on the date
of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the securities set forth above were
issued by the Company pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, or the provisions of Rule 504 of Regulation
D promulgated under the Securities Act. All such shares issued contained a restrictive legend and the holders confirmed that they
were acquiring the shares for investment and without intent to distribute the shares. All of the purchasers were friends or business
associates of the Company&rsquo;s management and all were experienced in making speculative investments, understood the risks associated
with investments, and could afford a loss of the entire investment. The Company did not utilize an underwriter or a placement agent
for any of these offerings of its securities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="b_007"></A>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="b_008"></A>ITEM 4. MINE SAFETY DISCLOSURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="b_009"></A>ITEM 5. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Subsequent Events</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2018, the Board of Directors
of NanoViricides, Inc. (the &ldquo;Company&rdquo;) elected James Sapirstein as a new member of the Board. Mr.&nbsp;Sapirstein is
an Independent Member of the Board of Directors and will serve as a member of the Company&rsquo;s Audit, Compensation and Nominating
Committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="c_001"></A>ITEM 6.&nbsp;&nbsp;EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 0.75in; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tv506169_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">31.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv506169_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tv506169_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">31.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv506169_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tv506169_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">32.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv506169_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Section 1350 Certification of Chief Executive Officer</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tv506169_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">32.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv506169_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Section 1350 Certification of Chief Financial Officer</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">101.INS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">101.SCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">101.CAL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">101.DEF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">101.LAB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">101.PRE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c_002"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NANOVIRICIDES, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Anil R. Diwan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%"><FONT STYLE="font-size: 10pt">Dated: November 14, 2018</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 30%"><FONT STYLE="font-size: 10pt">Anil R. Diwan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President, Chairman of the Board</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Meeta Vyas</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: November 14, 2018</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Meeta Vyas</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tv506169_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">I,</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Anil Diwan, certify that:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of NanoViricides, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal over financial reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-size: 10pt">Date: November 14, 2018</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>/s/ Anil Diwan</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name: Anil Diwan </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Title: President </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tv506169_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">I,</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Meeta Vyas, certify that:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of NanoViricides, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal over financial reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-size: 10pt">Date: November 14, 2018</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>/s/ Meeta Vyas</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name: Meeta Vyas </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Title: Chief Financial Officer, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Accounting and Financial Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tv506169_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. &sect;1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report
on Form 10-Q (the &ldquo;Report&rdquo;) of NanoViricides, Inc. (the &ldquo;Company&rdquo;) for the quarter ended September 30,
2018, the undersigned Anil Diwan, Interim Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned&rsquo;s knowledge
and belief:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-right: 0.8pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.5in; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%"><FONT STYLE="font-size: 10pt">Dated: November 14, 2018</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Anil Diwan</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Anil Diwan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Title: President,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing
certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, and is not being &ldquo;filed&rdquo; as part of the Form 10-Q or as a separate disclosure document for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to liability
under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32.1 is expressly and specifically incorporated
by reference in any such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement
required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and
Exchange Commission or its staff upon request.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tv506169_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. &sect;1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report
on Form 10-Q (the &ldquo;Report&rdquo;) of NanoViricides, Inc. (the &ldquo;Company&rdquo;) for the quarter ended September 30,
2018, the undersigned Meeta Vyas, the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned&rsquo;s knowledge and
belief:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Dated: November 14, 2018</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><I>/s/ Meeta Vyas</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name: Meeta Vyas</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title: Chief Financial Officer,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing
certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, and is not being &ldquo;filed&rdquo; as part of the Form 10-Q or as a separate disclosure document for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to liability
under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32.2 is expressly and specifically incorporated
by reference in any such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement
required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and
Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>nnvc-20180930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 14-November-2018 [06:15:38] {AM} - www.datatracks.com-->
<xbrli:xbrl xmlns:nnvc="http://www.nanoviricides.com/20180930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2018-01-31">
<link:schemaRef xlink:type="simple" xlink:href="nnvc-20180930.xsd" />
<xbrli:context id="P07_01_2018To09_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_11_2013To01_24_2014">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2013-09-11</xbrli:startDate>
<xbrli:endDate>2014-01-24</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_14_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-11-14</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P11_01_2017To11_13_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-11-01</xbrli:startDate>
<xbrli:endDate>2017-11-13</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2018To03_21_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-03-01</xbrli:startDate>
<xbrli:endDate>2018-03-21</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To07_19_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-07-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_19_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-07-19</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_TrademarkAndPatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnvc:TrademarkAndPatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnvc:StockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_June302019MembernnvcFuturePeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nnvc:FuturePeriodAxis">nnvc:June302019Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_June302020MembernnvcFuturePeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nnvc:FuturePeriodAxis">nnvc:June302020Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_June302021MembernnvcFuturePeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nnvc:FuturePeriodAxis">nnvc:June302021Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_June302022MembernnvcFuturePeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nnvc:FuturePeriodAxis">nnvc:June302022Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_June302023MembernnvcFuturePeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nnvc:FuturePeriodAxis">nnvc:June302023Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnvc:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_IssuanceDateOneMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nnvc:IssuanceDateOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_IssuanceDateTwoMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nnvc:IssuanceDateTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_IssuanceDateThreeMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nnvc:IssuanceDateThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_IssuanceDateFourMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nnvc:IssuanceDateFourMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_TheracourPharmaIncMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nnvc:TheracourPharmaIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_YearOneMembernnvcDeferredCompensationYearAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nnvc:DeferredCompensationYearAxis">nnvc:YearOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_YearTwoMembernnvcDeferredCompensationYearAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nnvc:DeferredCompensationYearAxis">nnvc:YearTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_YearThreeMembernnvcDeferredCompensationYearAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nnvc:DeferredCompensationYearAxis">nnvc:YearThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_AugustTwoThousandNineteenMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nnvc:AugustTwoThousandNineteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_PresidentMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_DirectorMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_MaximumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_MinimumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_MinimumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_MaximumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_OneYearEnded93018MemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:OneYearEnded93018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:PlacementAgentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_ScientificAdvisoryBoardMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_TheracourPharmaIncMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nnvc:TheracourPharmaIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_February2022MemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nnvc:February2022Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_DirectorMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_PresidentMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnvc:StockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_MaximumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_ScientificAdvisoryBoardMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:ScientificAdvisoryBoardMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:PlacementAgentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_TheracourPharmaIncMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nnvc:TheracourPharmaIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_StockWarrantsMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnvc:StockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_TrademarkAndPatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnvc:TrademarkAndPatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_WarrantMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_TheracourPharmaIncMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nnvc:TheracourPharmaIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_DrBoniukMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesCConvertibleDebentureMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:SeriesCConvertibleDebentureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnvc:DrBoniukMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesCConvertibleDebentureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesCConvertibleDebenturesMemberusgaapFinancialInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nnvc:SeriesCConvertibleDebenturesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P11_01_2017To11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-11-01</xbrli:startDate>
<xbrli:endDate>2017-11-13</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P11_01_2017To11_13_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesCConvertibleDebentureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-11-01</xbrli:startDate>
<xbrli:endDate>2017-11-13</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_13_2017_SeriesBConvertibleDebenturesMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesBConvertibleDebenturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-11-13</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-11-13</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_13_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesCConvertibleDebentureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-11-13</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_13_2013To09_12_2013_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:PlacementAgentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2013-08-13</xbrli:startDate>
<xbrli:endDate>2013-09-12</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_12_2013_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:PlacementAgentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2013-09-12</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_02_2014To01_24_2014_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:PlacementAgentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2014-01-02</xbrli:startDate>
<xbrli:endDate>2014-01-24</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn01_24_2014_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:PlacementAgentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2014-01-24</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To06_30_2018_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesCConvertibleDebentureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To06_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To06_30_2018_OneYearEnded63018MemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:OneYearEnded63018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P05_01_2013To05_30_2013_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2013-05-01</xbrli:startDate>
<xbrli:endDate>2013-05-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn05_30_2013_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nnvc:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2013-05-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2015To01_31_2015_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-01-01</xbrli:startDate>
<xbrli:endDate>2015-01-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_20_2014To07_02_2014_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2014-06-20</xbrli:startDate>
<xbrli:endDate>2014-07-02</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_02_2014_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">nnvc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2014-07-02</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_11_2018_PresidentMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-07-11</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_03_2010_ChiefScientificOfficerMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nnvc:ChiefScientificOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2010-03-03</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_03_2010_VicePresidentMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:VicePresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2010-03-03</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P02_16_2010To03_03_2010_VicePresidentMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:VicePresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2010-02-16</xbrli:startDate>
<xbrli:endDate>2010-03-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P02_16_2010To03_03_2010_ChiefScientificOfficerMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nnvc:ChiefScientificOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2010-02-16</xbrli:startDate>
<xbrli:endDate>2010-03-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_21_2018To10_02_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TheracourPharmaIncMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nnvc:TheracourPharmaIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-09-21</xbrli:startDate>
<xbrli:endDate>2018-10-02</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_11_2013To01_24_2014_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nnvc:PlacementAgentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2013-09-11</xbrli:startDate>
<xbrli:endDate>2014-01-24</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2017_StockWarrantsMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnvc:StockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2017_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001379006</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<dei:DocumentType id="Factid_2063561" contextRef="P07_01_2018To09_30_2018">10-Q</dei:DocumentType>
<dei:AmendmentFlag id="Factid_2063562" contextRef="P07_01_2018To09_30_2018">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate id="Factid_2063563" contextRef="P07_01_2018To09_30_2018">2018-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus id="Factid_2063564" contextRef="P07_01_2018To09_30_2018">2019</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_2063565" contextRef="P07_01_2018To09_30_2018">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_2063566" contextRef="P07_01_2018To09_30_2018">NANOVIRICIDES, INC.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Factid_2063567" contextRef="P07_01_2018To09_30_2018">0001379006</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate id="Factid_2063568" contextRef="P07_01_2018To09_30_2018">--06-30</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory id="Factid_2063569" contextRef="P07_01_2018To09_30_2018">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:TradingSymbol id="Factid_2063570" contextRef="P07_01_2018To09_30_2018">NNVC</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding id="Factid_2063571" contextRef="PAsOn11_14_2018" unitRef="shares" decimals="INF">69383000</dei:EntityCommonStockSharesOutstanding>
<dei:EntityEmergingGrowthCompany id="Factid_2063572" contextRef="P07_01_2018To09_30_2018">false</dei:EntityEmergingGrowthCompany>
<dei:EntitySmallBusiness id="Factid_2063573" contextRef="P07_01_2018To09_30_2018">false</dei:EntitySmallBusiness>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_2063574" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">7081771</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_2063575" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">6082365</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent id="Factid_2063576" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">240257</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent id="Factid_2063577" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">201532</us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent id="Factid_2063578" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">7322028</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_2063579" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">6283897</us-gaap:AssetsCurrent>
<us-gaap:IntangibleAssetsNetExcludingGoodwill id="Factid_2063590" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">374929</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill id="Factid_2063591" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">372860</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:SecurityDeposit id="Factid_2063592" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">3515</us-gaap:SecurityDeposit>
<us-gaap:SecurityDeposit id="Factid_2063593" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">3515</us-gaap:SecurityDeposit>
<nnvc:ServiceAgreements id="Factid_2063594" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">4647</nnvc:ServiceAgreements>
<nnvc:ServiceAgreements id="Factid_2063595" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">3222</nnvc:ServiceAgreements>
<us-gaap:OtherAssets id="Factid_2063596" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">8162</us-gaap:OtherAssets>
<us-gaap:OtherAssets id="Factid_2063597" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">6737</us-gaap:OtherAssets>
<us-gaap:Assets id="Factid_2063598" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">18546212</us-gaap:Assets>
<us-gaap:Assets id="Factid_2063599" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">17370521</us-gaap:Assets>
<us-gaap:CommitmentsAndContingencies id="Factid_2063608" contextRef="PAsOn06_30_2018" unitRef="USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_2063609" contextRef="PAsOn09_30_2018" unitRef="USD" xsi:nil="true" />
<us-gaap:PreferredStockValue id="Factid_2063610" contextRef="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">4531</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue id="Factid_2063611" contextRef="PAsOn09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">5064</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue id="Factid_2063612" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">69172</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue id="Factid_2063613" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">69383</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital id="Factid_2063614" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">101282707</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital id="Factid_2063615" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">101437413</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_2063616" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">-83692146</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_2063617" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">-85533609</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity id="Factid_2063619" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">15978251</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_2063620" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">18546212</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_2063621" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">17370521</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_2063622" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">1451906</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_2063623" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">778540</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses id="Factid_2063624" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">2230446</us-gaap:OperatingExpenses>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_2063625" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">1411483</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_2063626" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">627615</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingIncomeLoss id="Factid_2063627" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-2230446</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_2063628" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">24394</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:InterestExpense id="Factid_2063629" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">125000</us-gaap:InterestExpense>
<nnvc:DiscountOnConvertibleDebentures id="Factid_2063630" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">239351</nnvc:DiscountOnConvertibleDebentures>
<us-gaap:OperatingExpenses id="Factid_2063631" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">2039098</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss id="Factid_2063632" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-2039098</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_2063633" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">22084</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:InterestExpense id="Factid_2063634" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">0</us-gaap:InterestExpense>
<nnvc:DiscountOnConvertibleDebentures id="Factid_2063635" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">0</nnvc:DiscountOnConvertibleDebentures>
<us-gaap:DerivativeGainLossOnDerivativeNet id="Factid_2063636" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">564848</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Factid_2063637" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-2005555</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit id="Factid_2063638" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NonoperatingIncomeExpense id="Factid_2063640" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">224891</us-gaap:NonoperatingIncomeExpense>
<us-gaap:DerivativeGainLossOnDerivativeNet id="Factid_2063641" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">175551</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:NonoperatingIncomeExpense id="Factid_2063642" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">197635</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Factid_2063643" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-1841463</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit id="Factid_2063644" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss id="Factid_2063645" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-1841463</us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding id="Factid_2063646" contextRef="PAsOn06_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">4531394</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_2063647" contextRef="PAsOn06_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">4531</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_2063648" contextRef="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">69171740</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_2063649" contextRef="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">69172</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_2063650" contextRef="PAsOn06_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">101282707</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_2063651" contextRef="PAsOn06_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-83692146</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_2063652" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">17664264</us-gaap:StockholdersEquity>
<nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued id="Factid_2063653" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">532716</nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued>
<nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued id="Factid_2063654" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">533</nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued>
<nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued id="Factid_2063655" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">0</nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued>
<nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued id="Factid_2063656" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued>
<nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued id="Factid_2063657" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">54494</nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued>
<nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued id="Factid_2063658" contextRef="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued>
<nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued id="Factid_2063659" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">55027</nnvc:SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued>
<nnvc:StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne id="Factid_2063660" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">0</nnvc:StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne>
<nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne id="Factid_2063661" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne>
<nnvc:StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne id="Factid_2063662" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">191510</nnvc:StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne>
<nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne id="Factid_2063663" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">192</nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne>
<nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne id="Factid_2063664" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">79268</nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne>
<nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne id="Factid_2063665" contextRef="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne>
<nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne id="Factid_2063666" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">79460</nnvc:StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne>
<us-gaap:NetIncomeLoss id="Factid_2063667" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_2063668" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_2063669" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_2063670" contextRef="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-1841463</us-gaap:NetIncomeLoss>
<nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices id="Factid_2063672" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices>
<nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices id="Factid_2063673" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices>
<nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices id="Factid_2063674" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">1543</nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices>
<nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices id="Factid_2063675" contextRef="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices>
<nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices id="Factid_2063676" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">1543</nnvc:StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices>
<nnvc:StockIssuedForPaymentOfDirectorFeesShares id="Factid_2063677" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">0</nnvc:StockIssuedForPaymentOfDirectorFeesShares>
<nnvc:StockIssuedForPaymentOfDirectorFeesValue id="Factid_2063678" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:StockIssuedForPaymentOfDirectorFeesValue>
<nnvc:StockIssuedForPaymentOfDirectorFeesShares id="Factid_2063679" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">19310</nnvc:StockIssuedForPaymentOfDirectorFeesShares>
<nnvc:StockIssuedForPaymentOfDirectorFeesValue id="Factid_2063680" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">19</nnvc:StockIssuedForPaymentOfDirectorFeesValue>
<nnvc:StockIssuedForPaymentOfDirectorFeesValue id="Factid_2063681" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">7481</nnvc:StockIssuedForPaymentOfDirectorFeesValue>
<nnvc:StockIssuedForPaymentOfDirectorFeesValue id="Factid_2063682" contextRef="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</nnvc:StockIssuedForPaymentOfDirectorFeesValue>
<nnvc:StockIssuedForPaymentOfDirectorFeesValue id="Factid_2063683" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">7500</nnvc:StockIssuedForPaymentOfDirectorFeesValue>
<us-gaap:SharesOutstanding id="Factid_2063684" contextRef="PAsOn09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">5064110</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_2063685" contextRef="PAsOn09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">5064</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_2063686" contextRef="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">69382560</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_2063687" contextRef="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">69383</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_2063688" contextRef="PAsOn09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">101437413</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_2063689" contextRef="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-85533609</us-gaap:StockholdersEquity>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_2063692" contextRef="PAsOn09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD_per_Share" decimals="1">3.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_2063693" contextRef="P07_01_2018To09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">17724385</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:LeaseholdImprovementsGross id="Factid_2063696" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">8011230</us-gaap:LeaseholdImprovementsGross>
<us-gaap:LeaseholdImprovementsGross id="Factid_2063697" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">8020471</us-gaap:LeaseholdImprovementsGross>
<us-gaap:Land id="Factid_2063698" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">260000</us-gaap:Land>
<us-gaap:Land id="Factid_2063699" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">260000</us-gaap:Land>
<nnvc:PreferredSharesIssuedAsCompensation id="Factid_2063702" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">158799</nnvc:PreferredSharesIssuedAsCompensation>
<nnvc:PreferredSharesIssuedAsCompensation id="Factid_2063703" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">55027</nnvc:PreferredSharesIssuedAsCompensation>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="Factid_2063704" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">38250</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="Factid_2063705" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">86960</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:AdjustmentForAmortization id="Factid_2063708" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">2068</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization id="Factid_2063709" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">2069</us-gaap:AdjustmentForAmortization>
<nnvc:ChangeInFairValueOfDerivativeLiability id="Factid_2063710" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">564848</nnvc:ChangeInFairValueOfDerivativeLiability>
<nnvc:ChangeInFairValueOfDerivativeLiability id="Factid_2063711" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">175551</nnvc:ChangeInFairValueOfDerivativeLiability>
<us-gaap:AmortizationOfFinancingCosts id="Factid_2063712" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">239351</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts id="Factid_2063713" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:IncreaseDecreaseInPrepaidExpense id="Factid_2063714" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">2254</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense id="Factid_2063715" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-38725</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade id="Factid_2063716" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-45427</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade id="Factid_2063717" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">96758</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties id="Factid_2063718" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">478088</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties id="Factid_2063719" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">610989</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInOtherAccruedLiabilities id="Factid_2063720" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">188</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherAccruedLiabilities id="Factid_2063721" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-21874</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
<us-gaap:IncreaseDecreaseInInterestPayableNet id="Factid_2063722" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-41667</us-gaap:IncreaseDecreaseInInterestPayableNet>
<us-gaap:IncreaseDecreaseInInterestPayableNet id="Factid_2063723" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_2063724" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-1556788</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_2063725" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-962152</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:AdjustmentOfWarrantsGrantedForServices id="Factid_2063726" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">1543</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices id="Factid_2063727" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">5773</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_2063728" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-999406</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_2063729" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-1587221</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_2063731" contextRef="PAsOn06_30_2017" unitRef="USD" decimals="0">15099461</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:InterestPaidNet id="Factid_2063732" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">0</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet id="Factid_2063733" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">166667</us-gaap:InterestPaidNet>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_2063735" contextRef="PAsOn09_30_2017" unitRef="USD" decimals="0">13512240</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<nnvc:OfficeEquipmentGross id="Factid_2063738" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">57781</nnvc:OfficeEquipmentGross>
<nnvc:OfficeEquipmentGross id="Factid_2063739" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">57781</nnvc:OfficeEquipmentGross>
<us-gaap:FurnitureAndFixturesGross id="Factid_2063740" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">5607</us-gaap:FurnitureAndFixturesGross>
<us-gaap:FurnitureAndFixturesGross id="Factid_2063741" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">5607</us-gaap:FurnitureAndFixturesGross>
<us-gaap:FixturesAndEquipmentGross id="Factid_2063742" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">5683765</us-gaap:FixturesAndEquipmentGross>
<us-gaap:FixturesAndEquipmentGross id="Factid_2063743" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">5711778</us-gaap:FixturesAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_2063744" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">14018383</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_2063745" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">14055637</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_2063746" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">3177290</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_2063747" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">3348610</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_2063748" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">10841093</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_2063749" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">10707027</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Depreciation id="Factid_2063750" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">166189</us-gaap:Depreciation>
<us-gaap:Depreciation id="Factid_2063751" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">171320</us-gaap:Depreciation>
<us-gaap:FiniteLivedIntangibleAssetsGross id="Factid_2063752" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">458954</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="Factid_2063753" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">86094</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet id="Factid_2063754" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">372860</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross id="Factid_2063755" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">458954</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="Factid_2063756" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">84025</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet id="Factid_2063757" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">374929</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AdjustmentForAmortization id="Factid_2063758" contextRef="P07_01_2017To09_30_2017_TrademarkAndPatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="USD" decimals="0">2068</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization id="Factid_2063759" contextRef="P07_01_2018To09_30_2018_TrademarkAndPatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="USD" decimals="0">2069</us-gaap:AdjustmentForAmortization>
<us-gaap:DebtInstrumentUnamortizedDiscount id="Factid_2063761" contextRef="PAsOn09_30_2018_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">684633</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtConversionConvertedInstrumentAmount1 id="Factid_2063762" contextRef="P07_01_2017To06_30_2018_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">5000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:InterestExpenseDebt id="Factid_2063763" contextRef="P11_01_2017To11_13_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">314726</us-gaap:InterestExpenseDebt>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_2063765" contextRef="PAsOn11_13_2017_SeriesBConvertibleDebenturesMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_2063766" contextRef="PAsOn11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:GainsLossesOnExtinguishmentOfDebt id="Factid_2063767" contextRef="P11_01_2017To11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">1348247</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<nnvc:CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment id="Factid_2063768" contextRef="P07_01_2017To06_30_2018_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">125000</nnvc:CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_2063769" contextRef="P11_01_2017To11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">364337</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueOther id="Factid_2063771" contextRef="P11_01_2017To11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">314726</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_2063772" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">5500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_2063774" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">5500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<nnvc:SeriesPreferredShareIssuedForDebentureInterestSharesIssued id="Factid_2063775" contextRef="P03_01_2018To03_21_2018" unitRef="shares" decimals="INF">150000</nnvc:SeriesPreferredShareIssuedForDebentureInterestSharesIssued>
<nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage id="Factid_2063777" contextRef="P07_01_2018To09_30_2018_MinimumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.1922</nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage>
<nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage id="Factid_2063778" contextRef="P07_01_2018To09_30_2018_MaximumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.1925</nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_2063779" contextRef="P07_01_2018To09_30_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_2063780" contextRef="P07_01_2018To09_30_2018_MaximumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">P2Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_2063781" contextRef="P07_01_2018To09_30_2018_MinimumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">P2Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions id="Factid_2063782" contextRef="P07_01_2018To09_30_2018_MinimumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.2942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions id="Factid_2063783" contextRef="P07_01_2018To09_30_2018_MaximumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.3224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_2063784" contextRef="P07_01_2018To09_30_2018_MinimumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.5576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_2063785" contextRef="P07_01_2018To09_30_2018_MaximumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.6117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_2063786" contextRef="P07_01_2018To09_30_2018_MinimumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_2063787" contextRef="P07_01_2018To09_30_2018_MaximumMembersrtRangeAxis_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.0211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_2063795" contextRef="PAsOn09_12_2013_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="USD_per_Share" decimals="2">5.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_2063796" contextRef="PAsOn01_24_2014_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="USD_per_Share" decimals="2">6.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<nnvc:FairValueAssumptionExpectedVolatilityRate id="Factid_2063797" contextRef="P07_01_2017To06_30_2018_OneYearEnded63018MemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="2">0.56</nnvc:FairValueAssumptionExpectedVolatilityRate>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Factid_2063798" contextRef="PAsOn06_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">298092</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases id="Factid_2063799" contextRef="P07_01_2018To09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="Factid_2063800" contextRef="P07_01_2018To09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">-175551</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet id="Factid_2063801" contextRef="P07_01_2018To09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Factid_2063802" contextRef="PAsOn09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">122541</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance id="Factid_2063803" contextRef="PAsOn09_30_2018" unitRef="shares" decimals="INF">525000</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
<us-gaap:CommonStockSharesIssued id="Factid_2063804" contextRef="PAsOn03_03_2010_VicePresidentMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">35715</us-gaap:CommonStockSharesIssued>
<nnvc:AdditionalCommonStockSharesIssued id="Factid_2063805" contextRef="PAsOn03_03_2010_VicePresidentMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">35715</nnvc:AdditionalCommonStockSharesIssued>
<us-gaap:PreferredStockSharesIssued id="Factid_2063806" contextRef="PAsOn03_03_2010_VicePresidentMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">26786</us-gaap:PreferredStockSharesIssued>
<nnvc:AdditionalPreferredStockSharesIssued id="Factid_2063807" contextRef="PAsOn03_03_2010_VicePresidentMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">26786</nnvc:AdditionalPreferredStockSharesIssued>
<nnvc:IncreaseInBaseSalary id="Factid_2063808" contextRef="P02_16_2010To03_03_2010_VicePresidentMemberusgaapTitleOfIndividualAxis" unitRef="USD" decimals="0">150000</nnvc:IncreaseInBaseSalary>
<us-gaap:CommonStockSharesIssued id="Factid_2063809" contextRef="PAsOn03_03_2010_ChiefScientificOfficerMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">35715</us-gaap:CommonStockSharesIssued>
<nnvc:AdditionalCommonStockSharesIssued id="Factid_2063810" contextRef="PAsOn03_03_2010_ChiefScientificOfficerMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">35715</nnvc:AdditionalCommonStockSharesIssued>
<nnvc:IncreaseInBaseSalary id="Factid_2063811" contextRef="P02_16_2010To03_03_2010_ChiefScientificOfficerMemberusgaapTitleOfIndividualAxis" unitRef="USD" decimals="0">150000</nnvc:IncreaseInBaseSalary>
<us-gaap:PreferredStockSharesIssued id="Factid_2063812" contextRef="PAsOn05_30_2013_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">2572</us-gaap:PreferredStockSharesIssued>
<nnvc:IncreaseInBaseSalary id="Factid_2063813" contextRef="P05_01_2013To05_30_2013_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" unitRef="USD" decimals="0">9000</nnvc:IncreaseInBaseSalary>
<nnvc:IncreaseInBaseSalary id="Factid_2063814" contextRef="P01_01_2015To01_31_2015_ChiefFinancialOfficerMemberusgaapTitleOfIndividualAxis" unitRef="USD" decimals="0">10800</nnvc:IncreaseInBaseSalary>
<us-gaap:DueToOfficersOrStockholdersCurrent id="Factid_2063818" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">133333</us-gaap:DueToOfficersOrStockholdersCurrent>
<us-gaap:DueToOfficersOrStockholdersCurrent id="Factid_2063819" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">233333</us-gaap:DueToOfficersOrStockholdersCurrent>
<us-gaap:AccruedSalariesCurrent id="Factid_2063820" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">49576</us-gaap:AccruedSalariesCurrent>
<us-gaap:AccruedSalariesCurrent id="Factid_2063821" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">19716</us-gaap:AccruedSalariesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_2063822" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">48266</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_2063823" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">0</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_2063828" contextRef="PAsOn06_30_2017_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="shares" decimals="INF">6969588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_2063829" contextRef="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="shares" decimals="INF">11432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod id="Factid_2063831" contextRef="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="shares" decimals="INF">2868981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice id="Factid_2063832" contextRef="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="USD_per_Share" decimals="2">5.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_2063833" contextRef="PAsOn09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="shares" decimals="INF">4112039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_2063835" contextRef="PAsOn06_30_2017_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="USD_per_Share" decimals="2">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_2063836" contextRef="PAsOn09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="USD_per_Share" decimals="2">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_2063837" contextRef="PAsOn09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized id="Factid_2063838" contextRef="PAsOn09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">8500000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued id="Factid_2063839" contextRef="PAsOn09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">5064110</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued id="Factid_2063840" contextRef="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">4531394</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_2063841" contextRef="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized id="Factid_2063842" contextRef="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">8500000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding id="Factid_2063843" contextRef="PAsOn09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">5064110</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding id="Factid_2063844" contextRef="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">4531394</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_2063845" contextRef="PAsOn09_30_2018" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_2063846" contextRef="PAsOn09_30_2018" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Factid_2063847" contextRef="PAsOn09_30_2018" unitRef="shares" decimals="INF">69382560</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued id="Factid_2063848" contextRef="PAsOn06_30_2018" unitRef="shares" decimals="INF">69171740</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_2063849" contextRef="PAsOn06_30_2018" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_2063850" contextRef="PAsOn06_30_2018" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesOutstanding id="Factid_2063851" contextRef="PAsOn09_30_2018" unitRef="shares" decimals="INF">69382560</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding id="Factid_2063852" contextRef="PAsOn06_30_2018" unitRef="shares" decimals="INF">69171740</us-gaap:CommonStockSharesOutstanding>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Factid_2063857" contextRef="P07_01_2018To09_30_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Factid_2063858" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Factid_2063859" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">11920</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Factid_2063860" contextRef="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="Factid_2063861" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">11920</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:ShareBasedCompensation id="Factid_2063862" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">11920</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_2063863" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="Factid_2063864" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">-1425</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets id="Factid_2063865" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-14257</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_2063866" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">37254</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_2063867" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">30433</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NatureOfOperations id="Factid_2063868" contextRef="P07_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 1 - Organization and Nature of Business&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;NanoViricides, Inc. (the Company&amp;#8221;) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are a company with several drugs in various stages of early development. In our lead antiviral program against herpes viruses, i.e. the HerpeCide&amp;#8482; program alone, we have drug candidates against at least five indications at different stages of development. Of these, our shingles drug candidate is expected to enter human clinical trials in the very near future. It is in advanced, IND-enabling pre-clinical studies at present, and large-scale production is being performed to supply the safety-toxicology study. In addition, our drug candidates against HSV-1 &amp;#8220;cold sores&amp;#8221; and HSV-2 &amp;#8220;genital herpes&amp;#8221; are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). Chicken pox is re-emerging as a major disease especially in European countries, with 23,500 confirmed cases in the first six months of 2018. In addition, we have drugs in development against all influenzas in our FluCide&amp;#8482; program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (&amp;#8220;TheraCour&amp;#8221;), to which we have broad, exclusive licenses in perpetuity. The first license agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour.&amp;#160;&amp;#160;Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.&amp;#160;&amp;#160;In addition, the Company is negotiating a license for VZV (shingles, chicken pox virus), and the remaining human herpesviruses from TheraCour. For this purpose, the Company has conducted a valuation for the shingles and PHN indications. The negotiation process has begun in earnest, with Dr.&amp;#160;Irach Taraporewala being appointed as the new Chief Executive Officer of the Company, effective September 1, 2018. To date, TheraCour has not withheld any licenses for antiviral nanomedicines that NanoViricides has asked for, and we anticipate that the licenses to the remaining herpes viruses including VZV will be executed once the due diligence process is completed.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NatureOfOperations>
<us-gaap:SignificantAccountingPoliciesTextBlock id="Factid_2063869" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 2 - Summary of Significant Accounting Policies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Basis of Presentation &amp;#8211; Interim Financial Information&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.&amp;#160;&amp;#160;Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management,&amp;#160;considered necessary for a fair presentation of the results for the interim periods presented.&amp;#160;&amp;#160;Interim results are not necessarily indicative of the results for the full year.&amp;#160;&amp;#160;The accompanying financial statements and the information included under the heading &amp;#8220;Management&amp;#8217;s Discussion and Analysis or Plan of Operation&amp;#8221; should be read in conjunction with our Company&amp;#8217;s audited financial statements and related notes included in our Company&amp;#8217;s Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 13, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For a summary of significant accounting policies, see the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed on October 13, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Reclassifications and Prior Year Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified $296,678 of expenses related to the Company&amp;#8217;s laboratory facilities out of general and administrative expenses into research and development expenses for consistency with current year presentation. The reclassifications had no impact on the reported results of operations and net loss reported for the three months ended September 30, 2017.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Net Loss per Common Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Potentially&amp;#160;Outstanding&amp;#160;Dilutive&amp;#160;Common&amp;#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options and Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 208px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,412,039&lt;/td&gt;&lt;td style="width: 19px; padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 207px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,685,292&lt;/td&gt;&lt;td style="width: 18px; padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total potentially outstanding dilutive common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,412,039&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,685,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September 30, 2017, the number of potentially dilutive shares of the Company&amp;#8217;s common stock into which the Series C debenture&amp;#160;could be converted based upon the conversion provisions contained in the debenture was 952,381. The Series C debenture&amp;#160;was redeemed for common stock effective November 13, 2017.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has also issued 5,064,110 shares of Series A Preferred Stock to investors and others as of September 30, 2018. Only in the event of a &amp;#8220;change of control&amp;#8221; of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A &amp;#8220;Change of Control&amp;#8221; is defined as an event in which the Company&amp;#8217;s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company&amp;#8217;s intellectual property. In the absence of a Change of Control event, the Series A convertible Preferred Stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At September 30, 2018, the number of potentially dilutive shares of the Company&amp;#8217;s common stock into which these Series A Preferred shares can be converted into is 17,724,385, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following represents the basic and diluted per share calculations for loss from continuing operations:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&amp;#160;three&amp;#160;months ended&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;br/&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Calculation of basic and diluted loss per share of common stock:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 208px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(1,841,463&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 207px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(2,005,555&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Denominator for basic and diluted weighted average shares of common stock&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;69,185,965&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;63,307,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basic and diluted loss per share of common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.03&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.03&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Series C debenture&amp;#160;was redeemed for Common Stock effective November 13, 2017. See Note 7. The Series C debenture&amp;#160;was excluded from the loss per share calculation for the three-month period ended September 30, 2017 because the impact is anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Recently Issued Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the SEC issued the final rule on Disclosures About Changes in Stockholder&amp;#8217;s Equity For filings on Form 10-Q, which extends to interim periods the annual requirement in SEC Regulation S-X, Rule 3-04,2 to disclose (1) changes in stockholders&amp;#8217; equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders&amp;#8217; equity, in the form of reconciliation, for &amp;#8220;the current and comparative year-to-date [interim] periods, with subtotals for each interim period,&amp;#8221; i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 permits the disclosure of changes in stockholders&amp;#8217; equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. The staff of the SEC has indicated it would not object if the filer&amp;#8217;s first presentation of the changes in shareholders&amp;#8217; equity is included in its form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company expects to conform to this rule in its Form 10-Q for the quarter ending December 31, 2018. The Company believes that the final rule will not have a material effect on its consolidated financial statements and disclosures.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact on its financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;In July 2017, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2017-11. &amp;#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging &amp;#8211; Contracts in Entity&amp;#8217;s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;statements.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Factid_2063870" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Basis of Presentation &amp;#8211; Interim Financial Information&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.&amp;#160;&amp;#160;Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management,&amp;#160;considered necessary for a fair presentation of the results for the interim periods presented.&amp;#160;&amp;#160;Interim results are not necessarily indicative of the results for the full year.&amp;#160;&amp;#160;The accompanying financial statements and the information included under the heading &amp;#8220;Management&amp;#8217;s Discussion and Analysis or Plan of Operation&amp;#8221; should be read in conjunction with our Company&amp;#8217;s audited financial statements and related notes included in our Company&amp;#8217;s Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 13, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For a summary of significant accounting policies, see the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed on October 13, 2018.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription id="Factid_2063871" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Reclassifications and Prior Year Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified $296,678 of expenses related to the Company&amp;#8217;s laboratory facilities out of general and administrative expenses into research and development expenses for consistency with current year presentation. The reclassifications had no impact on the reported results of operations and net loss reported for the three months ended September 30, 2017.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:EarningsPerSharePolicyTextBlock id="Factid_2063872" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Net Loss per Common Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Potentially&amp;#160;Outstanding&amp;#160;Dilutive&amp;#160;Common&amp;#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options and Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 208px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,412,039&lt;/td&gt;&lt;td style="width: 19px; padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 207px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,685,292&lt;/td&gt;&lt;td style="width: 18px; padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total potentially outstanding dilutive common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,412,039&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,685,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September 30, 2017, the number of potentially dilutive shares of the Company&amp;#8217;s common stock into which the Series C debenture&amp;#160;could be converted based upon the conversion provisions contained in the debenture was 952,381. The Series C debenture&amp;#160;was redeemed for common stock effective November 13, 2017.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has also issued 5,064,110 shares of Series A Preferred Stock to investors and others as of September 30, 2018. Only in the event of a &amp;#8220;change of control&amp;#8221; of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A &amp;#8220;Change of Control&amp;#8221; is defined as an event in which the Company&amp;#8217;s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company&amp;#8217;s intellectual property. In the absence of a Change of Control event, the Series A convertible Preferred Stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At September 30, 2018, the number of potentially dilutive shares of the Company&amp;#8217;s common stock into which these Series A Preferred shares can be converted into is 17,724,385, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following represents the basic and diluted per share calculations for loss from continuing operations:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&amp;#160;three&amp;#160;months ended&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;br/&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Calculation of basic and diluted loss per share of common stock:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 208px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(1,841,463&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 207px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(2,005,555&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Denominator for basic and diluted weighted average shares of common stock&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;69,185,965&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;63,307,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basic and diluted loss per share of common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.03&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.03&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Series C debenture&amp;#160;was redeemed for Common Stock effective November 13, 2017. See Note 7. The Series C debenture&amp;#160;was excluded from the loss per share calculation for the three-month period ended September 30, 2017 because the impact is anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_2063873" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Recently Issued Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the SEC issued the final rule on Disclosures About Changes in Stockholder&amp;#8217;s Equity For filings on Form 10-Q, which extends to interim periods the annual requirement in SEC Regulation S-X, Rule 3-04,2 to disclose (1) changes in stockholders&amp;#8217; equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders&amp;#8217; equity, in the form of reconciliation, for &amp;#8220;the current and comparative year-to-date [interim] periods, with subtotals for each interim period,&amp;#8221; i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 permits the disclosure of changes in stockholders&amp;#8217; equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. The staff of the SEC has indicated it would not object if the filer&amp;#8217;s first presentation of the changes in shareholders&amp;#8217; equity is included in its form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company expects to conform to this rule in its Form 10-Q for the quarter ending December 31, 2018. The Company believes that the final rule will not have a material effect on its consolidated financial statements and disclosures.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact on its financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;In July 2017, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2017-11. &amp;#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging &amp;#8211; Contracts in Entity&amp;#8217;s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;statements.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_2063874" contextRef="P07_01_2018To09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">4412039</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_2063875" contextRef="P07_01_2017To09_30_2017_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">6685292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_2063876" contextRef="P07_01_2018To09_30_2018" unitRef="shares" decimals="INF">4412039</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_2063877" contextRef="P07_01_2017To09_30_2017" unitRef="shares" decimals="INF">6685292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:NetIncomeLoss id="Factid_2063879" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">-2005555</us-gaap:NetIncomeLoss>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_2063880" contextRef="P07_01_2018To09_30_2018" unitRef="shares" decimals="INF">69185965</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_2063881" contextRef="P07_01_2017To09_30_2017" unitRef="shares" decimals="INF">63307083</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_2063882" contextRef="P07_01_2018To09_30_2018" unitRef="USD_per_Share" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_2063883" contextRef="P07_01_2017To09_30_2017" unitRef="USD_per_Share" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
<nnvc:ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses id="Factid_2063884" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">296678</nnvc:ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses>
<us-gaap:ConvertiblePreferredStockTermsOfConversion id="Factid_2063886" contextRef="P07_01_2018To09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">60% or less</us-gaap:ConvertiblePreferredStockTermsOfConversion>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Factid_2063892" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 4 - Related Party Transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Related Parties&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Related parties with whom the Company had transactions are:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="border-bottom: 1pt solid black; white-space: nowrap; width: 472px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Related Parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; white-space: nowrap; width: 1377px; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Relationship&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anil R. Diwan&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chairman, President, significant stockholder and Director&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top; background-color:white"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Irach Taraporewala&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chief Executive Officer&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top; background-color:white"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;TheraCour Pharma, Inc.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;An entity owned and controlled by a significant stockholder&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top; background-color:white"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:top; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milton Boniuk, MD&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant stockholder&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 70%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: justify; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Account Payable &amp;#8211; Related Party&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: justify;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month&amp;#8217;&lt;/div&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;s invoice to be applied as a prepayment towards expenses.&amp;#160;&lt;/div&gt;On October 2, 2018, the Company entered into an agreement with TheraCour Pharma, Inc. for a waiver of the two month worth of prepaid balance advance of anticipated invoicing and the application of the current advance as a credit against current open invoices, Additionally, TheraCour has agreed to defer $25,000 per month of development fees for six months,&amp;#160;beginning&amp;#160;with&amp;#160;July&amp;#160;2018. Accounts payable due TheraCour on the reporting date was&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;718,457&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;107,468&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.25in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the three months ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;&lt;br/&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;&lt;br/&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-decoration: none; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs Paid to Related Parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 208px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 207px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company&amp;#8217;s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2018 and June 30, 2018.&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;846,688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;847,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Debenture Interest Payable to a Director&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Coupon interest expense on the $5,000,000 Series C Debenture&amp;#160;paid to Dr. Milton Boniuk for the three months ended September 30, 2017 was $125,000. The Series C debenture&amp;#160;was redeemed for Common Stock effective November 13, 2017. See Note 7.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock id="Factid_2063893" contextRef="P07_01_2018To09_30_2018">&lt;table style="width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 70%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: justify; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Account Payable &amp;#8211; Related Party&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: justify;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month&amp;#8217;&lt;/div&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;s invoice to be applied as a prepayment towards expenses.&amp;#160;&lt;/div&gt;On October 2, 2018, the Company entered into an agreement with TheraCour Pharma, Inc. for a waiver of the two month worth of prepaid balance advance of anticipated invoicing and the application of the current advance as a credit against current open invoices, Additionally, TheraCour has agreed to defer $25,000 per month of development fees for six months,&amp;#160;beginning&amp;#160;with&amp;#160;July&amp;#160;2018. Accounts payable due TheraCour on the reporting date was&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;718,457&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;107,468&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.25in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the three months ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;&lt;br/&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;&lt;br/&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-decoration: none; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs Paid to Related Parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 208px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 207px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company&amp;#8217;s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2018 and June 30, 2018.&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;846,688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;847,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent id="Factid_2063894" contextRef="PAsOn09_30_2018_TheracourPharmaIncMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">718457</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent id="Factid_2063895" contextRef="PAsOn06_30_2018_TheracourPharmaIncMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">107468</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_2063896" contextRef="P07_01_2018To09_30_2018_TheracourPharmaIncMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">846688</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_2063897" contextRef="P07_01_2017To09_30_2017_TheracourPharmaIncMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">847093</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:RelatedPartyTransactionDescriptionOfTransaction id="Factid_2063898" contextRef="P07_01_2018To09_30_2018">costs (direct and indirect) plus no more than 30% of direct costs</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
<us-gaap:OtherGeneralAndAdministrativeExpense id="Factid_2063899" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">2000</us-gaap:OtherGeneralAndAdministrativeExpense>
<nnvc:PercentageOfNetSalesAllocatedForRoyaltyPayments id="Factid_2063900" contextRef="P07_01_2018To09_30_2018" unitRef="pure" decimals="2">0.15</nnvc:PercentageOfNetSalesAllocatedForRoyaltyPayments>
<us-gaap:InterestExpenseDebt id="Factid_2063901" contextRef="P07_01_2017To09_30_2017_DrBoniukMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesCConvertibleDebentureMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">125000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt id="Factid_2063902" contextRef="P07_01_2017To09_30_2017" unitRef="USD" decimals="0">5000000</us-gaap:InterestExpenseDebt>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Factid_2063903" contextRef="P07_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 5 - Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, stated at cost, less accumulated depreciation consisted of the following:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 70.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;GMP Facility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,020,471&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,011,230&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Land&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;260,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;260,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office Equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and Fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,607&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,607&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab Equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,711,778&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,683,765&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,055,637&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,018,383&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less Accumulated Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,348,610&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,177,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment, Net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,707,027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,841,093&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense for the three months ended September 30, 2018 and 2017 was $171,320 and $166,189, respectively.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock id="Factid_2063904" contextRef="P07_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, stated at cost, less accumulated depreciation consisted of the following:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 70.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;GMP Facility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,020,471&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,011,230&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Land&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;260,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;260,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office Equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and Fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,607&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,607&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab Equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,711,778&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,683,765&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,055,637&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,018,383&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less Accumulated Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,348,610&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,177,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment, Net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,707,027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,841,093&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock id="Factid_2063905" contextRef="P07_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 6 - Trademark and Patents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trademark and patents, stated at cost, less accumulated amortization consisted of the following:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trademarks and Patents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;458,954&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;458,954&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less Accumulated Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(86,094&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(84,025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trademarks and Patents, Net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;372,860&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;374,929&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization expense amounted to $2,069&amp;#160;and $2,068 for the three months ended September 30, 2018 and 2017, respectively.&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock id="Factid_2063906" contextRef="P07_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trademark and patents, stated at cost, less accumulated amortization consisted of the following:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align:left;"&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trademarks and Patents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;458,954&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;458,954&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less Accumulated Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(86,094&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(84,025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trademarks and Patents, Net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;372,860&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;374,929&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:DebtDisclosureTextBlock id="Factid_2063907" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 7 - Convertible Debenture and Derivatives&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Debenture - Series C&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s Series C&amp;#160;Convertible Debenture, in the amount of $5,000,000, was redeemed on November 13, 2017. For the three month period ended September 30, 2017,&amp;#160;the Holder of the Company&amp;#8217;s Series C Convertible Debenture&amp;#160;elected to receive $125,000 of their coupon interest payment and $41,667 of deferred interest payment in cash.&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s Series C Debenture in the amount of $5,000,000 was due to mature on June 30, 2018. On November 13, 2017, the Company entered into a Debenture Redemption Agreement (the &amp;#8220;Agreement&amp;#8221;) with the Holder, to redeem (the &amp;#8220;Redemption&amp;#8221;) its $5,000,000 Series C Convertible Debenture (the &amp;#8220;Debenture&amp;#8221;) for an aggregate of 5,500,000 shares of the Company&amp;#8217;s $0.001 par value Common Stock (&amp;#8220;Purchase Price&amp;#8221;) comprising 5,000,000 shares for the principal of the Debenture and 500,000 shares for unpaid coupon interest from October 1, 2017 through June 30, 2018. The unpaid interest included $60,274 of accrued interest through November 13, 2017, $314,726 in coupon interest through June 30, 2018 and $125,000 of unpaid deferred interest. The price per share was equal to the closing price of the Company&amp;#8217;s stock on Friday, November 10, 2017 of one ($1.00) dollar per share. The Holder waived all early redemption penalty payments provided for in the Debenture for consideration of 150,000 shares of the Company&amp;#8217;s $0.001 par value Series A Convertible Preferred Stock. The Company did not incur placement agent fees in redemption of the Series C Convertible Debenture. The Company recognized a non-cash loss on extinguishment of debt of $1,348,247 on the extinguishment of the aforesaid principal attributable to the Series C Debentures into the Company&amp;#8217;s common and preferred stock. The loss on extinguishment arises from, the obligation to issue 150,000 shares of the Company&amp;#8217;s Series A Preferred shares with a fair value of $364,337, as of November 13, 2017, obligation to issue 314,726 shares of the Company&amp;#8217;s $0.001 par value Common Stock with a fair value of $314,726 as of November 13, 2017, in consideration of Debenture coupon interest from the redemption date through June 30, 2018, and unamortized discount of $684,633 as of the redemption date, offset by the derivative liability of ($&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,449&lt;/div&gt;) as of the redemption date.&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the redemption agreement for the Company&amp;#8217;s Series C Debenture, the Company issued 5,500,000 shares of its registered Common Stock from its shelf registration and the 150,000 shares of its Series A Preferred Stock upon receiving consent to issue the shares pursuant to New York Stock Exchange (&amp;#8220;NYSE&amp;#8221;) regulations. The Company submitted a request for authorization to issue the Common Stock and Series A Preferred Shares to the NYSE, which was authorized on March 18, 2018 and the shares were issued on March 21, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 2, 2014, in conjunction with the issuance of the Company&amp;#8217;s Series C Convertible Debentures, the Company issued 187,000 shares of its Series A Convertible Preferred Stock (the &amp;#8220;Series A&amp;#8221;) to Dr. Milton Boniuk, pursuant to the terms of the Debenture. Proceeds received in a financing transaction are allocated to the instruments issued prior to evaluating hybrid contracts for bifurcation of embedded derivatives. Since the Series A Convertible Preferred Stock is classified as equity, the proceeds allocated to the Preferred Stock are recorded at relative fair value. The fair value of the Series A was $1,645,606 at issuance and the relative fair value was calculated as $1,152,297. The remaining amount of the proceeds was allocated to the Debenture and a debt discount of $1,152,297 was recorded to offset the amount of the proceeds allocated to the Series A. Then, the embedded derivative was bifurcated at its fair value of $1,879,428 with the remaining balance allocated to the host instrument (Debenture). The total debt discount was amortized over the actual term of the Debenture using the effective interest method.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized amortization of this discount as an additional interest charge to &amp;#8220;Discount on convertible debentures&amp;#8221; in the amount of $ -0- and $239,351 for the three month periods ended September 30, 2018 and 2017, respectively.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:LongTermDebtNoncurrent id="Factid_2063908" contextRef="PAsOn11_13_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">5000000</us-gaap:LongTermDebtNoncurrent>
<nnvc:CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment id="Factid_2063909" contextRef="P07_01_2017To09_30_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">125000</nnvc:CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment>
<nnvc:DeferredInterestPayment id="Factid_2063910" contextRef="P07_01_2017To09_30_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">41667</nnvc:DeferredInterestPayment>
<us-gaap:ProceedsFromConvertibleDebt id="Factid_2063912" contextRef="P06_20_2014To07_02_2014_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">1645606</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:RepaymentsOfOtherDebt id="Factid_2063913" contextRef="P06_20_2014To07_02_2014_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">1152297</us-gaap:RepaymentsOfOtherDebt>
<us-gaap:DebtInstrumentUnamortizedDiscount id="Factid_2063914" contextRef="PAsOn07_02_2014_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">1152297</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtConversionConvertedInstrumentAmount1 id="Factid_2063915" contextRef="P06_20_2014To07_02_2014_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">1879428</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:AmortizationOfDebtDiscountPremium id="Factid_2063916" contextRef="P07_01_2018To09_30_2018_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium id="Factid_2063917" contextRef="P07_01_2017To09_30_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">239351</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:DerivativeLiabilities id="Factid_2063918" contextRef="PAsOn06_30_2018_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">15449</us-gaap:DerivativeLiabilities>
<us-gaap:StockIssuedDuringPeriodSharesOther id="Factid_2063919" contextRef="P11_01_2017To11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="shares" decimals="INF">314726</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:InterestPayableCurrent id="Factid_2063920" contextRef="PAsOn11_13_2017_SeriesCConvertibleDebentureMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="USD" decimals="0">60274</us-gaap:InterestPayableCurrent>
<us-gaap:DebtConversionDescription id="Factid_2063922" contextRef="P11_01_2017To11_13_2017">for an aggregate of 5,500,000 shares of the Company&amp;#8217;s $0.001 par value Common Stock (&amp;#8220;Purchase Price&amp;#8221;) comprising 5,000,000 shares for the principal of the Debenture and 500,000 shares for unpaid coupon interest from October 1, 2017 through June 30, 2018.</us-gaap:DebtConversionDescription>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Factid_2063925" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 9 - Equity Transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 11, 2018 the Board of Directors approved an extension of the employment agreement with Dr. Anil Diwan, the Company&amp;#8217;s President. Pursuant to the terms of the employment agreement, the Company&amp;#8217;s Board of Directors authorized the issuance of 525,000 of the Company&amp;#8217;s Series A preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30, 2020 and June 30, 2021&amp;#160;and are subject to forfeiture. The Company recognized a non-cash compensation expense related to the issuance of the Series A Preferred stock of $47,260 for the three months ended September 30, 2018.&amp;#160;The balance of $513,430 &lt;/div&gt;will be recognized as the shares vest&amp;#160;and service is rendered&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the three months ended September 30, 2018, the Company&amp;#8217;s Board of Directors authorized the issuance of 7,716 fully vested shares of its Series A Convertible Preferred stock for employee compensation. The Company recorded an expense of $7,767.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Series A Preferred stock was the following for the dates indicated:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-indent: 0.5in; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 50%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 585px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7/11/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;525,000&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;560,690&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 9px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7/31/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,572&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,795&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8/31/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,572&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,374&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-bottom: 1pt; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;9/30/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,572&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,598&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 1.5pt;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;532,716&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;568,457&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-indent: 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred stock at each issuance used the following inputs:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The common stock price was in the range $.42 to $.58;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculated weighted average number of shares of common stock in the period;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;c.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; 26.63&lt;/div&gt;% premium over the common shares for the voting preferences;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;d.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.22% to 19.25% of the total;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;e.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 2.09 years;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;f.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;29.42% to 32.24% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 55.76% to 61.17% volatility, 2.09% to 2.11% risk free rate) applied to the converted common.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 19, 2018, the Company entered into an Employment Agreement with Dr. Irach Taraporewala as Chief Executive Officer of the Company beginning on September 1, 2018. Dr. Taraporewala was granted options to purchase up to 300,000 shares of the Company&amp;#8217;s common stock, par value $0.001 per share at an exercise price equal to 20% above the closing bid price of $0.41 &lt;/div&gt;of the common stock on September 1, 2018 (&amp;#8220;Effective Date&amp;#8221;). The options shall vest in three, equal, annual installments commencing on the Effective Date. The fair value of the options &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;was $35,761 of which $11,920 was recognized and recorded as compensation expense for the three months ended September 30, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0in; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of the options granted to&amp;#160;Dr. Taraporewala on the date of grant using a lattice simulation model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0in; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 11,432 shares of common stock with an exercise price of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.41&lt;/div&gt; per share expiring in August 2022.&amp;#160;&amp;#160;The fair value of the warrants was $1,543 and was recorded as consulting expense for the three months ended September 30, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1642px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (year)&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;55.12&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected annual rate of quarterly dividends&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate(s)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.71&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the three months ended September 30, 2018, the Company&amp;#8217;s Board of Directors authorized the issuance of 191,510 fully vested shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $79,460 for the three months, which was the fair value on the dates of issuance.&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the three months ended September 30, 2018, the Company&amp;#8217;s Board of Directors authorized the issuance of 19,310 &lt;/div&gt;fully vested shares of its common stock with a restrictive legend for Director Services. The Company recorded an expense&amp;#160;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;of&amp;#160;$7,500 &lt;/div&gt;for the three months, which was the fair value on the date of &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;issuance.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<nnvc:ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock id="Factid_2063926" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Series A Preferred stock was the following for the dates indicated:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-indent: 0.5in; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 50%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 585px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7/11/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;525,000&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;560,690&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 9px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7/31/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,572&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,795&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;8/31/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,572&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,374&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-bottom: 1pt; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;9/30/2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,572&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,598&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 1.5pt;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;532,716&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;568,457&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nnvc:ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock>
<us-gaap:ScheduleOfStockholdersEquityTableTextBlock id="Factid_2063927" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1642px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (year)&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;55.12&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected annual rate of quarterly dividends&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate(s)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.71&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross id="Factid_2063928" contextRef="P07_01_2018To09_30_2018_IssuanceDateOneMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">525000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross id="Factid_2063929" contextRef="P07_01_2018To09_30_2018_IssuanceDateOneMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">560690</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross id="Factid_2063930" contextRef="P07_01_2018To09_30_2018_IssuanceDateTwoMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">2572</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross id="Factid_2063931" contextRef="P07_01_2018To09_30_2018_IssuanceDateTwoMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">2795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross id="Factid_2063932" contextRef="P07_01_2018To09_30_2018_IssuanceDateThreeMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">2572</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross id="Factid_2063933" contextRef="P07_01_2018To09_30_2018_IssuanceDateThreeMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">2374</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross id="Factid_2063934" contextRef="P07_01_2018To09_30_2018_IssuanceDateFourMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">2572</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross id="Factid_2063935" contextRef="P07_01_2018To09_30_2018_IssuanceDateFourMemberusgaapAwardDateAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">2598</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross id="Factid_2063936" contextRef="P07_01_2018To09_30_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="shares" decimals="INF">532716</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross id="Factid_2063937" contextRef="P07_01_2018To09_30_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">568457</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_2063938" contextRef="P07_01_2018To09_30_2018">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_2063939" contextRef="P07_01_2018To09_30_2018" unitRef="pure" decimals="4">0.5512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Factid_2063940" contextRef="P07_01_2018To09_30_2018_ScientificAdvisoryBoardMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="pure" decimals="5">0.00000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_2063941" contextRef="P07_01_2018To09_30_2018" unitRef="pure" decimals="4">0.0271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_2063942" contextRef="PAsOn09_30_2018" unitRef="shares" decimals="INF">7716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:RestrictedStockExpense id="Factid_2063943" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">7767</us-gaap:RestrictedStockExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_2063944" contextRef="P07_01_2018To07_19_2018" unitRef="shares" decimals="INF">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_2063945" contextRef="PAsOn07_19_2018" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="Factid_2063946" contextRef="P07_01_2018To07_19_2018" unitRef="pure" decimals="1">0.2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
<us-gaap:SharePrice id="Factid_2063947" contextRef="PAsOn07_19_2018" unitRef="USD_per_Share" decimals="2">0.41</us-gaap:SharePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 id="Factid_2063948" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">35761</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_2063950" contextRef="PAsOn07_11_2018_PresidentMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensation id="Factid_2063951" contextRef="P07_01_2018To09_30_2018_PresidentMemberusgaapTitleOfIndividualAxis" unitRef="USD" decimals="0">47260</us-gaap:ShareBasedCompensation>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Factid_2063952" contextRef="PAsOn09_30_2018_PresidentMemberusgaapTitleOfIndividualAxis" unitRef="USD" decimals="0">513430</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<nnvc:NumberOfCommonStockToBeIssuedUponConversionOfWarrants id="Factid_2063953" contextRef="P07_01_2018To09_30_2018_AugustTwoThousandNineteenMemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="shares" decimals="INF">11432</nnvc:NumberOfCommonStockToBeIssuedUponConversionOfWarrants>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_2063954" contextRef="PAsOn09_30_2018_February2022MemberdeiLegalEntityAxis_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="USD_per_Share" decimals="2">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_2063955" contextRef="P07_01_2018To09_30_2018_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="USD" decimals="0">1543</us-gaap:AllocatedShareBasedCompensationExpense>
<nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage id="Factid_2063956" contextRef="P07_01_2018To09_30_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="4">0.2663</nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_2063957" contextRef="PAsOn09_30_2018_DirectorMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">191510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<nnvc:RestrictedCommonStockAuthorizedForInterestPayable id="Factid_2063958" contextRef="P07_01_2018To09_30_2018_DirectorMemberusgaapTitleOfIndividualAxis" unitRef="shares" decimals="INF">19310</nnvc:RestrictedCommonStockAuthorizedForInterestPayable>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="Factid_2063959" contextRef="P07_01_2018To09_30_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD" decimals="0">79460</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:ShareBasedCompensation id="Factid_2063960" contextRef="P07_01_2018To09_30_2018_DirectorMemberusgaapTitleOfIndividualAxis" unitRef="USD" decimals="0">7500</us-gaap:ShareBasedCompensation>
<nnvc:FairValueMeasurementSignificantAssumptions id="Factid_2063962" contextRef="P07_01_2018To09_30_2018">a.The common stock price was in the range $.42 to $.58;b.The calculated weighted average number of shares of common stock in the period;c.A 26.63% premium over the common shares for the voting preferences;d.The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.22% to 19.25% of the total;e.The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 2.09 years;f.29.42% to 32.24% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 55.76% to 61.17% volatility, 2.09% to 2.11% risk free rate) applied to the converted common.</nnvc:FairValueMeasurementSignificantAssumptions>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Factid_2063963" contextRef="P07_01_2018To09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis">&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&amp;#160;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&amp;#160;of&amp;#160;&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&amp;#160;&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Exercise&lt;br/&gt;Price&amp;#160;&lt;br/&gt;per&amp;#160;share&amp;#160;&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Remaining&amp;#160;&lt;br/&gt;Contractual&amp;#160;Term&lt;br/&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 831px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Outstanding and exercisable at June 30, 2018&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,969,588&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4.80&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.53&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 37px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 188px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;11,432&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.41&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;2,868,981&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;5.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Outstanding and exercisable at September 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,112,039&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4.48&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.63&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Factid_2063968" contextRef="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&amp;#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&amp;#160;of&amp;#160;&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&amp;#160;&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Exercise&lt;br/&gt;Price&amp;#160;&lt;br/&gt;per&amp;#160;share&amp;#160;&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Remaining&amp;#160;&lt;br/&gt;Contractual&amp;#160;Term&lt;br/&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 831px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Granted&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;300,000&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.50&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 37px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 188px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Outstanding at September 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;300,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;2.92&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:SubsequentEventsTextBlock id="Factid_2063969" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 13&amp;#160;- Subsequent Events&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 29, 2018, the Board of Directors of NanoViricides, Inc. (the &amp;#8220;Company&amp;#8221;) elected James Sapirstein as a new member of the Board. Mr.&amp;#160;Sapirstein is an Independent Member of the Board of Directors and will serve as a member of the Company&amp;#8217;s Audit, Compensation and Nominating Committees.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Factid_2063970" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 12&amp;#160;- Commitments and Contingencies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Legal Proceedings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no pending legal proceedings against the Company to the best of the Company&amp;#8217;s knowledge as of the date hereof and to the Company&amp;#8217;s knowledge, no action, suit or proceeding has been threatened against the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Employment Agreements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an extension of employment agreement effective July 1, 2018 for a term of three years. Dr. Diwan&amp;#8217;s will be paid an annual base salary of $400,000. Additionally, Dr. Diwan was awarded a grant of 525,000 shares of the Company&amp;#8217;s Series A Preferred Stock. 175,000 shares vest equally on June 30, 2019, 2020 and 2021. Any unvested shares are subject to forfeiture.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company and Dr. Irach Taraporewala, the Company&amp;#8217;s Chief Executive Officer, entered into an employment agreement effective September 1, 2018, for a term of three years. Dr. Taraporewala&amp;#160;will be paid an annual base salary of $360,000. Additionally, Dr. Taraporewala was awarded a grant of 300,000 options to purchase shares of the Company&amp;#8217;s Common Stock. 100,000 options vested on September 1, 2018 and the remainder of the options will vest over the two&amp;#160;year&amp;#160;vesting&amp;#160;period&amp;#160;and are subject to forfeiture.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development.&amp;#160;&amp;#160;The employment agreement provides for a term of four years with a base salary of $150,000.&amp;#160;&amp;#160;In addition, the Company issued 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock upon entering into the agreement, and issued an additional 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock on each anniversary date of the agreement. The shares of Series A Preferred Stock were issued in recognition of Dr. Tatake&amp;#8217;s work towards the achievement of several patents by the Company. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer.&amp;#160;&amp;#160;The employment agreement provided for a term of four years with a base salary of $150,000.&amp;#160;&amp;#160;In addition, the Company issued 35,715 shares of common stock upon entering into the agreement, and issued an additional 35,715 shares of common stock on each anniversary date of the agreement. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer.&amp;#160;&amp;#160;The employment agreement provided for a term of three years with a base salary of $9,000 per month and 2,572 shares of Series A Preferred Stock, also on a monthly basis. On January 1, 2015, her cash compensation was increased to $10,800 per month. The Agreement is renewable on an annual basis. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;License Agreements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is dependent upon its license agreement with TheraCour (See Note 4). &lt;/div&gt; If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. The Company is currently negotiating for a license for VZV&amp;#160;from the Licensor, TheraCour. For this purpose, the Company has conducted a valuation for the shingles and PHN indications. Dr. Irach Taraporewala was appointed as the new Chief Executive Officer of the Company, effective September 1, 2018, and is leading the negotiation process with TheraCour. TheraCour has not withheld any licenses for antiviral nanomedicines sought by the Company and we anticipate that the licenses for VZV will be executed once the due diligence process is completed.&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense id="Factid_2063971" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">400000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="Factid_2063972" contextRef="P07_01_2018To09_30_2018_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="shares" decimals="INF">175000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="Factid_2063973" contextRef="P07_01_2018To09_30_2018_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="shares" decimals="INF">175000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="Factid_2063974" contextRef="P07_01_2018To09_30_2018_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis" unitRef="shares" decimals="INF">175000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense id="Factid_2063975" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_YearOneMembernnvcDeferredCompensationYearAxis" unitRef="USD" decimals="0">360000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense id="Factid_2063976" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_YearTwoMembernnvcDeferredCompensationYearAxis" unitRef="USD" decimals="0">300000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense id="Factid_2063977" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_YearThreeMembernnvcDeferredCompensationYearAxis" unitRef="USD" decimals="0">100000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
<us-gaap:FairValueDisclosuresTextBlock id="Factid_2063978" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 11&amp;#160;- Fair Value Measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements&lt;div style="font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September 30, 2018 and June 30, 2018 the estimated fair values of the liabilities measured on a recurring basis are as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;2018:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&amp;#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&amp;#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&amp;#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; width: 61%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 61%;"&gt;Derivative liability - warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;"&gt;122,541&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;;text-align:left;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;Fair Value Measurements at&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;June 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; background-color: rgb(204, 238, 255); width: 61%; vertical-align: bottom;"&gt;Derivative liability - warrants&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; text-align: left; vertical-align: bottom; padding: 0in;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;"&gt;298,092&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In conjunction with the Company&amp;#8217;s registered direct offerings of Units, consisting of the Company&amp;#8217;s common stock and warrants, on September 12, 2013 and January 24, 2014, the Company &lt;/div&gt;issued an aggregate of &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,425,363 warrants, of which 2,479,935&amp;#160;&lt;/div&gt;and 5,290,006, are outstanding at September 30, 2018 and June 30, 2018, respectively. Additionally, the Company &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;issued 135,216 &lt;/div&gt;warrants&amp;#160;to the placement agents of which&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;76,306&amp;#160;&lt;/div&gt;and 135,216, are also outstanding at September 30, 2018 and June 30, 2018, respectively, for a total number &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;of 2,556,241 &lt;/div&gt;and 5,425,222 warrants outstanding and issued as of September 30, 2018 and June 30, 2018,&amp;#160;respectively,&amp;#160;pursuant to the aforesaid registered direct &lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;offerings.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Warrants were valued as of September 30, 2018 and June 30, 2018 with the following assumptions:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The 5-year warrants issued on 9/12/13 and 1/24/14 included Investor and Placement Agent Warrants with an exercise price of $5.25 and $6.05 (subject to adjustments-full ratchet reset).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-align: justify; text-indent: -17.95pt; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock price would fluctuate with the Company projected volatility.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-align: justify; text-indent: -17.95pt; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of&amp;#160;&lt;div style="font-weight:bold;display:inline;"&gt;2 times&lt;/div&gt;&amp;#160;the projected exercise/reset price or&amp;#160;&lt;div style="font-weight:bold;display:inline;"&gt;2 times&lt;/div&gt;&amp;#160;the stock price.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="width: 50%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1 Year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 81%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;9/30/18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6/30/18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;56&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160; &amp;#160;&amp;#160;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160; &amp;#160; &amp;#160; &amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Using Significant Unobservable Inputs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 2.8pt; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 15.4pt; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0pt 0px; text-align: center; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1604px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Beginning balance at July 1, 2018&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 208px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;298,092&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Additions during the year&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Change in fair value&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(175,551&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Transfer in and out of Level 3&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;Balance at September 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;122,541&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock id="Factid_2063979" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September 30, 2018 and June 30, 2018 the estimated fair values of the liabilities measured on a recurring basis are as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&amp;#160;2018:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&amp;#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&amp;#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&amp;#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; width: 61%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 61%;"&gt;Derivative liability - warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;"&gt;122,541&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;;text-align:left;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;Fair Value Measurements at&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;June 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; background-color: rgb(204, 238, 255); width: 61%; vertical-align: bottom;"&gt;Derivative liability - warrants&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; text-align: left; vertical-align: bottom; padding: 0in;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;"&gt;298,092&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="Factid_2063983" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2018:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160; &amp;#160;&amp;#160;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160; &amp;#160; &amp;#160; &amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;Measurement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Using Significant Unobservable Inputs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 2.8pt; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 15.4pt; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0pt 0px; text-align: center; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1604px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Beginning balance at July 1, 2018&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 208px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;298,092&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Additions during the year&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Change in fair value&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(175,551&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Transfer in and out of Level 3&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;Balance at September 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;122,541&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:DerivativeLiabilitiesNoncurrent id="Factid_2063984" contextRef="PAsOn09_30_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent id="Factid_2063985" contextRef="PAsOn09_30_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent id="Factid_2063986" contextRef="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">122541</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent id="Factid_2063990" contextRef="PAsOn06_30_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent id="Factid_2063991" contextRef="PAsOn06_30_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent id="Factid_2063992" contextRef="PAsOn06_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">298092</us-gaap:DerivativeLiabilitiesNoncurrent>
<nnvc:FairValueAssumptionExpectedVolatilityRate id="Factid_2063993" contextRef="P07_01_2018To09_30_2018_OneYearEnded93018MemberusgaapStatementClassOfStockAxis" unitRef="pure" decimals="2">0.64</nnvc:FairValueAssumptionExpectedVolatilityRate>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_2063995" contextRef="PAsOn09_30_2018_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="shares" decimals="INF">76306</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_2063996" contextRef="PAsOn09_30_2018_ScientificAdvisoryBoardMemberusgaapSubsidiarySaleOfStockAxis" unitRef="shares" decimals="INF">2556241</us-gaap:ClassOfWarrantOrRightOutstanding>
<nnvc:WarrantExpirationTerm id="Factid_2063997" contextRef="P01_02_2014To01_24_2014_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">P5Y</nnvc:WarrantExpirationTerm>
<nnvc:WarrantExpirationTerm id="Factid_2063998" contextRef="P08_13_2013To09_12_2013_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis">P5Y</nnvc:WarrantExpirationTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_2063999" contextRef="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">P6M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_2064000" contextRef="PAsOn06_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_2064002" contextRef="PAsOn09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_2064003" contextRef="P07_01_2017To06_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">P6M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_2064004" contextRef="PAsOn06_30_2017_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_2064005" contextRef="PAsOn06_30_2017_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_2064006" contextRef="PAsOn06_30_2018_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_2064007" contextRef="P07_01_2018To09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm id="Factid_2064008" contextRef="P07_01_2018To09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis">P0Y</nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_2064009" contextRef="PAsOn09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_2064010" contextRef="P07_01_2018To09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis">P2Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_2064011" contextRef="P07_01_2018To09_30_2018" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_2064012" contextRef="PAsOn09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_2064013" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Factid_2064014" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" unitRef="pure" decimals="5">0.00000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_2064015" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" unitRef="pure" decimals="4">0.0271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<nnvc:WarrantsExercisable id="Factid_2064017" contextRef="P07_01_2018To09_30_2018_June302019MembernnvcFuturePeriodAxis" unitRef="shares" decimals="INF">3679127</nnvc:WarrantsExercisable>
<nnvc:WarrantsExercisable id="Factid_2064018" contextRef="P07_01_2018To09_30_2018_June302020MembernnvcFuturePeriodAxis" unitRef="shares" decimals="INF">68592</nnvc:WarrantsExercisable>
<nnvc:WarrantsExercisable id="Factid_2064019" contextRef="P07_01_2018To09_30_2018_June302021MembernnvcFuturePeriodAxis" unitRef="shares" decimals="INF">57160</nnvc:WarrantsExercisable>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="Factid_2064020" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">35761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:StockOptionPlanExpense id="Factid_2064021" contextRef="P07_01_2018To09_30_2018" unitRef="USD" decimals="0">11920</us-gaap:StockOptionPlanExpense>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_2064022" contextRef="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="USD_per_Share" decimals="2">0.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Factid_2064023" contextRef="P11_01_2017To11_13_2017" unitRef="shares" decimals="INF">150000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Factid_2064024" contextRef="P11_01_2017To11_13_2017_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="shares" decimals="INF">150000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Factid_2064025" contextRef="P06_20_2014To07_02_2014_SeriesAConvertiblePreferredStockMemberusgaapDebtConversionByUniqueDescriptionAxis" unitRef="shares" decimals="INF">187000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Factid_2064026" contextRef="P07_01_2017To09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesCConvertibleDebenturesMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">952381</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:SharePrice id="Factid_2064027" contextRef="PAsOn09_30_2018" unitRef="USD_per_Share" decimals="2">0.42</us-gaap:SharePrice>
<us-gaap:SharePrice id="Factid_2064028" contextRef="PAsOn09_30_2018_MaximumMembersrtRangeAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="USD_per_Share" decimals="2">0.58</us-gaap:SharePrice>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Factid_2064029" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Potentially&amp;#160;Outstanding&amp;#160;Dilutive&amp;#160;Common&amp;#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options and Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 208px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,412,039&lt;/td&gt;&lt;td style="width: 19px; padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 207px; border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,685,292&lt;/td&gt;&lt;td style="width: 18px; padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total potentially outstanding dilutive common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,412,039&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,685,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following represents the basic and diluted per share calculations for loss from continuing operations:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&amp;#160;the&amp;#160;three&amp;#160;months ended&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;br/&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Calculation of basic and diluted loss per share of common stock:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1321px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 208px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(1,841,463&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 207px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(2,005,555&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Denominator for basic and diluted weighted average shares of common stock&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;69,185,965&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;63,307,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basic and diluted loss per share of common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.03&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: 2.5pt double black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.03&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<nnvc:SharePriceAsPerRedemptionAgreement id="Factid_2064030" contextRef="PAsOn09_30_2018" unitRef="USD_per_Share" decimals="2">1.00</nnvc:SharePriceAsPerRedemptionAgreement>
<us-gaap:AccountsPayableTradeCurrent id="Factid_2064033" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">320097</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableTradeCurrent id="Factid_2064034" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">223339</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent id="Factid_2064035" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">718457</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent id="Factid_2064036" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">107468</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent id="Factid_2064037" contextRef="PAsOn09_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">122541</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent id="Factid_2064038" contextRef="PAsOn06_30_2018_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">298092</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_2064039" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">231175</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_2064040" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">253049</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_2064041" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">1392270</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_2064042" contextRef="PAsOn06_30_2018" unitRef="USD" decimals="0">881948</us-gaap:LiabilitiesCurrent>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_2064043" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" unitRef="pure" decimals="4">0.5509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<nnvc:WarrantsExercisable id="Factid_2064044" contextRef="P07_01_2018To09_30_2018_June302022MembernnvcFuturePeriodAxis" unitRef="shares" decimals="INF">45728</nnvc:WarrantsExercisable>
<nnvc:WarrantsExercisable id="Factid_2064045" contextRef="P07_01_2018To09_30_2018_June302023MembernnvcFuturePeriodAxis" unitRef="shares" decimals="INF">261432</nnvc:WarrantsExercisable>
<nnvc:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="Factid_2064048" contextRef="P07_01_2018To09_30_2018_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" unitRef="pure" decimals="4">0.0500</nnvc:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Factid_2064049" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 10 - Stock Warrants and Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Stock Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&amp;#160;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&amp;#160;of&amp;#160;&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&amp;#160;&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Exercise&lt;br/&gt;Price&amp;#160;&lt;br/&gt;per&amp;#160;share&amp;#160;&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Remaining&amp;#160;&lt;br/&gt;Contractual&amp;#160;Term&lt;br/&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 831px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Outstanding and exercisable at June 30, 2018&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;6,969,588&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4.80&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.53&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 37px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 188px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;11,432&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.41&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Expired&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;2,868,981&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;5.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Outstanding and exercisable at September 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4,112,039&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;4.48&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.63&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;Of the above warrants,&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;3,679,127 &lt;/div&gt;expire in fiscal year ending June 30, 2019;&amp;#160;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;68,592 &lt;/div&gt;expire in fiscal year ending June 30, 2020,&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; 57,160 &lt;/div&gt;expire in fiscal year ending June 30, 2021, 45,728 expire in the fiscal year ending June 30, 2022 and 261,432 warrants expire in the fiscal year ending June 30, 2023.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Stock Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&amp;#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&amp;#160;of&amp;#160;&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&amp;#160;&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Exercise&lt;br/&gt;Price&amp;#160;&lt;br/&gt;per&amp;#160;share&amp;#160;&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&amp;#160;&lt;br/&gt;Remaining&amp;#160;&lt;br/&gt;Contractual&amp;#160;Term&lt;br/&gt;(years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 831px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Granted&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;300,000&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.50&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 38px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;-&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 37px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; width: 188px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;Outstanding at September 30, 2018&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;300,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;2.92&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Of the above options, 100,000 &lt;/div&gt;are vested and exercisable as of&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; September 30, 2018, 100,000 &lt;/div&gt;become vested and exercisable on September 1, 2019 and 100,000 become vested and exercisable on September 1, 2020. The options expire on August 31, 2021. The options will not become vested and exercisable until the option is vested pursuant to the vesting schedule set forth above, provided that Dr. Taraporewala continues to be employed by, or provide service to, the Company. If Dr. Taraporewala&amp;#8217;s continuous service terminates for any reason other than cause, any such option exercisable as of the date of termination may be exercised at any time by the participant prior to the expiration date. If Dr. Taraporewala&amp;#8217;s continuous service should be terminated for &amp;#8220;Cause&amp;#8221; (as defined in the option), then any outstanding option, vested or unvested, shall terminate immediately and shall no longer be exercisable&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of the option grant at $35,761 and recognized the estimated value of the vested and exercisable options as a compensation expense of $11,920 for the three months ended September 30, 2018.&amp;#160;The Company will recognize the remaining unrecognized fair value of the option grant of&amp;#160;$23,841&amp;#160;in installments over&amp;#160;the&amp;#160;vesting&amp;#160;period.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;/div&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;The Company estimated the fair value of the options granted to Dr. Taraporewala on the date of grant using a lattice model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1642px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected life (year)&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;3&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;55.09&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected annual rate of quarterly dividends&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.00&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Risk-free rate(s)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;2.71&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected forfeiture (attrition) rate (%)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none; font-size: 10pt; text-align: justify;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility is based on historical volatility of the Company&amp;#8217;s common stock and the expected life of options. The Company estimates forfeitures at the time of valuation and reduces expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ or are expected to differ, from the previous estimate.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Factid_2064050" contextRef="P07_01_2018To09_30_2018">&lt;div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;The Company estimated the fair value of the options granted to Dr. Taraporewala on the date of grant using a lattice model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 1642px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected life (year)&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 189px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;3&lt;/td&gt;&lt;td style="width: 18px; font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;55.09&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected annual rate of quarterly dividends&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.00&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Risk-free rate(s)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;2.71&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Expected forfeiture (attrition) rate (%)&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="Factid_2064051" contextRef="PAsOn09_30_2018_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="Factid_2064052" contextRef="PAsOn09_30_2018_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="Factid_2064053" contextRef="PAsOn09_30_2018_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock id="Factid_2064055" contextRef="P07_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 3 - Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the financial statements, the Company has an accumulated deficit at September 30, 2018 of approximately $85.5 million and a net loss of approximately $1.8 million and net cash used in operating activities of approximately $1 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2018, the Company had available cash and cash equivalents of approximately $6.1 million. These factors raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management adjusted its planned expenditures, activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional financing.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background: none;"&gt;The Company has made several adjustments to its past expenditures in the ensuing annual budget, eliminating several expenses including a reduction in workforce and consultants to the extent feasible without affecting its program of drug development. In addition, the Company has focused its efforts primarily on a single lead program to minimize cost outlays, namely taking the shingles drug candidate against VZV into human clinical trials. Management&amp;#8217;s budget indicates that these changes have freed up sufficient funds to allow for the ensuing costs of the external advanced IND-enabling studies of this drug candidate. Management has considered several options for obtaining additional funds that will be needed for future human clinical trials and to obtain the additional license from TheraCour for VZV and the remaining human herpes viruses. The Company is also evaluating the possibility of obtaining a mortgage on its fully owned cGMP-capable laboratory facility in Shelton, CT, in order to free up a portion of the fixed capital for usage as liquid working capital.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, the Company believes that it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these milestones, the Company would experience substantial improvement in the liquidity of the Company&amp;#8217;s stock, and would significantly improve the Company&amp;#8217;s ability to raise funds on the public markets at terms that may be substantially superior to the terms we are offered at present.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management believes that as a result of the&amp;#160;management plan, the Company&amp;#8217;s existing resources and access to the capital markets will be sufficient to fund the Company&amp;#8217;s planned operations and expenditures through November 2019. However, the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The accompanying unaudited financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"&gt;&lt;div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_2064056" contextRef="P09_21_2018To10_02_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TheracourPharmaIncMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">25000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_2064057" contextRef="PAsOn06_30_2018_ScientificAdvisoryBoardMemberusgaapSubsidiarySaleOfStockAxis" unitRef="shares" decimals="INF">5425222</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_2064058" contextRef="PAsOn06_30_2018_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="shares" decimals="INF">135216</us-gaap:ClassOfWarrantOrRightOutstanding>
<nnvc:WarrantsIssued id="Factid_2064059" contextRef="P09_11_2013To01_24_2014" unitRef="shares" decimals="INF">5425363</nnvc:WarrantsIssued>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_2064060" contextRef="PAsOn09_30_2018" unitRef="shares" decimals="INF">2479935</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_2064061" contextRef="PAsOn06_30_2018" unitRef="shares" decimals="INF">5290006</us-gaap:ClassOfWarrantOrRightOutstanding>
<nnvc:WarrantsIssued id="Factid_2064062" contextRef="P09_11_2013To01_24_2014_PlacementAgentsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="shares" decimals="INF">135216</nnvc:WarrantsIssued>
<nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue id="Factid_2064069" contextRef="P07_01_2018To09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">0</nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_2064070" contextRef="PAsOn09_30_2018_StockWarrantsMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Factid_2064102" contextRef="PAsOn09_30_2018" unitRef="USD" decimals="0">23841</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm id="Factid_2064621" contextRef="P07_01_2018To09_30_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">P0Y</nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Factid_2106891" contextRef="P07_01_2018To09_30_2018">&lt;div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 8 &amp;#8211; Accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following:&lt;/div&gt;&lt;/div&gt;&lt;div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;September&lt;/div&gt; &lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;201&lt;div style="font-weight:bold;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 74%; padding: 0px 0in; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Severance payment- Eugene Seymour&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;133,333&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;233,333&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued&amp;#160;&amp;#160;payroll&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;49,576&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;19,716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional Services&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;48,266&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid black; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;231,175&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;253,049&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Factid_2106999" contextRef="P07_01_2018To09_30_2018">&lt;div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following:&lt;/div&gt;&lt;/div&gt;&lt;div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &amp;quot;times new roman&amp;quot;, serif; background: none; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;September&lt;/div&gt; &lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;201&lt;div style="font-weight:bold;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 74%; padding: 0px 0in; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Severance payment- Eugene Seymour&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;133,333&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;233,333&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued&amp;#160;&amp;#160;payroll&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;49,576&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;19,716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional Services&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;48,266&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid black; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;231,175&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"&gt;&lt;div style="font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;253,049&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"&gt;&lt;div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<nnvc:ScheduleOfProjectedAnnualVolatilityTableTextBlock id="Factid_2119489" contextRef="P07_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The next capital raise would fluctuate with an annual volatility. &lt;/div&gt;&lt;div style="font-size:10pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are:&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="width: 50%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1 Year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 81%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;9/30/18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6/30/18&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0px 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;56&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0px 0.0001pt 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nnvc:ScheduleOfProjectedAnnualVolatilityTableTextBlock>
<xbrli:unit id="USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nnvc-20180930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 14-November-2018 [06:15:38] {AM} - www.datatracks.com-->
<schema targetNamespace="http://www.nanoviricides.com/20180930" elementFormDefault="qualified" xmlns:nnvc="http://www.nanoviricides.com/20180930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2018-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.nanoviricides.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>1001 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/BalanceSheets" id="BalanceSheets">
<link:definition>1002 - Statement - Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
<link:definition>1003 - Statement - Balance Sheets [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StatementsOfOperations" id="StatementsOfOperations">
<link:definition>1004 - Statement - Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
<link:definition>1005 - Statement - Statement of Changes in Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
<link:definition>1006 - Statement - Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/OrganizationAndNatureOfBusiness" id="OrganizationAndNatureOfBusiness">
<link:definition>1007 - Disclosure - Organization and Nature of Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
<link:definition>1009 - Disclosure - Liquidity and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1010 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1011 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/TrademarkAndPatents" id="TrademarkAndPatents">
<link:definition>1012 - Disclosure - Trademark and Patents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivatives" id="ConvertibleDebentureAndDerivatives">
<link:definition>1013 - Disclosure - Convertible Debenture and Derivatives</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1014 - Disclosure - Accrued expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/EquityTransactions" id="EquityTransactions">
<link:definition>1015 - Disclosure - Equity Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptions" id="StockWarrantsAndOptions">
<link:definition>1016 - Disclosure - Stock Warrants and Options</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1017 - Disclosure - Fair Value Measurement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1018 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1019 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>1022 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1023 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsTables" id="TrademarkAndPatentsTables">
<link:definition>1024 - Disclosure - Trademark and Patents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1025 - Disclosure - Accrued expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/EquityTransactionsTables" id="EquityTransactionsTables">
<link:definition>1026 - Disclosure - Equity Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables" id="StockWarrantsAndOptionsTables">
<link:definition>1027 - Disclosure - Stock Warrants and Options (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1028 - Disclosure - Fair Value Measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>1029 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
<link:definition>1030 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>1031 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/LiquidityAndGoingConcernDetailsTextual" id="LiquidityAndGoingConcernDetailsTextual">
<link:definition>1032 - Disclosure - Liquidity and Going Concern (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>1033 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
<link:definition>1034 - Disclosure - Related Party Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
<link:definition>1035 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
<link:definition>1036 - Disclosure - Property and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsDetails" id="TrademarkAndPatentsDetails">
<link:definition>1037 - Disclosure - Trademark and Patents (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsDetailsTextual" id="TrademarkAndPatentsDetailsTextual">
<link:definition>1038 - Disclosure - Trademark and Patents (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivativesDetailsTextual" id="ConvertibleDebentureAndDerivativesDetailsTextual">
<link:definition>1039 - Disclosure - Convertible Debenture and Derivatives (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
<link:definition>1040 - Disclosure - Accrued expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetails" id="EquityTransactionsDetails">
<link:definition>1041 - Disclosure - Equity Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetails1" id="EquityTransactionsDetails1">
<link:definition>1042 - Disclosure - Equity Transactions (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetailsTextual" id="EquityTransactionsDetailsTextual">
<link:definition>1043 - Disclosure - Equity Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails" id="StockWarrantsAndOptionsDetails">
<link:definition>1044 - Disclosure - Stock Warrants and Options (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails1" id="StockWarrantsAndOptionsDetails1">
<link:definition>1045 - Disclosure - Stock Warrants and Options (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails2" id="StockWarrantsAndOptionsDetails2">
<link:definition>1046 - Disclosure - Stock Warrants and Options (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetailsTextual" id="StockWarrantsAndOptionsDetailsTextual">
<link:definition>1047 - Disclosure - Stock Warrants and Options (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails" id="FairValueMeasurementDetails">
<link:definition>1048 - Disclosure - Fair Value Measurement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails1" id="FairValueMeasurementDetails1">
<link:definition>1049 - Disclosure - Fair Value Measurement (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails2" id="FairValueMeasurementDetails2">
<link:definition>1050 - Disclosure - Fair Value Measurement (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetailsTextual" id="FairValueMeasurementDetailsTextual">
<link:definition>1051 - Disclosure - Fair Value Measurement (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nanoviricides.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
<link:definition>1052 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="nnvc-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="nnvc-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="nnvc-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="nnvc-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
<import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
<element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DocumentAndEntityInformationAbstract" substitutionGroup="xbrli:item" />
<element name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesAConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentClassTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DebtInstrumentClassTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DebtInstrumentClassTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DebtInstrumentClassTypeDomain" substitutionGroup="xbrli:item" />
<element name="ServiceAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="nnvc_ServiceAgreements" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BalanceSheetsParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_BalanceSheetsParentheticalAbstract" substitutionGroup="xbrli:item" />
<element name="DiscountOnConvertibleDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_DiscountOnConvertibleDebentures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedForPaymentOfDirectorFeesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_StockIssuedForPaymentOfDirectorFeesValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedForPaymentOfDirectorFeesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_StockIssuedForPaymentOfDirectorFeesShares" substitutionGroup="xbrli:item" />
<element name="PreferredSharesIssuedAsCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_PreferredSharesIssuedAsCompensation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ChangeInFairValueOfDerivativeLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" substitutionGroup="xbrli:item" />
<element name="StockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_StockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfProjectedAnnualVolatilityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_AccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_AccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="FinancingArrangementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_FinancingArrangementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="FinancingArrangementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_FinancingArrangementDomain" substitutionGroup="xbrli:item" />
<element name="ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SeriesCConvertibleDebenturesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesCConvertibleDebenturesMember" substitutionGroup="xbrli:item" />
<element name="TheracourPharmaIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_TheracourPharmaIncMember" substitutionGroup="xbrli:item" />
<element name="OptionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_OptionAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="OptionDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_OptionDomain" substitutionGroup="xbrli:item" />
<element name="SeriesCConvertibleDebentureMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesCConvertibleDebentureMember" substitutionGroup="xbrli:item" />
<element name="DrBoniukMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DrBoniukMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetSalesAllocatedForRoyaltyPayments" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" substitutionGroup="xbrli:item" />
<element name="OfficeEquipmentGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="nnvc_OfficeEquipmentGross" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfTrademarksAndPatentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_ScheduleOfTrademarksAndPatentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="TrademarksAndPatentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_TrademarksAndPatentsLineItems" substitutionGroup="xbrli:item" />
<element name="TrademarkAndPatentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_TrademarkAndPatentsMember" substitutionGroup="xbrli:item" />
<element name="SeriesBConvertibleDebenturesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesBConvertibleDebenturesMember" substitutionGroup="xbrli:item" />
<element name="CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SharePriceAsPerRedemptionAgreement" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="nnvc_SharePriceAsPerRedemptionAgreement" substitutionGroup="xbrli:item" />
<element name="DeferredInterestPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_DeferredInterestPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SeriesPreferredShareIssuedForDebentureInterestSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" substitutionGroup="xbrli:item" />
<element name="IssuanceDateOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_IssuanceDateOneMember" substitutionGroup="xbrli:item" />
<element name="IssuanceDateTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_IssuanceDateTwoMember" substitutionGroup="xbrli:item" />
<element name="IssuanceDateThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_IssuanceDateThreeMember" substitutionGroup="xbrli:item" />
<element name="IssuanceDateFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_IssuanceDateFourMember" substitutionGroup="xbrli:item" />
<element name="ScientificAdvisoryBoardMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_ScientificAdvisoryBoardMember" substitutionGroup="xbrli:item" />
<element name="SeasideAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_SeasideAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SeasideDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_SeasideDomain" substitutionGroup="xbrli:item" />
<element name="AugustTwoThousandNineteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_AugustTwoThousandNineteenMember" substitutionGroup="xbrli:item" />
<element name="February2022Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_February2022Member" substitutionGroup="xbrli:item" />
<element name="NumberOfCommonStockToBeIssuedUponConversionOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" substitutionGroup="xbrli:item" />
<element name="RestrictedCommonStockAuthorizedForInterestPayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_RestrictedCommonStockAuthorizedForInterestPayable" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementSignificantAssumptions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_FairValueMeasurementSignificantAssumptions" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" substitutionGroup="xbrli:item" />
<element name="FuturePeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_FuturePeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="FuturePeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_FuturePeriodDomain" substitutionGroup="xbrli:item" />
<element name="June302019Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_June302019Member" substitutionGroup="xbrli:item" />
<element name="June302020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_June302020Member" substitutionGroup="xbrli:item" />
<element name="June302021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_June302021Member" substitutionGroup="xbrli:item" />
<element name="June302022Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_June302022Member" substitutionGroup="xbrli:item" />
<element name="June302023Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_June302023Member" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_WarrantsExercisable" substitutionGroup="xbrli:item" />
<element name="OneYearEnded63018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_OneYearEnded63018Member" substitutionGroup="xbrli:item" />
<element name="OneYearEnded93018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_OneYearEnded93018Member" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionExpectedVolatilityRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_FairValueAssumptionExpectedVolatilityRate" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentRedemptionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DebtInstrumentRedemptionAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DebtInstrumentRedemptionDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DebtInstrumentRedemptionDomain" substitutionGroup="xbrli:item" />
<element name="PlacementAgentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_PlacementAgentsMember" substitutionGroup="xbrli:item" />
<element name="WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_WarrantsIssued" substitutionGroup="xbrli:item" />
<element name="WarrantExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_WarrantExpirationTerm" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_CommitmentsAndContingenciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ChiefScientificOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_ChiefScientificOfficerMember" substitutionGroup="xbrli:item" />
<element name="SeriesConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_SeriesConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="DeferredCompensationYearAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DeferredCompensationYearAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DeferredCompensationYearDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_DeferredCompensationYearDomain" substitutionGroup="xbrli:item" />
<element name="YearOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_YearOneMember" substitutionGroup="xbrli:item" />
<element name="YearTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_YearTwoMember" substitutionGroup="xbrli:item" />
<element name="YearThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_YearThreeMember" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="nnvc_CommitmentsAndContingenciesLineItems" substitutionGroup="xbrli:item" />
<element name="AdditionalCommonStockSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="nnvc_AdditionalCommonStockSharesIssued" substitutionGroup="xbrli:item" />
<element name="AdditionalPreferredStockSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="nnvc_AdditionalPreferredStockSharesIssued" substitutionGroup="xbrli:item" />
<element name="IncreaseInBaseSalary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="nnvc_IncreaseInBaseSalary" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nnvc-20180930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 14-November-2018 [06:15:38] {AM} - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#BalanceSheets" roleURI="http://www.nanoviricides.com/role/BalanceSheets" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementsOfOperations" roleURI="http://www.nanoviricides.com/role/StatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementsOfCashFlows" roleURI="http://www.nanoviricides.com/role/StatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#PropertyAndEquipmentDetails" roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#TrademarkAndPatentsDetails" roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#AccruedExpensesDetails" roleURI="http://www.nanoviricides.com/role/AccruedExpensesDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssets" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_us-gaap_SecurityDeposit" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ServiceAgreements" xlink:label="loc_NNVC_ServiceAgreements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_NNVC_ServiceAgreements" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="40" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DiscountOnConvertibleDebentures" xlink:label="loc_NNVC_DiscountOnConvertibleDebentures" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_NNVC_DiscountOnConvertibleDebentures" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="20" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/PropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_LeaseholdImprovementsGross" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_Land" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OfficeEquipmentGross" xlink:label="loc_NNVC_OfficeEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_NNVC_OfficeEquipmentGross" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_FurnitureAndFixturesGross" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_FixturesAndEquipmentGross" use="optional" order="50" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/TrademarkAndPatentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="20" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PreferredSharesIssuedAsCompensation" xlink:label="loc_NNVC_PreferredSharesIssuedAsCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NNVC_PreferredSharesIssuedAsCompensation" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_NNVC_ChangeInFairValueOfDerivativeLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NNVC_ChangeInFairValueOfDerivativeLiability" use="optional" order="70" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="90" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="100" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="110" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" use="optional" order="120" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" use="optional" order="130" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" use="optional" order="140" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="150" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="20" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="30" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nnvc-20180930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 14-November-2018 [06:15:39] {AM} - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#DocumentAndEntityInformation" roleURI="http://www.nanoviricides.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#BalanceSheets" roleURI="http://www.nanoviricides.com/role/BalanceSheets" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#BalanceSheetsParenthetical" roleURI="http://www.nanoviricides.com/role/BalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementsOfOperations" roleURI="http://www.nanoviricides.com/role/StatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementOfChangesInStockholdersEquity" roleURI="http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementsOfCashFlows" roleURI="http://www.nanoviricides.com/role/StatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsTables" roleURI="http://www.nanoviricides.com/role/EquityTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsTables" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#LiquidityAndGoingConcernDetailsTextual" roleURI="http://www.nanoviricides.com/role/LiquidityAndGoingConcernDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#PropertyAndEquipmentDetails" roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#TrademarkAndPatentsDetails" roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#TrademarkAndPatentsDetailsTextual" roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#ConvertibleDebentureAndDerivativesDetailsTextual" roleURI="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivativesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#AccruedExpensesDetails" roleURI="http://www.nanoviricides.com/role/AccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsDetails" roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsDetails1" roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsDetailsTextual" roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetails" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetails1" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetails2" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails2" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetailsTextual" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetails" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetails1" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetails2" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails2" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetailsTextual" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.nanoviricides.com/role/CommitmentsAndContingenciesDetailsTextual" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_187664" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_187667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentInformationTable_187667" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_187666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_187667" xlink:to="loc_us-gaap_StatementClassOfStockAxis_187666" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_187665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187666" xlink:to="loc_us-gaap_ClassOfStockDomain_187665" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_187665_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187666" xlink:to="loc_us-gaap_ClassOfStockDomain_187665_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_187411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentType_187411" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_187412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_AmendmentFlag_187412" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_187421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentPeriodEndDate_187421" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_187422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentFiscalYearFocus_187422" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_187423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentFiscalPeriodFocus_187423" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_187436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityRegistrantName_187436" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_187437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityCentralIndexKey_187437" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_187453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_CurrentFiscalYearEndDate_187453" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_187458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityFilerCategory_187458" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_187540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_TradingSymbol_187540" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_187547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_187547" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_187659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityEmergingGrowthCompany_187659" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_187661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntitySmallBusiness_187661" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_38" xlink:to="loc_us-gaap_StatementTable_30" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_us-gaap_StatementClassOfStockAxis_31" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_31" xlink:to="loc_us-gaap_ClassOfStockDomain_32" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_32_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_31" xlink:to="loc_us-gaap_ClassOfStockDomain_32_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_32" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_48" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33" xlink:to="loc_us-gaap_RelatedPartyDomain_49" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_49_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33" xlink:to="loc_us-gaap_RelatedPartyDomain_49_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_34" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_34" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_35" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_35_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_34" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_35_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_us-gaap_FinancialInstrumentAxis_36" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37" xlink:to="loc_us-gaap_WarrantMember_51" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_38" xlink:to="loc_us-gaap_AssetsAbstract_39" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_AssetsCurrentAbstract_40" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_53" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40" xlink:to="loc_us-gaap_AssetsCurrent_54" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_55" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_56" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_57" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_58" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_60" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_OtherAssetsAbstract_43" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherAssetsAbstract_43" xlink:to="loc_us-gaap_SecurityDeposit_61" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ServiceAgreements" xlink:label="loc_nnvc_ServiceAgreements_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherAssetsAbstract_43" xlink:to="loc_nnvc_ServiceAgreements_62" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherAssetsAbstract_43" xlink:to="loc_us-gaap_OtherAssets_63" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_Assets_64" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_LiabilitiesAbstract_45" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_65" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_66" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_69" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_LiabilitiesCurrent_71" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_235492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_235492" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_StockholdersEquityAbstract_47" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_PreferredStockValue_75" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_CommonStockValue_76" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_AdditionalPaidInCapital_77" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_StockholdersEquity_79" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_CommitmentsAndContingencies_74" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_80" use="optional" order="48" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/BalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_100" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_StatementTable_97" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_98" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_98" xlink:to="loc_us-gaap_ClassOfStockDomain_99" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_99_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_98" xlink:to="loc_us-gaap_ClassOfStockDomain_99_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_99" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_101" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_102" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_103" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockSharesIssued_104" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_105" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_106" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_107" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockSharesIssued_108" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_109" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_174" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_StatementTable_172" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_172" xlink:to="loc_us-gaap_StatementScenarioAxis_173" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_173" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_179" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_173" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_179_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_OperatingExpensesAbstract_175" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_180" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_181" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_OperatingExpenses_182" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_OperatingIncomeLoss_183" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_184" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_InterestExpense_185" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DiscountOnConvertibleDebentures" xlink:label="loc_nnvc_DiscountOnConvertibleDebentures_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_nnvc_DiscountOnConvertibleDebentures_187" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_188" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_189" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_191" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_NetIncomeLoss_192" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_259282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_259282" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_259283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_259283" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_224" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_StatementTable_220" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_220" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_221" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_221" xlink:to="loc_us-gaap_EquityComponentDomain_222" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_222_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_221" xlink:to="loc_us-gaap_EquityComponentDomain_222_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_PreferredStockMember_225" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_CommonStockMember_226" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_227" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_RetainedEarningsMember_228" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_220" xlink:to="loc_us-gaap_StatementClassOfStockAxis_223" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_223" xlink:to="loc_us-gaap_ClassOfStockDomain_229" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_229_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_223" xlink:to="loc_us-gaap_ClassOfStockDomain_229_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_StockholdersEquity_230" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_SharesOutstanding_231" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" xlink:label="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued_234" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" xlink:label="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued_235" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:label="loc_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne_242" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:label="loc_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne_243" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" xlink:label="loc_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices_244" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedForPaymentOfDirectorFeesValue" xlink:label="loc_nnvc_StockIssuedForPaymentOfDirectorFeesValue_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedForPaymentOfDirectorFeesValue_246" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedForPaymentOfDirectorFeesShares" xlink:label="loc_nnvc_StockIssuedForPaymentOfDirectorFeesShares_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedForPaymentOfDirectorFeesShares_247" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_NetIncomeLoss_248" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_259284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_259284" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_617" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_StatementTable_614" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_614" xlink:to="loc_us-gaap_StatementClassOfStockAxis_615" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_615" xlink:to="loc_us-gaap_ClassOfStockDomain_625" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_615" xlink:to="loc_us-gaap_ClassOfStockDomain_625_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_614" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_616" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_616" xlink:to="loc_us-gaap_RelatedPartyDomain_626" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_626_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_616" xlink:to="loc_us-gaap_RelatedPartyDomain_626_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_639" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_641" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_642" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_643" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_644" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_645" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PreferredSharesIssuedAsCompensation" xlink:label="loc_nnvc_PreferredSharesIssuedAsCompensation_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_nnvc_PreferredSharesIssuedAsCompensation_628" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_629" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_630" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_Depreciation_633" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_AdjustmentForAmortization_634" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_nnvc_ChangeInFairValueOfDerivativeLiability_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_nnvc_ChangeInFairValueOfDerivativeLiability_635" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_636" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_259285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensation_259285" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" xlink:to="loc_us-gaap_NetIncomeLoss_627" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_646" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_621" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_621" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_647" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_623" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_623" xlink:to="loc_us-gaap_InterestPaidNet_652" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_649" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_650" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_130" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_130" xlink:to="loc_us-gaap_StatementTable_126" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_StatementClassOfStockAxis_127" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_127" xlink:to="loc_us-gaap_ClassOfStockDomain_128" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_128_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_127" xlink:to="loc_us-gaap_ClassOfStockDomain_128_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_129" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_129" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_132" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_132_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_129" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_132_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" xlink:label="loc_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_130" xlink:to="loc_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock_133" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_130" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_134" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xlink:to="loc_us-gaap_AwardTypeAxis_138" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockWarrantsMember" xlink:label="loc_nnvc_StockWarrantsMember_235600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141" xlink:to="loc_nnvc_StockWarrantsMember_235600" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_139" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_139" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_142" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_142_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_139" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_142_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_235599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_142" xlink:to="loc_us-gaap_StockOptionMember_235599" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_259486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xlink:to="loc_us-gaap_TitleOfIndividualAxis_259486" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_259486" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259487" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259487_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_259486" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259487_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_143" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_259485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_259485" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesLineItems" xlink:label="loc_nnvc_AccountingPoliciesLineItems_203" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesTable" xlink:label="loc_nnvc_AccountingPoliciesTable_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nnvc_AccountingPoliciesLineItems_203" xlink:to="loc_nnvc_AccountingPoliciesTable_199" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_199" xlink:to="loc_us-gaap_FinancialInstrumentAxis_200" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_200" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_200" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201" xlink:to="loc_us-gaap_WarrantMember_204" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_199" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_202" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_202" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_205" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_205_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_202" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_205_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_AccountingPoliciesLineItems_203" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_206" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_211" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_StatementTable_209" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_210" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_210" xlink:to="loc_us-gaap_ClassOfStockDomain_213" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_210" xlink:to="loc_us-gaap_ClassOfStockDomain_213_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_212" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_212" xlink:to="loc_us-gaap_NetIncomeLoss_214" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_212" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_212" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_216" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesLineItems" xlink:label="loc_nnvc_AccountingPoliciesLineItems_269" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesTable" xlink:label="loc_nnvc_AccountingPoliciesTable_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_nnvc_AccountingPoliciesTable_253" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_254" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_254" xlink:to="loc_us-gaap_TypeOfAdoptionMember_270" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_270_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_254" xlink:to="loc_us-gaap_TypeOfAdoptionMember_270_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_srt_RangeAxis_255" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_255" xlink:to="loc_srt_RangeMember_271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_271_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_255" xlink:to="loc_srt_RangeMember_271_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_256" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_256" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_256" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_258" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_258" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_273" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_273_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_258" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_273_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_259" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_259" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_259" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_260" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_260" xlink:to="loc_us-gaap_EquityComponentDomain_275" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_275_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_260" xlink:to="loc_us-gaap_EquityComponentDomain_275_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_259306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_275" xlink:to="loc_us-gaap_CommonStockMember_259306" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_261" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_261" xlink:to="loc_us-gaap_ClassOfStockDomain_262" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_261" xlink:to="loc_us-gaap_ClassOfStockDomain_262_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_276" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_263" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_263" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_277" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_277_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_263" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_277_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FinancingArrangementAxis" xlink:label="loc_nnvc_FinancingArrangementAxis_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_nnvc_FinancingArrangementAxis_264" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FinancingArrangementDomain" xlink:label="loc_nnvc_FinancingArrangementDomain_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_FinancingArrangementAxis_264" xlink:to="loc_nnvc_FinancingArrangementDomain_278" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FinancingArrangementDomain" xlink:label="loc_nnvc_FinancingArrangementDomain_278_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_FinancingArrangementAxis_264" xlink:to="loc_nnvc_FinancingArrangementDomain_278_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_StatementScenarioAxis_265" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_265" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_279" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_279_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_265" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_279_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" xlink:to="loc_us-gaap_RelatedPartyDomain_280" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_280_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" xlink:to="loc_us-gaap_RelatedPartyDomain_280_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_267" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_267" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_281" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_281_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_267" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_281_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_268" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_268" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_282" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_268" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_282_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_259307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_FinancialInstrumentAxis_259307" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_259307" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_259307" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebenturesMember" xlink:label="loc_nnvc_SeriesCConvertibleDebenturesMember_259310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308" xlink:to="loc_nnvc_SeriesCConvertibleDebenturesMember_259310" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_284" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_285" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_PreferredStockSharesIssued_286" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" xlink:label="loc_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses_259304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses_259304" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_259305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_259305" use="optional" order="52" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/LiquidityAndGoingConcernDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_259336" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_259333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_StatementTable_259333" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_259334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_259333" xlink:to="loc_us-gaap_StatementClassOfStockAxis_259334" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_259335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_259334" xlink:to="loc_us-gaap_ClassOfStockDomain_259335" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_259335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_259334" xlink:to="loc_us-gaap_ClassOfStockDomain_259335_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_259337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_259337" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_259338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_259338" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_259349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_NetIncomeLoss_259349" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_259351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_259351" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_323" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_323" xlink:to="loc_us-gaap_StatementTable_313" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_StatementClassOfStockAxis_314" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314" xlink:to="loc_us-gaap_ClassOfStockDomain_324" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_324_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314" xlink:to="loc_us-gaap_ClassOfStockDomain_324_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_dei_LegalEntityAxis_315" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_315" xlink:to="loc_dei_EntityDomain_316" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_315" xlink:to="loc_dei_EntityDomain_316_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TheracourPharmaIncMember" xlink:label="loc_nnvc_TheracourPharmaIncMember_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_316" xlink:to="loc_nnvc_TheracourPharmaIncMember_325" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_TitleOfIndividualAxis_317" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_317" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_326" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_326_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_317" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_326_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_318" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_318" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_327" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_327_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_318" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_327_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_319" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_319" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_328" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_319" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_328_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OptionAxis" xlink:label="loc_nnvc_OptionAxis_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_nnvc_OptionAxis_320" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OptionDomain" xlink:label="loc_nnvc_OptionDomain_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_OptionAxis_320" xlink:to="loc_nnvc_OptionDomain_329" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OptionDomain" xlink:label="loc_nnvc_OptionDomain_329_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_OptionAxis_320" xlink:to="loc_nnvc_OptionDomain_329_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_321" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_321" xlink:to="loc_us-gaap_DebtConversionNameDomain_322" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_322_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_321" xlink:to="loc_us-gaap_DebtConversionNameDomain_322_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_323" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_331" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_323" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_332" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_349" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_StatementClassOfStockAxis_339" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_339" xlink:to="loc_us-gaap_ClassOfStockDomain_340" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_340_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_339" xlink:to="loc_us-gaap_ClassOfStockDomain_340_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebentureMember" xlink:label="loc_nnvc_SeriesCConvertibleDebentureMember_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_340" xlink:to="loc_nnvc_SeriesCConvertibleDebentureMember_351" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_dei_LegalEntityAxis_341" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_341" xlink:to="loc_dei_EntityDomain_352" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_352_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_341" xlink:to="loc_dei_EntityDomain_352_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TheracourPharmaIncMember" xlink:label="loc_nnvc_TheracourPharmaIncMember_260642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_352" xlink:to="loc_nnvc_TheracourPharmaIncMember_260642" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_342" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_342" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_353" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_353_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_342" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_353_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_TitleOfIndividualAxis_343" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_343" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_354" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_354_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_343" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_354_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_344" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_344" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_355" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_355_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_344" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_355_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_260643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_355" xlink:to="loc_us-gaap_SubsequentEventMember_260643" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_345" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_345" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_356" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_356_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_345" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_356_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_346" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_346" xlink:to="loc_us-gaap_RelatedPartyDomain_347" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_346" xlink:to="loc_us-gaap_RelatedPartyDomain_347_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DrBoniukMember" xlink:label="loc_nnvc_DrBoniukMember_357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_347" xlink:to="loc_nnvc_DrBoniukMember_357" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_348" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_348" xlink:to="loc_us-gaap_DebtConversionNameDomain_358" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_358_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_348" xlink:to="loc_us-gaap_DebtConversionNameDomain_358_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_359" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_360" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_InterestExpenseDebt_365" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" xlink:label="loc_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments_246203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments_246203" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_260641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_260641" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/PropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_StatementClassOfStockAxis_369" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_369" xlink:to="loc_us-gaap_ClassOfStockDomain_371" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_369" xlink:to="loc_us-gaap_ClassOfStockDomain_371_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_372" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_Land_373" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OfficeEquipmentGross" xlink:label="loc_nnvc_OfficeEquipmentGross_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_nnvc_OfficeEquipmentGross_374" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_375" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_FixturesAndEquipmentGross_376" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_377" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_378" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_379" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/PropertyAndEquipmentDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_384" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_384" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_382" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_382" xlink:to="loc_us-gaap_StatementClassOfStockAxis_383" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_383" xlink:to="loc_us-gaap_ClassOfStockDomain_385" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_385_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_383" xlink:to="loc_us-gaap_ClassOfStockDomain_385_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_384" xlink:to="loc_us-gaap_Depreciation_386" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/TrademarkAndPatentsDetails">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarksAndPatentsLineItems" xlink:label="loc_nnvc_TrademarksAndPatentsLineItems_391" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfTrademarksAndPatentsTable" xlink:label="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_391" xlink:to="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_389" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_389" xlink:to="loc_us-gaap_StatementClassOfStockAxis_390" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_390" xlink:to="loc_us-gaap_ClassOfStockDomain_392" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_392_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_390" xlink:to="loc_us-gaap_ClassOfStockDomain_392_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_391" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_393" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_391" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_394" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_391" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_395" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/TrademarkAndPatentsDetailsTextual">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarksAndPatentsLineItems" xlink:label="loc_nnvc_TrademarksAndPatentsLineItems_401" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfTrademarksAndPatentsTable" xlink:label="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_401" xlink:to="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_398" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_398" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_399" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_399" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_399" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarkAndPatentsMember" xlink:label="loc_nnvc_TrademarkAndPatentsMember_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400" xlink:to="loc_nnvc_TrademarkAndPatentsMember_402" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_401" xlink:to="loc_us-gaap_AdjustmentForAmortization_403" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_441" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtInstrumentTable_424" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_425" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_425" xlink:to="loc_us-gaap_DebtConversionNameDomain_426" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_425" xlink:to="loc_us-gaap_DebtConversionNameDomain_426_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesBConvertibleDebenturesMember" xlink:label="loc_nnvc_SeriesBConvertibleDebenturesMember_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_426" xlink:to="loc_nnvc_SeriesBConvertibleDebenturesMember_442" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_426" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_443" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebentureMember" xlink:label="loc_nnvc_SeriesCConvertibleDebentureMember_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_426" xlink:to="loc_nnvc_SeriesCConvertibleDebentureMember_444" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_FinancialInstrumentAxis_427" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_427" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_445" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_445_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_427" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_445_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_TitleOfIndividualAxis_428" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_428" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_446" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_428" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_446_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_429" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_429" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_447" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_447_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_429" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_447_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_AwardTypeAxis_430" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_430" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_448" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_430" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_448_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_srt_RangeAxis_431" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_431" xlink:to="loc_srt_RangeMember_432" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_431" xlink:to="loc_srt_RangeMember_432_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_433" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_433" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_434" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_434_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_433" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_434_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_StatementScenarioAxis_435" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_435" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_436" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_435" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_436_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_437" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_437" xlink:to="loc_us-gaap_EquityComponentDomain_438" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_438_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_437" xlink:to="loc_us-gaap_EquityComponentDomain_438_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_438" xlink:to="loc_us-gaap_CommonStockMember_454" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_StatementClassOfStockAxis_439" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_439" xlink:to="loc_us-gaap_ClassOfStockDomain_440" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_440_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_439" xlink:to="loc_us-gaap_ClassOfStockDomain_440_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_440" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_455" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_475" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_458" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_459" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_460" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_461" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_462" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_463" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_InterestExpenseDebt_472" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_476" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" xlink:label="loc_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment_479" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_481" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_482" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DerivativeLiabilities_483" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_484" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_485" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SharePriceAsPerRedemptionAgreement" xlink:label="loc_nnvc_SharePriceAsPerRedemptionAgreement_486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_SharePriceAsPerRedemptionAgreement_486" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredInterestPayment" xlink:label="loc_nnvc_DeferredInterestPayment_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_DeferredInterestPayment_494" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" xlink:label="loc_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued_496" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_235593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_InterestPayableCurrent_235593" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_235601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_235601" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_259403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtConversionDescription_259403" use="optional" order="57" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_244298" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_244295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_StatementTable_244295" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_244296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_244295" xlink:to="loc_us-gaap_StatementClassOfStockAxis_244296" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_244297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_244296" xlink:to="loc_us-gaap_ClassOfStockDomain_244297" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_244297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_244296" xlink:to="loc_us-gaap_ClassOfStockDomain_244297_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent_244299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrent_244299" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_244300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_AccruedSalariesCurrent_244300" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_244301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_244301" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_244302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_244302" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_499" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_499" xlink:to="loc_us-gaap_AwardDateAxis_500" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_500" xlink:to="loc_us-gaap_AwardDateDomain_501" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_501_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_500" xlink:to="loc_us-gaap_AwardDateDomain_501_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateOneMember" xlink:label="loc_nnvc_IssuanceDateOneMember_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateOneMember_505" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateTwoMember" xlink:label="loc_nnvc_IssuanceDateTwoMember_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateTwoMember_506" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateThreeMember" xlink:label="loc_nnvc_IssuanceDateThreeMember_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateThreeMember_507" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateFourMember" xlink:label="loc_nnvc_IssuanceDateFourMember_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateFourMember_508" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_499" xlink:to="loc_us-gaap_StatementClassOfStockAxis_502" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_502" xlink:to="loc_us-gaap_ClassOfStockDomain_503" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_502" xlink:to="loc_us-gaap_ClassOfStockDomain_503_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_515" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_516" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_517" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_520" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_521" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_521" xlink:to="loc_us-gaap_RelatedPartyDomain_522" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_522_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_521" xlink:to="loc_us-gaap_RelatedPartyDomain_522_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScientificAdvisoryBoardMember" xlink:label="loc_nnvc_ScientificAdvisoryBoardMember_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_522" xlink:to="loc_nnvc_ScientificAdvisoryBoardMember_527" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_srt_RangeAxis_523" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_523" xlink:to="loc_srt_RangeMember_524" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_523" xlink:to="loc_srt_RangeMember_524_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_us-gaap_StatementClassOfStockAxis_525" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_525" xlink:to="loc_us-gaap_ClassOfStockDomain_530" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_530_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_525" xlink:to="loc_us-gaap_ClassOfStockDomain_530_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_235735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_235735" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_235736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_235735" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_235736" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_235736_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_235735" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_235736_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_531" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_532" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_533" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_534" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_563" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_537" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_StatementClassOfStockAxis_538" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_538" xlink:to="loc_us-gaap_ClassOfStockDomain_539" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_539_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_538" xlink:to="loc_us-gaap_ClassOfStockDomain_539_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_539" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_564" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_539" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_565" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeasideAxis" xlink:label="loc_nnvc_SeasideAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_nnvc_SeasideAxis_540" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeasideDomain" xlink:label="loc_nnvc_SeasideDomain_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_SeasideAxis_540" xlink:to="loc_nnvc_SeasideDomain_566" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeasideDomain" xlink:label="loc_nnvc_SeasideDomain_566_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_SeasideAxis_540" xlink:to="loc_nnvc_SeasideDomain_566_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_541" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_541" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_567" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_567_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_541" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_567_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_TitleOfIndividualAxis_542" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_542" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_542" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" xlink:to="loc_us-gaap_DirectorMember_568" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" xlink:to="loc_us-gaap_PresidentMember_569" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_544" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_544" xlink:to="loc_us-gaap_EquityComponentDomain_572" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_544" xlink:to="loc_us-gaap_EquityComponentDomain_572_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_545" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_545" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_545" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546" xlink:to="loc_us-gaap_WarrantMember_573" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_srt_RangeAxis_547" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_547" xlink:to="loc_srt_RangeMember_548" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_548_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_547" xlink:to="loc_srt_RangeMember_548_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_548" xlink:to="loc_srt_MinimumMember_574" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_548" xlink:to="loc_srt_MaximumMember_575" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_549" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_576" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_576_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_576_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_550" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_550" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_577" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_550" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_577_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_551" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_551" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_578" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_578_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_551" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_578_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_VestingAxis_552" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_552" xlink:to="loc_us-gaap_VestingDomain_553" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_552" xlink:to="loc_us-gaap_VestingDomain_553_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_554" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_554" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_555" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_554" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_555_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_StatementScenarioAxis_556" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_556" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_582" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_556" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_582_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_557" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_557" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_583" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_583_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_557" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_583_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_558" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_558" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_584" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_558" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_584_default" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_dei_LegalEntityAxis_559" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_559" xlink:to="loc_dei_EntityDomain_560" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_560_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_559" xlink:to="loc_dei_EntityDomain_560_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AugustTwoThousandNineteenMember" xlink:label="loc_nnvc_AugustTwoThousandNineteenMember_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_560" xlink:to="loc_nnvc_AugustTwoThousandNineteenMember_585" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_February2022Member" xlink:label="loc_nnvc_February2022Member_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_560" xlink:to="loc_nnvc_February2022Member_587" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_561" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_561" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_561" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588_default" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_562" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_562" xlink:to="loc_us-gaap_DebtConversionNameDomain_589" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_589_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_562" xlink:to="loc_us-gaap_DebtConversionNameDomain_589_default" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_235885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_AwardTypeAxis_235885" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_235886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_235885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_235886" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_235886_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_235885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_235886_default" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_238215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_238215" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_238216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_238215" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_238216" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_238216_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_238215" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_238216_default" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_590" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" xlink:label="loc_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants_591" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_594" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_595" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensation_597" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage_599" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_600" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_601" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_602" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_603" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_RestrictedCommonStockAuthorizedForInterestPayable" xlink:label="loc_nnvc_RestrictedCommonStockAuthorizedForInterestPayable_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_RestrictedCommonStockAuthorizedForInterestPayable_604" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_605" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_235794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_235794" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235795" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FairValueMeasurementSignificantAssumptions" xlink:label="loc_nnvc_FairValueMeasurementSignificantAssumptions_235843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_FairValueMeasurementSignificantAssumptions_235843" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_238171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharePrice_238171" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_259428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_RestrictedStockExpense_259428" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_259429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_259429" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_259430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_259430" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_259432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_259432" use="optional" order="90" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_235625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_235625" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_235626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_235625" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_235626" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_235627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_235626" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_235627" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_235627_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_235626" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_235627_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_235628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_235627" xlink:to="loc_us-gaap_StockOptionMember_235628" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_235631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_235631" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235633" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_235635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_235635" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_235640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_235640" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_235641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_235641" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_235643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_235643" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm_235649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm_235649" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235651" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_235652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_235652" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_659" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_659" xlink:to="loc_us-gaap_AwardTypeAxis_660" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockWarrantsMember" xlink:label="loc_nnvc_StockWarrantsMember_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661" xlink:to="loc_nnvc_StockWarrantsMember_663" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_664" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_665" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_667" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_668" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_670" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_672" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_673" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235622" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_259589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_259589" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_259598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_259589" xlink:to="loc_us-gaap_TitleOfIndividualAxis_259598" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_259598" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_259598" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_259600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_259600" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_259593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_259593" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_259594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_259594" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_259595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_259595" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_259596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_259596" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="loc_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_260398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_260398" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_TitleOfIndividualAxis_678" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_678" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_682" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_682_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_678" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_682_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FuturePeriodAxis" xlink:label="loc_nnvc_FuturePeriodAxis_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_nnvc_FuturePeriodAxis_679" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FuturePeriodDomain" xlink:label="loc_nnvc_FuturePeriodDomain_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_FuturePeriodAxis_679" xlink:to="loc_nnvc_FuturePeriodDomain_680" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FuturePeriodDomain" xlink:label="loc_nnvc_FuturePeriodDomain_680_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_FuturePeriodAxis_679" xlink:to="loc_nnvc_FuturePeriodDomain_680_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302019Member" xlink:label="loc_nnvc_June302019Member_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302019Member_684" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302020Member" xlink:label="loc_nnvc_June302020Member_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302020Member_685" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302021Member" xlink:label="loc_nnvc_June302021Member_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302021Member_686" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302022Member" xlink:label="loc_nnvc_June302022Member_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302022Member_687" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302023Member" xlink:label="loc_nnvc_June302023Member_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302023Member_688" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_259602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_VestingAxis_259602" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_259603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_259602" xlink:to="loc_us-gaap_VestingDomain_259603" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_259603_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_259602" xlink:to="loc_us-gaap_VestingDomain_259603_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_259604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_259603" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_259604" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_259603" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259607" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_259603" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259608" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_260395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_StatementScenarioAxis_260395" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_260396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_260395" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_260396" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_260396_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_260395" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_260396_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantsExercisable" xlink:label="loc_nnvc_WarrantsExercisable_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_nnvc_WarrantsExercisable_689" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_259606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_259606" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_259610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_259610" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_259611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_StockOptionPlanExpense_259611" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_262756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_262756" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_702" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_702" xlink:to="loc_us-gaap_StatementTable_693" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_StatementClassOfStockAxis_694" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_694" xlink:to="loc_us-gaap_ClassOfStockDomain_703" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_703_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_694" xlink:to="loc_us-gaap_ClassOfStockDomain_703_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_704" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_705" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_706" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_FinancialInstrumentAxis_697" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_697" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_697" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698" xlink:to="loc_us-gaap_WarrantMember_707" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_699" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_699" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_700" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_700_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_699" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_700_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_701" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_701" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_709" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_709_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_701" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_709_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_702" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_710" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_716" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_716" xlink:to="loc_us-gaap_StatementTable_713" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_713" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714" xlink:to="loc_us-gaap_ClassOfStockDomain_715" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714" xlink:to="loc_us-gaap_ClassOfStockDomain_715_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OneYearEnded63018Member" xlink:label="loc_nnvc_OneYearEnded63018Member_235724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_715" xlink:to="loc_nnvc_OneYearEnded63018Member_235724" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OneYearEnded93018Member" xlink:label="loc_nnvc_OneYearEnded93018Member_259542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_715" xlink:to="loc_nnvc_OneYearEnded93018Member_259542" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_nnvc_FairValueAssumptionExpectedVolatilityRate_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_716" xlink:to="loc_nnvc_FairValueAssumptionExpectedVolatilityRate_719" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_728" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_StatementTable_722" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_StatementClassOfStockAxis_723" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_723" xlink:to="loc_us-gaap_ClassOfStockDomain_729" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_723" xlink:to="loc_us-gaap_ClassOfStockDomain_729_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_FinancialInstrumentAxis_724" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_724" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_724" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725" xlink:to="loc_us-gaap_WarrantMember_730" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_726" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_726" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_727" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_726" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_727_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentRedemptionAxis" xlink:label="loc_nnvc_DebtInstrumentRedemptionAxis_244321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_nnvc_DebtInstrumentRedemptionAxis_244321" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentRedemptionDomain" xlink:label="loc_nnvc_DebtInstrumentRedemptionDomain_244322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_DebtInstrumentRedemptionAxis_244321" xlink:to="loc_nnvc_DebtInstrumentRedemptionDomain_244322" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentRedemptionDomain" xlink:label="loc_nnvc_DebtInstrumentRedemptionDomain_244322_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_DebtInstrumentRedemptionAxis_244321" xlink:to="loc_nnvc_DebtInstrumentRedemptionDomain_244322_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_732" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_733" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_734" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_735" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_744" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_us-gaap_StatementTable_739" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_StatementClassOfStockAxis_740" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_740" xlink:to="loc_us-gaap_ClassOfStockDomain_745" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_745_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_740" xlink:to="loc_us-gaap_ClassOfStockDomain_745_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_741" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_741" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_741" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PlacementAgentsMember" xlink:label="loc_nnvc_PlacementAgentsMember_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" xlink:to="loc_nnvc_PlacementAgentsMember_746" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScientificAdvisoryBoardMember" xlink:label="loc_nnvc_ScientificAdvisoryBoardMember_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" xlink:to="loc_nnvc_ScientificAdvisoryBoardMember_747" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_srt_RangeAxis_743" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_743" xlink:to="loc_srt_RangeMember_748" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_748_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_743" xlink:to="loc_srt_RangeMember_748_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_749" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantsIssued" xlink:label="loc_nnvc_WarrantsIssued_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_nnvc_WarrantsIssued_750" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantExpirationTerm" xlink:label="loc_nnvc_WarrantExpirationTerm_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_nnvc_WarrantExpirationTerm_751" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_752" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommitmentsAndContingenciesLineItems" xlink:label="loc_nnvc_CommitmentsAndContingenciesLineItems_773" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommitmentsAndContingenciesTable" xlink:label="loc_nnvc_CommitmentsAndContingenciesTable_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_nnvc_CommitmentsAndContingenciesTable_755" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_dei_LegalEntityAxis_756" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_756" xlink:to="loc_dei_EntityDomain_774" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_774_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_756" xlink:to="loc_dei_EntityDomain_774_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_TitleOfIndividualAxis_757" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_757" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_757" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_775" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ChiefScientificOfficerMember" xlink:label="loc_nnvc_ChiefScientificOfficerMember_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_nnvc_ChiefScientificOfficerMember_776" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VicePresidentMember" xlink:label="loc_us-gaap_VicePresidentMember_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_us-gaap_VicePresidentMember_778" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_779" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_srt_RangeAxis_759" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_759" xlink:to="loc_srt_RangeMember_780" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_780_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_759" xlink:to="loc_srt_RangeMember_780_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_StatementClassOfStockAxis_760" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_760" xlink:to="loc_us-gaap_ClassOfStockDomain_761" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_761_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_760" xlink:to="loc_us-gaap_ClassOfStockDomain_761_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesConvertiblePreferredStockMember_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_761" xlink:to="loc_nnvc_SeriesConvertiblePreferredStockMember_781" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_762" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_762" xlink:to="loc_us-gaap_RelatedPartyDomain_783" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_783_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_762" xlink:to="loc_us-gaap_RelatedPartyDomain_783_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_763" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_763" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_784" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_784_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_763" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_784_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_764" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_764" xlink:to="loc_us-gaap_EquityComponentDomain_765" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_765_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_764" xlink:to="loc_us-gaap_EquityComponentDomain_765_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredCompensationYearAxis" xlink:label="loc_nnvc_DeferredCompensationYearAxis_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_nnvc_DeferredCompensationYearAxis_766" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredCompensationYearDomain" xlink:label="loc_nnvc_DeferredCompensationYearDomain_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nnvc_DeferredCompensationYearAxis_766" xlink:to="loc_nnvc_DeferredCompensationYearDomain_767" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredCompensationYearDomain" xlink:label="loc_nnvc_DeferredCompensationYearDomain_767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nnvc_DeferredCompensationYearAxis_766" xlink:to="loc_nnvc_DeferredCompensationYearDomain_767_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearOneMember" xlink:label="loc_nnvc_YearOneMember_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_DeferredCompensationYearDomain_767" xlink:to="loc_nnvc_YearOneMember_786" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearTwoMember" xlink:label="loc_nnvc_YearTwoMember_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_DeferredCompensationYearDomain_767" xlink:to="loc_nnvc_YearTwoMember_787" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearThreeMember" xlink:label="loc_nnvc_YearThreeMember_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_DeferredCompensationYearDomain_767" xlink:to="loc_nnvc_YearThreeMember_788" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_768" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_768" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_769" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_769_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_768" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_769_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_770" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_770" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_790" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_790_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_770" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_790_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_VestingAxis_771" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_771" xlink:to="loc_us-gaap_VestingDomain_772" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_772_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_771" xlink:to="loc_us-gaap_VestingDomain_772_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_791" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259512" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259513" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_CommonStockSharesIssued_792" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AdditionalCommonStockSharesIssued" xlink:label="loc_nnvc_AdditionalCommonStockSharesIssued_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_nnvc_AdditionalCommonStockSharesIssued_793" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_PreferredStockSharesIssued_794" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AdditionalPreferredStockSharesIssued" xlink:label="loc_nnvc_AdditionalPreferredStockSharesIssued_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_nnvc_AdditionalPreferredStockSharesIssued_795" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IncreaseInBaseSalary" xlink:label="loc_nnvc_IncreaseInBaseSalary_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_nnvc_IncreaseInBaseSalary_796" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_797" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_798" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_800" use="optional" order="53" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nnvc-20180930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 14-November-2018 [06:15:38] {AM} - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DocumentAndEntityInformationAbstract" xlink:label="loc_nnvc_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DocumentAndEntityInformationAbstract" xlink:to="lab_nnvc_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesAConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_SeriesAConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesAConvertiblePreferredStockMember" xlink:to="lab_nnvc_SeriesAConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DebtInstrumentClassTypeAxis" xml:lang="en-US">Debt Instrument Class Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis" xlink:to="lab_nnvc_DebtInstrumentClassTypeAxis" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DebtInstrumentClassTypeDomain" xml:lang="en-US">Debt Instrument Class Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DebtInstrumentClassTypeDomain" xlink:to="lab_nnvc_DebtInstrumentClassTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Derivative liability - Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less Accumulated Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xml:lang="en-US">TRADEMARK AND PATENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Trademark and patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Trademarks and Patents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Less Accumulated Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Trademark and patents, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsAbstract" xml:lang="en-US">OTHER ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ServiceAgreements" xlink:label="loc_nnvc_ServiceAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ServiceAgreements" xml:lang="en-US">Service Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_ServiceAgreements" xml:lang="en-US">Service agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ServiceAgreements" xlink:to="lab_nnvc_ServiceAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ServiceAgreements" xml:lang="en-US">This fact represents service agreements.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Other Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liability - warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDERS' EQUITY:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 5,064,110 and 4,531,394 shares issued and outstanding, at September 30, 2018 and June 30, 2018, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 150,000,000 shares authorized, 69,382,560 and 69,171,740 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_BalanceSheetsParentheticalAbstract" xlink:label="loc_nnvc_BalanceSheetsParentheticalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_BalanceSheetsParentheticalAbstract" xml:lang="en-US">Balance Sheets Parenthetical [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_BalanceSheetsParentheticalAbstract" xlink:to="lab_nnvc_BalanceSheetsParentheticalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">OPERATING EXPENSES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">LOSS FROM OPERATIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DiscountOnConvertibleDebentures" xlink:label="loc_nnvc_DiscountOnConvertibleDebentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DiscountOnConvertibleDebentures" xml:lang="en-US">Discount On Convertible Debentures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_nnvc_DiscountOnConvertibleDebentures" xml:lang="en-US">Discount on convertible debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DiscountOnConvertibleDebentures" xlink:to="lab_nnvc_DiscountOnConvertibleDebentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_DiscountOnConvertibleDebentures" xml:lang="en-US">The amount of discount associated with convertible debentures, charged against earnings in the reporting period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Change in fair value of derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">INCOME TAX PROVISION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">NET LOSS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss attributable to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share &#8211; basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per share of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Denominator for basic and diluted weighted average shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" xlink:label="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" xml:lang="en-US">Series A Preferred Shares Issued During Period Employee Stock Compensation Value Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" xml:lang="en-US">Series A Preferred stock issued for employee stock compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" xlink:to="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" xml:lang="en-US">Value of preferred stock shares issued during period as employee stock compensation.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" xlink:label="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" xml:lang="en-US">Series A Preferred Shares Issued During Period Employee Stock Compensation Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" xml:lang="en-US">Series A Preferred stock issued for employee stock compensation (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" xlink:to="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" xml:lang="en-US">Number of series A preferred stock issued during period as employee stock compensation.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:label="loc_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xml:lang="en-US">Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xml:lang="en-US">Common stock issued for consulting and legal services rendered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:to="lab_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xml:lang="en-US">Value of stock issued during the period as a compensation for consulting and legal services.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:label="loc_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xml:lang="en-US">Stock Issued During July Share Issued For Share Based Compensation Consulting And Legal Service One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xml:lang="en-US">Common stock issued for consulting and legal services rendered (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:to="lab_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xml:lang="en-US">Number of shares issued during the period as a compensation for consulting and legal services.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" xlink:label="loc_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" xml:lang="en-US">Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" xml:lang="en-US">Warrants issued to Scientific Advisory Board</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" xlink:to="lab_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" xml:lang="en-US">Value of stock issued during the period as a compensation for consulting and legal services.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedForPaymentOfDirectorFeesValue" xlink:label="loc_nnvc_StockIssuedForPaymentOfDirectorFeesValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_StockIssuedForPaymentOfDirectorFeesValue" xml:lang="en-US">Stock Issued For Payment Of Director Fees Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_nnvc_StockIssuedForPaymentOfDirectorFeesValue" xml:lang="en-US">Common shares issued for Directors fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_StockIssuedForPaymentOfDirectorFeesValue" xlink:to="lab_nnvc_StockIssuedForPaymentOfDirectorFeesValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_StockIssuedForPaymentOfDirectorFeesValue" xml:lang="en-US">The amount represents the stock issued during the period for payment of director fees.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedForPaymentOfDirectorFeesShares" xlink:label="loc_nnvc_StockIssuedForPaymentOfDirectorFeesShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_StockIssuedForPaymentOfDirectorFeesShares" xml:lang="en-US">Stock Issued For Payment Of Director Fees Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_StockIssuedForPaymentOfDirectorFeesShares" xml:lang="en-US">Common shares issued for Directors fees (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_StockIssuedForPaymentOfDirectorFeesShares" xlink:to="lab_nnvc_StockIssuedForPaymentOfDirectorFeesShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_StockIssuedForPaymentOfDirectorFeesShares" xml:lang="en-US">The amount represents the stock issued during the period for payment of director fees.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Stock options issued for compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Accounts payable - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US">Deferred interest payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PreferredSharesIssuedAsCompensation" xlink:label="loc_nnvc_PreferredSharesIssuedAsCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_PreferredSharesIssuedAsCompensation" xml:lang="en-US">Preferred Shares Issued As Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_PreferredSharesIssuedAsCompensation" xml:lang="en-US">Preferred shares issued as compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_PreferredSharesIssuedAsCompensation" xlink:to="lab_nnvc_PreferredSharesIssuedAsCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_PreferredSharesIssuedAsCompensation" xml:lang="en-US">Amount of preferred shares issued as compensation by the entity during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Common shares issued as compensation and for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Warrants granted to Scientific Advisory Board</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_nnvc_ChangeInFairValueOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change In Fair Value Of Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_nnvc_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change in fair value of derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ChangeInFairValueOfDerivativeLiability" xlink:to="lab_nnvc_ChangeInFairValueOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Net Increase or Decrease in the fair value of the derivative liability of derivatives included in earnings.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt discount on convertible debenture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" xlink:label="loc_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" xml:lang="en-US">Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" xlink:to="lab_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" xml:lang="en-US">Tabular disclosure of fair value of stock at each date of issuance.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockWarrantsMember" xlink:label="loc_nnvc_StockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_StockWarrantsMember" xml:lang="en-US">Stock Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_StockWarrantsMember" xlink:to="lab_nnvc_StockWarrantsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" xlink:label="loc_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" xml:lang="en-US">Schedule Of Projected Annual Volatility [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" xlink:to="lab_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" xml:lang="en-US">Tabular disclosure of the projected annual volatility for the valuation dates.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesTable" xlink:label="loc_nnvc_AccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_AccountingPoliciesTable" xml:lang="en-US">Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_AccountingPoliciesTable" xlink:to="lab_nnvc_AccountingPoliciesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesLineItems" xlink:label="loc_nnvc_AccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_AccountingPoliciesLineItems" xml:lang="en-US">Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_AccountingPoliciesLineItems" xlink:to="lab_nnvc_AccountingPoliciesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xml:lang="en-US">Calculation of basic and diluted loss per share of common stock:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FinancingArrangementAxis" xlink:label="loc_nnvc_FinancingArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_FinancingArrangementAxis" xml:lang="en-US">Financing Arrangement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_FinancingArrangementAxis" xlink:to="lab_nnvc_FinancingArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_FinancingArrangementAxis" xml:lang="en-US">Financing Arrangement.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FinancingArrangementDomain" xlink:label="loc_nnvc_FinancingArrangementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_FinancingArrangementDomain" xml:lang="en-US">Financing Arrangement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_FinancingArrangementDomain" xlink:to="lab_nnvc_FinancingArrangementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_FinancingArrangementDomain" xml:lang="en-US">Financing Arrangement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per share, Outstanding (dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per share, Outstanding (dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" xlink:label="loc_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" xml:lang="en-US">Reclassification of General and Administrative Expenses into Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" xlink:to="lab_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" xml:lang="en-US">Amount of Reclassification of Company's laboratory facilities General and Administrative Expenses into Research and Development Expenses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebenturesMember" xlink:label="loc_nnvc_SeriesCConvertibleDebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesCConvertibleDebenturesMember" xml:lang="en-US">Series C Convertible Debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesCConvertibleDebenturesMember" xlink:to="lab_nnvc_SeriesCConvertibleDebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_SeriesCConvertibleDebenturesMember" xml:lang="en-US">Series C Convertible Debentures</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TheracourPharmaIncMember" xlink:label="loc_nnvc_TheracourPharmaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_TheracourPharmaIncMember" xml:lang="en-US">Theracour Pharma Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_TheracourPharmaIncMember" xlink:to="lab_nnvc_TheracourPharmaIncMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OptionAxis" xlink:label="loc_nnvc_OptionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_OptionAxis" xml:lang="en-US">Option [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_OptionAxis" xlink:to="lab_nnvc_OptionAxis" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OptionDomain" xlink:label="loc_nnvc_OptionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_OptionDomain" xml:lang="en-US">Option [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_OptionDomain" xlink:to="lab_nnvc_OptionDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xml:lang="en-US">Debt Conversion Description [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionNameDomain" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Net Account Payable to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebentureMember" xlink:label="loc_nnvc_SeriesCConvertibleDebentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesCConvertibleDebentureMember" xml:lang="en-US">Series C Convertible Debenture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesCConvertibleDebentureMember" xlink:to="lab_nnvc_SeriesCConvertibleDebentureMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DrBoniukMember" xlink:label="loc_nnvc_DrBoniukMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DrBoniukMember" xml:lang="en-US">Dr. Boniuk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DrBoniukMember" xlink:to="lab_nnvc_DrBoniukMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US">Other General and Administrative Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" xlink:label="loc_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" xml:lang="en-US">Percentage Of Net Sales Allocated For Royalty Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" xlink:to="lab_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" xml:lang="en-US">Royalty expense calculated as a percentage of net sales.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xml:lang="en-US">Leasehold Improvements, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xml:lang="en-US">GMP Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Land" xml:lang="en-US">Land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OfficeEquipmentGross" xlink:label="loc_nnvc_OfficeEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_OfficeEquipmentGross" xml:lang="en-US">Office Equipment Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_OfficeEquipmentGross" xml:lang="en-US">Office Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_OfficeEquipmentGross" xlink:to="lab_nnvc_OfficeEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_OfficeEquipmentGross" xml:lang="en-US">Gross amount, at the balance sheet date, of office equipment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xml:lang="en-US">Furniture and Fixtures, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xml:lang="en-US">Furniture and Fixtures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross" xlink:to="lab_us-gaap_FurnitureAndFixturesGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FixturesAndEquipmentGross" xml:lang="en-US">Fixtures and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FixturesAndEquipmentGross" xml:lang="en-US">Lab Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixturesAndEquipmentGross" xlink:to="lab_us-gaap_FixturesAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfTrademarksAndPatentsTable" xlink:label="loc_nnvc_ScheduleOfTrademarksAndPatentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ScheduleOfTrademarksAndPatentsTable" xml:lang="en-US">Schedule Of Trademarks And Patents [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ScheduleOfTrademarksAndPatentsTable" xlink:to="lab_nnvc_ScheduleOfTrademarksAndPatentsTable" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarksAndPatentsLineItems" xlink:label="loc_nnvc_TrademarksAndPatentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_TrademarksAndPatentsLineItems" xml:lang="en-US">Trademarks And Patents [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems" xlink:to="lab_nnvc_TrademarksAndPatentsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Trademarks and Patents, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarkAndPatentsMember" xlink:label="loc_nnvc_TrademarkAndPatentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_TrademarkAndPatentsMember" xml:lang="en-US">Trademark and Patents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_TrademarkAndPatentsMember" xlink:to="lab_nnvc_TrademarkAndPatentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesBConvertibleDebenturesMember" xlink:label="loc_nnvc_SeriesBConvertibleDebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesBConvertibleDebenturesMember" xml:lang="en-US">Series B Convertible Debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesBConvertibleDebenturesMember" xlink:to="lab_nnvc_SeriesBConvertibleDebenturesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xml:lang="en-US">Repayments of Other Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" xlink:label="loc_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" xml:lang="en-US">Common Stock Value Issued For Debt Instrument Periodic Interest Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" xlink:to="lab_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" xml:lang="en-US">This element represents the value of common stock issued for debt instrument periodic interest payment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SharePriceAsPerRedemptionAgreement" xlink:label="loc_nnvc_SharePriceAsPerRedemptionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SharePriceAsPerRedemptionAgreement" xml:lang="en-US">Share price as per Redemption Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SharePriceAsPerRedemptionAgreement" xlink:to="lab_nnvc_SharePriceAsPerRedemptionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_SharePriceAsPerRedemptionAgreement" xml:lang="en-US">It represents the share price as per redemption agreement.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredInterestPayment" xlink:label="loc_nnvc_DeferredInterestPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DeferredInterestPayment" xml:lang="en-US">Deferred Interest Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DeferredInterestPayment" xlink:to="lab_nnvc_DeferredInterestPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_DeferredInterestPayment" xml:lang="en-US">The amount of deferred interest payment.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" xlink:label="loc_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" xml:lang="en-US">Series Preferred Share Issued For Debenture Interest Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" xlink:to="lab_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" xml:lang="en-US">It represents number of shares issued series A preferred shares issued for debenture interest.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionDescription" xml:lang="en-US">Debt Conversion, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionDescription" xlink:to="lab_us-gaap_DebtConversionDescription" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToOfficersOrStockholdersCurrent" xml:lang="en-US">Due to Officers or Stockholders, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueToOfficersOrStockholdersCurrent" xml:lang="en-US">Severance payment- Eugene Seymour</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="lab_us-gaap_DueToOfficersOrStockholdersCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued payroll</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Professional Services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateAxis" xml:lang="en-US">Award Date [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateOneMember" xlink:label="loc_nnvc_IssuanceDateOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_IssuanceDateOneMember" xml:lang="en-US">Issuance Date One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_IssuanceDateOneMember" xlink:to="lab_nnvc_IssuanceDateOneMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateTwoMember" xlink:label="loc_nnvc_IssuanceDateTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_IssuanceDateTwoMember" xml:lang="en-US">Issuance Date Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_IssuanceDateTwoMember" xlink:to="lab_nnvc_IssuanceDateTwoMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateThreeMember" xlink:label="loc_nnvc_IssuanceDateThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_IssuanceDateThreeMember" xml:lang="en-US">Issuance Date Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_IssuanceDateThreeMember" xlink:to="lab_nnvc_IssuanceDateThreeMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateFourMember" xlink:label="loc_nnvc_IssuanceDateFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_IssuanceDateFourMember" xml:lang="en-US">Issuance Date Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_IssuanceDateFourMember" xlink:to="lab_nnvc_IssuanceDateFourMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScientificAdvisoryBoardMember" xlink:label="loc_nnvc_ScientificAdvisoryBoardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ScientificAdvisoryBoardMember" xml:lang="en-US">Scientific Advisory Board [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ScientificAdvisoryBoardMember" xlink:to="lab_nnvc_ScientificAdvisoryBoardMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life (year)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected annual rate of quarterly dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate(s)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeasideAxis" xlink:label="loc_nnvc_SeasideAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeasideAxis" xml:lang="en-US">Seaside [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeasideAxis" xlink:to="lab_nnvc_SeasideAxis" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeasideDomain" xlink:label="loc_nnvc_SeasideDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeasideDomain" xml:lang="en-US">Seaside [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeasideDomain" xlink:to="lab_nnvc_SeasideDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PresidentMember" xml:lang="en-US">President [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PresidentMember" xlink:to="lab_us-gaap_PresidentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xml:lang="en-US">Auction Market Preferred Securities, Stock Series [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xml:lang="en-US">Auction Market Preferred Securities, Stock Series, Title [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AugustTwoThousandNineteenMember" xlink:label="loc_nnvc_AugustTwoThousandNineteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_AugustTwoThousandNineteenMember" xml:lang="en-US">August Two Thousand Nineteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_AugustTwoThousandNineteenMember" xml:lang="en-US">August 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_AugustTwoThousandNineteenMember" xlink:to="lab_nnvc_AugustTwoThousandNineteenMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_February2022Member" xlink:label="loc_nnvc_February2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_February2022Member" xml:lang="en-US">February 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_February2022Member" xlink:to="lab_nnvc_February2022Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued For Services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" xlink:label="loc_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" xml:lang="en-US">Number Of Common Stock To Be Issued Upon Conversion Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" xml:lang="en-US">Number Of Common Stock To Be Issued Upon Conversion Of Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" xlink:to="lab_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" xml:lang="en-US">The number of common stock to be issued upon exercise of warrants.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" xlink:to="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" xml:lang="en-US">Percentage of voting rights.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_RestrictedCommonStockAuthorizedForInterestPayable" xlink:label="loc_nnvc_RestrictedCommonStockAuthorizedForInterestPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_RestrictedCommonStockAuthorizedForInterestPayable" xml:lang="en-US">Restricted common stock authorized for interest payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_RestrictedCommonStockAuthorizedForInterestPayable" xlink:to="lab_nnvc_RestrictedCommonStockAuthorizedForInterestPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_RestrictedCommonStockAuthorizedForInterestPayable" xml:lang="en-US">Restricted common stock authorized for interest payable.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Shares, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FairValueMeasurementSignificantAssumptions" xlink:label="loc_nnvc_FairValueMeasurementSignificantAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_FairValueMeasurementSignificantAssumptions" xml:lang="en-US">Fair Value Measurement Significant Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_FairValueMeasurementSignificantAssumptions" xlink:to="lab_nnvc_FairValueMeasurementSignificantAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_FairValueMeasurementSignificantAssumptions" xml:lang="en-US">Description of significant assumptions used by management to measure fair value.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted Stock or Unit Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense" xlink:to="lab_us-gaap_RestrictedStockExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Number of Shares, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per share, Granted (dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per share, Expired (dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options expirations, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding (in dollars)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding (in dollars)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding (in dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options granted, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Granted (in dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xml:lang="en-US">The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="loc_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xml:lang="en-US">Expected forfeiture (attrition) rate (%)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xml:lang="en-US">The estimated measure of the percentage by which a shares are expected to get forfeited (attrition) during a period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FuturePeriodAxis" xlink:label="loc_nnvc_FuturePeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_FuturePeriodAxis" xml:lang="en-US">Future Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_FuturePeriodAxis" xlink:to="lab_nnvc_FuturePeriodAxis" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FuturePeriodDomain" xlink:label="loc_nnvc_FuturePeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_FuturePeriodDomain" xml:lang="en-US">Future Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_FuturePeriodDomain" xlink:to="lab_nnvc_FuturePeriodDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302019Member" xlink:label="loc_nnvc_June302019Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_June302019Member" xml:lang="en-US">June 30, 2019 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_June302019Member" xlink:to="lab_nnvc_June302019Member" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302020Member" xlink:label="loc_nnvc_June302020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_June302020Member" xml:lang="en-US">June 30, 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_June302020Member" xlink:to="lab_nnvc_June302020Member" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302021Member" xlink:label="loc_nnvc_June302021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_June302021Member" xml:lang="en-US">June 30, 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_June302021Member" xlink:to="lab_nnvc_June302021Member" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302022Member" xlink:label="loc_nnvc_June302022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_June302022Member" xml:lang="en-US">June 30 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_June302022Member" xlink:to="lab_nnvc_June302022Member" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302023Member" xlink:label="loc_nnvc_June302023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_June302023Member" xml:lang="en-US">June 30, 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_June302023Member" xlink:to="lab_nnvc_June302023Member" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantsExercisable" xlink:label="loc_nnvc_WarrantsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_WarrantsExercisable" xml:lang="en-US">Warrants Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_WarrantsExercisable" xlink:to="lab_nnvc_WarrantsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_WarrantsExercisable" xml:lang="en-US">Aggregate amount of warrants are exercisable during the reporting period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionPlanExpense" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense" xlink:to="lab_us-gaap_StockOptionPlanExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OneYearEnded63018Member" xlink:label="loc_nnvc_OneYearEnded63018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_OneYearEnded63018Member" xml:lang="en-US">One Year Ended 6 30 18 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_OneYearEnded63018Member" xml:lang="en-US">One Year Ended 6/30/18</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_OneYearEnded63018Member" xlink:to="lab_nnvc_OneYearEnded63018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_OneYearEnded63018Member" xml:lang="en-US">One Year Ended 6/30/18</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OneYearEnded93018Member" xlink:label="loc_nnvc_OneYearEnded93018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_OneYearEnded93018Member" xml:lang="en-US">One Year Ended 9 30 18 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_OneYearEnded93018Member" xml:lang="en-US">One Year Ended 9/30/18</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_OneYearEnded93018Member" xlink:to="lab_nnvc_OneYearEnded93018Member" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_nnvc_FairValueAssumptionExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_FairValueAssumptionExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumption Expected Volatility Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_FairValueAssumptionExpectedVolatilityRate" xlink:to="lab_nnvc_FairValueAssumptionExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_FairValueAssumptionExpectedVolatilityRate" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Additions during the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xml:lang="en-US">Transfer in and out of Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentRedemptionAxis" xlink:label="loc_nnvc_DebtInstrumentRedemptionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DebtInstrumentRedemptionAxis" xml:lang="en-US">Debt Instrument Redemption [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DebtInstrumentRedemptionAxis" xlink:to="lab_nnvc_DebtInstrumentRedemptionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_DebtInstrumentRedemptionAxis" xml:lang="en-US">Debt Instrument, Redemption</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentRedemptionDomain" xlink:label="loc_nnvc_DebtInstrumentRedemptionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DebtInstrumentRedemptionDomain" xml:lang="en-US">Debt Instrument Redemption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DebtInstrumentRedemptionDomain" xlink:to="lab_nnvc_DebtInstrumentRedemptionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_DebtInstrumentRedemptionDomain" xml:lang="en-US">Debt Instrument, Redemption</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PlacementAgentsMember" xlink:label="loc_nnvc_PlacementAgentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_PlacementAgentsMember" xml:lang="en-US">Placement Agents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_PlacementAgentsMember" xlink:to="lab_nnvc_PlacementAgentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantsIssued" xlink:label="loc_nnvc_WarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_WarrantsIssued" xml:lang="en-US">Warrants Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_WarrantsIssued" xlink:to="lab_nnvc_WarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_WarrantsIssued" xml:lang="en-US">Reflects the number of warrants issued.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantExpirationTerm" xlink:label="loc_nnvc_WarrantExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_WarrantExpirationTerm" xml:lang="en-US">Warrant Expiration Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_WarrantExpirationTerm" xlink:to="lab_nnvc_WarrantExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_WarrantExpirationTerm" xml:lang="en-US">Reflects the term of warrants.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommitmentsAndContingenciesTable" xlink:label="loc_nnvc_CommitmentsAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable" xlink:to="lab_nnvc_CommitmentsAndContingenciesTable" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ChiefScientificOfficerMember" xlink:label="loc_nnvc_ChiefScientificOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_ChiefScientificOfficerMember" xml:lang="en-US">Chief Scientific Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_ChiefScientificOfficerMember" xlink:to="lab_nnvc_ChiefScientificOfficerMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VicePresidentMember" xlink:label="loc_us-gaap_VicePresidentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VicePresidentMember" xml:lang="en-US">Vice President [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VicePresidentMember" xlink:to="lab_us-gaap_VicePresidentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember" xml:lang="en-US">Chief Financial Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefFinancialOfficerMember" xlink:to="lab_us-gaap_ChiefFinancialOfficerMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_SeriesConvertiblePreferredStockMember" xml:lang="en-US">Series Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_SeriesConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_SeriesConvertiblePreferredStockMember" xlink:to="lab_nnvc_SeriesConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredCompensationYearAxis" xlink:label="loc_nnvc_DeferredCompensationYearAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DeferredCompensationYearAxis" xml:lang="en-US">Deferred Compensation Year [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DeferredCompensationYearAxis" xlink:to="lab_nnvc_DeferredCompensationYearAxis" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredCompensationYearDomain" xlink:label="loc_nnvc_DeferredCompensationYearDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_DeferredCompensationYearDomain" xml:lang="en-US">Deferred Compensation Year [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_DeferredCompensationYearDomain" xlink:to="lab_nnvc_DeferredCompensationYearDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearOneMember" xlink:label="loc_nnvc_YearOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_YearOneMember" xml:lang="en-US">Year One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_YearOneMember" xlink:to="lab_nnvc_YearOneMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearTwoMember" xlink:label="loc_nnvc_YearTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_YearTwoMember" xml:lang="en-US">Year Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_YearTwoMember" xlink:to="lab_nnvc_YearTwoMember" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearThreeMember" xlink:label="loc_nnvc_YearThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_YearThreeMember" xml:lang="en-US">Year Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_YearThreeMember" xlink:to="lab_nnvc_YearThreeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommitmentsAndContingenciesLineItems" xlink:label="loc_nnvc_CommitmentsAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems" xlink:to="lab_nnvc_CommitmentsAndContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AdditionalCommonStockSharesIssued" xlink:label="loc_nnvc_AdditionalCommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_AdditionalCommonStockSharesIssued" xml:lang="en-US">Additional Common Stock Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_AdditionalCommonStockSharesIssued" xml:lang="en-US">Additional Common Stock Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_AdditionalCommonStockSharesIssued" xlink:to="lab_nnvc_AdditionalCommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_AdditionalCommonStockSharesIssued" xml:lang="en-US">Total number of additional common shares of an entity that have been sold or granted to shareholders.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AdditionalPreferredStockSharesIssued" xlink:label="loc_nnvc_AdditionalPreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_AdditionalPreferredStockSharesIssued" xml:lang="en-US">Additional Preferred Stock Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_AdditionalPreferredStockSharesIssued" xml:lang="en-US">Additional Preferred Stock Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_AdditionalPreferredStockSharesIssued" xlink:to="lab_nnvc_AdditionalPreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_AdditionalPreferredStockSharesIssued" xml:lang="en-US">Total number of additional nonredeemable preferred shares issued to shareholders.</label>
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IncreaseInBaseSalary" xlink:label="loc_nnvc_IncreaseInBaseSalary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_nnvc_IncreaseInBaseSalary" xml:lang="en-US">Increase In Base Salary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_nnvc_IncreaseInBaseSalary" xml:lang="en-US">Increase In Base Salary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nnvc_IncreaseInBaseSalary" xlink:to="lab_nnvc_IncreaseInBaseSalary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nnvc_IncreaseInBaseSalary" xml:lang="en-US">This element represents the certain amount of estimated salary increase in their base.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nnvc-20180930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks version 3.0 on 14-November-2018 [06:15:38] {AM} - www.datatracks.com-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#DocumentAndEntityInformation" roleURI="http://www.nanoviricides.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#BalanceSheets" roleURI="http://www.nanoviricides.com/role/BalanceSheets" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#BalanceSheetsParenthetical" roleURI="http://www.nanoviricides.com/role/BalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementsOfOperations" roleURI="http://www.nanoviricides.com/role/StatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementOfChangesInStockholdersEquity" roleURI="http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StatementsOfCashFlows" roleURI="http://www.nanoviricides.com/role/StatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#OrganizationAndNatureOfBusiness" roleURI="http://www.nanoviricides.com/role/OrganizationAndNatureOfBusiness" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#LiquidityAndGoingConcern" roleURI="http://www.nanoviricides.com/role/LiquidityAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#RelatedPartyTransactions" roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#PropertyAndEquipment" roleURI="http://www.nanoviricides.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#TrademarkAndPatents" roleURI="http://www.nanoviricides.com/role/TrademarkAndPatents" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#ConvertibleDebentureAndDerivatives" roleURI="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivatives" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#AccruedExpenses" roleURI="http://www.nanoviricides.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactions" roleURI="http://www.nanoviricides.com/role/EquityTransactions" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptions" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptions" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurement" roleURI="http://www.nanoviricides.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#CommitmentsAndContingencies" roleURI="http://www.nanoviricides.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SubsequentEvents" roleURI="http://www.nanoviricides.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#RelatedPartyTransactionsTables" roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#PropertyAndEquipmentTables" roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#TrademarkAndPatentsTables" roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#AccruedExpensesTables" roleURI="http://www.nanoviricides.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsTables" roleURI="http://www.nanoviricides.com/role/EquityTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsTables" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementTables" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#LiquidityAndGoingConcernDetailsTextual" roleURI="http://www.nanoviricides.com/role/LiquidityAndGoingConcernDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#PropertyAndEquipmentDetails" roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://www.nanoviricides.com/role/PropertyAndEquipmentDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#TrademarkAndPatentsDetails" roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#TrademarkAndPatentsDetailsTextual" roleURI="http://www.nanoviricides.com/role/TrademarkAndPatentsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#ConvertibleDebentureAndDerivativesDetailsTextual" roleURI="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivativesDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#AccruedExpensesDetails" roleURI="http://www.nanoviricides.com/role/AccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsDetails" roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsDetails1" roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#EquityTransactionsDetailsTextual" roleURI="http://www.nanoviricides.com/role/EquityTransactionsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetails" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetails1" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetails2" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails2" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#StockWarrantsAndOptionsDetailsTextual" roleURI="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetails" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetails1" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails1" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetails2" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetails2" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#FairValueMeasurementDetailsTextual" roleURI="http://www.nanoviricides.com/role/FairValueMeasurementDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="nnvc-20180930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.nanoviricides.com/role/CommitmentsAndContingenciesDetailsTextual" />
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DocumentAndEntityInformationAbstract" xlink:label="loc_nnvc_DocumentAndEntityInformationAbstract_187668" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_187667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DocumentAndEntityInformationAbstract_187668" xlink:to="loc_dei_DocumentInformationTable_187667" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_187666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_187667" xlink:to="loc_us-gaap_StatementClassOfStockAxis_187666" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_187665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_187666" xlink:to="loc_us-gaap_ClassOfStockDomain_187665" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_187664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_187667" xlink:to="loc_dei_DocumentInformationLineItems_187664" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_187411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentType_187411" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_187412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_AmendmentFlag_187412" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_187421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentPeriodEndDate_187421" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_187422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentFiscalYearFocus_187422" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_187423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_DocumentFiscalPeriodFocus_187423" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_187436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityRegistrantName_187436" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_187437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityCentralIndexKey_187437" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_187453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_CurrentFiscalYearEndDate_187453" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_187458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityFilerCategory_187458" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_187540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_TradingSymbol_187540" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_187547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_187547" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_187659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntityEmergingGrowthCompany_187659" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_187661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_187664" xlink:to="loc_dei_EntitySmallBusiness_187661" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="loc_us-gaap_StatementTable_30" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_us-gaap_StatementClassOfStockAxis_31" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_31" xlink:to="loc_us-gaap_ClassOfStockDomain_32" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_32" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_48" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33" xlink:to="loc_us-gaap_RelatedPartyDomain_49" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_34" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_34" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_35" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_us-gaap_FinancialInstrumentAxis_36" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37" xlink:to="loc_us-gaap_WarrantMember_51" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30" xlink:to="loc_us-gaap_StatementLineItems_38" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_38" xlink:to="loc_us-gaap_AssetsAbstract_39" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_AssetsCurrentAbstract_40" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_53" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_40" xlink:to="loc_us-gaap_AssetsCurrent_54" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_55" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_56" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_57" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_58" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_42" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_60" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_OtherAssetsAbstract_43" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_43" xlink:to="loc_us-gaap_SecurityDeposit_61" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ServiceAgreements" xlink:label="loc_nnvc_ServiceAgreements_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_43" xlink:to="loc_nnvc_ServiceAgreements_62" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_43" xlink:to="loc_us-gaap_OtherAssets_63" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39" xlink:to="loc_us-gaap_Assets_64" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_LiabilitiesAbstract_45" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_65" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_66" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_235492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_235492" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_69" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_45" xlink:to="loc_us-gaap_LiabilitiesCurrent_71" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_CommitmentsAndContingencies_74" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_StockholdersEquityAbstract_47" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_PreferredStockValue_75" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_CommonStockValue_76" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_AdditionalPaidInCapital_77" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_47" xlink:to="loc_us-gaap_StockholdersEquity_79" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_44" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_80" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/BalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_BalanceSheetsParentheticalAbstract" xlink:label="loc_nnvc_BalanceSheetsParentheticalAbstract_96" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_BalanceSheetsParentheticalAbstract_96" xlink:to="loc_us-gaap_StatementTable_97" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_98" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_98" xlink:to="loc_us-gaap_ClassOfStockDomain_99" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_99" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_101" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_97" xlink:to="loc_us-gaap_StatementLineItems_100" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_103" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockSharesIssued_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_106" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_107" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockSharesIssued_108" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_100" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_109" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_171" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_171" xlink:to="loc_us-gaap_StatementTable_172" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_172" xlink:to="loc_us-gaap_StatementScenarioAxis_173" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_173" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_172" xlink:to="loc_us-gaap_StatementLineItems_174" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_OperatingExpensesAbstract_175" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_180" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_181" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_OperatingExpenses_182" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_175" xlink:to="loc_us-gaap_OperatingIncomeLoss_183" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_184" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_InterestExpense_185" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DiscountOnConvertibleDebentures" xlink:label="loc_nnvc_DiscountOnConvertibleDebentures_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_nnvc_DiscountOnConvertibleDebentures_187" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_188" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_176" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_189" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_191" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_NetIncomeLoss_192" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_259282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_259282" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_259283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_174" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_259283" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_219" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_219" xlink:to="loc_us-gaap_StatementTable_220" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_220" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_221" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_221" xlink:to="loc_us-gaap_EquityComponentDomain_222" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_PreferredStockMember_225" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_CommonStockMember_226" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_227" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_222" xlink:to="loc_us-gaap_RetainedEarningsMember_228" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_220" xlink:to="loc_us-gaap_StatementClassOfStockAxis_223" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_223" xlink:to="loc_us-gaap_ClassOfStockDomain_229" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_220" xlink:to="loc_us-gaap_StatementLineItems_224" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_StockholdersEquity_230" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_SharesOutstanding_231" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued" xlink:label="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued_234" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued" xlink:label="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued_235" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:label="loc_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne_242" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne" xlink:label="loc_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne_243" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_259284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_259284" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices" xlink:label="loc_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices_244" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedForPaymentOfDirectorFeesValue" xlink:label="loc_nnvc_StockIssuedForPaymentOfDirectorFeesValue_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedForPaymentOfDirectorFeesValue_246" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockIssuedForPaymentOfDirectorFeesShares" xlink:label="loc_nnvc_StockIssuedForPaymentOfDirectorFeesShares_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_nnvc_StockIssuedForPaymentOfDirectorFeesShares_247" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_NetIncomeLoss_248" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_StockholdersEquity_249" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_224" xlink:to="loc_us-gaap_SharesOutstanding_250" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_613" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_613" xlink:to="loc_us-gaap_StatementTable_614" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_614" xlink:to="loc_us-gaap_StatementClassOfStockAxis_615" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_615" xlink:to="loc_us-gaap_ClassOfStockDomain_625" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_614" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_616" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_616" xlink:to="loc_us-gaap_RelatedPartyDomain_626" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_614" xlink:to="loc_us-gaap_StatementLineItems_617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" xlink:to="loc_us-gaap_NetIncomeLoss_627" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PreferredSharesIssuedAsCompensation" xlink:label="loc_nnvc_PreferredSharesIssuedAsCompensation_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_nnvc_PreferredSharesIssuedAsCompensation_628" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_629" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_630" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_259285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_ShareBasedCompensation_259285" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_Depreciation_633" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_AdjustmentForAmortization_634" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_nnvc_ChangeInFairValueOfDerivativeLiability_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_nnvc_ChangeInFairValueOfDerivativeLiability_635" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_636" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_639" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_641" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_642" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_643" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_644" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_620" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_645" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_618" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_646" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_621" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_621" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_647" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_649" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_650" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_651" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_617" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_623" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_623" xlink:to="loc_us-gaap_InterestPaidNet_652" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/OrganizationAndNatureOfBusiness">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_808" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_808" xlink:to="loc_us-gaap_NatureOfOperations_809" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_823" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_823" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_824" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/LiquidityAndGoingConcern">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_246199" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_246200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_246199" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_246200" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/TrademarkAndPatents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_11" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_12" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivatives">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_15" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_244287" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_244288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_244287" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_244288" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_17" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_18" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_21" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_24" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_235658" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_235659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_235658" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_235659" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_85" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_235515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_235515" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_87" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_88" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_90" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_90" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_91" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_93" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_93" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_94" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_111" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_111" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_112" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/TrademarkAndPatentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_114" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_114" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_115" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_244290" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_244291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_244290" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_244291" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_125" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_125" xlink:to="loc_us-gaap_StatementTable_126" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_StatementClassOfStockAxis_127" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_127" xlink:to="loc_us-gaap_ClassOfStockDomain_128" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_129" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_129" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_StatementLineItems_130" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock" xlink:label="loc_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_130" xlink:to="loc_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock_133" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_130" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_134" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_136" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_136" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xlink:to="loc_us-gaap_AwardTypeAxis_138" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockWarrantsMember" xlink:label="loc_nnvc_StockWarrantsMember_235600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_141" xlink:to="loc_nnvc_StockWarrantsMember_235600" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_139" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_139" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_142" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_235599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_142" xlink:to="loc_us-gaap_StockOptionMember_235599" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_259486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xlink:to="loc_us-gaap_TitleOfIndividualAxis_259486" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_259486" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259487" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_143" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_259485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_140" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_259485" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_145" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_145" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_146" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock" xlink:label="loc_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_145" xlink:to="loc_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock_147" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_145" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_148" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_198" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesTable" xlink:label="loc_nnvc_AccountingPoliciesTable_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_198" xlink:to="loc_nnvc_AccountingPoliciesTable_199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_199" xlink:to="loc_us-gaap_FinancialInstrumentAxis_200" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_200" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_201" xlink:to="loc_us-gaap_WarrantMember_204" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_199" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_202" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_202" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_205" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesLineItems" xlink:label="loc_nnvc_AccountingPoliciesLineItems_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_199" xlink:to="loc_nnvc_AccountingPoliciesLineItems_203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesLineItems_203" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_206" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_208" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_208" xlink:to="loc_us-gaap_StatementTable_209" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_210" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_210" xlink:to="loc_us-gaap_ClassOfStockDomain_213" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementLineItems_211" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_211" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_212" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_212" xlink:to="loc_us-gaap_NetIncomeLoss_214" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_212" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_212" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_252" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesTable" xlink:label="loc_nnvc_AccountingPoliciesTable_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_252" xlink:to="loc_nnvc_AccountingPoliciesTable_253" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_254" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_254" xlink:to="loc_us-gaap_TypeOfAdoptionMember_270" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_srt_RangeAxis_255" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_255" xlink:to="loc_srt_RangeMember_271" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_256" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_256" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_258" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_258" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_273" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_259" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_259" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_274" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_260" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_260" xlink:to="loc_us-gaap_EquityComponentDomain_275" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_259306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_275" xlink:to="loc_us-gaap_CommonStockMember_259306" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_261" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_261" xlink:to="loc_us-gaap_ClassOfStockDomain_262" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_276" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_263" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_263" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_277" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FinancingArrangementAxis" xlink:label="loc_nnvc_FinancingArrangementAxis_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_nnvc_FinancingArrangementAxis_264" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FinancingArrangementDomain" xlink:label="loc_nnvc_FinancingArrangementDomain_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_FinancingArrangementAxis_264" xlink:to="loc_nnvc_FinancingArrangementDomain_278" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_StatementScenarioAxis_265" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_265" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_279" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_266" xlink:to="loc_us-gaap_RelatedPartyDomain_280" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_267" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_267" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_281" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_268" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_268" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_282" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_259307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_us-gaap_FinancialInstrumentAxis_259307" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_259307" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebenturesMember" xlink:label="loc_nnvc_SeriesCConvertibleDebenturesMember_259310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_259308" xlink:to="loc_nnvc_SeriesCConvertibleDebenturesMember_259310" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AccountingPoliciesLineItems" xlink:label="loc_nnvc_AccountingPoliciesLineItems_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesTable_253" xlink:to="loc_nnvc_AccountingPoliciesLineItems_269" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_283" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_284" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_285" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_PreferredStockSharesIssued_286" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses" xlink:label="loc_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses_259304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses_259304" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_259305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_AccountingPoliciesLineItems_269" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_259305" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/LiquidityAndGoingConcernDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_259331" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_259333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_259331" xlink:to="loc_us-gaap_StatementTable_259333" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_259334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_259333" xlink:to="loc_us-gaap_StatementClassOfStockAxis_259334" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_259335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_259334" xlink:to="loc_us-gaap_ClassOfStockDomain_259335" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_259336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_259333" xlink:to="loc_us-gaap_StatementLineItems_259336" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_259337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_259337" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_259338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_259338" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_259349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_NetIncomeLoss_259349" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_259351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_259336" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_259351" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_312" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_312" xlink:to="loc_us-gaap_StatementTable_313" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_StatementClassOfStockAxis_314" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314" xlink:to="loc_us-gaap_ClassOfStockDomain_324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_dei_LegalEntityAxis_315" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_315" xlink:to="loc_dei_EntityDomain_316" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TheracourPharmaIncMember" xlink:label="loc_nnvc_TheracourPharmaIncMember_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_316" xlink:to="loc_nnvc_TheracourPharmaIncMember_325" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_TitleOfIndividualAxis_317" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_317" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_326" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_318" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_318" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_327" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_319" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_319" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_328" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OptionAxis" xlink:label="loc_nnvc_OptionAxis_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_nnvc_OptionAxis_320" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OptionDomain" xlink:label="loc_nnvc_OptionDomain_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_OptionAxis_320" xlink:to="loc_nnvc_OptionDomain_329" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_321" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_321" xlink:to="loc_us-gaap_DebtConversionNameDomain_322" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_StatementLineItems_323" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_323" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_331" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_323" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_332" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_337" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_337" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_StatementClassOfStockAxis_339" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_339" xlink:to="loc_us-gaap_ClassOfStockDomain_340" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebentureMember" xlink:label="loc_nnvc_SeriesCConvertibleDebentureMember_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_340" xlink:to="loc_nnvc_SeriesCConvertibleDebentureMember_351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_dei_LegalEntityAxis_341" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_341" xlink:to="loc_dei_EntityDomain_352" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TheracourPharmaIncMember" xlink:label="loc_nnvc_TheracourPharmaIncMember_260642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_352" xlink:to="loc_nnvc_TheracourPharmaIncMember_260642" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_342" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_342" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_353" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_TitleOfIndividualAxis_343" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_343" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_354" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_344" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_344" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_355" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_260643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_355" xlink:to="loc_us-gaap_SubsequentEventMember_260643" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_345" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_345" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_356" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_346" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_346" xlink:to="loc_us-gaap_RelatedPartyDomain_347" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DrBoniukMember" xlink:label="loc_nnvc_DrBoniukMember_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_347" xlink:to="loc_nnvc_DrBoniukMember_357" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_348" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_348" xlink:to="loc_us-gaap_DebtConversionNameDomain_358" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_338" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_349" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_359" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_360" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_InterestExpenseDebt_365" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments" xlink:label="loc_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments_246203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments_246203" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_260641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_349" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_260641" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/PropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_367" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_367" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_StatementClassOfStockAxis_369" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_369" xlink:to="loc_us-gaap_ClassOfStockDomain_371" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_372" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_Land_373" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OfficeEquipmentGross" xlink:label="loc_nnvc_OfficeEquipmentGross_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_nnvc_OfficeEquipmentGross_374" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaap_FixturesAndEquipmentGross_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_FixturesAndEquipmentGross_376" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_377" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_378" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_370" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_379" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/PropertyAndEquipmentDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_381" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_381" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_382" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_382" xlink:to="loc_us-gaap_StatementClassOfStockAxis_383" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_383" xlink:to="loc_us-gaap_ClassOfStockDomain_385" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_382" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_384" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_384" xlink:to="loc_us-gaap_Depreciation_386" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/TrademarkAndPatentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_388" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfTrademarksAndPatentsTable" xlink:label="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_388" xlink:to="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_389" xlink:to="loc_us-gaap_StatementClassOfStockAxis_390" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_390" xlink:to="loc_us-gaap_ClassOfStockDomain_392" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarksAndPatentsLineItems" xlink:label="loc_nnvc_TrademarksAndPatentsLineItems_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_389" xlink:to="loc_nnvc_TrademarksAndPatentsLineItems_391" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_391" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_393" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_391" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_394" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_391" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_395" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/TrademarkAndPatentsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_397" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScheduleOfTrademarksAndPatentsTable" xlink:label="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_397" xlink:to="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_398" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_398" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_399" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_399" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarkAndPatentsMember" xlink:label="loc_nnvc_TrademarkAndPatentsMember_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_400" xlink:to="loc_nnvc_TrademarkAndPatentsMember_402" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_TrademarksAndPatentsLineItems" xlink:label="loc_nnvc_TrademarksAndPatentsLineItems_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_ScheduleOfTrademarksAndPatentsTable_398" xlink:to="loc_nnvc_TrademarksAndPatentsLineItems_401" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_TrademarksAndPatentsLineItems_401" xlink:to="loc_us-gaap_AdjustmentForAmortization_403" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_423" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_423" xlink:to="loc_us-gaap_DebtInstrumentTable_424" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_425" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_425" xlink:to="loc_us-gaap_DebtConversionNameDomain_426" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesBConvertibleDebenturesMember" xlink:label="loc_nnvc_SeriesBConvertibleDebenturesMember_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_426" xlink:to="loc_nnvc_SeriesBConvertibleDebenturesMember_442" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_426" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_443" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesCConvertibleDebentureMember" xlink:label="loc_nnvc_SeriesCConvertibleDebentureMember_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_426" xlink:to="loc_nnvc_SeriesCConvertibleDebentureMember_444" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_FinancialInstrumentAxis_427" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_427" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_445" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_TitleOfIndividualAxis_428" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_428" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_446" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_429" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_429" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_447" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_AwardTypeAxis_430" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_430" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_448" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_srt_RangeAxis_431" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_431" xlink:to="loc_srt_RangeMember_432" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_433" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_433" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_434" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_StatementScenarioAxis_435" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_435" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_436" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_437" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_437" xlink:to="loc_us-gaap_EquityComponentDomain_438" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_438" xlink:to="loc_us-gaap_CommonStockMember_454" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_StatementClassOfStockAxis_439" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_439" xlink:to="loc_us-gaap_ClassOfStockDomain_440" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_440" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_455" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_424" xlink:to="loc_us-gaap_DebtInstrumentLineItems_441" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_458" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_459" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_460" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_461" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_462" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_463" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_InterestExpenseDebt_472" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_475" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_476" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment" xlink:label="loc_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment_479" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_481" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_482" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DerivativeLiabilities_483" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_484" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_485" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SharePriceAsPerRedemptionAgreement" xlink:label="loc_nnvc_SharePriceAsPerRedemptionAgreement_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_SharePriceAsPerRedemptionAgreement_486" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredInterestPayment" xlink:label="loc_nnvc_DeferredInterestPayment_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_DeferredInterestPayment_494" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued" xlink:label="loc_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued_496" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_235593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_InterestPayableCurrent_235593" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_235601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_235601" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_259403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441" xlink:to="loc_us-gaap_DebtConversionDescription_259403" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_244293" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_244295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_244293" xlink:to="loc_us-gaap_StatementTable_244295" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_244296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_244295" xlink:to="loc_us-gaap_StatementClassOfStockAxis_244296" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_244297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_244296" xlink:to="loc_us-gaap_ClassOfStockDomain_244297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_244298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_244295" xlink:to="loc_us-gaap_StatementLineItems_244298" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaap_DueToOfficersOrStockholdersCurrent_244299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_DueToOfficersOrStockholdersCurrent_244299" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_244300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_AccruedSalariesCurrent_244300" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_244301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_244301" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_244302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244298" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_244302" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_498" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_498" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_499" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_499" xlink:to="loc_us-gaap_AwardDateAxis_500" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_500" xlink:to="loc_us-gaap_AwardDateDomain_501" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateOneMember" xlink:label="loc_nnvc_IssuanceDateOneMember_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateOneMember_505" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateTwoMember" xlink:label="loc_nnvc_IssuanceDateTwoMember_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateTwoMember_506" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateThreeMember" xlink:label="loc_nnvc_IssuanceDateThreeMember_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateThreeMember_507" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IssuanceDateFourMember" xlink:label="loc_nnvc_IssuanceDateFourMember_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_501" xlink:to="loc_nnvc_IssuanceDateFourMember_508" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_499" xlink:to="loc_us-gaap_StatementClassOfStockAxis_502" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_502" xlink:to="loc_us-gaap_ClassOfStockDomain_503" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_515" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_499" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_516" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_504" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_517" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_519" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_519" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_520" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_521" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_521" xlink:to="loc_us-gaap_RelatedPartyDomain_522" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScientificAdvisoryBoardMember" xlink:label="loc_nnvc_ScientificAdvisoryBoardMember_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_522" xlink:to="loc_nnvc_ScientificAdvisoryBoardMember_527" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_srt_RangeAxis_523" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_523" xlink:to="loc_srt_RangeMember_524" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_us-gaap_StatementClassOfStockAxis_525" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_525" xlink:to="loc_us-gaap_ClassOfStockDomain_530" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_235735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_235735" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_235736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_235735" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_235736" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_531" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_532" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_533" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_526" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_534" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/EquityTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_536" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_536" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_537" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_StatementClassOfStockAxis_538" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_538" xlink:to="loc_us-gaap_ClassOfStockDomain_539" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesAConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesAConvertiblePreferredStockMember_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_539" xlink:to="loc_nnvc_SeriesAConvertiblePreferredStockMember_564" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_539" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_565" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeasideAxis" xlink:label="loc_nnvc_SeasideAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_nnvc_SeasideAxis_540" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeasideDomain" xlink:label="loc_nnvc_SeasideDomain_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_SeasideAxis_540" xlink:to="loc_nnvc_SeasideDomain_566" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_541" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_541" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_567" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_TitleOfIndividualAxis_542" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_542" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" xlink:to="loc_us-gaap_DirectorMember_568" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_543" xlink:to="loc_us-gaap_PresidentMember_569" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_544" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_544" xlink:to="loc_us-gaap_EquityComponentDomain_572" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_545" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_545" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_546" xlink:to="loc_us-gaap_WarrantMember_573" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_srt_RangeAxis_547" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_547" xlink:to="loc_srt_RangeMember_548" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_548" xlink:to="loc_srt_MinimumMember_574" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_548" xlink:to="loc_srt_MaximumMember_575" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_549" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_549" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_576" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_550" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_550" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_577" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_551" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_551" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_578" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_VestingAxis_552" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_552" xlink:to="loc_us-gaap_VestingDomain_553" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_554" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_554" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_555" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_StatementScenarioAxis_556" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_556" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_582" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_557" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_557" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_583" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_558" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_558" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_584" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_dei_LegalEntityAxis_559" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_559" xlink:to="loc_dei_EntityDomain_560" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AugustTwoThousandNineteenMember" xlink:label="loc_nnvc_AugustTwoThousandNineteenMember_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_560" xlink:to="loc_nnvc_AugustTwoThousandNineteenMember_585" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_February2022Member" xlink:label="loc_nnvc_February2022Member_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_560" xlink:to="loc_nnvc_February2022Member_587" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_561" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_561" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_562" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_562" xlink:to="loc_us-gaap_DebtConversionNameDomain_589" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_235885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_AwardTypeAxis_235885" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_235886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_235885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_235886" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_238215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_238215" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_238216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_238215" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_238216" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_537" xlink:to="loc_us-gaap_ClassOfStockLineItems_563" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_590" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants" xlink:label="loc_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants_591" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_594" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_595" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensation_597" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage_599" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_600" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_601" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_602" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_603" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_RestrictedCommonStockAuthorizedForInterestPayable" xlink:label="loc_nnvc_RestrictedCommonStockAuthorizedForInterestPayable_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_RestrictedCommonStockAuthorizedForInterestPayable_604" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_605" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_235794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_235794" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235795" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FairValueMeasurementSignificantAssumptions" xlink:label="loc_nnvc_FairValueMeasurementSignificantAssumptions_235843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_nnvc_FairValueMeasurementSignificantAssumptions_235843" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_238171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharePrice_238171" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_259428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_RestrictedStockExpense_259428" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_259429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_259429" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_259430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_259430" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_259432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_563" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_259432" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_235624" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_235625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_235624" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_235625" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_235626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_235625" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_235626" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_235627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_235626" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_235627" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_235628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_235627" xlink:to="loc_us-gaap_StockOptionMember_235628" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_235625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_235631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_235631" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_235633" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_235635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_235635" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_235639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_235639" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_235640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_235640" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_235641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_235641" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_235643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_235643" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_235646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_235646" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm_235649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm_235649" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235651" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_235652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_235652" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_259558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_235629" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_259558" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_658" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_658" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_659" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_659" xlink:to="loc_us-gaap_AwardTypeAxis_660" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_StockWarrantsMember" xlink:label="loc_nnvc_StockWarrantsMember_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_661" xlink:to="loc_nnvc_StockWarrantsMember_663" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_664" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_665" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_666" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_667" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_668" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_669" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_670" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_235622" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_672" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_662" xlink:to="loc_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_673" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_259588" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_259589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_259588" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_259589" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_259598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_259589" xlink:to="loc_us-gaap_TitleOfIndividualAxis_259598" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_259598" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_259600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_259599" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_259600" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_259589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_259593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_259593" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_259594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_259594" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_259595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_259595" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_259596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_259596" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="loc_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_260398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259590" xlink:to="loc_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_260398" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_676" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_676" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_TitleOfIndividualAxis_678" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_678" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_682" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FuturePeriodAxis" xlink:label="loc_nnvc_FuturePeriodAxis_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_nnvc_FuturePeriodAxis_679" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FuturePeriodDomain" xlink:label="loc_nnvc_FuturePeriodDomain_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_FuturePeriodAxis_679" xlink:to="loc_nnvc_FuturePeriodDomain_680" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302019Member" xlink:label="loc_nnvc_June302019Member_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302019Member_684" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302020Member" xlink:label="loc_nnvc_June302020Member_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302020Member_685" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302021Member" xlink:label="loc_nnvc_June302021Member_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302021Member_686" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302022Member" xlink:label="loc_nnvc_June302022Member_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302022Member_687" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_June302023Member" xlink:label="loc_nnvc_June302023Member_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_FuturePeriodDomain_680" xlink:to="loc_nnvc_June302023Member_688" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_259602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_VestingAxis_259602" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_259603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_259602" xlink:to="loc_us-gaap_VestingDomain_259603" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_259604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_259603" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_259604" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_259603" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259607" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_259603" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259608" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_260395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_StatementScenarioAxis_260395" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_260396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_260395" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_260396" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantsExercisable" xlink:label="loc_nnvc_WarrantsExercisable_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_nnvc_WarrantsExercisable_689" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_259606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_259606" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_259610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_259610" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_259611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_StockOptionPlanExpense_259611" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_262756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_681" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_262756" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_692" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_692" xlink:to="loc_us-gaap_StatementTable_693" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_StatementClassOfStockAxis_694" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_694" xlink:to="loc_us-gaap_ClassOfStockDomain_703" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_704" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_705" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_706" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_FinancialInstrumentAxis_697" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_697" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_698" xlink:to="loc_us-gaap_WarrantMember_707" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_699" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_699" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_700" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_701" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_701" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_709" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_693" xlink:to="loc_us-gaap_StatementLineItems_702" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_702" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_710" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_712" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_712" xlink:to="loc_us-gaap_StatementTable_713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_713" xlink:to="loc_us-gaap_StatementClassOfStockAxis_714" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_714" xlink:to="loc_us-gaap_ClassOfStockDomain_715" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OneYearEnded63018Member" xlink:label="loc_nnvc_OneYearEnded63018Member_235724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_715" xlink:to="loc_nnvc_OneYearEnded63018Member_235724" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_OneYearEnded93018Member" xlink:label="loc_nnvc_OneYearEnded93018Member_259542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_715" xlink:to="loc_nnvc_OneYearEnded93018Member_259542" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_713" xlink:to="loc_us-gaap_StatementLineItems_716" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_FairValueAssumptionExpectedVolatilityRate" xlink:label="loc_nnvc_FairValueAssumptionExpectedVolatilityRate_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_716" xlink:to="loc_nnvc_FairValueAssumptionExpectedVolatilityRate_719" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_721" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_721" xlink:to="loc_us-gaap_StatementTable_722" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_StatementClassOfStockAxis_723" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_723" xlink:to="loc_us-gaap_ClassOfStockDomain_729" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentRedemptionAxis" xlink:label="loc_nnvc_DebtInstrumentRedemptionAxis_244321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_nnvc_DebtInstrumentRedemptionAxis_244321" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentRedemptionDomain" xlink:label="loc_nnvc_DebtInstrumentRedemptionDomain_244322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DebtInstrumentRedemptionAxis_244321" xlink:to="loc_nnvc_DebtInstrumentRedemptionDomain_244322" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeAxis" xlink:label="loc_nnvc_DebtInstrumentClassTypeAxis_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_nnvc_DebtInstrumentClassTypeAxis_726" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DebtInstrumentClassTypeDomain" xlink:label="loc_nnvc_DebtInstrumentClassTypeDomain_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DebtInstrumentClassTypeAxis_726" xlink:to="loc_nnvc_DebtInstrumentClassTypeDomain_727" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_FinancialInstrumentAxis_724" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_724" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_725" xlink:to="loc_us-gaap_WarrantMember_730" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_722" xlink:to="loc_us-gaap_StatementLineItems_728" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_732" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_733" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_734" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_735" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_728" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_736" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/FairValueMeasurementDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_738" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_738" xlink:to="loc_us-gaap_StatementTable_739" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_StatementClassOfStockAxis_740" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_740" xlink:to="loc_us-gaap_ClassOfStockDomain_745" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_741" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_741" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_PlacementAgentsMember" xlink:label="loc_nnvc_PlacementAgentsMember_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" xlink:to="loc_nnvc_PlacementAgentsMember_746" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ScientificAdvisoryBoardMember" xlink:label="loc_nnvc_ScientificAdvisoryBoardMember_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_742" xlink:to="loc_nnvc_ScientificAdvisoryBoardMember_747" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_srt_RangeAxis_743" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_743" xlink:to="loc_srt_RangeMember_748" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_StatementLineItems_744" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_749" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantsIssued" xlink:label="loc_nnvc_WarrantsIssued_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_nnvc_WarrantsIssued_750" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_WarrantExpirationTerm" xlink:label="loc_nnvc_WarrantExpirationTerm_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_nnvc_WarrantExpirationTerm_751" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_744" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_752" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nanoviricides.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_754" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommitmentsAndContingenciesTable" xlink:label="loc_nnvc_CommitmentsAndContingenciesTable_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_754" xlink:to="loc_nnvc_CommitmentsAndContingenciesTable_755" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_dei_LegalEntityAxis_756" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_756" xlink:to="loc_dei_EntityDomain_774" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_TitleOfIndividualAxis_757" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_757" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_775" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_ChiefScientificOfficerMember" xlink:label="loc_nnvc_ChiefScientificOfficerMember_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_nnvc_ChiefScientificOfficerMember_776" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VicePresidentMember" xlink:label="loc_us-gaap_VicePresidentMember_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_us-gaap_VicePresidentMember_778" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_758" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_779" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_srt_RangeAxis_759" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_759" xlink:to="loc_srt_RangeMember_780" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_StatementClassOfStockAxis_760" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_760" xlink:to="loc_us-gaap_ClassOfStockDomain_761" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_SeriesConvertiblePreferredStockMember" xlink:label="loc_nnvc_SeriesConvertiblePreferredStockMember_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_761" xlink:to="loc_nnvc_SeriesConvertiblePreferredStockMember_781" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_762" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_762" xlink:to="loc_us-gaap_RelatedPartyDomain_783" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_763" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_763" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_784" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_764" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_764" xlink:to="loc_us-gaap_EquityComponentDomain_765" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredCompensationYearAxis" xlink:label="loc_nnvc_DeferredCompensationYearAxis_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_nnvc_DeferredCompensationYearAxis_766" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_DeferredCompensationYearDomain" xlink:label="loc_nnvc_DeferredCompensationYearDomain_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DeferredCompensationYearAxis_766" xlink:to="loc_nnvc_DeferredCompensationYearDomain_767" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearOneMember" xlink:label="loc_nnvc_YearOneMember_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DeferredCompensationYearDomain_767" xlink:to="loc_nnvc_YearOneMember_786" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearTwoMember" xlink:label="loc_nnvc_YearTwoMember_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DeferredCompensationYearDomain_767" xlink:to="loc_nnvc_YearTwoMember_787" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_YearThreeMember" xlink:label="loc_nnvc_YearThreeMember_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_DeferredCompensationYearDomain_767" xlink:to="loc_nnvc_YearThreeMember_788" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_768" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_768" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_769" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_770" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_770" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_790" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_us-gaap_VestingAxis_771" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_771" xlink:to="loc_us-gaap_VestingDomain_772" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_791" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_259512" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_259513" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_CommitmentsAndContingenciesLineItems" xlink:label="loc_nnvc_CommitmentsAndContingenciesLineItems_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesTable_755" xlink:to="loc_nnvc_CommitmentsAndContingenciesLineItems_773" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_CommonStockSharesIssued_792" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AdditionalCommonStockSharesIssued" xlink:label="loc_nnvc_AdditionalCommonStockSharesIssued_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_nnvc_AdditionalCommonStockSharesIssued_793" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_PreferredStockSharesIssued_794" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_AdditionalPreferredStockSharesIssued" xlink:label="loc_nnvc_AdditionalPreferredStockSharesIssued_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_nnvc_AdditionalPreferredStockSharesIssued_795" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nnvc-20180930.xsd#nnvc_IncreaseInBaseSalary" xlink:label="loc_nnvc_IncreaseInBaseSalary_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_nnvc_IncreaseInBaseSalary_796" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_797" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_798" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nnvc_CommitmentsAndContingenciesLineItems_773" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_800" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823197824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 14, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NANOVIRICIDES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001379006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NNVC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,383,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823930992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,082,365<span></span>
</td>
<td class="nump">$ 7,081,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">201,532<span></span>
</td>
<td class="nump">240,257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">6,283,897<span></span>
</td>
<td class="nump">7,322,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">14,055,637<span></span>
</td>
<td class="nump">14,018,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(3,348,610)<span></span>
</td>
<td class="num">(3,177,290)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,707,027<span></span>
</td>
<td class="nump">10,841,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>TRADEMARK AND PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Trademark and patents</a></td>
<td class="nump">458,954<span></span>
</td>
<td class="nump">458,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(86,094)<span></span>
</td>
<td class="num">(84,025)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Trademark and patents, net</a></td>
<td class="nump">372,860<span></span>
</td>
<td class="nump">374,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">3,515<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ServiceAgreements', window );">Service agreements</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other Assets</a></td>
<td class="nump">6,737<span></span>
</td>
<td class="nump">8,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">17,370,521<span></span>
</td>
<td class="nump">18,546,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">320,097<span></span>
</td>
<td class="nump">223,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable &#8211; related party</a></td>
<td class="nump">718,457<span></span>
</td>
<td class="nump">107,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">231,175<span></span>
</td>
<td class="nump">253,049<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,392,270<span></span>
</td>
<td class="nump">881,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 150,000,000 shares authorized, 69,382,560 and 69,171,740 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively</a></td>
<td class="nump">69,383<span></span>
</td>
<td class="nump">69,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">101,437,413<span></span>
</td>
<td class="nump">101,282,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(85,533,609)<span></span>
</td>
<td class="num">(83,692,146)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">15,978,251<span></span>
</td>
<td class="nump">17,664,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">17,370,521<span></span>
</td>
<td class="nump">18,546,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability - warrants</a></td>
<td class="nump">122,541<span></span>
</td>
<td class="nump">298,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 5,064,110 and 4,531,394 shares issued and outstanding, at September 30, 2018 and June 30, 2018, respectively</a></td>
<td class="nump">$ 5,064<span></span>
</td>
<td class="nump">$ 4,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ServiceAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This fact represents service agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ServiceAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823347568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets [Parenthetical] - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">69,382,560<span></span>
</td>
<td class="nump">69,171,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">69,382,560<span></span>
</td>
<td class="nump">69,171,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">5,064,110<span></span>
</td>
<td class="nump">4,531,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">5,064,110<span></span>
</td>
<td class="nump">4,531,394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823284912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,411,483<span></span>
</td>
<td class="nump">$ 1,451,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">627,615<span></span>
</td>
<td class="nump">778,540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,039,098<span></span>
</td>
<td class="nump">2,230,446<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(2,039,098)<span></span>
</td>
<td class="num">(2,230,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income</a></td>
<td class="nump">22,084<span></span>
</td>
<td class="nump">24,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_DiscountOnConvertibleDebentures', window );">Discount on convertible debentures</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(239,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivatives</a></td>
<td class="nump">175,551<span></span>
</td>
<td class="nump">564,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">197,635<span></span>
</td>
<td class="nump">224,891<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(1,841,463)<span></span>
</td>
<td class="num">(2,005,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX PROVISION</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (1,841,463)<span></span>
</td>
<td class="num">$ (2,005,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share &#8211; basic and diluted</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding &#8211; basic and diluted</a></td>
<td class="nump">69,185,965<span></span>
</td>
<td class="nump">63,307,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_DiscountOnConvertibleDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of discount associated with convertible debentures, charged against earnings in the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_DiscountOnConvertibleDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810483312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Changes in Stockholders' Equity - 3 months ended Sep. 30, 2018 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2018</a></td>
<td class="nump">$ 17,664,264<span></span>
</td>
<td class="nump">$ 4,531<span></span>
</td>
<td class="nump">$ 69,172<span></span>
</td>
<td class="nump">$ 101,282,707<span></span>
</td>
<td class="num">$ (83,692,146)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,531,394<span></span>
</td>
<td class="nump">69,171,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued', window );">Series A Preferred stock issued for employee stock compensation</a></td>
<td class="nump">55,027<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">54,494<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued', window );">Series A Preferred stock issued for employee stock compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,716<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne', window );">Common stock issued for consulting and legal services rendered</a></td>
<td class="nump">79,460<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">79,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne', window );">Common stock issued for consulting and legal services rendered (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">191,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options issued for compensation</a></td>
<td class="nump">11,920<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,920<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices', window );">Warrants issued to Scientific Advisory Board</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_StockIssuedForPaymentOfDirectorFeesValue', window );">Common shares issued for Directors fees</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">7,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_StockIssuedForPaymentOfDirectorFeesShares', window );">Common shares issued for Directors fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,841,463)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,841,463)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2018</a></td>
<td class="nump">$ 15,978,251<span></span>
</td>
<td class="nump">$ 5,064<span></span>
</td>
<td class="nump">$ 69,383<span></span>
</td>
<td class="nump">$ 101,437,413<span></span>
</td>
<td class="num">$ (85,533,609)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,064,110<span></span>
</td>
<td class="nump">69,382,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of series A preferred stock issued during period as employee stock compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock shares issued during period as employee stock compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a compensation for consulting and legal services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period as a compensation for consulting and legal services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period as a compensation for consulting and legal services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_StockIssuedForPaymentOfDirectorFeesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the stock issued during the period for payment of director fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_StockIssuedForPaymentOfDirectorFeesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_StockIssuedForPaymentOfDirectorFeesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the stock issued during the period for payment of director fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_StockIssuedForPaymentOfDirectorFeesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823802704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,841,463)<span></span>
</td>
<td class="num">$ (2,005,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_PreferredSharesIssuedAsCompensation', window );">Preferred shares issued as compensation</a></td>
<td class="nump">55,027<span></span>
</td>
<td class="nump">158,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common shares issued as compensation and for services</a></td>
<td class="nump">86,960<span></span>
</td>
<td class="nump">38,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrants granted to Scientific Advisory Board</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">11,920<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">171,320<span></span>
</td>
<td class="nump">166,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="num">(175,551)<span></span>
</td>
<td class="num">(564,848)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount on convertible debenture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">239,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">38,725<span></span>
</td>
<td class="num">(2,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">14,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">96,758<span></span>
</td>
<td class="num">(45,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable - related party</a></td>
<td class="nump">610,989<span></span>
</td>
<td class="nump">478,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(21,874)<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Deferred interest payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,667)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(962,152)<span></span>
</td>
<td class="num">(1,556,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(37,254)<span></span>
</td>
<td class="num">(30,433)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(999,406)<span></span>
</td>
<td class="num">(1,587,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">7,081,771<span></span>
</td>
<td class="nump">15,099,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">6,082,365<span></span>
</td>
<td class="nump">13,512,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 166,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the derivative liability of derivatives included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_PreferredSharesIssuedAsCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred shares issued as compensation by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_PreferredSharesIssuedAsCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814597008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1 - Organization and Nature of Business</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">NanoViricides, Inc. (the Company&#8221;) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We are a company with several drugs in various stages of early development. In our lead antiviral program against herpes viruses, i.e. the HerpeCide&#8482; program alone, we have drug candidates against at least five indications at different stages of development. Of these, our shingles drug candidate is expected to enter human clinical trials in the very near future. It is in advanced, IND-enabling pre-clinical studies at present, and large-scale production is being performed to supply the safety-toxicology study. In addition, our drug candidates against HSV-1 &#8220;cold sores&#8221; and HSV-2 &#8220;genital herpes&#8221; are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). Chicken pox is re-emerging as a major disease especially in European countries, with 23,500 confirmed cases in the first six months of 2018. In addition, we have drugs in development against all influenzas in our FluCide&#8482; program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (&#8220;TheraCour&#8221;), to which we have broad, exclusive licenses in perpetuity. The first license agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour.&#160;&#160;Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.&#160;&#160;In addition, the Company is negotiating a license for VZV (shingles, chicken pox virus), and the remaining human herpesviruses from TheraCour. For this purpose, the Company has conducted a valuation for the shingles and PHN indications. The negotiation process has begun in earnest, with Dr.&#160;Irach Taraporewala being appointed as the new Chief Executive Officer of the Company, effective September 1, 2018. To date, TheraCour has not withheld any licenses for antiviral nanomedicines that NanoViricides has asked for, and we anticipate that the licenses to the remaining herpes viruses including VZV will be executed once the due diligence process is completed.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788982448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 2 - Summary of Significant Accounting Policies</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Basis of Presentation &#8211; Interim Financial Information</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management,&#160;considered necessary for a fair presentation of the results for the interim periods presented.&#160;&#160;Interim results are not necessarily indicative of the results for the full year.&#160;&#160;The accompanying financial statements and the information included under the heading &#8220;Management&#8217;s Discussion and Analysis or Plan of Operation&#8221; should be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 13, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For a summary of significant accounting policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed on October 13, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Reclassifications and Prior Year Adjustments</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified $296,678 of expenses related to the Company&#8217;s laboratory facilities out of general and administrative expenses into research and development expenses for consistency with current year presentation. The reclassifications had no impact on the reported results of operations and net loss reported for the three months ended September 30, 2017.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Net Loss per Common Share</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Potentially&#160;Outstanding&#160;Dilutive&#160;Common&#160;Shares</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Three Months</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Three Months</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Ended</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Ended</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Options and Warrants</div></div></td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 208px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,412,039</td><td style="width: 19px; padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 207px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,685,292</td><td style="width: 18px; padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Total potentially outstanding dilutive common shares</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,412,039</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,685,292</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2017, the number of potentially dilutive shares of the Company&#8217;s common stock into which the Series C debenture&#160;could be converted based upon the conversion provisions contained in the debenture was 952,381. The Series C debenture&#160;was redeemed for common stock effective November 13, 2017.</div></div><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has also issued 5,064,110 shares of Series A Preferred Stock to investors and others as of September 30, 2018. Only in the event of a &#8220;change of control&#8221; of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A &#8220;Change of Control&#8221; is defined as an event in which the Company&#8217;s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company&#8217;s intellectual property. In the absence of a Change of Control event, the Series A convertible Preferred Stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At September 30, 2018, the number of potentially dilutive shares of the Company&#8217;s common stock into which these Series A Preferred shares can be converted into is 17,724,385, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following represents the basic and diluted per share calculations for loss from continuing operations:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;three&#160;months ended<div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/>September 30,</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Calculation of basic and diluted loss per share of common stock:</div></div></td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Net loss attributable to common stockholders</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 208px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(1,841,463</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 207px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(2,005,555</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Denominator for basic and diluted weighted average shares of common stock</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">69,185,965</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">63,307,083</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Basic and diluted loss per share of common stock</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(0.03</div></div></td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(0.03</div></div></td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Series C debenture&#160;was redeemed for Common Stock effective November 13, 2017. See Note 7. The Series C debenture&#160;was excluded from the loss per share calculation for the three-month period ended September 30, 2017 because the impact is anti-dilutive.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Recently Issued Accounting Pronouncements</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the SEC issued the final rule on Disclosures About Changes in Stockholder&#8217;s Equity For filings on Form 10-Q, which extends to interim periods the annual requirement in SEC Regulation S-X, Rule 3-04,2 to disclose (1) changes in stockholders&#8217; equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders&#8217; equity, in the form of reconciliation, for &#8220;the current and comparative year-to-date [interim] periods, with subtotals for each interim period,&#8221; i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 permits the disclosure of changes in stockholders&#8217; equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. The staff of the SEC has indicated it would not object if the filer&#8217;s first presentation of the changes in shareholders&#8217; equity is included in its form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company expects to conform to this rule in its Form 10-Q for the quarter ending December 31, 2018. The Company believes that the final rule will not have a material effect on its consolidated financial statements and disclosures.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact on its financial statements.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;">In July 2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11. &#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">statements.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814628928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 3 - Liquidity and Going Concern </div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the financial statements, the Company has an accumulated deficit at September 30, 2018 of approximately $85.5 million and a net loss of approximately $1.8 million and net cash used in operating activities of approximately $1 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2018, the Company had available cash and cash equivalents of approximately $6.1 million. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management adjusted its planned expenditures, activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional financing.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify; background: none;">The Company has made several adjustments to its past expenditures in the ensuing annual budget, eliminating several expenses including a reduction in workforce and consultants to the extent feasible without affecting its program of drug development. In addition, the Company has focused its efforts primarily on a single lead program to minimize cost outlays, namely taking the shingles drug candidate against VZV into human clinical trials. Management&#8217;s budget indicates that these changes have freed up sufficient funds to allow for the ensuing costs of the external advanced IND-enabling studies of this drug candidate. Management has considered several options for obtaining additional funds that will be needed for future human clinical trials and to obtain the additional license from TheraCour for VZV and the remaining human herpes viruses. The Company is also evaluating the possibility of obtaining a mortgage on its fully owned cGMP-capable laboratory facility in Shelton, CT, in order to free up a portion of the fixed capital for usage as liquid working capital.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Company believes that it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these milestones, the Company would experience substantial improvement in the liquidity of the Company&#8217;s stock, and would significantly improve the Company&#8217;s ability to raise funds on the public markets at terms that may be substantially superior to the terms we are offered at present.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management believes that as a result of the&#160;management plan, the Company&#8217;s existing resources and access to the capital markets will be sufficient to fund the Company&#8217;s planned operations and expenditures through November 2019. However, the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The accompanying unaudited financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798793536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 4 - Related Party Transactions</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Related Parties</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Related parties with whom the Company had transactions are:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align:top"><td style="border-bottom: 1pt solid black; white-space: nowrap; width: 472px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Related Parties</div></div></td><td style="white-space: nowrap; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; white-space: nowrap; width: 1377px; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Relationship</div></div></td></tr><tr style="vertical-align:top"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:top; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Anil R. Diwan</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Chairman, President, significant stockholder and Director</div></td></tr><tr style="vertical-align:top; background-color:white"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:top; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Irach Taraporewala</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer</div></td></tr><tr style="vertical-align:top; background-color:white"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:top; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">TheraCour Pharma, Inc.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">An entity owned and controlled by a significant stockholder</div></td></tr><tr style="vertical-align:top; background-color:white"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:top; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Milton Boniuk, MD</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Significant stockholder</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="6" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">September 30,</div></div><br/><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">June 30,</div></div><br/><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 70%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: justify; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Account Payable &#8211; Related Party</div></div></div></div></td><td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: justify;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month&#8217;</div><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">s invoice to be applied as a prepayment towards expenses.&#160;</div>On October 2, 2018, the Company entered into an agreement with TheraCour Pharma, Inc. for a waiver of the two month worth of prepaid balance advance of anticipated invoicing and the application of the current advance as a credit against current open invoices, Additionally, TheraCour has agreed to defer $25,000 per month of development fees for six months,&#160;beginning&#160;with&#160;July&#160;2018. Accounts payable due TheraCour on the reporting date was</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">718,457</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">107,468</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.25in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For the three months ended</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;<br/>2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;<br/>2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-decoration: none; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="text-decoration:underline;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs Paid to Related Parties</div></div></td><td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 208px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 207px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company&#8217;s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2018 and June 30, 2018.</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">846,688</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">847,093</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Debenture Interest Payable to a Director</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Coupon interest expense on the $5,000,000 Series C Debenture&#160;paid to Dr. Milton Boniuk for the three months ended September 30, 2017 was $125,000. The Series C debenture&#160;was redeemed for Common Stock effective November 13, 2017. See Note 7.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814640496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 5 - Property and Equipment</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, stated at cost, less accumulated depreciation consisted of the following:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 70.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">GMP Facility</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,020,471</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,011,230</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">260,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">260,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Office Equipment</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">57,781</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">57,781</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Furniture and Fixtures</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,607</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,607</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Lab Equipment</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,711,778</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,683,765</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Property and Equipment</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">14,055,637</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">14,018,383</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less Accumulated Depreciation</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,348,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,177,290</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, Net</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,707,027</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,841,093</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the three months ended September 30, 2018 and 2017 was $171,320 and $166,189, respectively.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788621744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trademark and Patents<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 6 - Trademark and Patents</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trademark and patents, stated at cost, less accumulated amortization consisted of the following:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trademarks and Patents</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">458,954</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">458,954</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less Accumulated Amortization</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(86,094</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(84,025</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trademarks and Patents, Net</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">372,860</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">374,929</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense amounted to $2,069&#160;and $2,068 for the three months ended September 30, 2018 and 2017, respectively.&#160;</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814561984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debenture and Derivatives<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 7 - Convertible Debenture and Derivatives&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration:underline;display:inline;">Debenture - Series C</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Series C&#160;Convertible Debenture, in the amount of $5,000,000, was redeemed on November 13, 2017. For the three month period ended September 30, 2017,&#160;the Holder of the Company&#8217;s Series C Convertible Debenture&#160;elected to receive $125,000 of their coupon interest payment and $41,667 of deferred interest payment in cash.&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Series C Debenture in the amount of $5,000,000 was due to mature on June 30, 2018. On November 13, 2017, the Company entered into a Debenture Redemption Agreement (the &#8220;Agreement&#8221;) with the Holder, to redeem (the &#8220;Redemption&#8221;) its $5,000,000 Series C Convertible Debenture (the &#8220;Debenture&#8221;) for an aggregate of 5,500,000 shares of the Company&#8217;s $0.001 par value Common Stock (&#8220;Purchase Price&#8221;) comprising 5,000,000 shares for the principal of the Debenture and 500,000 shares for unpaid coupon interest from October 1, 2017 through June 30, 2018. The unpaid interest included $60,274 of accrued interest through November 13, 2017, $314,726 in coupon interest through June 30, 2018 and $125,000 of unpaid deferred interest. The price per share was equal to the closing price of the Company&#8217;s stock on Friday, November 10, 2017 of one ($1.00) dollar per share. The Holder waived all early redemption penalty payments provided for in the Debenture for consideration of 150,000 shares of the Company&#8217;s $0.001 par value Series A Convertible Preferred Stock. The Company did not incur placement agent fees in redemption of the Series C Convertible Debenture. The Company recognized a non-cash loss on extinguishment of debt of $1,348,247 on the extinguishment of the aforesaid principal attributable to the Series C Debentures into the Company&#8217;s common and preferred stock. The loss on extinguishment arises from, the obligation to issue 150,000 shares of the Company&#8217;s Series A Preferred shares with a fair value of $364,337, as of November 13, 2017, obligation to issue 314,726 shares of the Company&#8217;s $0.001 par value Common Stock with a fair value of $314,726 as of November 13, 2017, in consideration of Debenture coupon interest from the redemption date through June 30, 2018, and unamortized discount of $684,633 as of the redemption date, offset by the derivative liability of ($<div style="letter-spacing: 0px; top: 0px;;display:inline;">15,449</div>) as of the redemption date.&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the redemption agreement for the Company&#8217;s Series C Debenture, the Company issued 5,500,000 shares of its registered Common Stock from its shelf registration and the 150,000 shares of its Series A Preferred Stock upon receiving consent to issue the shares pursuant to New York Stock Exchange (&#8220;NYSE&#8221;) regulations. The Company submitted a request for authorization to issue the Common Stock and Series A Preferred Shares to the NYSE, which was authorized on March 18, 2018 and the shares were issued on March 21, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On July 2, 2014, in conjunction with the issuance of the Company&#8217;s Series C Convertible Debentures, the Company issued 187,000 shares of its Series A Convertible Preferred Stock (the &#8220;Series A&#8221;) to Dr. Milton Boniuk, pursuant to the terms of the Debenture. Proceeds received in a financing transaction are allocated to the instruments issued prior to evaluating hybrid contracts for bifurcation of embedded derivatives. Since the Series A Convertible Preferred Stock is classified as equity, the proceeds allocated to the Preferred Stock are recorded at relative fair value. The fair value of the Series A was $1,645,606 at issuance and the relative fair value was calculated as $1,152,297. The remaining amount of the proceeds was allocated to the Debenture and a debt discount of $1,152,297 was recorded to offset the amount of the proceeds allocated to the Series A. Then, the embedded derivative was bifurcated at its fair value of $1,879,428 with the remaining balance allocated to the host instrument (Debenture). The total debt discount was amortized over the actual term of the Debenture using the effective interest method.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized amortization of this discount as an additional interest charge to &#8220;Discount on convertible debentures&#8221; in the amount of $ -0- and $239,351 for the three month periods ended September 30, 2018 and 2017, respectively.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814563072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Note 8 &#8211; Accrued expenses</div></div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following:</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"><tr><td style="padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom; white-space: nowrap;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">September</div> <div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">30,</div></div></div></div><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2018</div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">June 30,</div></div></div></div><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">201<div style="font-weight:bold;display:inline;">8</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 74%; padding: 0px 0in; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Severance payment- Eugene Seymour</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">133,333</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">233,333</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued&#160;&#160;payroll</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">49,576</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">19,716</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Professional Services</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">48,266</div></div></td><td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">-</div></div></td><td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid black; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">231,175</div></div></td><td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">253,049</div></div></td><td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810502736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 9 - Equity Transactions</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On July 11, 2018 the Board of Directors approved an extension of the employment agreement with Dr. Anil Diwan, the Company&#8217;s President. Pursuant to the terms of the employment agreement, the Company&#8217;s Board of Directors authorized the issuance of 525,000 of the Company&#8217;s Series A preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30, 2020 and June 30, 2021&#160;and are subject to forfeiture. The Company recognized a non-cash compensation expense related to the issuance of the Series A Preferred stock of $47,260 for the three months ended September 30, 2018.&#160;The balance of $513,430 </div>will be recognized as the shares vest&#160;and service is rendered<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended September 30, 2018, the Company&#8217;s Board of Directors authorized the issuance of 7,716 fully vested shares of its Series A Convertible Preferred stock for employee compensation. The Company recorded an expense of $7,767.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Series A Preferred stock was the following for the dates indicated:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-indent: 0.5in; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 50%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 585px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7/11/2018</div></td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 142px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">525,000</div></td><td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 9px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="width: 141px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">560,690</div></td><td style="width: 9px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7/31/2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,572</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,795</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8/31/2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,572</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,374</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-bottom: 1pt; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">9/30/2018</div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,572</div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,598</div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 1.5pt;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">532,716</div></td><td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">568,457</div></td><td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-indent: 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred stock at each issuance used the following inputs:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The common stock price was in the range $.42 to $.58;</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The calculated weighted average number of shares of common stock in the period;</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">c.</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A<div style="letter-spacing: 0px; top: 0px;;display:inline;"> 26.63</div>% premium over the common shares for the voting preferences;</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">d.</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.22% to 19.25% of the total;</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">e.</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 2.09 years;</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 24px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">f.</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">29.42% to 32.24% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 55.76% to 61.17% volatility, 2.09% to 2.11% risk free rate) applied to the converted common.</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On July 19, 2018, the Company entered into an Employment Agreement with Dr. Irach Taraporewala as Chief Executive Officer of the Company beginning on September 1, 2018. Dr. Taraporewala was granted options to purchase up to 300,000 shares of the Company&#8217;s common stock, par value $0.001 per share at an exercise price equal to 20% above the closing bid price of $0.41 </div>of the common stock on September 1, 2018 (&#8220;Effective Date&#8221;). The options shall vest in three, equal, annual installments commencing on the Effective Date. The fair value of the options <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">was $35,761 of which $11,920 was recognized and recorded as compensation expense for the three months ended September 30, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0in; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of the options granted to&#160;Dr. Taraporewala on the date of grant using a lattice simulation model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0in; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 11,432 shares of common stock with an exercise price of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">.41</div> per share expiring in August 2022.&#160;&#160;The fair value of the warrants was $1,543 and was recorded as consulting expense for the three months ended September 30, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1642px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected life (year)</div></td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 189px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4</div></td><td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">55.12</div></td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected annual rate of quarterly dividends</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate(s)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.71</div></td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended September 30, 2018, the Company&#8217;s Board of Directors authorized the issuance of 191,510 fully vested shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $79,460 for the three months, which was the fair value on the dates of issuance.&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended September 30, 2018, the Company&#8217;s Board of Directors authorized the issuance of 19,310 </div>fully vested shares of its common stock with a restrictive legend for Director Services. The Company recorded an expense&#160;<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">of&#160;$7,500 </div>for the three months, which was the fair value on the date of <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">issuance.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656032400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants and Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 10 - Stock Warrants and Options</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Stock Warrants</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Warrants</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;<br/>Shares</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;<br/>Average&#160;<br/>Exercise<br/>Price&#160;<br/>per&#160;share&#160;<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;<br/>Remaining&#160;<br/>Contractual&#160;Term<br/>(years)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 831px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Outstanding and exercisable at June 30, 2018</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,969,588</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4.80</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.53</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 37px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 188px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Granted</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">11,432</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.41</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Expired</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">2,868,981</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">5.25</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Outstanding and exercisable at September 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,112,039</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4.48</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.63</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;">Of the above warrants,<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;3,679,127 </div>expire in fiscal year ending June 30, 2019;&#160;<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">68,592 </div>expire in fiscal year ending June 30, 2020,<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> 57,160 </div>expire in fiscal year ending June 30, 2021, 45,728 expire in the fiscal year ending June 30, 2022 and 261,432 warrants expire in the fiscal year ending June 30, 2023.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Stock Options</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Options</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;<br/>Shares</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;<br/>Average&#160;<br/>Exercise<br/>Price&#160;<br/>per&#160;share&#160;<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;<br/>Remaining&#160;<br/>Contractual&#160;Term<br/>(years)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Outstanding at June 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 831px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Granted</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">300,000</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.50</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 37px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 188px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">-</td><td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Outstanding at September 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">300,000</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.50</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">2.92</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">-</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Of the above options, 100,000 </div>are vested and exercisable as of<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> September 30, 2018, 100,000 </div>become vested and exercisable on September 1, 2019 and 100,000 become vested and exercisable on September 1, 2020. The options expire on August 31, 2021. The options will not become vested and exercisable until the option is vested pursuant to the vesting schedule set forth above, provided that Dr. Taraporewala continues to be employed by, or provide service to, the Company. If Dr. Taraporewala&#8217;s continuous service terminates for any reason other than cause, any such option exercisable as of the date of termination may be exercised at any time by the participant prior to the expiration date. If Dr. Taraporewala&#8217;s continuous service should be terminated for &#8220;Cause&#8221; (as defined in the option), then any outstanding option, vested or unvested, shall terminate immediately and shall no longer be exercisable<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of the option grant at $35,761 and recognized the estimated value of the vested and exercisable options as a compensation expense of $11,920 for the three months ended September 30, 2018.&#160;The Company will recognize the remaining unrecognized fair value of the option grant of&#160;$23,841&#160;in installments over&#160;the&#160;vesting&#160;period.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"></div><div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;">The Company estimated the fair value of the options granted to Dr. Taraporewala on the date of grant using a lattice model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1642px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected life (year)</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">3</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected volatility</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">55.09</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected annual rate of quarterly dividends</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.00</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Risk-free rate(s)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">2.71</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">%</td></tr><tr><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr><tr><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected forfeiture (attrition) rate (%)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">5.00</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">%</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-family: &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none; font-size: 10pt; text-align: justify;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility is based on historical volatility of the Company&#8217;s common stock and the expected life of options. The Company estimates forfeitures at the time of valuation and reduces expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ or are expected to differ, from the previous estimate.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785626752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 11&#160;- Fair Value Measurement</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements<div style="font-style:italic;display:inline;">&#160;</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2018 and June 30, 2018 the estimated fair values of the liabilities measured on a recurring basis are as follows:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div></td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;2018:</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;2)</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;3)</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; width: 61%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 61%;">Derivative liability - warrants</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;">-</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;">-</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;">122,541</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;;text-align:left;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">Fair Value Measurements at</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">June 30, 2018:</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">(Level 1)</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">(Level 2)</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">(Level 3)</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;">&#160;</td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;">&#160;</td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;">&#160;</td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; background-color: rgb(204, 238, 255); width: 61%; vertical-align: bottom;">Derivative liability - warrants</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; text-align: left; vertical-align: bottom; padding: 0in;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;">-</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;">-</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;">298,092</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the Company&#8217;s registered direct offerings of Units, consisting of the Company&#8217;s common stock and warrants, on September 12, 2013 and January 24, 2014, the Company </div>issued an aggregate of <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,425,363 warrants, of which 2,479,935&#160;</div>and 5,290,006, are outstanding at September 30, 2018 and June 30, 2018, respectively. Additionally, the Company <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">issued 135,216 </div>warrants&#160;to the placement agents of which<div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;76,306&#160;</div>and 135,216, are also outstanding at September 30, 2018 and June 30, 2018, respectively, for a total number <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">of 2,556,241 </div>and 5,425,222 warrants outstanding and issued as of September 30, 2018 and June 30, 2018,&#160;respectively,&#160;pursuant to the aforesaid registered direct <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">offerings.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Warrants were valued as of September 30, 2018 and June 30, 2018 with the following assumptions:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The 5-year warrants issued on 9/12/13 and 1/24/14 included Investor and Placement Agent Warrants with an exercise price of $5.25 and $6.05 (subject to adjustments-full ratchet reset).</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-align: justify; text-indent: -17.95pt; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The stock price would fluctuate with the Company projected volatility.</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-align: justify; text-indent: -17.95pt; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of&#160;<div style="font-weight:bold;display:inline;">2 times</div>&#160;the projected exercise/reset price or&#160;<div style="font-weight:bold;display:inline;">2 times</div>&#160;the stock price.</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top"><td style="width: 48px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 24px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are:</div></td></tr></table><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="width: 50%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1 Year</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 81%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">9/30/18</div></div></td><td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">64</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6/30/18</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2018:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurement</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160;&#160;<div style="font-weight:bold;display:inline;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</div></div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurement</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Using Significant Unobservable Inputs</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-top: 0px; padding-bottom: 0px;"><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 2.8pt; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative</div></div></div><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 15.4pt; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability-</div></div></div><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0pt 0px; text-align: center; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant</div></div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1604px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Beginning balance at July 1, 2018</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 208px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">298,092</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Additions during the year</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Change in fair value</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(175,551</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Transfer in and out of Level 3</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">Balance at September 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">122,541</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814578880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 12&#160;- Commitments and Contingencies</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Legal Proceedings</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There are no pending legal proceedings against the Company to the best of the Company&#8217;s knowledge as of the date hereof and to the Company&#8217;s knowledge, no action, suit or proceeding has been threatened against the Company.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Employment Agreements</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an extension of employment agreement effective July 1, 2018 for a term of three years. Dr. Diwan&#8217;s will be paid an annual base salary of $400,000. Additionally, Dr. Diwan was awarded a grant of 525,000 shares of the Company&#8217;s Series A Preferred Stock. 175,000 shares vest equally on June 30, 2019, 2020 and 2021. Any unvested shares are subject to forfeiture.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company and Dr. Irach Taraporewala, the Company&#8217;s Chief Executive Officer, entered into an employment agreement effective September 1, 2018, for a term of three years. Dr. Taraporewala&#160;will be paid an annual base salary of $360,000. Additionally, Dr. Taraporewala was awarded a grant of 300,000 options to purchase shares of the Company&#8217;s Common Stock. 100,000 options vested on September 1, 2018 and the remainder of the options will vest over the two&#160;year&#160;vesting&#160;period&#160;and are subject to forfeiture.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development.&#160;&#160;The employment agreement provides for a term of four years with a base salary of $150,000.&#160;&#160;In addition, the Company issued 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock upon entering into the agreement, and issued an additional 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock on each anniversary date of the agreement. The shares of Series A Preferred Stock were issued in recognition of Dr. Tatake&#8217;s work towards the achievement of several patents by the Company. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer.&#160;&#160;The employment agreement provided for a term of four years with a base salary of $150,000.&#160;&#160;In addition, the Company issued 35,715 shares of common stock upon entering into the agreement, and issued an additional 35,715 shares of common stock on each anniversary date of the agreement. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer.&#160;&#160;The employment agreement provided for a term of three years with a base salary of $9,000 per month and 2,572 shares of Series A Preferred Stock, also on a monthly basis. On January 1, 2015, her cash compensation was increased to $10,800 per month. The Agreement is renewable on an annual basis. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">License Agreements</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is dependent upon its license agreement with TheraCour (See Note 4). </div> If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. The Company is currently negotiating for a license for VZV&#160;from the Licensor, TheraCour. For this purpose, the Company has conducted a valuation for the shingles and PHN indications. Dr. Irach Taraporewala was appointed as the new Chief Executive Officer of the Company, effective September 1, 2018, and is leading the negotiation process with TheraCour. TheraCour has not withheld any licenses for antiviral nanomedicines sought by the Company and we anticipate that the licenses for VZV will be executed once the due diligence process is completed.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647174096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 13&#160;- Subsequent Events</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On October 29, 2018, the Board of Directors of NanoViricides, Inc. (the &#8220;Company&#8221;) elected James Sapirstein as a new member of the Board. Mr.&#160;Sapirstein is an Independent Member of the Board of Directors and will serve as a member of the Company&#8217;s Audit, Compensation and Nominating Committees.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823336656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Basis of Presentation &#8211; Interim Financial Information</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management,&#160;considered necessary for a fair presentation of the results for the interim periods presented.&#160;&#160;Interim results are not necessarily indicative of the results for the full year.&#160;&#160;The accompanying financial statements and the information included under the heading &#8220;Management&#8217;s Discussion and Analysis or Plan of Operation&#8221; should be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 13, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For a summary of significant accounting policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed on October 13, 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Reclassifications and Prior Year Adjustments</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified $296,678 of expenses related to the Company&#8217;s laboratory facilities out of general and administrative expenses into research and development expenses for consistency with current year presentation. The reclassifications had no impact on the reported results of operations and net loss reported for the three months ended September 30, 2017.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Net Loss per Common Share</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Potentially&#160;Outstanding&#160;Dilutive&#160;Common&#160;Shares</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Three Months</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Three Months</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Ended</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Ended</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Options and Warrants</div></div></td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 208px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,412,039</td><td style="width: 19px; padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 207px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,685,292</td><td style="width: 18px; padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Total potentially outstanding dilutive common shares</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,412,039</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,685,292</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2017, the number of potentially dilutive shares of the Company&#8217;s common stock into which the Series C debenture&#160;could be converted based upon the conversion provisions contained in the debenture was 952,381. The Series C debenture&#160;was redeemed for common stock effective November 13, 2017.</div></div><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has also issued 5,064,110 shares of Series A Preferred Stock to investors and others as of September 30, 2018. Only in the event of a &#8220;change of control&#8221; of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A &#8220;Change of Control&#8221; is defined as an event in which the Company&#8217;s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company&#8217;s intellectual property. In the absence of a Change of Control event, the Series A convertible Preferred Stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At September 30, 2018, the number of potentially dilutive shares of the Company&#8217;s common stock into which these Series A Preferred shares can be converted into is 17,724,385, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following represents the basic and diluted per share calculations for loss from continuing operations:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;three&#160;months ended<div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/>September 30,</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Calculation of basic and diluted loss per share of common stock:</div></div></td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Net loss attributable to common stockholders</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 208px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(1,841,463</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 207px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(2,005,555</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Denominator for basic and diluted weighted average shares of common stock</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">69,185,965</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">63,307,083</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Basic and diluted loss per share of common stock</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(0.03</div></div></td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(0.03</div></div></td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Series C debenture&#160;was redeemed for Common Stock effective November 13, 2017. See Note 7. The Series C debenture&#160;was excluded from the loss per share calculation for the three-month period ended September 30, 2017 because the impact is anti-dilutive.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Recently Issued Accounting Pronouncements</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the SEC issued the final rule on Disclosures About Changes in Stockholder&#8217;s Equity For filings on Form 10-Q, which extends to interim periods the annual requirement in SEC Regulation S-X, Rule 3-04,2 to disclose (1) changes in stockholders&#8217; equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders&#8217; equity, in the form of reconciliation, for &#8220;the current and comparative year-to-date [interim] periods, with subtotals for each interim period,&#8221; i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 permits the disclosure of changes in stockholders&#8217; equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. The staff of the SEC has indicated it would not object if the filer&#8217;s first presentation of the changes in shareholders&#8217; equity is included in its form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company expects to conform to this rule in its Form 10-Q for the quarter ending December 31, 2018. The Company believes that the final rule will not have a material effect on its consolidated financial statements and disclosures.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact on its financial statements.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;">In July 2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11. &#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial <div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">statements.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814718016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; white-space: nowrap; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Potentially&#160;Outstanding&#160;Dilutive&#160;Common&#160;Shares</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Three Months</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Three Months</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Ended</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Ended</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Options and Warrants</div></div></td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 208px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,412,039</td><td style="width: 19px; padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="width: 19px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 207px; border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,685,292</td><td style="width: 18px; padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Total potentially outstanding dilutive common shares</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,412,039</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,685,292</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following represents the basic and diluted per share calculations for loss from continuing operations:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;three&#160;months ended<div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/>September 30,</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Calculation of basic and diluted loss per share of common stock:</div></div></td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Net loss attributable to common stockholders</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 208px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(1,841,463</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 207px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(2,005,555</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Denominator for basic and diluted weighted average shares of common stock</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">69,185,965</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">63,307,083</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Basic and diluted loss per share of common stock</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(0.03</div></div></td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(0.03</div></div></td><td style="padding-bottom: 2.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">)</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618125984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions [Table Text Block]</a></td>
<td class="text"><table style="width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="6" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">September 30,</div></div><br/><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">June 30,</div></div><br/><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 70%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: justify; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Account Payable &#8211; Related Party</div></div></div></div></td><td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 11%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: justify; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: justify;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month&#8217;</div><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">s invoice to be applied as a prepayment towards expenses.&#160;</div>On October 2, 2018, the Company entered into an agreement with TheraCour Pharma, Inc. for a waiver of the two month worth of prepaid balance advance of anticipated invoicing and the application of the current advance as a credit against current open invoices, Additionally, TheraCour has agreed to defer $25,000 per month of development fees for six months,&#160;beginning&#160;with&#160;July&#160;2018. Accounts payable due TheraCour on the reporting date was</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">718,457</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.5pt double black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">107,468</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.25in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="6" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For the three months ended</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;<br/>2018</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;<br/>2017</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1321px; font: 10pt &quot;times new roman&quot;, times, serif; text-decoration: none; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="text-decoration:underline;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs Paid to Related Parties</div></div></td><td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 208px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 38px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 207px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company&#8217;s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2018 and June 30, 2018.</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">846,688</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">847,093</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814748752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, stated at cost, less accumulated depreciation consisted of the following:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 70.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">GMP Facility</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,020,471</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,011,230</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">260,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">260,000</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Office Equipment</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">57,781</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">57,781</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Furniture and Fixtures</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,607</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,607</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Lab Equipment</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,711,778</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,683,765</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Property and Equipment</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">14,055,637</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">14,018,383</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less Accumulated Depreciation</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,348,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3,177,290</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, Net</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,707,027</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,841,093</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6592000688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trademark and Patents (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trademark and patents, stated at cost, less accumulated amortization consisted of the following:</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; margin-right: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trademarks and Patents</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">458,954</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 11.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">458,954</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less Accumulated Amortization</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(86,094</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(84,025</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; text-indent: -0.13in; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trademarks and Patents, Net</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">372,860</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">374,929</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-right: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793097408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following:</div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="width: 100%; border-collapse: collapse; border-spacing: 0px;;text-align:left;"><tr><td style="padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom; white-space: nowrap;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">September</div> <div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">30,</div></div></div></div><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2018</div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 1pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-top: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">June 30,</div></div></div></div><div style="text-align: center; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; white-space: nowrap;"><div style="white-space: nowrap; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">201<div style="font-weight:bold;display:inline;">8</div></div></div></div></div></td><td style="border-top: none; border-image: initial; padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal; text-align: center; white-space: nowrap;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></div></td><td style="padding: 0in; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 74%; padding: 0px 0in; font-size: 10pt; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Severance payment- Eugene Seymour</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">133,333</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">233,333</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0in; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued&#160;&#160;payroll</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">49,576</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">19,716</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Professional Services</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 1pt solid black; border-top: none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">48,266</div></div></td><td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">-</div></div></td><td style="border-image: initial; background: rgb(204, 238, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0in 1pt; font-size: 10pt; width: 74%; vertical-align: bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses</div></div></td><td style="background: rgb(255, 255, 255); padding: 0in 0in 1pt; font-size: 10pt; width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; border-bottom: 1pt solid black; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">231,175</div></div></td><td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in 0in 1pt;"><div style="font-size: 10pt; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="text-align: left; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="border-top: 0px none; border-image: initial; border-bottom: 1pt solid black; background: rgb(255, 255, 255); padding: 0in; font-size: 10pt; white-space: nowrap; width: 10%; text-align: right; vertical-align: bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; white-space: nowrap;"><div style="font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">253,049</div></div></td><td style="border-image: initial; background: rgb(255, 255, 255); padding: 0in 0in 0.5pt; font-size: 10pt; white-space: nowrap; width: 1%; text-align: left; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656612736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock', window );">Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Series A Preferred stock was the following for the dates indicated:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-indent: 0.5in; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 50%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 585px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7/11/2018</div></td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 142px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">525,000</div></td><td style="width: 10px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 9px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="width: 141px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">560,690</div></td><td style="width: 9px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7/31/2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,572</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,795</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8/31/2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,572</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,374</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-bottom: 1pt; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">9/30/2018</div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,572</div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,598</div></td><td style="padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 1.5pt;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">532,716</div></td><td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="border-bottom: 2.5pt double black; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">568,457</div></td><td style="padding-bottom: 1.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Stockholders Equity [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1642px; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected life (year)</div></td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="width: 189px; text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4</div></td><td style="width: 18px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">55.12</div></td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected annual rate of quarterly dividends</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">0.00</div></td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td></tr><tr style="vertical-align:bottom; background-color:white"><td style="padding-left: 17.85pt; text-indent: -9pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate(s)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="text-align: right; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2.71</div></td><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of stock at each date of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ScheduleOfFairValueOfStockClassifiedByIssuanceDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824769168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants and Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="margin: 0in 0px 0.0001pt 0in; text-align: justify; font-family: &quot;times new roman&quot;, serif; background: none; font-size: 10pt;">The Company estimated the fair value of the options granted to Dr. Taraporewala on the date of grant using a lattice model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.3in; text-align: justify; text-indent: 0.4in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.3in; text-align: justify; text-indent: 0.4in; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1642px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected life (year)</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">3</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected volatility</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">55.09</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected annual rate of quarterly dividends</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.00</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 17.85pt; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Risk-free rate(s)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">2.71</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">%</td></tr><tr><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr><tr><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Expected forfeiture (attrition) rate (%)</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">5.00</div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">%</div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Options</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;<br/>Shares</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;<br/>Average&#160;<br/>Exercise<br/>Price&#160;<br/>per&#160;share&#160;<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;<br/>Remaining&#160;<br/>Contractual&#160;Term<br/>(years)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Outstanding at June 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 831px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Granted</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">300,000</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.50</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 37px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; width: 188px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">-</td><td style="font-size: 10pt; width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Outstanding at September 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">300,000</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.50</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">2.92</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="border-bottom: 1pt solid black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">-</td><td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0px; padding-top: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnvc_StockWarrantsMember', window );">Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Warrants</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;<br/>Shares</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;<br/>Average&#160;<br/>Exercise<br/>Price&#160;<br/>per&#160;share&#160;<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;<br/>Remaining&#160;<br/>Contractual&#160;Term<br/>(years)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value<br/>($)</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td colspan="2" style="font-size: 10pt; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 831px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Outstanding and exercisable at June 30, 2018</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">6,969,588</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4.80</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 189px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.53</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 37px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 188px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Granted</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">11,432</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.41</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Expired</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">2,868,981</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">5.25</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: justify; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Outstanding and exercisable at September 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4,112,039</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">4.48</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">.63</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nnvc_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nnvc_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656612736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2018 and June 30, 2018 the estimated fair values of the liabilities measured on a recurring basis are as follows:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;at</div></div></td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">September 30,&#160;2018:</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;2)</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;3)</div></div></td><td style="font-size: 10pt; padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;;width:;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; width: 61%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; width: 10%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; width: 1%; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 61%;">Derivative liability - warrants</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;">-</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;">-</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 1%;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 10%;">122,541</td><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-top: 0px; width: 1%;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;;text-align:left;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="10" style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">Fair Value Measurements at</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="10" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">June 30, 2018:</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in 0in 1pt; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">(Level 1)</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">(Level 2)</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 1pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-size: 10pt; font-weight: normal; text-align: center; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;"><div style="white-space: nowrap;;font-weight:bold;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">(Level 3)</div></div></td><td style="font-size: 10pt; font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 61%; vertical-align: bottom;">&#160;</td><td style="font-size: 10pt; padding: 0in; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;">&#160;</td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;">&#160;</td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td><td colspan="2" style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%;">&#160;</td><td style="font-size: 10pt; padding: 0in; white-space: nowrap; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px; background-color: rgb(204, 238, 255); width: 61%; vertical-align: bottom;">Derivative liability - warrants</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2.5pt double black; text-align: left; vertical-align: bottom; padding: 0in;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;">-</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;">-</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 2.5pt; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: left; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;">$</td><td style="border-bottom: 2.5pt double black; font-size: 10pt; text-align: right; padding: 0in; white-space: nowrap; background-color: rgb(204, 238, 255); width: 10%; vertical-align: bottom;">298,092</td><td style="font-size: 10pt; text-align: left; padding: 0in 0in 1.5pt; white-space: nowrap; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock', window );">Schedule Of Projected Annual Volatility [Table Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The next capital raise would fluctuate with an annual volatility. </div><div style="font-size:10pt;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are:</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="width: 50%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1 Year</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 81%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">9/30/18</div></div></td><td style="background: rgb(204, 238, 255); width: 2%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">64</div></div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6/30/18</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">56</div></div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2018:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurement</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160;&#160;<div style="font-weight:bold;display:inline;">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</div></div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurement</div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Using Significant Unobservable Inputs</div></div></td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: center; padding-top: 0px; padding-bottom: 0px;"><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 2.8pt; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative</div></div></div><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0pt 0px; text-align: center; text-indent: 15.4pt; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability-</div></div></div><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0pt 0px; text-align: center; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant</div></div></div></td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 1604px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Beginning balance at July 1, 2018</td><td style="width: 38px; font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 208px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">298,092</td><td style="width: 18px; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Additions during the year</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Change in fair value</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(175,551</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">Transfer in and out of Level 3</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="border-bottom: 1pt solid black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">-</td><td style="padding-bottom: 1pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">Balance at September 30, 2018</td><td style="font: 10pt &quot;times new roman&quot;, times, serif; padding-bottom: 2.5pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="border-bottom: 2.5pt double black; font: 10pt &quot;times new roman&quot;, times, serif; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">122,541</td><td style="padding-bottom: 1.5pt; font: 10pt &quot;times new roman&quot;, times, serif; text-align: left; padding-left: 0px; padding-top: 0px;">&#160;</td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the projected annual volatility for the valuation dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ScheduleOfProjectedAnnualVolatilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789721504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">4,412,039<span></span>
</td>
<td class="nump">6,685,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">4,412,039<span></span>
</td>
<td class="nump">6,685,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811048144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Calculation of basic and diluted loss per share of common stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (1,841,463)<span></span>
</td>
<td class="num">$ (2,005,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator for basic and diluted weighted average shares of common stock</a></td>
<td class="nump">69,185,965<span></span>
</td>
<td class="nump">63,307,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share of common stock</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823672800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 13, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,412,039<span></span>
</td>
<td class="nump">6,685,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses', window );">Reclassification of General and Administrative Expenses into Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,724,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60% or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,064,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,531,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series C Convertible Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Reclassification of Company's laboratory facilities General and Administrative Expenses into Research and Development Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ReclassificationOfGeneralAndAdministrativeExpensesIntoResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nnvc_SeriesCConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nnvc_SeriesCConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823559504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 6,082,365<span></span>
</td>
<td class="nump">$ 13,512,240<span></span>
</td>
<td class="nump">$ 7,081,771<span></span>
</td>
<td class="nump">$ 15,099,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">(85,533,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (83,692,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(1,841,463)<span></span>
</td>
<td class="num">(2,005,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="num">$ (962,152)<span></span>
</td>
<td class="num">$ (1,556,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810887248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,411,483<span></span>
</td>
<td class="nump">$ 1,451,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember', window );">Theracour Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Net Account Payable to related party</a></td>
<td class="nump">718,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 846,688<span></span>
</td>
<td class="nump">$ 847,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823723296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related Party Transaction, Description of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">costs (direct and indirect) plus no more than 30% of direct costs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments', window );">Percentage Of Net Sales Allocated For Royalty Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,411,483<span></span>
</td>
<td class="nump">1,451,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember', window );">Theracour Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 846,688<span></span>
</td>
<td class="nump">847,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember', window );">Theracour Pharma Inc [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesCConvertibleDebentureMember', window );">Series C Convertible Debenture [Member] | Dr. Boniuk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty expense calculated as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888428&amp;loc=SL77919370-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77911099&amp;loc=d3e36975-112693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918703-209980<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888430&amp;loc=SL77919784-209982<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesCConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_SeriesCConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_DrBoniukMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_DrBoniukMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823505088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">GMP Facility</a></td>
<td class="nump">$ 8,020,471<span></span>
</td>
<td class="nump">$ 8,011,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_OfficeEquipmentGross', window );">Office Equipment</a></td>
<td class="nump">57,781<span></span>
</td>
<td class="nump">57,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and Fixtures</a></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Lab Equipment</a></td>
<td class="nump">5,711,778<span></span>
</td>
<td class="nump">5,683,765<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">14,055,637<span></span>
</td>
<td class="nump">14,018,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less Accumulated Depreciation</a></td>
<td class="num">(3,348,610)<span></span>
</td>
<td class="num">(3,177,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net</a></td>
<td class="nump">$ 10,707,027<span></span>
</td>
<td class="nump">$ 10,841,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_OfficeEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, at the balance sheet date, of office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_OfficeEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794796944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 171,320<span></span>
</td>
<td class="nump">$ 166,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823132912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trademark and Patents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_TrademarksAndPatentsLineItems', window );"><strong>Trademarks And Patents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Trademarks and Patents</a></td>
<td class="nump">$ 458,954<span></span>
</td>
<td class="nump">$ 458,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less Accumulated Amortization</a></td>
<td class="num">(86,094)<span></span>
</td>
<td class="num">(84,025)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Trademarks and Patents, Net</a></td>
<td class="nump">$ 372,860<span></span>
</td>
<td class="nump">$ 374,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_TrademarksAndPatentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_TrademarksAndPatentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792139328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trademark and Patents (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_TrademarksAndPatentsLineItems', window );"><strong>Trademarks And Patents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="nump">$ 2,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnvc_TrademarkAndPatentsMember', window );">Trademark and Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_TrademarksAndPatentsLineItems', window );"><strong>Trademarks And Patents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="nump">$ 2,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_TrademarksAndPatentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_TrademarksAndPatentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnvc_TrademarkAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnvc_TrademarkAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825872784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debenture and Derivatives (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 13, 2017</div></th>
<th class="th"><div>Jul. 02, 2014</div></th>
<th class="th"><div>Mar. 21, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jul. 19, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_SharePriceAsPerRedemptionAgreement', window );">Share price as per Redemption Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued', window );">Series Preferred Share Issued For Debenture Interest Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionDescription', window );">Debt Conversion, Description</a></td>
<td class="text">for an aggregate of 5,500,000 shares of the Company&#8217;s $0.001 par value Common Stock (&#8220;Purchase Price&#8221;) comprising 5,000,000 shares for the principal of the Debenture and 500,000 shares for unpaid coupon interest from October 1, 2017 through June 30, 2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 684,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesBConvertibleDebenturesMember', window );">Series B Convertible Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">239,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,645,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Repayments of Other Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,879,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">$ 1,348,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock Issued During Period, Value, Conversion of Convertible Securities</a></td>
<td class="nump">$ 364,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="nump">314,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock Issued During Period, Value, Other</a></td>
<td class="nump">$ 314,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesCConvertibleDebentureMember', window );">Series C Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="nump">314,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment', window );">Common Stock Value Issued For Debt Instrument Periodic Interest Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_DeferredInterestPayment', window );">Deferred Interest Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="nump">60,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term Debt, Excluding Current Maturities</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the value of common stock issued for debt instrument periodic interest payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_CommonStockValueIssuedForDebtInstrumentPeriodicInterestPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_DeferredInterestPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred interest payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_DeferredInterestPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of shares issued series A preferred shares issued for debenture interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_SeriesPreferredShareIssuedForDebentureInterestSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_SharePriceAsPerRedemptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the share price as per redemption agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_SharePriceAsPerRedemptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesBConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesBConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesCConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=nnvc_SeriesCConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823564000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Severance payment- Eugene Seymour</a></td>
<td class="nump">$ 133,333<span></span>
</td>
<td class="nump">$ 233,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">49,576<span></span>
</td>
<td class="nump">19,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional Services</a></td>
<td class="nump">48,266<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
<td class="nump">$ 231,175<span></span>
</td>
<td class="nump">$ 253,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813028768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details) - Series A Preferred Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="nump">532,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock Issued During Period, Value, Share-based Compensation, Gross | $</a></td>
<td class="nump">$ 568,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateOneMember', window );">Issuance Date One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="nump">525,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock Issued During Period, Value, Share-based Compensation, Gross | $</a></td>
<td class="nump">$ 560,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateTwoMember', window );">Issuance Date Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock Issued During Period, Value, Share-based Compensation, Gross | $</a></td>
<td class="nump">$ 2,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateThreeMember', window );">Issuance Date Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock Issued During Period, Value, Share-based Compensation, Gross | $</a></td>
<td class="nump">$ 2,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateFourMember', window );">Issuance Date Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock Issued During Period, Value, Share-based Compensation, Gross | $</a></td>
<td class="nump">$ 2,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=nnvc_IssuanceDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=nnvc_IssuanceDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=nnvc_IssuanceDateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=nnvc_IssuanceDateFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=nnvc_IssuanceDateFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785493120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (year)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">55.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate(s)</a></td>
<td class="nump">2.71%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_ScientificAdvisoryBoardMember', window );">Scientific Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected annual rate of quarterly dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_ScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_ScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826755968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jul. 11, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,920<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FairValueMeasurementSignificantAssumptions', window );">Fair Value Measurement Significant Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a.The common stock price was in the range $.42 to $.58;b.The calculated weighted average number of shares of common stock in the period;c.A 26.63% premium over the common shares for the voting preferences;d.The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.22% to 19.25% of the total;e.The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 2.09 years;f.29.42% to 32.24% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 55.76% to 61.17% volatility, 2.09% to 2.11% risk free rate) applied to the converted common.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock or Unit Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member] | August 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants', window );">Number Of Common Stock To Be Issued Upon Conversion Of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member] | February 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_RestrictedCommonStockAuthorizedForInterestPayable', window );">Restricted common stock authorized for interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued For Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage', window );">Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage', window );">Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage', window );">Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_FairValueMeasurementSignificantAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of significant assumptions used by management to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_FairValueMeasurementSignificantAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock to be issued upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_NumberOfCommonStockToBeIssuedUponConversionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_RestrictedCommonStockAuthorizedForInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted common stock authorized for interest payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_RestrictedCommonStockAuthorizedForInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nnvc_AugustTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nnvc_AugustTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nnvc_February2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nnvc_February2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823835136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants and Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Granted (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,969,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,112,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Outstanding (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Granted (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Expired (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Outstanding (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (years), Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 11 days<span></span>
</td>
<td class="text">6 months 11 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding (in dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options expirations, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813706368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants and Options (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Granted (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnvc_StockWarrantsMember', window );">Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Outstanding (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per share, Outstanding (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate Intrinsic Value, Granted (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options granted, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nnvc_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nnvc_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760142480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants and Options (Details 2)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (year)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">55.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate(s)</a></td>
<td class="nump">2.71%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (year)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">55.09%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected annual rate of quarterly dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate(s)</a></td>
<td class="nump">2.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture (attrition) rate (%)</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a shares are expected to get forfeited (attrition) during a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813737472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants and Options (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 35,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock or Unit Option Plan Expense | $</a></td>
<td class="nump">11,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $</a></td>
<td class="nump">$ 23,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-based Compensation Award, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FuturePeriodAxis=nnvc_June302019Member', window );">June 30, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantsExercisable', window );">Warrants Exercisable</a></td>
<td class="nump">3,679,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FuturePeriodAxis=nnvc_June302020Member', window );">June 30, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantsExercisable', window );">Warrants Exercisable</a></td>
<td class="nump">68,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FuturePeriodAxis=nnvc_June302021Member', window );">June 30, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantsExercisable', window );">Warrants Exercisable</a></td>
<td class="nump">57,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FuturePeriodAxis=nnvc_June302022Member', window );">June 30 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantsExercisable', window );">Warrants Exercisable</a></td>
<td class="nump">45,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FuturePeriodAxis=nnvc_June302023Member', window );">June 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantsExercisable', window );">Warrants Exercisable</a></td>
<td class="nump">261,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_WarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of warrants are exercisable during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_WarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_FuturePeriodAxis=nnvc_June302019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_FuturePeriodAxis=nnvc_June302019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_FuturePeriodAxis=nnvc_June302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_FuturePeriodAxis=nnvc_June302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_FuturePeriodAxis=nnvc_June302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_FuturePeriodAxis=nnvc_June302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_FuturePeriodAxis=nnvc_June302022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_FuturePeriodAxis=nnvc_June302022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_FuturePeriodAxis=nnvc_June302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_FuturePeriodAxis=nnvc_June302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794105760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability, Noncurrent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability, Noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability, Noncurrent</a></td>
<td class="nump">$ 122,541<span></span>
</td>
<td class="nump">$ 298,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656588592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Details 1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_OneYearEnded63018Member', window );">One Year Ended 6/30/18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FairValueAssumptionExpectedVolatilityRate', window );">Fair Value Assumption Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nnvc_OneYearEnded93018Member', window );">One Year Ended 9/30/18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_FairValueAssumptionExpectedVolatilityRate', window );">Fair Value Assumption Expected Volatility Rate</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_FairValueAssumptionExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_FairValueAssumptionExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_OneYearEnded63018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_OneYearEnded63018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_OneYearEnded93018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_OneYearEnded93018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810803120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Details 2) - Derivative liability - Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 298,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions during the year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(175,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Transfer in and out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 122,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813630464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Details Textual) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2014</div></th>
<th class="th"><div>Sep. 12, 2013</div></th>
<th class="th"><div>Jan. 24, 2014</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,479,935<span></span>
</td>
<td class="nump">5,290,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantsIssued', window );">Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,425,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nnvc_PlacementAgentsMember', window );">Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,306<span></span>
</td>
<td class="nump">135,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantsIssued', window );">Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_WarrantExpirationTerm', window );">Warrant Expiration Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 6.05<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 6.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nnvc_ScientificAdvisoryBoardMember', window );">Scientific Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,556,241<span></span>
</td>
<td class="nump">5,425,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_WarrantExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_WarrantExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nnvc_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nnvc_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nnvc_ScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nnvc_ScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6824812992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>May 30, 2013</div></th>
<th class="th"><div>Mar. 03, 2010</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,382,560<span></span>
</td>
<td class="nump">69,171,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-based Compensation Award, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Year One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Year Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Year Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=nnvc_ChiefScientificOfficerMember', window );">Chief Scientific Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AdditionalCommonStockSharesIssued', window );">Additional Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_IncreaseInBaseSalary', window );">Increase In Base Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_VicePresidentMember', window );">Vice President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AdditionalCommonStockSharesIssued', window );">Additional Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_AdditionalPreferredStockSharesIssued', window );">Additional Preferred Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_IncreaseInBaseSalary', window );">Increase In Base Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_IncreaseInBaseSalary', window );">Increase In Base Salary</a></td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnvc_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_AdditionalCommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of additional common shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_AdditionalCommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_AdditionalPreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of additional nonredeemable preferred shares issued to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_AdditionalPreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_IncreaseInBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the certain amount of estimated salary increase in their base.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_IncreaseInBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_DeferredCompensationYearAxis=nnvc_YearOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_DeferredCompensationYearAxis=nnvc_YearOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_DeferredCompensationYearAxis=nnvc_YearTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_DeferredCompensationYearAxis=nnvc_YearTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnvc_DeferredCompensationYearAxis=nnvc_YearThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnvc_DeferredCompensationYearAxis=nnvc_YearThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=nnvc_ChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=nnvc_ChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_VicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_VicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nnvc_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nnvc_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_RNPLX;N[?_V/@B*#OX=1?R"U!+ P04    " !KA&Y-F5R<(Q &  "<)P
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M47T^EMQQ(%D_/2>"^4U3_ %02P,$%     @ :X1N3:\*X3Q$!   SQ,  !@
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ML3U4T"$24>*I0IF%R%FH8Q8B9UP.3AOFB.O"5J!M8E?'1!''6:AC%B)G'!)
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M-TWO0XOJ4\AN[\O=]:+RS_UPFH?S]O*)Z7+1-Z?I\UEV_8:W_@]02P,$%
M  @ :X1N32E!V[!" @  R@<  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6R-E=N.VR 417_%\@<,^((OD6.IDZIJI5:*IFK[3!(26V,;%T@\_?L"=BP'
MF$GR8&Y[']8AB%,,E+WRBA#AO;5-Q]=^)42_ H#O*])B_D1[TLF5(V4M%G+(
M3H#WC."#-K4-""%,0(OKSB\+/;=E94'/HJD[LF4>/[<M9O^>24.'M1_XUXF7
M^E0)-0'*HL<G\I.(7_V6R1&8HQSJEG2\IIW'R''M?PI6FP J@U;\KLG %WU/
MI;*C]%4-OAW6/E1$I"%[H4)@V5S(AC2-BB0Y_DY!_7E/95SVK]&_Z.1E,CO,
MR88V?^J#J-9^YGL'<L3G1KS0X2N9$D*^-V7_G5Q((^6*1.ZQIPW77V]_YH*V
M4Q2)TN*WL:T[W0[C"KK:W(9P,H2S(8@_-$23(3(,8"33J7[& I<%HX/'QG^K
MQ^I2!*M('N9>3>JSTVLR6RYG+V42%N"BXDR2YU$2+B2&8N-0I+,$R/UGB- )
M$6I_O(2(#(A1DFE)IR7P"<+  +FGNF&)G"R1S1(;+*,$+78)$!Q_!L\CRANF
MV,D4VTS(8(JMG9(\RD*4F$@N89 &:?P.$7(2(9LH,8C0HT0NX4=$B9,HL8G>
M\:=.?VK[4R.C]*$[>$]UPY(Y63*;)3-8,NO0,N2Z@?=U-SRYDR>W>7*#)[?V
M03")@\#DL74QBH(HC]T\LD(X7RUH$:70?+;@@T@.H9L)+!Y55>5^8':J.^[M
MJ)#OLWY%CY0*(H/")QFNDH5U'C3D*%0WE7TV5I=Q(&@_54XPE^_R/U!+ P04
M    " !KA&Y-WM/K+!P#  #^"P  &    'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;(V6;V_:,!#&OTJ4]VW\-W$J0"I,TR9M4M5IV^L4#$1-8I88Z+[];">%
M8!]T;YK8><[WNZOU<).C:E^[K90Z>JNKIIO&6ZUW#TG2+;>R+KI[M9.-^;)6
M;5UHLVPW2;=K9;%R0765$(32I"[*)IY-W-Y3.YNHO:[*1CZU4;>OZZ+].Y>5
M.DYC'+]O/)>;K;8;R6RR*S;RA]0_=T^M626G4U9E+9NN5$W4RO4T?L0/"RQL
M@%/\*N6Q&[U'MI07I5[MXNMJ&B-+)"NYU/:(PCP.<B&KRIYD./X,A\:GG#9P
M_/Y^^F=7O"GFI>CD0E6_RY7>3F,11RNY+O:5?E;'+W(HB,?14/TW>9"5D5L2
MDV.IJL[]C9;[3JMZ.,6@U,5;_RP;]SSV7U(ZA,$!9 @@IP"3^U8 '0+H.8"Y
MXGLR5^JG0A>S2:N.4=O_MW:%O13X@9IF+NVFZYW[9JKMS.YAEN%)<K#G#))Y
M+R$CR5F1F,-/&0B484Z"<'*98!$J,@)GH& -U,73<3R%XQD8SUP\&\<SKP>]
M)'.2IN\!PY@)ZI4"Z3C.40KS<)"'ASS<X^DE?)0G)5F*/=DBE&69X S!-"E(
MDX8TJ4>3!FD(HCG*A8<#Z A%C%WI3@;R9"%/YO%D09X[& @2WB(2()$([Y^
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MM5):&E!T;Q"W9A@_+2JYUO8U,^]M/Y'V"ZUVP[2=G$;^V3]02P,$%     @
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M,N==TQ+;&V!U!$E!Z&[WB4C&%2[S&#N:,M>#$US!T2 [2,G,WP,(/18XP9?
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MWVR<?Z.U R]E=^-7J/,/;'$$-"Z8G[UMIC6;'*?[^061Y1F7_P!02P,$%
M  @ :X1N314/J(VW 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX
M;6QM4VUOVR 0_BN('U 2XK119%MJ6E6;M$E1IVV?B7U^48'S ,?=OQ]@UW4[
M?P'NN.>YYXXC'="\V ; D5<EM<UHXUQW9,P6#2AA;[ #[6\J-$HX;YJ:V<Z
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M;#$4U#X</^+93F,V&=[T\P]BRS<N_@!02P,$%     @ :X1N32.-D9RW 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL;5-M;]L@$/XKB!]0
M$N*T461;:EI5F[1)4:=MGXE]?E&!\P#'W;\?8-=U.W\![KCGN>>.(QW0O-@&
MP)%7);7-:.-<=V3,%@TH86^P ^UO*C1*.&^:FMG.@"@C2$G&-YM;ID2K:9Y&
MW]GD*?9.MAK.AMA>*6'^GD#BD-$M?7,\MW7C@H/E:2=J^ 'N9W<VWF(S2]DJ
MT+9%30Q4&;W?'D])B(\!OUH8[.),0B47Q)=@?"TSN@F"0$+A H/PVQ4>0,I
MY&7\F3CIG#( E^<W]J=8NZ_E(BP\H/S=EJ[)Z(&2$BK12_>,PQ>8ZME3,A7_
M#:X@?7A0XG,4*&U<2=%;AVIB\5*4>!WW5L=]&&]VAPFV#N 3@,^ 0\S#QD11
M^:-P(D\-#L2,O>]$>.+MD?O>%,$96Q'OO'CKO==\NT]2=@U$4\QIC.'+F#F"
M>?8Y!5]+<>+_P?DZ?+>J<!?ANP\*]^L$R2I!$@F2#P2WGTI<B[G[E(0M>JK
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M+$FC%2!E4U6MU$JK5&V?O3" %5^H;9;T[SLV+"$I?;$]XSEGSHS'^6CLL^L
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MQH?C!SS;:<PFPYM^_D%L^<;E7U!+ P04    " !KA&Y--I6& [<!  #2 P
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M=WBVTYA-AC?]_(/8\HW+OU!+ P04    " !KA&Y-0[(A?[<!  #2 P  &0
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MLQW';#2\Z:8?Q.9O7+P!4$L#!!0    ( &N$;DVQ_;]*N $  -(#   9
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M;*<QFPQO^OD'L>4;EW\!4$L#!!0    ( &N$;DW:1N@SWP$   $%   9
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;&U4;8^<(!#^*X0?<*RZZG:C)K?7
M-&W2)IMK>OW,ZOB2 [& Z_7?%]"SUO)%F.&9YYE!9K))R%?5 FCTQEFO<MQJ
M/9P)464+G*H',4!O3FHA.=7&E U1@P1:N2#.2'@X)(33KL=%YGQ7661BU*SK
MX2J1&CFG\O<%F)AR'.!WQW/7M-HZ2)$-M('OH'\,5VDLLK)4'8=>=:)'$NH<
M/P;G2VKQ#O#2P:0V>V0KN0GQ:HTO58X/-B%@4&K+0,URAR=@S!*9-'XMG'B5
MM(';_3O[)U>[J>5&%3P)]K.K=)OC$T85U'1D^EE,GV&I)\9H*?XKW($9N,W$
M:)2"*?=%Y:BTX N+2873MWGM>K=.\TE\6L+\ >$2$*X!)Z=#9B&7^4>J:9%)
M,2$YW_U [2\.SJ&YF](ZW56X,Y.\,MY[$9R"C-PMT8*YS)APBUD1Q+"O$J%/
MXA+^%Q[ZPR-OAI$+C[;J4>(G.'H)CH[@^$^)X:Y$'R;RB\1>D=A#<-R)^#"Q
M7R3QBB0>@F0GXL.D?I'4*Y)Z"$X[$1_FPTZ$;)X@!]FXYE.H%&/O&G_C7?O[
M,71/^"]\'@[?J&RZ7J&;T*81W'.MA=!@4CD\F%MMS3Q:#0:UMMO4[.7<E;.A
MQ; ,'+).O>(/4$L#!!0    ( &N$;DT? #6YL@$  -(#   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;&U3VXZ<, S]E2@?L %FNFU'@+2SJU4KM=)H
MJ[;/&3 0;2XT"</V[^L$AM(I+\0V/L?'CI./QKZZ#L"3-R6U*VCG?7]@S%4=
M*.[N3 \:_S3&*N[1M2USO05>1Y"2+$N2>Z:XT+3,8^QDR]P,7@H-)TO<H!2W
MOX\@S5C0E%X#+Z+M? BP,N]Y"]_ ?^]/%CVVL-1"@7;":&*A*>A#>CCN0WY,
M^"%@="N;A$[.QKP&YW-=T"0( @F5#PP<CPL\@I2!"&7\FCGI4C( U_:5_3GV
MCKV<N8-'(W^*VG<%_4!)#0T?I'\QXR>8^WE'R=S\%[B Q/2@!&M41KKX)=7@
MO%$S"TI1_&TZA8[G./-?8=N ; 9D-P V%8K*G[CG96[-2.PT^YZ'*TX/&<ZF
M"L$XBO@/Q3N,7LKT8Y*S2R":<XY33K;.63(8LB\ELJT2Q^P_>+8-WVTJW$7X
M;EU]=[]-L-\DV$>"_3\MIC<M;N7<JF2KF2JP;=PF1RHSZ+C)J^BRL ]9O)._
MZ=.V?^6V%=J1L_%XLW'^C3$>4$IRARO4X0-;' F-#^9[M.VT9I/C33^_(+8\
MX_(/4$L#!!0    ( &N$;DV@G[<HMP$  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;&U3[8Z<(!1]%<(#+#/JM-.)FNQLT[1)FTRVZ?8WHU<E
M"UP+.&[?OH"NM5O_ /=RSKD?7/(1S;/M !QY45+;@G;.]2?&;-6!XO8.>]#^
MID&CN/.F:9GM#? ZDI1DR6[WCBDN-"WSZ+N8,L?!2:'A8H@=E.+F]QDDC@7=
MTU?'HV@[%QRLS'O>PG=P/_J+\19;5&JA0%N!FAAH"GJ_/YVS@(^ )P&C79U)
MJ.2*^!R,+W5!=R$AD%"YH,#]=H,'D#((^31^S9IT"1F(Z_.K^J=8NZ_ERBT\
MH/PI:M<5]$A)#0T?I'O$\3/,]1PHF8O_"C>0'AXR\3$JE#:NI!JL0S6K^%04
M?YEVH>,^3C>'XTS;)B0S(5D(QQB'38%BYA^YXV5N<"1FZGW/PQ/O3XGO316<
ML17QSB=OO?=6[C^D.;L%H1ESGC#)&K,@F%=?0B1;(<[)?_1DFYYN9IA&>KJ.
MGJ7; MFF0!8%LG]*S-Z4N(4YO G"5CU58-HX3994..@XR2OO,K#W27R3O_!I
MVK]QTPIMR16=?]G8_P;1@4]E=^='J/,?;#$D-"X<W_NSF<9L,ASV\P]BRS<N
M_P!02P,$%     @ :X1N36]5 G&W 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL;5/;;IPP$/T5RQ\0[[(DNUD!4C91U4JMM$K5]-D+ UCQ
MA=IF2?^^8T,H37FQ/>-SSEP\S@9C7UT+X,F;DMKEM/6^.S+FRA84=S>F XTW
MM;&*>S1MPUQG@5>1I"1+-IL[IKC0M,BB[VR+S/1>"@UG2URO%+>_3R#-D-,M
M?7<\BZ;UP<&*K.,-? ?_HSM;M-BL4@D%V@FCB84ZIP_;XRD-^ AX$3"XQ9F$
M2B[&O ;C2Y7334@())0^*'#<KO (4@8A3./7I$GGD(&X/+^K?XJU8RT7[N#1
MR)^B\FU.#Y144/->^F<S?(:IGEM*IN*_PA4DPD,F&*,TTL65E+WS1DTJF(KB
M;^,N=-R'\2:]GVCKA&0B)#/A$..P,5#,_(E[7F36#,2.O>]X>.+M,<'>E,$9
M6Q'O,'F'WFNQO;_+V#4(39C3B$F6F!G!4'T.D:R%."7_T9-U^FXUPUVD[Y;1
MT_VZ0+HJD$:!])\2]Q]*7,,</@1ABYXJL$V<)D=*T^LXR0OO/+ /27R3O_!Q
MVK]QVPCMR,5X?-G8_]H8#YC*Y@9'J,4/-AL2:A^.>SS;<<Q&PYMN^D%L_L;%
M'U!+ P04    " !KA&Y-.7O]'K8!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6QU4V%OW" ,_2N('U!RN6O7GI)(O595)[72J=.ZSUSB)*B
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M^PQ"C3E.\3WQPIO6^@0ILIXU\ WL]_ZB7406E8I+Z Q7'=)0Y_@I/9V/'A\
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MQ:P-IC.8#^$F"9,L7KAQ -6K2M7/+2EU2DH=DA:5*HM)9Y6R;;A)MUFZD.0
MQG&P#C:Q6U+FE)0Y)"4+21:SG9L/5L'RB/Z'LF+0[!)3X!?SWH57LVLG]769
M1:>6\A#I1["(5ZK5V,[P1F/[U#?,+VTGO".3ZHF9AW!F3((2&:S4>36J-4X+
M F>IIVLUY[9!V(5D_=C[T-2 RS]02P,$%     @ :X1N3>Y,809T @  D0@
M !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULC5;;CJ(P&'X5P@,,],1A
MHB:K,YO=9#<QLYG=ZZI5R0!EVZJS;[]M0:+PD^B%M.4[_%\/P.PBU8<^"F&"
MSZJL]3P\&M,\1Y'>'D7%]9-L1&WO[*6JN+%==8ATHP3?>5)51CB.DZCB11TN
M9GYLK18S>3)E48NU"O2IJKCZMQ2EO,Q#%%X'WHK#T;B!:#%K^$'\$N:]62O;
MBWJ575&)6A>R#I38S\,OZ/D544?PB-^%N.B;=N"B;*3\<)WONWD8NXI$*;;&
M27![.8N5*$NG9.OXVXF&O:<CWK:OZE]]>!MFP[58R?)/L3/'>9B%P4[L^:DT
M;_+R372!6!ATZ7^(LR@MW%5B/;:RU/X_V)ZTD56G8DNI^&=[+6I_O73Z5QI,
MP!T!]X1V<B8)I".01PFT(]!'":PCL $A:K/[R7SAAB]F2EX"U>Z'AKMMAYZ9
M7:ZM&_2KX^_9^=1V]+S A,VBLQ/J,,L6@^\PR3UF!6#N$2]C1#J O (B:0^)
M;(X^# ;#8,\GM_PI 0(*$"] [P2R0=(6PSRF]AA*$8Y)/L@[QB5)QG".X8(H
M6! =%T32@5&+26^,<)XD:0;[,-"' 3Z#X$LV"H18;'^P3P+Z)".?9(*?@OST
M\17.0('L@17.QD'3%%.2,=@I!YUR8$H'>V358E!\8T6>)EP<"CK \=B'QL/3
M"8'0A,_$@P(!$GCH@T93Q^*$(A0/3_H82!E!)*<31<$''F&@*#(A 1]Y1![?
M4@@^I @ZI=GP\4='B7-F8<-5B&Z>W.YE_9.K0U'K8".-?0GX1_5>2B.L9OQD
MU8[V^Z#OE&)O7#.U;=6^)-N.D4WW 1#U7R&+_U!+ P04    " !KA&Y-4B_W
M,6$"  #>!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R-5=%NFS 4
M_17$>PLVMB%1@E323INT25&G;<].X@14P,QVDN[O9QM*B?&JY2'8EW/N/>=B
M+JLK%R^R9$P%KTW=RG58*M4MHTCN2]90><\[UNH[1RX:JO16G"+9"48/EM34
M$8QC$C6T:L-\96-;D:_X6=55R[8BD.>FH>)/P6I^78<@? L\5Z=2F4"4KSIZ
M8M^9^M%MA=Y%8Y9#U;!65KP-!#NNPP>P?"(&;P$_*W:5DW5@G.PX?S&;+X=U
M&!M!K&9[93)0?;FP#:MKDTC+^#WD#,>2ACA=OV7_9+UK+SLJV8;7OZJ#*M=A
M%@8'=J3G6CWSZV<V^,%A,)C_RBZLUG"C1-?8\UK:_V!_EHHW0Q8MI:&O_;5J
M[?7:W\%DH/D)<"# D:!K?T1(!D+R3D ?$M! 0/]+P ,!.X2H]VZ;^4@5S5>"
M7P/1'X>.FE,'EE@_KKT)VJ=C[^E^2AV]Y!"A570QB09,T6/@! -&1*2SCR6@
MKT0!9W1X6V S1Z0.Y-&3)+V%/'D@"/N%)MY>)#8!NDE G%[TF-1B6HLA<083
M@AU+<QQ(,( 0Q8ZQ.3"-,Y"FP''G28CCQ0*1?SP+Y+6(/!:=/A8]!D\JW648
M)PF)%XYV---TER5D <&D;3>BL%<4]HC*'%%X+@ID2!=*G,9[@'IJ8OWS2R)>
M2<0CR7%?D+G[!8$ NZ?;@P,8DS3+'$71Y*5MF#C9"2J#/3^WRASL270<T@_0
MO/1.O #+33]KW]/TD_\;%:>JE<&.*SU2[(M_Y%PQK3.^UTTK]<=FW-3LJ,PR
MU6O1C]Q^HW@W?$VB\9.6_P502P,$%     @ :X1N3?\[$V$B @  V@4  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULA539;MLP$/P501\0ZJ".&+*
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MNEH(WGJB^WD;:G81GA/=_8-9M,VV[W1[I%Z]KL(X6@170^0PZPX3#C!DB-D
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M,/8<.'&NF.9$#SKW7-\E^DG)3LH,4ST6W8':311OW&4AZ&\LJ_]02P,$%
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M#0?.SKK=$K.7W;30';2H^TG(&\:Q[3]02P,$%     @ :X1N31O1!-KQ 0
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MS$5* [:4Z,[^U\I.Q"G@<#%NF]B]&N;"$!C9CB./3',W_P-02P,$%     @
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M*+*-0;CFHRB.N(JP PG77H@1OL#V(N+;35]@\Q# &<@9Y\1U9+J2_Y0(&X@
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MAG/ZX:8IC^,[B.#R(F3Q'U!+ P04    " !KA&Y-<].]/> "   !"P  &0
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M$ZVQX96TSVASE(K7+HJV4M/7[ETV]GWNOA#D:&$"< 30$[3V+0)T!/A.N*V
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MS>/R<FY5]B4&1(KN,Z7650O^L%W"3:L^-3[9ZM\T=KV[G+RY?'=Y=WE>1C$
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M@NF"111KI(,#FQN:5L/N>8&5X@;!X\WYQ8>;<[WCN\E_ED_,_A: </?I\A8
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M1(L0_.9">0'8G#[P\NO.)8'G*L^A'=SJ=V@^T,,TK8IGGU4"E/ K_@)_KN:
M( C"642R]U2#;*T874,@9&L%D/ST?S\%AY_@3LR ;$6M7](<\4">B3Y'P=NW
MGUK]P- @WCO]WNH?M8-3=V[4 %M*NQTC9%CKZ*_P+E *A5*1$CX$$\-"SW<H
M(>%&4>Q#S3CD2]OKHWT9;_HBII,'(449/(3OX/#R^*LV=\ %0%6H</+N):-W
M7;YH;MJ*&!B(T,DO$4NT@# 7JUW%[?6H>RU.77YZ.;D\NPV#,Y7<HZW\?)JN
MHI?OHVRZR^X9Y5,2@H5NP(45'&4ZR!H$<@PA7<87QQ^""*Z )@@A+@ZT$NT
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M_E#X!U#"C*,'IY(K!-<CUWXSZR&HVG(Y:"^B>*)B_9.:HANXX@T@TM<8A6_
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M3>HT,1W'7LQ)JZ=PFE802!>P%!H-T(PT%W+PY!27S3EM>B)8'4JWZQ@-IRE
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M*7*B<S;GT/AF_M?!X8"^03!$IMB$\;XJ=#$0_WF()?[/ANRP59B#;!A..N(
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MMH"6MEE2'"75SBD_3<=G*_GQ[IS*?C*%J5>)(?WW]RK3T7<U1;=,5?W\R</
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M[X)+@G,KF4W*\E]%6"T@_WXM(]S&BJ7V,RA$X 3>T&[@J<X1PC ^[0';;>B
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M0)@'?.M^FHS1>X_1:*;V.I?7/F6N@+.WAI%ZG7WFZW6?>JI9;7*'ZM<^59>
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M&^'!<ABU&BAB.-I?<$8:=FD+CG\*DA]02P,$%     @ :X1N3?-]7[1+!
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M4$L! A0#%     @ :X1N33?Z2@GN    *P(  !$              ( !F0$
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ :X1N39E<G",0!@  G"<
M !,              ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !KA&Y-*$!Y^WX"  #?"   &               @ 'W"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ :X1N3:\*X3Q$!   SQ,
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M965T-BYX;6Q02P$"% ,4    " !KA&Y-3$X6(;(!  #2 P  &
M    @ &U'0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M:X1N314/J(VW 0  T@,  !@              ( !G1\  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &N$;DT<\\,1L@$  -(#   8
M          "  8HA  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " !KA&Y-L4_L[;4!  #2 P  &0              @ %R(P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &N$;DT6^!*BMP$  -(#
M   9              "  5XE  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ :X1N32,%MTRV 0  T@,  !D              ( !3"<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !KA&Y-(XV1
MG+<!  #2 P  &0              @ $Y*0  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( &N$;DW>:.&UN $  -$#   9
M  "  2<K  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M:X1N38#$UZ:U 0  T@,  !D              ( !%BT  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " !KA&Y--I6& [<!  #2 P  &0
M            @ $"+P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( &N$;DW L+O!M@$  -(#   9              "  ? P  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ :X1N34.R(7^W 0
MT@,  !D              ( !W3(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " !KA&Y-L?V_2K@!  #2 P  &0              @ '+
M-   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &N$;DW:
M1N@SWP$   $%   9              "  ;HV  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ :X1N31\ -;FR 0  T@,  !D
M     ( !T#@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &N$;DTI9.H>N@$  /8#   9              "
M 7!"  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ :X1N
M3=S1)1+N 0  I 4  !D              ( !840  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " !KA&Y-4Q2?.LX!  "<!   &0
M        @ &&1@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( &N$;DV+T9*K  (  'T%   9              "  8M(  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ :X1N34!*B((9 @  C 4
M !D              ( !PDH  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " !KA&Y-[DQA!G0"  "1"   &0              @ $230
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &N$;DU2+_<Q
M80(  -X&   9              "  ;U/  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ :X1N3?\[$V$B @  V@4  !D
M ( !55(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !K
MA&Y-I;>TL'$"  "]"   &0              @ &N5   >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &N$;DVAOVL]9P(  ,X'   9
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M970S.2YX;6Q02P$"% ,4    " !KA&Y-_0P6&O$!   Z!0  &0
M    @ &H9   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M &N$;DT0W3LNB (  )H)   9              "  =!F  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ :X1N31O1!-KQ 0  @P4  !D
M             ( !CVD  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " !KA&Y-@I11!J($   4&0  &0              @ &W:P  >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( &N$;DUST[T]X (
M  $+   9              "  9!P  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ :X1N32%6N_B/ @  <0D  !D              ( !
MIW,  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !KA&Y-
ME+;^4"@"   D!P  &0              @ %M=@  >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( &N$;DV-2"R_VP(  "0,   9
M      "  <QX  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ :X1N30M/JA?F 0  8@4  !D              ( !WGL  'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !KA&Y-;' #0N !  #P!
M&0              @ '[?0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( &N$;DT?C=33^@$  "T%   9              "  1*   !X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ :X1N3;SA;OV6
M @    D  !D              ( !0X(  'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " !KA&Y-47F+#K,#  !=$@  &0
M@ $0A0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( &N$
M;DW820(EJ4P  ,,N 0 4              "  ?J(  !X;"]S:&%R9613=')I
M;F=S+GAM;%!+ 0(4 Q0    ( &N$;DT6CT+330(  "$,   -
M  "  =75  !X;"]S='EL97,N>&UL4$L! A0#%     @ :X1N3?-]7[1+!
MZR(   \              ( !3=@  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( &N$;DT*Z!86Z $  ,$?   :              "  <7<  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &N$;DTG19'&S0$  )H?
M   3              "  >7>  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   ] #T G1   ./@      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>120</ContextCount>
  <ElementCount>204</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Balance Sheets [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets [Parenthetical]</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/OrganizationAndNatureOfBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Trademark and Patents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/TrademarkAndPatents</Role>
      <ShortName>Trademark and Patents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Convertible Debenture and Derivatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivatives</Role>
      <ShortName>Convertible Debenture and Derivatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/AccruedExpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Equity Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/EquityTransactions</Role>
      <ShortName>Equity Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stock Warrants and Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StockWarrantsAndOptions</Role>
      <ShortName>Stock Warrants and Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/RelatedPartyTransactions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/PropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Trademark and Patents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/TrademarkAndPatentsTables</Role>
      <ShortName>Trademark and Patents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/TrademarkAndPatents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Equity Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/EquityTransactionsTables</Role>
      <ShortName>Equity Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/EquityTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Stock Warrants and Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables</Role>
      <ShortName>Stock Warrants and Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/StockWarrantsAndOptions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/FairValueMeasurement</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Liquidity and Going Concern (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/LiquidityAndGoingConcernDetailsTextual</Role>
      <ShortName>Liquidity and Going Concern (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Trademark and Patents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/TrademarkAndPatentsDetails</Role>
      <ShortName>Trademark and Patents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/TrademarkAndPatentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Trademark and Patents (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/TrademarkAndPatentsDetailsTextual</Role>
      <ShortName>Trademark and Patents (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/TrademarkAndPatentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Convertible Debenture and Derivatives (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivativesDetailsTextual</Role>
      <ShortName>Convertible Debenture and Derivatives (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/ConvertibleDebentureAndDerivatives</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/AccruedExpensesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Equity Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/EquityTransactionsDetails</Role>
      <ShortName>Equity Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/EquityTransactionsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Equity Transactions (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/EquityTransactionsDetails1</Role>
      <ShortName>Equity Transactions (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/EquityTransactionsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Equity Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/EquityTransactionsDetailsTextual</Role>
      <ShortName>Equity Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/EquityTransactionsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Stock Warrants and Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails</Role>
      <ShortName>Stock Warrants and Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Stock Warrants and Options (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails1</Role>
      <ShortName>Stock Warrants and Options (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Stock Warrants and Options (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetails2</Role>
      <ShortName>Stock Warrants and Options (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Stock Warrants and Options (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/StockWarrantsAndOptionsDetailsTextual</Role>
      <ShortName>Stock Warrants and Options (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/StockWarrantsAndOptionsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/FairValueMeasurementDetails</Role>
      <ShortName>Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/FairValueMeasurementTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Fair Value Measurement (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/FairValueMeasurementDetails1</Role>
      <ShortName>Fair Value Measurement (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/FairValueMeasurementTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Fair Value Measurement (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/FairValueMeasurementDetails2</Role>
      <ShortName>Fair Value Measurement (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/FairValueMeasurementTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Fair Value Measurement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/FairValueMeasurementDetailsTextual</Role>
      <ShortName>Fair Value Measurement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/FairValueMeasurementTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nnvc-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanoviricides.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanoviricides.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nnvc-20180930.xml</File>
    <File>nnvc-20180930.xsd</File>
    <File>nnvc-20180930_cal.xml</File>
    <File>nnvc-20180930_def.xml</File>
    <File>nnvc-20180930_lab.xml</File>
    <File>nnvc-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001144204-18-059983-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-18-059983-xbrl.zip
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MDWT04D&DA/?&OR4(UA,7#YMM.7Z1'E[Z9OY5;U*R62"L"_?6DGN5%)*P<U[
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MO63IBH7OW)"P+>K:;D)8\ -<LT*'F9)1:TELT.XG.^,L?.V&M&U1<KS;5Q2
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M][ 3N'ZX:_UWYW/KZICE6[#$Q$ZL+<I7.91\-S$N>6\)%XRPT(+M>D_@-]$
MP7\<0^-79(5>,#1;*?32%LQRS7%KV&G-J69_0JN4O@J>2%YIA':KKW:K-=\0
MZ0CT%8[B/VP3'H/GKKZ"?+(Z*EA;[L!CJMOM]W:DHWQ!'5PO!2O5'7CL]!2E
M?QQZ^6JX/ZX=%DWB\K52L"G)@4>+W$H5!-FUF ZLDZ(3W\..%+FE* ?224!J
MD-I_Z_!97JHZ29SW'_SJ9D/>X8(\/*6%\FU_OS-5C9-^\3"_VWKOCUQ#-U1G
M=J^:;,V"+:VS#]WSY-[_1NSL0!ZYV0P O [*H[-+>?3.Y3+DP5<,<@!5T$5E
MJI8LV(FXM=A_,]7Y9.E,[[7AFVW'4XM'!&$?M<(,I#) PIL^,]6%QR,%_S"\
MQ]\M>^0RYPF/?=U84]]SOS+@48.'B#ZJ7W&]'1<T860:;G2F/3\;?T4]E>^!
M5N82$_!TMVHFMI)7)B$,!_(P,>78"7-E2&_!\^]\1WM4<[K=]S/U81;8]I($
M*6\OPU4L[E*,A0XM#>2"2T,ER;0YWSUZ+USO4,S?0"HN1 =YJ6(#N>"Z4.4!
MF^1R[X9SD"G%-)?Q5)+X%"Q>40(T"QO.JR"L7!#TX;MN+-UX,G1?-<4VTH7O
M/=H.IEA=VTY8%R@KL,))MXMJA0:[^&53NB M9MD>WB!3&HHST_XN\SUH^?L?
M$-) A XA%$MCX)OA83@5$U:L5%V[VU>ZN2DNN3MY<6G*P@SEALX[9Z@8M>G#
M!<EYSW*><L/?W?'4ZL'L.WD681&E.7I:AZW<7-^=LU68X(B[T./=6#A'A'D$
MS":RW&1V+5O?E1[GA.^&;\U5[IG@>-\\C\B-+$+N.9:8_LM'@XWO-0.H-\:&
M)HYD.G4P#9G287OFK+B-*(ZZ;%VQ?-1MS]N6\%O#+F1JCW$]=0,'VQ:\1#%(
M45;"++T=UV)M=?NMM4QG,35GMG>Z0:S;!C5O*YKE%:56ZW@-/C);(&'J6Q?X
M4+ZWQ>==\*'(@\)@O?+9-SMXJXN)MW&9YTL(/G-R10>9NE?K'/]KX_\2 >'*
MUV]+;*Z-+UA\=BMB@]I*7.0X&A<0F*E6M<Z9O&%J RO_C9O0M+1ZQPH-#_O*
M)C3=.?:8N2[W%]@282%MVYQA'+1Z6=H6O'D;&G/G3<7D)V]"7XGEQK_X:'JR
M+"U==.Q_YX-!/"V=K!L6ZHPGT+BQ4+3#06_83=:D*IW/,H7(BQNY-Y98.\H]
M9SE87-MG+@=M%^)4E$Z[C!R2Q?R6*<Y/+U/#$0LAX3LRXLR4&=JG.%N#WF X
M*&/[;3'':PG47?_YZW1;&!2LFK2EM(MOV>U;(/NUN)G*4/.]+7:!Z8ZBM.1V
M&=O\^["X&[8-&>37LRK+F2T#<.=\,-^O9[]=0@XF\A4MDG8I\LYN(HBB(D_/
MC(L>W1RT5S1CVEMOF^QQS6(<K5H3B5?VL[ROZ..TIVXS@_D#2,O9V' 1:$7)
MN'TQF^GKMGQ%9P-&5U2BVQ>CG6Y;:2<+PFS":.%AG%_E;G=,5VD8KRBD5]-A
MO*03X&!%>;Y*C>4%?0+79GEYP;]*C>H%+&]066&P5@'!W5>$6#T6EP=@18^N
MIL;1DO=OLA]7O)#?PO6B^8Z8!7:G"U-7N##?0NJ4OM+O;$Q=<6BNL^9= 6AF
MBO>M*]D2H;G,TF5J^^T GZLM5 $Z"]>OW1RI"^B,:U6YW^P%W5;SIV")":#[
ME?WI&Z[AL:!*O%B:P>RH!\O(*^ UR!13VV^S^3VS7PF)%SRZ7GI%BQ,5=\&-
M@]UV.%:&K=,4?Z]@>O-N^C&?J,S+**5[<,3F/R[+; D=*>:8S7_S)K25T*-B
M+;H6=*OZ8EN:V/L6-36SA)90=*BI=)9W\LLEI13J%Q[.7:?O"U"_M'/62O*#
M16\<(!K@W&&%*[$/,M4&-Y _]H%*SN(+4U,6#R4T0FK+G63>T&8\?%&Q^M/M
M.&A5E5,*8;"X:E]:WA_^W?3>Z<:3Y'HSD[T_&\,]S;$Z,<S96^G?U<GTW9^^
M[;WSC ES)8L]2XX]4:WXAX;D@HD;OY/XC2Y,HMY*BCSUWDD3U7DPK.;(]CQ[
M\E:2IR_1=YX]37_AX'9)\-5(U7X\.+9OZ6\E"[S@N[-_?_#>[8S,S.M ;*;M
MO)6<A]$KN2'A_W_]3C*9YS&GZ4Y5[(0:D!KQ :2Y4U.=O34LTUA&\C/?&'H[
MLDT]]YXOML<D16I*M\Z#:H4UB;&3N="Y9(^EC[X+U[LN/O\-O"!\UZ+/A],N
MHJ]I6)CC#=^<=PVK1AKGQ,/8M<40"Z_=! A(U+\I/;G*:E)-XP&8Q"#(&,]J
MI*<-%/)%M>P_#,?0#)VY#0D\X;GT"IR?A%&':LV$P@:MEO+NM62XDBI9<$=S
M9-A3"% FJL9\S]!44W*8RU1'>^0C5&=/S+2%Z]#$@R1WBMT93.-??#'&DO E
M.M9H>6+.K)&\I<&? ?=-<*\8;Q%C'P:\[O@/+K"$OXY43WHR''BW88U94 <'
M#0(\'@('GU>\Y(^RX!TF)WS"=& 53 9H6GNT0(@/LW,I)03.I>G:X0,"4H'C
MIF!9&AO,U,7W0(+A25->BY8?HH47V\\6( !/;0/!>*OJ>-)8U<).IF/;$<PS
M%W &2I]9\*=KN,BW:LY<)  % &\#-P:0B/G'^^;X0!J>62@_>(8+?YHF_A??
M-'5LW>?"D5S0$VOZTT"^S5\^WS5-XP=+7@-<_>F#OQ6D6HSI3.?/>?0!JY(&
MR.'J]AQ0#%#\#'$2,.H[$3L912:>_FP[/U"^X*SAF<#$N?1-R!84P9_K>KZ.
M;W9]A)++&69CKMXGAJ8>Y*6.F0>(08T @("2D1_YACN!2OL'" > Z;X)O]!G
M%HQ$#=1C"7(!29*&:W,ZJ HD#FQ$9$FCF026@#F@#QQJICI"VV<[@69@?*)J
M)#OAFMSS"ILT\CP)ST,^J%H^Z!^,CSXU<A7/AO<(=&#&D!F8?+!+3ZICV+Z+
MMO4!B =K" ['G"4-SCDX,#ZZ3:;J$IHQX2# !#TXZD12'[!TN">!T9K"(^!'
MWT6W9YRS<VYJ?L4?+L$-!'ZO,VB]B^\V@>T&&MM']8EE+4CP<+#'\'KX, :3
M!82#I0YF)O"+;H QX^GP,1LI!FZYD7?A/<B'^PA"-.&R],O0AK*@T 9Z0X;5
M9_)-=.B_T,N"PE5'&OL8/H.H/'P,_*SJ3WA<6 ?W_^6JR2QU9*(3G3JL&3TL
MM,O PA1=?6C<3< E:W+/DG(CKC1B_"&1204R77\Z!84A.<*( ^I?#(U[8?Z&
M&5>@&BPY-?(-=2#F7^__:"I2%)_([^ YNN3:0%TB:.%$XJ6MY*4/S,)%K  '
MJ<L=EA1)S#<\!G]+2GT,CL%^%NPLTI,%U^7JY5RZ#^_A[_--+W3[AO:#61!4
MO. O\*>I V!0I)H*<.7.28APP@2$&Q 33!A(]H__YP_IU1\JYM:!SVK^RW81
M%\$UZ@]5^O77/YIM*7+G@G_^>[/]^ERZ3+[;A9BNR2 &>T!%JAC[3; ["T9M
MO+H%"T(Z>#$0^LG'^3HRBE7W,)NA(09RJ]WHRC(ZS;'!D:")>B,"E_ =*-,U
M7J0)6)Q'/B!P.CZ'A.2@X_<F0\QHY)D\%C1]9OU+Y5<A@*Y-?\&(3@5+"W%V
M\\>;BYNK^X9TQ:P''P;F)YBSJF\^J\[(=Q[$,+!Y8?? GE0Y$"C+KSP_&A[C
M5AZ(0$O!S;E$ 4+=%%F' .$V< ,B2N>%=#&,#R.$J>@QU0@^2"IXF=#G-G"L
M/QGB7%C^!?'XA4NG8+@\?E(57*II@JWW1?S ER+!8)K<_L*LQ5$OT;J(^44X
M<T[XF.B2Y!2Z@7X#Q@Y,;D*+-G)L%5PO>]%,F+S"%T :MO?A]FN*!MK#C3 Q
M4Q+6,K@"3)3#^%X9/HR],,U'S\2-;DP@".J>33V^Q28I#3"N<K<A/>"K??0X
M\9L;.#\S]6<PEM$KPLFJYS"5;PF%LU#A_- S"%<B JW -;AOI5_YMS>3B6_9
M.AL;>-1< P^%)E)Z%1I5$,BO#+0"5MZ5/D:_?OPC]<-E],.E^(%';_?&9&JR
ME^BW>_SM)C3_7*T7K@%$?#0<';V N!)"+$NZ9B/'1S4K792( MA,+'K$LH2[
MXPTPZ;= *!>QW%.R/L^S(7>^@^58/-0\OF/9\])4/(-7>L#C8T!(%AZ--#X:
M0E7AJ@9WOX&/9&G(-A(K$+$/#197DAXP5_?""<:A<\H9QE__7046($Z4/D$8
M-7U4<>T#O@Y^YY$,8D>@YM*V_NE;.,7GZGZE1B%& #8V8Z^Y0F\U'R+.  &Y
MXDY%#4EI&FC.'FP/RP9A/).". ^<PB"ND8K!.,FOA9G YSEL H%!#/Q$#(4R
M W.9 (1TS66(2QZ^,[4QK$_2] @:AK@(HV8$&TQQ3%^L]82RCP)+OKCQZY?D
M?$*8A(@IN OLE,9<ES]WQ!Y\OIX#,3]HP@NBL:LD2F\<%2S1-]51IQ W/ZNF
M&H3M8"%M@P,O6(-!3\ /X4N?^-A ) :'O$,E!4PUXO6:><.#4=TW6T)T-1(6
M"JFU;#&8N(%%T416$"41S^1R%K_2JW?X,-7](5:MA-:>&7^ 9J#Y%_<@O=$;
M@H&94&QJ>@@RA+''<\@0)L\&Q(NCA+VUL2@4'TX^KFB"7V;X3:@+C-MMM%1P
M[<+(4,(_/*QQ)8UL1V<.[I!%L9:A>X]O%5G^&SA*O*8)#M+VO;=CXX7I[\XD
MC/8#?\KOP[^G. K$W^'+/"?ZI$<$)#\Z\4=\#?X5[\]E=]I2F^00C6 A$=RJ
MT_@, !O/V";:??<;!"P?35O[D=V;*Y:PD]F;RXTL,"(1P4BQ0(;_%,4S\W&)
M!=-6U7P'DR4P7Q9XM%8Z\H+YN^/-+Z]%X9G':[C!(\)8*!4PA\\&S=K/XM'@
M>O6YH*CYS$8_#'@6/M#U'/L':PHL)%X4Q[Y-+INW$K;7-/#I\[\'0HM^%R$C
M/LQ;(V"LX"YA2VI*]_YD@@X=C%$"BU(,1BE$XP:;A16#6[W M6 -NA#8%DSO
M=HC!=>=^%8,&6:)=62+!$RX;&EJ1F^:A"V0RAU^==S,O7HG&ZTZLKHIX+IPZ
M*LH[B5<8-R925 4)YSJH/;RRJ$VK!XCK!5FR;[N"QI$8L]SUN@-;.)PYJEJP
MX8;1D6^I,,?!^8P1&)IQ9&C<,"=;3$,=9N*I)IRS\0D7+F(QG"T[;*HZ_ G\
MV8[.Z^7R::<:QV%3!R94QA0GM3!3PA4\<X:_XUQ1#[<%?K<X+3P;G-O%BPD0
MI:FI);;?S^_/I5\N+NY262HX8<SR8,3&4DP*D2I\D\%+)@3I(S 5A!G[!*#=
M_$^Q@N3 Q!%F98J,1'R%.;4IGG'?_*]PXIOH?8NW?'K1'K%. DZ()P8O2<5I
M"@WX5S;%QNW60^[ZQ047'$[Z9WRM8";I-I\=BUDHXYL<P8OG>1K;MB>4XC">
M0LD7?B(I<2K"N6BN>L6*0D$HC'W',MQ'AH 8XTHI)TV-D\>E5S"U [?&M0XD
MB^$)5P<%FU'ICJ^:[FLQ*0?L-$+]VU,83R+G!6R)*JI.-&(Q\2>#0T48,IQG
M8^S/EPJDL6HXX29E*G$&ON*[;.':2LC=E&>FN^$].$W/75@25X=/P:5HU$OX
M>H-O@XG%F2>VZ)UC'V0T8VK^6F%F5"X<@_/J#]"A2SS,X#\_,I4O6B0&S.=(
ME%%DT7_G2M@JRQ= Y9@/LY" 9DR^15ZB67]RL]1]M'U<#T<V53YTM7 E#Y-]
M<(3A^LY<*AE_98BP@D8F8B_8T\M[9#AP_R,6MH$;TUS<$L,6&-+??8M);5DL
M1L'O)DM8@OM/E[A:?JMY-E^R:@=K5N0I]Q9#%?22"X,84L>Q!R[7W,:[\6J/
MFUCM2489P6H/*H\EUZ=3-N/"LG!_3[AD'/R;&A&R&W6P&S3Y.AUH5-B&[7]Y
MZ2O3L%8,MY-!+B+N)T+<ZTC8($Q*G/FL\5I2W3%+YHR@43]S=LD</,^/"SM@
M3GB@I$XP#DLN#CF1!0H.E 1K SPKB$_!@K.VX@')^3M?E7!9XA&A$7M4<8(8
M)!Q@#":FW!C,\64),?>&(-&.-JW%$D>8@)&BZJ?6L-?H]0<\M?QE*I(#PGEH
MD"20%T1&IT-FR6,^ML_S98(E+I% K$] LP 3L400O8-G"2\\0!5=MH'4%LO,
M #Z*RDP<HF*>9&*U[NC:*#_HT8$0.TC?%2%RG/@1Q,G].D3#M!5![H/<Q_%'
MP]@]\C<T96#A)%%Z2>+U-FH<^M8+CHN@2-:+K%>]K!<F;FAQ<(0611,6Q15E
M)T7Z)\\4'<TDWIX*UR>C.X+37,]!G71)%872)4LT/, 53EY+$#^%3\8R2QA@
M1L4-=9]OJ.&#Q&[6N71EF/REAR"-'_NV\:R%.!Z6)'7!+1D.)!X3BXU%_FWX
M/,RQ%0>^^:ZAQO>@; T"89%]G>01TV]=G^?50I1J^P^/H?"FP>F/YZ [>P-#
MZ[#V+@;2H@*BN#RL2!!?H+,14.,[Q4][D7,@YU!)<)!SV&F637Q02N3WNX\@
M-7&F(C*CBVREL'1/;,ZF\<- O# 'VCM12&65L==44PMR5QK!H8X96'9'G(UH
MAF]Z6P/ TC3]0+9L^:<EP!'(GSN6DCFVDI@ 5L3L'10OXB!0DY>?F;IP9_B)
M$X:O$4>"@NM2Q"7._(1BY:$+6(%P^(@SQHDK]?0,/'&R-SGJ-%YKXIT4*+)I
MLG$HQ/"K^*1R^$WJ///Z)XY3&LYSL/$AIC07F\-HGG(%Y5"$YY7D@19!5=;[
MLUY)B,_33H")!/62:YL&Q/DF&(J,>7QVU.D6*MWX],XF]]S%OC(6<Z+0>OSE
M5>#3XF_$6D_\MZC2OG2E)P]:N> H!V^;0RMQ?(\&_>Z4L&0 %!GTK1T.^GJ,
MWVO;B24%4>C:HZ^J.JXX>03!(X<@.8"J:H9&7WI1!-,%/O-T@>,8>=4GC^!W
MQ/ CPU]5S=#(2][S"5/#CF/(59\\PMTQXHY,?1U6=G<YY%:M[-9C2&;R@P?'
ML0A+(#UFD/:/ Z1E.Y%:.(R:4+Q@>"YTVKS><Y49JI\*ZD<Q@>:P%*]C4!.9
M.LU$BDY+[H"+:0_@GV[W=9[9#7,^VBTE9*@<IXW"W#KBV)-+#GK+\G3<?P29
MNVL[Y4"2[<'V<MQ=G#:G]2$^9558M2M,[&SQ)."N)0_VR]ZV!I#SUVETE%9#
M;@^+*6\'H>!F&EM3.31,JC-,^C4<)KU&;]!MM(:ME<H;U&B8;.GR>?X=3:XJ
M0G&)0[H2/-0VOC\&1=2/XF.0.L'_Z":\ISG#_69C8\KU#H0=:&]S9]'\T07P
M-0O95\]L:Q*E$^()\25-4FN"^-PF7G-^2#.9ZH '\AYC-[7HF._!+ZW6.>.Z
MGY5_J=4IXR5A344@4G<\5+AVPH674T6PL:1P0A0;QQ5F%E5L3%6>X=4714]>
MT<T#>Y=+EW&)EQB16MCO("@%@X5S>#=B?QH44A0_N$$S3M%XF/?XQ J9<7N3
MZ-F\R>NPVVJT!XJHV+CL_7BQPW1L%AL6T4PP$O?=_&(_!6TWV^M57RS2?WI%
MA1,:F<<^,I,%5'F[5=.U>9TE &6W(?<Z#461$Z,P0/0%]C8+JBK=<\#"N#-@
MN !Z'3=NPXW]6\5M\SF"V+J9=UD138&?@I;$:K+%2=![AY>7LD!!9O2;\B[;
MJ1;;WT;D)8H^Q?6QXI)/0&W[O)O@R_ $9).#\!R>DZ#F,J+F,DL-/!\[8UNB
MRRYVXN8< 7NQ-<JS7IR"1]O4458C -.$23WY;]BNQ<2.L_:SA;]PR2!]:"&]
M&7]'4-]5_!:+2MSQ:$P;TH0Y#VA;'4G5_O3!?B4[Z(1:#PJ_YA&7VS?]7+H1
M.E-'+F^.R]^?$8X00"-IAB]2*I@'D"$:!R<OX=8\J1%1NTNW67"MZC@SWF&8
MUSMCV&H&9Q"\VPWGC;>"C_O2"*OJ@F)S'-)@]P[)97D#*'BD!JA)N2-^+X@%
M7&6_U0&OTA7\!Y)*]M$):P9A?V@8^J)FD$"^:X0]C8/W\ I"-N^L >P!;TF1
MVS@HN0?,T6D=RJ/5W5=LY2>H.-HQ0Z/B841<',UA0?%R41MMQ,MJ<LL=F*G8
M.B5*F8FBZ+SB65#[$6V4CP^,RY?7M*99W:%7A[6&)<"@FF6UKEE6T9W3ZN](
M5*(^63T."&7JR"3^<%CBSV1OC.I:OY'S!C^F)CEK;RW3B2<R+@6,"YT^7'4/
M'8HE6%83EB=X#+9R26S5!LEE/$/'I<#L9#ZJ42YF]'/-()9.V"D+MQX\4!8N
M):&?F-0)_C5*0J<C6%6BN#:HH^%??1[J1_$Q2)W@7R/O5ZF:(YM-9K^$O:Y4
MSW.,D2\V[.:R?X(TJ84 V$&1@UV7 1!%#JJEBY]6$1V4^*C8L8]72F/041J=
M7KN.0G]-J#XXJOM51'6K(<O=1K?;72GTD@?E+E!-T[PCHK@VX17%N=7GH7X4
M'X/4"?Y'-\VK5J6-*V;9$\-2/=OAV;W9W<-,0_K\GO*U2T.@8@"5B)][PX8R
MZ#:&O<7Q\PX2&JC^!4'^<)!O-]IROR$/%B^$U 3R-%T\(HIK$Z91O%Q]'NI'
M\3%(G>!/T\4UIXNM\VXE2S-^7#.-=:,LUO*"]+7%N'94R]\@Z;:/&Z_5C-3W
M!(V?UM;U7D59RAQA7[)\)9_+[;7EN0#]AYN@[$E:K\G*D)6IABC)RIR\E:'R
MHU02Y'A+@A P=ERFJ (5B=8JOWDI9GOW*\MOPF/Q:X])_6)5/ME+4*B-ES7"
MBDAS<\U$$21."E["JTXT>;$)O-*P=5%R(J>0*M8-5'U7%'DS)B D#VO$J99G
M-,.Z=74HW7:$8X&,) &CPD8R+WP4/!D>"%TK<M,\=(%,YO"K\V[^RC11=/)&
MU)B]T#1@#&M12G>.;<%G#2SRJDZ@!%>R8]L@N)#QJR"RZ@ZC"E>PO+&D"_\!
MB)'B4L#WGR[#6MCX)]81-B7'YV5RI2O#U2".\S%9[6)D^UY0+Q?+)HLH4IQ7
M$F +:@-_^M/'\LW7F YGP,L?7'P4_#D!\#3_LQ&4"@;Y0+#GBJ+:P(DQ"6)
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MY^$U&L=956 (.V'@JX)N=OZ$+]0^L6:P:*'JZ E$G"W6MP 07&PCU52#-G1
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M2%Q+[C2D5GL _W2[KZ,39WU<@]^7)8NV,FIBRG9;^^* RW"BGJITI\[XOHS
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M2^;?_J3T>@UE,&Q(#G.G3/.,)V;.SI>IGEL$23B*]V?R6304#-U[?*O(\M^
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M#@,FC.1M]?5NJSR"_,67W)^LP/$C/KU'QP4M?)R%)]WQ^C%0XC4)SL*A,U
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M1V[(@8UP+\=1F'YK1\$38--JU3MM,5O;J!N=G[0G'X-#UPDG-1&N_23C-L,
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M0S.I\B4UL#E]%:':E]3 YHRY0!7-3\5\*0\@Q744UYVOH:4&-JH!2/'>016
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M__(!AX^^9[/ 6W+CLK79C<MC7LB*@PI .4C.#4[UWGE13+/':WGN_-7UN,#
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MMV3-0K&@@P&!-'\!*6T9#J.EBUP,X 08F>*# V9Q!\-%-'<8T5F# 5@['%$
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MDD*,]H@JJJ*B2!C6JV\CUPY<O8!1!N5.L!\C5[C!NR7&/@]QSK[2 #L!-.\
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MZA3Y6%[-(;:8CUVHE8OH_/C]SOM]9SU;3B7Q63B#*0>5V!;:;Q&[8=Y_P#O
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M&05KR9D1C?O.<=Y*\^4/E_[T7U!+ P04    " !KA&Y-9YA8[;Y-  #2-@4
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M6?1S5O2_3L9!7JA)*=<[M 7_OP^K9A_XKSX<]#[T#W[ZGH5KN:!-F*]?4WW
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MG4@3/&X\P9S_ZAF%%0D.5U)571?H1U'[B0"V6Q]+0Z0(K02VE\JHXR%39W/
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M".T Q#4B'GZ?C6RWR%%A->$6"%:FJLU!$F;GE3@@/O?78(<!XP<!M&X8=IK
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MS5,)7'7LM/RZT>=/)!4-K(PK=PI!QMCJ$")(Y_Z12\A?]&__'U!+ P04
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M^] 4:]LU+,L(1&-T<NV=@Y3G6(S5!:JB0WT!K9[ST\^WM^?7]ZC \(_P();
M0XQE"38<OF@/LB>R!J?_=_[7/5G$;.G">IF?DA7!@:S)?PJV>]5]L2&]RW?O
MAB/B@$0(4!"'B/VC1;I 08XJ:L3(85:AHT>VIO_ #>GDPWCFDGZY&PS5T@-^
MC.*8JBG9H(*9F<;8)&1S.T),_BX=F],T#3:.@\O<8.,UW#G#FQ0_!U%X_O49
MQQDN?;/"^4G:.W1V,H[[F"K;H;)A/=%#S>ZV?..B(>A.6HF./L*5T !:L9JN
M5.%6J/J5Z?0S;ROGXV F6>+(>O%<M/9F)6JT H5PM@F9Q?+##9$D2S=')H)G
M>NYPC4WV5F;D3EVQT7AX#U>0+1 C9!-_3;I A-B#S=C0L=VN;LYO[_^,EM=G
MZ/S?/U_>?");-5@?;@XZWJ6;(\X#,_J8)L*'!J:$/IA.-09+HV%DWMF*;C!L
M%+AJ#3/163-?S'R=(9S+AN"%H7?,PMC$.S;A</FV7N]W>Q:"=H:?4[R.6 HS
M\N\M9@\*XG"Y2](\^AO[NY1]U<IOLD^X7#1.)Q=NO=ETC=I]+U#=.T-YN_\%
MZCFDA=H0ALM'F,@>6DQAJ^^YAGIO<D VXWBO<)8A&39 E_H3NPANES"Q?_!@
M9436:P,W%GZLB@K^[3<2GBTIU,/HKH86*)Z#?Q.G,H9_M?R]6 ^UC,%FP^/>
MG"_CG,B9/A<J#BX($^=?U]L]?>C_,4G"+]%V:W!N8->-0W.W'%\?=PTYJH[,
MZ-G!J[H/5'7R[9P'"D8F-7*H][?+L_-/R]M_8^<*-\O[\VO8Z(4AT.P;VQ!<
M.HTMCW)\%;W@L,^H[IQ!3^HVVEPW#D&@+B%YS6B0P,KF.6P@*ZT,E[4Z/NZC
ML"SV->&X:.H=O O27]E,]4P6>'/<"!L>FHSA/V,#N!$/P/%+ ",C$3P),+(0
M+\R]M1]HK_N'.0!I9WZX!/E8;9U$>^?8[@KJ9&"20;<'%3@8E-$9P"0CXW;[
M*IUYXF(TAFGA=#16Z=>2?^12W[LE_KBE/<P6?^"XA"L0X4[?M\7\F$6\>S-:
MY4\X-0ZI%[9V:"1B;OO88:W0_"'V1OM90Y;O_W1^B^!C[15PZ.-9@06'KX/P
M>I]&^>$,/],\6@KH<BU=O@OBN.03^Q0M4-ED<JR&>$,G=;,=HP6_8=$$=&\E
M 0'W>$F,@'$)MUZB-5X^IIB]BI*FZ! T=)A&B^-1D%:*MD%-(ZBT6,:L!E)6
M7::Y$FN_G]%J1M4;U6TUD>O]4Y2A#?'A*,7E^5*&,D[8WPTIT3KI*L5L=0*U
M*M&L1F"6X,/Y UIZ&"PYH,*E5=$R[I$G52HDW*1,%?%@\$A3@PP*7U=E<@":
M_S NLAT^)=N0[#'HW6I^,-B>F7?A$*,6X^*.VAK2^LJ<91F$CGD>,Z;+Y<GE
MU>7]Y?D=NZ*\NU^=_MN?5E=GY[=WOV.!T/=_AC0.6QCVS<<6@S &9F=+T&9C
M9B%^F87^57;+$D"?9BMPH0(W7*:!]3K9D[7X37"@B:/92:G!*RX5E=OP7 7W
M@FLDUAJ5S1>($8"_41PXBN>B.7!,J X]@C!/'73 T-]*PDJ,TMH,).1P]B ;
MC]XPVJET":EO)F(]L-)6T/_\N^_?OWOW#R@MQ_=,\^UZ9$%*!&I,20D_IS:5
M[G'8FMV,#$E&X]9ZI)P+D$7;HE9C'XS$FG_9>W='N_L!')][\$)?BW&!J:H!
M#K)ST1LFL$4: <.)"1K!V8C=[A/^%HDGVQ8-DGV <),%TPK,:C*'L-;PKTCZ
M6;4_@$\VP\?03ESZQ8/$I29HZEN!"91<IC4=<+[KR8FNU7EGN_'OJA/<99ZG
MT<,^9PO\/*%[EIDS"QK%ZM@-3'!P"WJ.97]6Z]/I;+?.DRZUH+"UV]Q: FX%
M&:K:E;D618+ !;K,,K*RA(WQ,1N!IN!85@SKO[_][NW;=W1GCEZ*$7Z_^,/;
MMXNW;]^BK*@D'.(L>HSI9G>!_K!X^\??+]Z]>\LN=7Z_^,.'=XL//_R^:AHQ
MZ;#?DJ9>+\NT>$?,@.6A1A_>+A!%$FOVK_L8UW]9(-+),UY33[\%/2A00%J0
M$DR&9X?Y/IMRR=K4GEQ3EUD\>3ZY.X9.->MYS<YP]67.M<2J_@&]^P.SJ;9=
M!?O\*4FCOU&[^N,/BP_?OU_\X8^%89'_?/?W[Q9___NW:LLZ/L.2 95+)2E!
MJ<.3M3!D#CG8W@11>!F?!L\1V4NJSM5D%"Y/U:1<<R<\=4M$FZ(H1F5CL!.U
M(;S3=(RO">]K,>].SZG4B.%.J=1P<5F:, ^B&(?G04J3[+8?"IV1=<E:&9QM
M0NRT=*'!6/A2A@41JJC0JVY.&$8X_2L<0[L8-*9N)A_6"K8VHRG&^%J-I@"#
M/ *PVOH#;_G';?5A#GN-1E$<]HK& ID2W8CUDV!+=WUP:<W'< E[5&)^1 *S
M+XMR%G]/$Z,G<4Y<&([79&>NV:))J1SOUN3<B[9 9>NBX$*[/>36S6((JT^?
M+N]I-MLBPO-T=7U_>?WQ_/KT\AST<9\!CD0[* V(_(F0-KL4E9!Z%!&MOC!M
M14*#7YF:LE_,J?U!F,RQ/H4^&]RO*L$UXJ5A.6?>/6%,@X?H$NH)Y]$Z4*4U
M,Z9T]1;1:!22Y0(JJ%"'3'%CY.P9H+EJ.N\"S?4"=0=#F%JEK.)?R$[/;G!Z
M1\\1C:]EY!V W=0HQJ2]O"&T*$E105V<*2-"CU@'@,52Q@ZO/&ZNSYG1JRA&
M8;+=!FE&BPD5I\?<P07<38H.F.K+%1TJH<R-,9$MZ_-\8S/C"<',2S &K5D5
M-*@A\L.4K(92FA!W)^./S<C0I;85&;1@;:2XQ[.TCXH(V#9JWDWM O;2<N 0
MNO80"8< ;0M=%)G801="L#:P:NYO+0VA0PEL#=U1F)I$B\HGNS =3-<X$OE@
MH"U$@#$3,Q$ #"2&9<#^Q8@:)M+%8FG?#7[Q<MLR:F!'L&&Q@*$B:,6?K4J+
M*8M]BI(*QHP,EO5=\_%F>S)H$#YN3 RPI+ )^"T)QXQV/R*E@+0!Z3)>A'^/
M@B?-N/=M!Z(!C1;P4'L/CA&SC8>:#!+VZE6Z&/L>;#B&C:-C!0M?]AHFF-(:
M!.@NXS)>)SO,5F;T;MRHM)"$PFF*<1G7?%9QVA+538'OV0S%SF?<5LK<9:1?
MR<+=&L=!&B7+KY$J=$?2WFF\GYAC+N2O_)D A#0 !8=2R'Q8ET+"#H%1?OUS
M3!]61)L(AV?)+HA4)5,4-"X!HN!<!I(%:K5&OQ3M83&CDS^'&YWP'>;$?<9I
M0,.QJNP:)OG[Y30N\^4J..>RTU9MZR0B'N2YLQK S?GMDL;_H?/_N#F_OH,-
M =2"ADNYJT.,RQ<F&2;#?5K&X1E^P=N$U9LL^5* 7D/G]%V)>@3\DY*B/8N6
M:U%4M@#WEF3$.,*& O8MB0&:^&<D!E!R9Q$?<4RL<TO++(>[*(ZH9=+7F7J;
MT%(ZM K]*/IX*BF*6NL=&FC+&#>6H$,#:1V&R.K;AR&L !=)-HLCV$61T6((
MJ*"  :]%R'=2<RS+6@>Z^C%>]0 BMSC%N%(7TA6VAD!OAULY?LL#IE>T(5!A
M.C.6KU9W=^CB=O4)E0OYU;4?"W@>%E(0\YAP!^/K)$ZZ?)0F9;!;-:!U"'&3
MD?31TZ:I,5^2S5IJW7"Y,F1,1:FZR^O3U:=S,IAB4_LM:.8K8Y#U3<0888Y+
M'4GY4DT!&D+7!9%48Q#7(%):"]A9C^U8+N,<$WYR%+&&X"65M%@25EG2 LEI
MI5\F4+T)<"W=UN_M<2D%QN1[5+OZWA:<8C&G;N_\A-H75-<5J7[$D\NS*&.Y
MVE=Q*_?=&7[ <;Y/A1M),S)7CRWU_',)7TL*M(H[^?X:(M>0'3N0)$;KUD!"
MZ4"<O18U1%7GJ:A+2!D5E+37R/T31L&NT,D&A95^@BQ+UA$+3/X2Y4\292W0
M^BE('VGFNL<@BJE?JE(L13$BLQ6M64EKT9-E0Y&J!*A,99-B^"/ADVZX5G'S
MMVMLENE:2@N2[EH^$GF^Z 6B5.7NGAIA^Z=KOH3[^ V_27;?(6,Z?2+_A2G,
M-D%4A9M3!-=TGN3!U@!.G@Q;@S8/3@J&G!#X<3)@>R( <Q!FOU$K=C8+%/.F
M[,6VWWJ[#Q5!2 WO@HRK2*RS)VR5AW9)G)W@39+BHMU]\!5GYU_S-$C2,(J#
M]'"9XUU&QD-$E1.9;=F(BB6P<H,TXU>=1S+.)3U)-&0YG5$<HN:3J/DF>F ?
MK<R:?7:!NI]!U7=@;-VMX-CA^<GYQ>KVO#HPO%_^!VP$C /#$\>ASFIUKAT7
M8;)TG2<XQAME<E<IA7.'(>):8NRD:75.@UZ5K<'.("VXKZT,W=RN?KJ\NUQ=
MPUN;%"UB2Y%"Q>%B%.=&]ZZ]=BX7G3T.N84FSKNWK%YE8M5R?WZ/Z.PQ?2I3
M0E0=;QA4R3"1\I;\!+.C!>/.]'K1D#\4]*"Y;CU?*E/I@6XT1-Z VUR(7($[
MCU5EMJ[>B)\$6;2F<8K1=I\K7Z=J*1UZ-?TH^ABJLZW7.0T6B%$50;,%'8QY
MV@^F-@B:Q: R DI:5\%]J(<6SC0T0]NV']Q)G_5FJ,48DTW'\"$MWM":^C[
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MH''4!(V7M:%?/W#[TD5YC5]RL4 U'_7A8GGOWV(%*H883M*%D)*B@^X9)&Q
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M.*+Q+V1]<A%]90\M=<L!!8W+Y/\*SKD4QU5;ML:L6@,O!L8/ +3*@ XX7'4
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MC&<N24OG8=("G7]=;_<AW4B6\D:?@MR#@W^U$KB4=TH-0$7UM&HJ&(?Q=&C
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M*A*?PWJG]!G5:O-S0!?R^2J]C1Z?<LVS)@6-RQJG"LZYR@CLY5NR065KFBJ
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MA#5&YKYX=BO _K%Y*88C/3376]ID^UB]F8T)!!4\O+V+R&R\B=;D>ZVMLS1
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M_:"@:.9OLDJFS/9FQQ_XVI.R?$]FM_437L58&U%@U0O\^DXR.O,56;'<*KM
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M$6>"G;" XCR8*R1X1;Y:_!?Y!^WEG_\O4$L#!!0    ( &N$;DW@SG<9Q5
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MZ!&(Y7,"/7]*8.ZF9JLCWDG#T=VS.=]=81')E["UQEDX-I_Q>"<-1W>7)K"
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M5<![?BJ.V61M9X>;QN)E441H7C*X@T:R0Z>Z<2DE8D^VL0(8X/*[XE[-YR0
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MD0A0QH</-S/F1Q8 $K@VI'XLV ;%;<?_#_'7B'T)_J_WT->0ZHWBEC@4*XH
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M#FAB=O3C6?J$:0>69NCB*8LF49@N'\+B\1^=&8JU 8$X%O@BF:%R$'[7MZQ
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M\('Q1X#DM9?Q-H#2MS ;34P(<X2OT8M'K"K'+&L%2&GK,:M(,&"NB@CACBP
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M%L 3!3W9G,TJ? BYQL8OR^2NG_6ZB?EA\2&<A^D2(U/T+8!S-/9)31Z.!RF
M8FSMHEU]C8S-U8^NOO$_RIZ;:=HUB-G1NCE:*[D=^(B6^6*C,Q)"N2">+_+G
M)(W^Q2;72<I71[B)6E,SR4^ O!T-KK"O;DHQ(&KGE3GPZ<"RL17'Q7+[R<I?
M5M@]1@7DC)M0V.3+@AL^1M-26BH;D>6?"TX_.NI7UU+']D2"J&8CNZ2PUND'
M#HR/[[_^?U!+ 0(4 Q0    ( &N$;DTV/V?<\MP  'U($  1
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2      8 !@"* 0  J.0!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
